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Water is the basis for all living organisms on Earth and most biochemical processes proceed in 
aqueous environments. To study biological systems, chemists have developed numerous 
procedures to perform chemical transformations in the presence of water. However, there is still a 
limited scope of reactions that proceed efficiently and reliably under physiological conditions. The 
search for new techniques to enable selective and reliable modifications of biomolecules and 
small molecules alike, has attracted the attention of many researchers in academia and industry. 
Such "water-friendly" reactions are highly desired for different areas of biochemical research, 
such as bioconjugation techniques and drug discovery procedures. 
Schiff base formation is a workhorse in bioconjugation science, although the reactions proceed 
slowly under neutral conditions without catalysts. We investigated oxime and hydrazone 
formations of ortho-boronate carbonyl compounds with hydroxylamines and hydrazines. The 
boronic acid was found to strongly increase the Schiff base formation rate, which enabled the 
fluorescent labeling of antibodies. Hydrazones with an adjacent boronic acid group undergo a 
secondary cyclization reaction to form a stable, aromatic boron-heterocycle (BIQ, 4,3-
borazaroisoquinoline). Upon modulation of the electronic properties of this boron-heterocycle with 
different substituents, we developed a blue fluorophore that formed upon cyclization to the BIQ 
product (Figure 1a). 
 
Figure 1. a) Rate-enhanced Schiff base formation of a hydrazone with an ortho-boronic acid aldehyde to obtain a 
fluorogenic boron-heterocycle. b) Generation of a DNA-encoded macrocycle library for the identification of protein 
binders. The shown macrocycle was determined to bind AGP with low micromolar affinity. 
Based on the results from the bioconjugation techniques, we developed a library of macrocycles, 
in which every compound was attached to a DNA strand containing the information about the 
macrocycle structure. Despite initial difficulties, we obtained a 1.4 million member DNA-encoded 
library of natural product-like macrocycles with high scaffold diversity. After thorough analysis of 
the library properties, we screened the encoded macrocylce collection against three human 
proteins. Several hits were found and resynthesized without DNA tag. Binding affinities to the 
target proteins were evaluated by biophysical techniques. Differential scanning fluorimetry 
enabled the parallel screening of the hit compounds, giving a qualitative measurement for the 
protein affinities. Isothermal titration calorimetry yielded quantitative dissociation rate constants 
for the most promising compounds. We discovered a novel macrocyclic ligand for α-1-acid 
glycoprotein (AGP) with a low micromolar affinity (Figure 1b), which holds promise for the 
development of new drug candidates. The developed encoded library methodology was shown to 
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"There is much pleasure to be 
gained from useless knowledge." 




Part I: Boron-Assisted Oxime, Hydrazone and BIQ Formation 
1. Introduction to Bioconjugations with α-Effect Nucleophiles 
In this part, the influences of boron substituents on α-effect nucleophile condensations are 
presented and an insight into the reaction mechanism is given. The conducted assays led to 
successful labeling of an antibody and the development of a stable boron-containing turn-on 
fluorophore. Before the discussion of the experimental results, the most important concepts of 
bioconjugation are described, followed by an introduction to Schiff base condensations and 
fluorescent labeling of biomolecules. 
1.1 Bioconjugations 
Biomolecule Classes 
The chemical cross-linking of biological molecules (e.g. proteins, peptides, carbohydrates, nucleic 
acids and lipids) with another moiety is termed bioconjugation.[1] The coupling partners of these 
biomolecules include other biological molecules, synthetic polymers, dyes, drugs, small 
molecules and many other possibilities. The connection between the two moieties is established 
with a wide range of different chemical transformations. However, certain reactions or reaction 
types have proven to be more applicable and useful than others. These reactions must proceed 
under mild aqueous conditions and in the presence of the biomolecule's (native) functional 
groups. Bioconjugation reactions usually target nucleophilic and electrophilic moieties on the 
native biomolecule or synthetically incorporated reactive handles.[1] 
 
Figure 2. Overview of the most important biomolecule classes. a) Proteins and peptides. Shown is the primary structure 
of an Ala-Ser-His-Glu stretch. b) Carbohydrates, with the example of a galactose-β-1,4-glucose stretch.  
c) Oligonucleotides. Displayed is a DNA stretch with the four nucleobases adenine (A), thymine (T), guanine (G) and 
cytosine (C). RNA contains an additional 2'-hydroxyl group at the ribose unit and thymine is replaced by uracil (U).  
d) Lipids. The shown example is a phospholipid. Typical lengths for the fatty acids are n = 6-14 with varying degrees of 
unsaturation. R represents the common headgroups like ethanolamine, glycerol, choline, serine and inositol. 
The most commonly used modification sites in protein/peptide bioconjugations are the lysine 
sidechain primary amine, the cysteine thiol and the N-terminus of the backbone (Figure 2a). 
Other amino acids displaying functionalities in their sidechains, such as carboxylic acid groups 
(Asp, Glu, C-terminus), alcohols (Ser, Thr, Tyr), other amine groups (Arg, Trp, His) or the 
methionine thioether, may be considered, but are not as commonly targeted.[2] Modification sites 
of proteins may also be chemically introduced during peptide synthesis or by genome alteration 
to incorporate unnatural amino acid residues during protein expression.[3–5]  
The second class of biomolecules, carbohydrates (Figure 2b), natively displays many hydroxyl 
groups that are susceptible to chemical modification, although carbohydrates show poor 
nucleophilicity in aqueous solvent. Amino-sugars and sugar-acids, however, display highly 
reactive moieties amenable to chemical modifications. Such amino- and acid-saccharides are 
found in glycosaminoglycans like chondroitin and heparin.[1] The repetitive manner of the sugar 
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challenging, which is the major drawback in carbohydrate bioconjugation chemistry. For 
carbohydrates with a reducing end, the aldehyde or ketone moiety (from the equilibrium between 
the linear carbonyl form and the cyclic hemiacetal form) allows modifications with amines, 
hydrazines or hydroxylamines by condensation reactions. Polysaccharides without a reducing 
end require chemical modification to introduce electrophilic moieties that undergo the 
bioconjugation reaction. Periodate oxidation transforms vicinal diols of the sugar moieties to 
aldehydes and cyanogen bromide is used for the generation of cyanate esters. Such electrophilic 
substituents are well suited to establish the desired chemical linkage with a nucleophilic coupling 
partner.[1]  
Oligonucleotides, such as DNA and RNA, are very important targets in biochemical research 
(Figure 2c). To study the different mechanisms and functions of these macromolecules, selective 
chemical modifications are highly desirable. However, nucleic acids are not as readily modified as 
proteins are. The chemical structure of oligonucleotides comprise a ribose-phosphate polymer 
backbone with attached nucleobases. DNA consists of deoxyribose sugars with two pyrimidine 
and two purine nucleobases (cytosine, thymine, adenine and guanine). RNA displays an 
additional 2'-hydroxyl group at the sugar backbone (ribose) with the same nucleobases as for 
DNA, except thymine, which is replaced by uracil (uracil lacks the exocyclic methyl group). DNA 
and RNA undergo Watson-Crick base-pairing and form double-stranded helical structures.[6] 
Oligonucleotides usually display a phosphate group at the 5'-terminus and in the case of RNA a 
vicinal diol at the 3'-terminus. Termini modifications are achieved by carbodiimide chemistry with 
the phosphate group or periodate oxidation of the RNA's vicinal diol to generate aldehydes. 
Nucleobase modifications are possible as well, but often require single-stranded oligonucleotides. 
Cytosine is transformed to 6-sulfo-cytosine with sodium bisulfite for subsequent transamination 
reactions. The purine bases (adenine and guanine) can be brominated and used for proximate 
substitution reactions. Due to the repetitive manner of the nucleotides, site-specific modifications 
are extremely difficult to achieve. Enzymatic methods to introduce chemical modifications have 
been used for small-scale labeling with radioactive isotopes, biotin, fluorescent dyes or specific 
functional groups.[1] The chemical modification of synthetic oligonucleotides is achieved more 
readily compared to native DNA and RNA because the alterations are introduced by standard 
phosphoramidite chemistry during solid-phase synthesis. Aminoalkyl and thioalkyl linkers as well 
as azido and alkyne groups are commonly employed as bioorthogonal modifications. Non-
specific bioconjugation has been achieved in a few instances, for example with psoralen  
(a furanocoumarin) that intercalates with the double-stranded DNA and undergoes a [2+2] 
cycloaddition with pyrimidines (especially thymine) upon UV irradiation.[1]  
The last group of biomolecules discussed here are lipids (Figure 2d). The most commonly 
occurring lipids in Nature are phospholipids that consist of a glycerol backbone with two fatty 
acids and a phosphate group attached. The phosphate headgroup is often attached to other 
functional groups such as choline, glycerol, ethanolamine, serine or inositol. The lipids' 
modification site is usually the functionalized headgroup, because the fatty acids are mostly 
unreactive and not exposed to the aqueous media.[1] 
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Bioconjugate Reactions with Amines 
 
Figure 3. Different modification reactions of amines and α-effect amines. a) Condensation with an aldehyde (R= H) or 
ketone (R= alkyl/aryl) to an imine, which can be reduced to a secondary amine (reductive amination). b) Condensation 
reaction of a hydroxylamine (X= O) to an oxime or a hydrazine (X= NH)/hydrazide (X= C(=O)NH) to a hydrazone.  
c) Amide coupling of an amine with a carboxylic acid. For this transformation additional coupling reagents to activate the 
carboxylic acid are required. d) Condensation reaction of an amine with an isocyanate (X= O) or an isothiocyanate 
(X= S) to the urea or thiourea product. 
Amines and their derivatives are the most versatile functional group occurring naturally in 
biological molecules. Especially proteins and peptides often display several sidechain amines 
from lysine residues that can be chemically modified.[2,7] In the presence of an aldehyde or a 
ketone, amines will undergo a condensation reaction to the imine, also known as a Schiff base. 
However, imine formation is reversible and the hydrolytic stability of this linkage is low. For that 
reason, reductive amination procedures with sodium cyanoborohydride are employed to form 
stable, irreversible secondary amines (Figure 3a).  
α-Effect nucleophiles, such as hydroxylamines, hydrazines and hydrazides, also undergo 
condensation reactions with carbonyl moieties to form the more stable oxime and hydrazone 
linkages (Figure 3b). These transformations are also reversible, but show good hydrolytic 
stability. This type of reactions will be discussed in more detail in Chapter 1.2.  
A versatile and widespread modification is the acylation reaction of amines (Figure 3c). Reaction 
of a carboxylic acid with an amine generates an irreversible and hydrolytically stable amide. 
Since carboxylic acids are unreactive, an activating agent (coupling reagent) is required. Under 
physiological conditions, carbodiimides, such as EDC, are often employed in combination with an 
additive to generate a more hydrolytically stable activated ester. There is a large collection of 
coupling reagents and additives with various reaction properties. However, N-hydroxysuccinimide 
and its water-soluble, sulfonated variant are the most commonly used additives in combination 
with a carbodiimide for activated ester formation. Since succinimidyl esters are very slow in 
modifying alcohols, phenols and aromatic amines, they are the reagent of choice for selective 
lysine modifications. Many succinimidyl esters are commercially available or can be synthesized 
in a simple procedure, prior to bioconjugation.  
Iso(thio)cyanates are another group of amine modifying reagents (Figure 3d). The formed urea 
or thiourea products show good hydrolytic stability and the reactions are usually irreversible. 
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compounds are commercially available as well as their synthesis can be tricky. Fluorophores are 
often available as isothiocyanates such as fluorescein isothiocyanate (FITC) or 
tetramethylrhodamine isothiocyanate (TRITC).  
There are many more amine-modifying reactions with other electrophilic groups, such as sulfonyl 
chlorides, epoxides or cyanate esters. However, these reactions often show low chemoselectivity 
for amines, hydrolytic stability and slow reaction rates.[1] 
Bioconjugate Reactions with Thiols 
 
Figure 4. Modification reactions of thiols. a) Reaction of a thiol with the maleimide Michael acceptor. The 
thiosuccinimide moiety subsequently hydrolyses to a mixture of succinimic acid derivatives. b) Reaction of a thiol with 
iodoacetamide in a nucleophilic substitution (SN2). c) Disulfide exchange with the activated disulfide 2,2'-
dipyridyldisulfide. d) Chemical structure of 5,5'-dithiobis-(2-nitrobenzoic acid), the Ellman's reagent, another disulfide 
activating compound. 
Thiols are a functional group frequently targeted for modifications.[2,7] They are good nucleophiles 
in a broader pH range and are less abundant in biomolecules than amines. Thiols often arise 
from cysteine residues and they are prone to forming disulfide bridges with other thiol groups. For 
this reason, reducing agents are added prior to modification to generate the reactive thiol group in 
situ. The scarcity of thiols, along with their reactivity, enable high selectivity for bioconjugation 
reactions.[1]  
A common modification of thiols is achieved by Michael addition with maleimides (Figure 4a). 
Although amines are able to perform an aza-Michael addition with maleimides (pH > 8.5), thiols 
preferentially react with them due to their higher nucleophilicity at lower pH values (pH 6.5-7.5). 
Maleimides are slowly hydrolyzed in an aqueous environment even after thioether formation,[8] 
however the generated succinimic acid derivative keeps a stable connection between the linked 
moieties.[1] 
The good nucleophilic properties of the thiol group facilitate modifications by substitution. Alkyl 
halides and haloacetamides readily undergo substitution reactions with thiols (Figure 4b). Iodo 
compounds (and especially iodoacetamides) are preferred due to their higher reaction rates 
compared to other halides. The drawback of these iodocompounds is their sensitivity to light, 
which generates iodine (I2) that interacts with biomolecules. [1] 
Another approach for thiol modifications is the formation of activated disulfides (Figure 4c). This 
procedure is selective for thiols and does not show hydrolytic difficulties. For the activation of a 
thiol group, pyridine disulfides or the Ellman's reagent (Figure 4d) are commonly employed. The 
mixed, activated disulfide undergoes a second reaction with a sulfur nucleophile to form the 











































byproducts, which are both detectable in the UV, allowing measurement and quantification of the 
modification progress. However, this conjugation technique is sensitive to reduction, which 
renders the connection impractical (or in some applications desirable) for in vivo experiments due 
to high intracellular reducing agent concentrations (e.g. glutathione).[1] 
Bioconjugate Reactions with Hydroxyls 
 
Figure 5. Bioconjugation of vicinal diols with boronic acids. The boronic acids are in equilibrium in aqueous medium with 
the corrsponding boronates. 
Aromatic and aliphatic hydroxy groups are much less reactive in aqueous medium than amine or 
thiol moieties. In some of the presented reactions (e. g. ester formation with succinimidyl active 
esters), hydroxy groups may generate side products, although, only in minor quantities. Selective 
hydroxy modifications are more difficult compared to amines and thiols. Boronic acids provide a 
possibility to reversibly modify diols (Figure 5). This technique has been employed in 
carbohydrate chemistry for modification of aliphatic diols[9–11] or sensing catechols such as 
dopamine.[12,13] Phenylboronic acid derivatives may be incorporated into proteins, other 
biomolecules, gels or a solid support to enable a connection with carbohydrates or other diol-
containing compounds.[1] 
Bioconjugate Reactions with Click Chemistry 
In 2001, Barry Sharpless and co-workers defined the concept of click chemistry for certain 
reaction types.[14] They defined the prerequisite of such reactions to be modular, wide in scope, 
stereospecific, with simple reaction conditions, to give high yields and inoffensive byproducts. 
Furthermore, the starting materials and reagents must be readily available, the solvent must be 
benign (such as water) and the products must be easily isolated by simple, non-chromatographic 
methods. These characteristics are typically only achieved if the reactions display a high 
thermodynamic driving force, usually greater than 20 kcal mol-1. The reaction classes that they 
defined to fulfill these conditions include cycloadditions (1,3-dipolar cycloadditions and Diels-
Alder reactions), nucleophilic substitution chemistry (ring-opening of strained heterocycles such 
as epoxides, aziridines and episulfonium ions), non-aldol type carbonyl chemistry (urea 
formation, oxime ethers, hydrazones and amides) and additions to carbon-carbon multiple bonds 
(epoxidation, dihydroxylation, aziridination, sulfenyl halide addition and Michael additions of 
nucleophiles). From this definition, several of the previously discussed reactions (oxime 
condensation, hydrazone formation, (thio)urea formation with iso(thio)cyanates, Michael addition 
of sulfur nucleophiles to maleimides) fulfill the criteria to be "click" reactions.  
Due to its widespread use, the copper(I)-catalyzed azide-alkyne cycloaddition reaction (CuAAC) 
has become known simply as "the click reaction" over the last couple of years.[15] For this reason, 
other reactions that fulfill the criteria put forth by Sharpless are depicted as click-type reactions 
and the term click reaction is now reserved for the CuAAC. In the following sections, we discuss 
three frequently used click-type reactions, the CuAAC, the strain-promoted [3+2] azide-alkyne 



















Figure 6. a) General scheme of the copper-catalyzed azide-alkyne click reaction. b) Representative example of a click 
reaction with in-situ generated copper(I) catalyst.[16] 
1,3-Dipolar cycloaddition reactions, which describe the formation of cyclic products from a 1,3-
dipole and a multiple bond system, the dipolarophile, have been known for decades and have 
seen extensive use in organic synthesis. In 1963, Huisgen published reports about the formation 
and mechanism of 1,3-dipolar cycloadditions[17] along with the kinetics of these reactions.[18] The 
most frequently used dipolarophiles are alkenes and alkynes, however, carbonyl compounds can 
also undergo 1,3-dipolar cycloaddition reactions. There are many different dipole molecules such 
as azomethine ylides, nitrones, diazoalkanes and azides. The most popular 1,3-dipolar 
cycloaddition is by far the reaction between an azide and an alkyne. This transformation requires 
high temperatures and yields a mixture of 1,4- and 1,5-disubstituted 1,2,3-triazoles. In 2002, two 
groups (Sharpless and Meldal) reported the selective formation of 1,4-disubstituted 1,2,3-
triazoles at ambient temperature with the use of a copper(I) catalyst (Figure 6).[16,19] The click 
reaction has since then been extensively applied to the development of new small 
molecules[15,20], but also to bioconjugation reactions with proteins[21], carbohydrates[22], 
oligonucleotides[23] and even living cells.[24] Azides and alkynes are functional moieties that are 
easily accessible, versatile and show high stability towards non-reducing environments with very 
high selectivity. However, the employed copper(I) catalysts are sensitive to oxidation and they 
can also generate reactive oxygen species from the copper-catalyzed reduction of oxygen (O2) 
by ascorbate.[24,25] These reactive oxygen species can potentially damage biomolecules, leading 
to loss of biological activity. Furthermore, the oxidized ascorbic acid (dehydroascorbate) 
potentially induces damage by electrophilic interactions with lysine, arginine and cysteine 
sidechains.[25] This renders the copper catalysts toxic to most living cells. Special copper ligands 
were developed to increase the reaction rates of the click chemistry and to minimize the oxidative 
damage of the biomolecules.[24,26,27] 
 
Figure 7. Strain-promoted azide-alkyne cycloaddition reaction. a) General reaction scheme of a strained cyclooctyne 
and an azide. b) Several examples of strained cyclooctynes. DBCO = Dibenzocyclooctyne-amine, BCN = 
Bicyclononyne, DIFO3 = Difluorocyclooctyne-3. 
An alternative click-type reaction was rediscovered in 2004 by the Bertozzi group.[28] The reaction 
between strained alkynes (usually cyclooctynes or larger rings) and azides had been reported in 
the 1960's, but were forgotten for a long time (Figure 7a). Bertozzi et al. reported the use of 
modified cyclooctynes for strain-promoted [3+2] alkyne-azide cycloadditions (SPAAC) for the 
selective modification of biomolecules and living cells.[28] This reaction has become popular due 
to the lack of potentially harmful catalysts.[29] Series of novel cyclooctynes were synthesized 
(Figure 7b shows a few examples of commonly employed cyclooctynes) to increase the reaction 
rates (up to 0.9 M-1s-1) so that the process became useful for low concentration modifications of 
biomolecules under physiological conditions.[29] The driving force of this transformation was found 
to be the highly favorable enthalpic release of ring-strain (nearly 18 kcal mol-1).[28] This technique 
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modifications within single cells.[31] Nevertheless, the SPAAC also possesses several 
disadvantages, such as lack of regiospecificity for the reaction product, which yields triazole 
mixtures. Aqueous solubility of the strained alkynes may also be a concern, which may demand 
the use of organic solvents to ensure the conjugation reaction can proceed. The reduced stability 
of certain alkyne reactants may cause problems, however, several stable cyclooctynes have 
been developed. The size of the employed strained alkynes for the bioorthogonal connections 
should also be considered in respect to the physicochemical properties of the alkyne reactants.[32] 
 
Figure 8. a) General scheme for the inverse electron-demand Diels-Alder reaction. b) The fastest inverse electron-
demand Diels-Alder reaction known for bioconjugation applications.[33] 
Another type of cycloaddition is the Diels-Alder reaction of tetrazines with different dienophiles in 
an inverse electron-demand assembly. This means that, in contrast to classic Diels-Alder 
reactions, the diene (tetrazine) is electron-poor and the dienophile is the electron-rich species.[34] 
The reaction of tetrazines with different dienophiles, such as cyclopropenes, cyclooctynes and 
terminal alkenes has been described, however, the reaction with trans-cyclooctene dienophiles 
attracts the most interest for bioconjugation reactions.[33] The mechanism for this reaction 
proceeds via a [4+2] cycloaddition step to form a strained, bicyclic intermediate, which undergoes 
a Retro-Diels-Alder reaction to generate one molecule of nitrogen (N2) and the 4,5-
dihdropyridazine intermediate, which usually isomerises to the 1,4-dihydropyridazine product 
(Figure 8a).[35] In certain cases, the 1,4-dihydropyridazine is further oxidized to the corresponding 
pyridazine.[34] The inverse electron-demand Diels-Alder reaction (IEDDA) is the fastest 
bioconjugation method to date. Optimization of the tetrazine and trans-cyclooctene structures led 
to the development of a conjugation reaction with a second order rate constant of  
3'300'000 M-1s-1 (Figure 8b).[33] This reaction is more than 10'000 times faster than the best 
CuAAC reactions.[34] Along with the high selectivity and the mild conditions of the IEDDA, it 
represents the almost perfect reaction type for demanding biological applications. However, the 
stability of the trans-cyclooctene[36] and the tetrazine[37] under certain conditions is a limitation that 
needs to be addressed. Furthermore, the complicated synthesis of the two coupling partners is a 
major limitation of this procedure.[34] The IEDDA has proven valuable for many applications in 
biomedical research including cell labeling, in vivo imaging or antibody modifications.[38] 
Next to the presented bioconjugation methods, there are many other chemical processes that are 
potentially useful for bioconjugation applications.[7,39] Suzuki-Miyaura cross coupling was used for 
the modification of proteins and oligonucleotides,[40–42] selective peptide modifications by amide 
couplings with potassium acyltrifluoroborates (KAT) were performed[43] and even multicomponent 
reactions, such as the Passerini or Ugi reactions, were employed.[44] 
Reaction Rates 
There are several criteria that must be fulfilled for a chemical reaction to be useful in 
bioconjugation. First, the chemoselectivity of the reaction is important to avoid undesired side 
reactions. The stability and availability of the reagents must be considered, as well as the size 
and solubility of the newly introduced connection. The reaction conditions must also be 
compatible with the biomolecules. Toxic reactants or catalysts may be used for in vitro coupling 
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are not possible with toxic compounds. A 1:1 stoichiometry is often required for the labeling of 
large biomolecules at high dilution to achieve the required chemoselectivity and to avoid 
undesired side reactions. For that purpose, the employed reaction needs to proceed efficiently at 
very low concentrations, which requires a high reaction rate constant.[45] 
Table 1. Reaction rates of different bioconjugation methods. The values were adapted from literature reports.[45,46] 








Condensation[a]   1.3 x 10
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- stability of reagents 
- synthetically complex building 
blocks 
KAT   
22 - acidic additive necessary for faster reaction rates 
[a] uncatalyzed reaction. 
A list of different bioconjugation reactions with the highest rate constants known to date and 
some remarks concerning the reagents and reaction conditions are depicted in Table 1. The 
majority of the presented reactions show second order rate constants between 1 and 1000 M-1s-1. 
Exceptions are the uncatalyzed oxime condensation that is three magnitudes slower and the 
IEDDA, which is up to three magnitudes faster than the other listed transformations. Depending 
on the nature of the bioconjugation reaction and the coupling partners, one should choose the 
best fitting method in terms of reagents, toxicity, selectivity and reaction speed. For example, live 
imaging of cell processes requires extremely high reaction rate constants that are only provided 
by the IEDDA, whereas the unspecific in vitro labeling of a simple protein with a fluorophore is 
perfectly achieved by thiol-maleimide Michael addition or an isothiocyanate modification of the 
lysine sidechains. 
Cross-Linking Strategies 
As we discussed in the previous sections, there are many different functional groups that have 
been employed for bioconjugation assays. However, biomolecules usually display just a few 
reactive moieties such as amines, thiols, carboxylic acids and alcohol groups. For example, 
cycloadditions require special functional groups such as azides, alkynes, dienes or tetrazines. 
Such moieties need to be chemically introduced into the biomolecule. In the simplest 
implementation, a biomolecule label (e.g. a fluorophore) is directly introduced by the reaction with 




























artificial functions, change certain groups to another functionality or install a chemical spacer. 
Chemical functional linkers are very powerful tools to achieve this task. The cross-linking of two 
biomolecules is often just possible with the incorporation of a functionalized spacing unit. 
Synthetic spacers may also be required to maintain enzyme activity after modification with certain 
functionalities or for biomolecule immobilization techniques. 
 
Figure 9. a) Covalent linkage of two amines with disuccinimidyl glutarate. b) Covalent linkage of an amine with a thiol 
compound using an N-hydroxysuccinimide/maleimide linker. c) Functional groups interconversion examples. From left to 
right: carboxylic acid to amine, carboxylic acid to thiol, amine to carboxylic acid. Further functional group 
interconversions are possible with other reagents. d) A few reagent examples of the introduction of cycloaddition 
functional groups into biomolecules. 
Figure 9a and Figure 9b show examples of the crosslinking of molecules with either the same or 
different functional groups. Many different linkers have been used for the construction of such 
crosslinks with the naturally occurring reactive groups in biomolecules.[1] Figure 9c shows a few 
examples of the interconversion of functional groups with the shortest possible handle. 
Interconversions of carboxylic acids to amines or thiols as well as amines to carboxylic acids or 
thiols are achieved within a few simple reaction steps.[1] For the more elaborate cycloaddition 
reactions, the functional groups always need to be incorporated into the biomolecule either by 
functional group modifications (usually amines and thiols) or during the synthetic/enzymatic 
production of the biomolecule (Figure 9d).[3,32,34] 
Another frequently used linking strategy is to take advantage of the biotin and avidin  
(or streptavidin) interaction. Biotin and streptavidin undergo the strongest non-covalent biological 
connection known (KD= 4 x 10-14 M).[47] Immobilization of streptavidin on a solid support is 
commonly employed to immobilize other biomolecules on a solid support or to selectively "fish 



















































































1.2 α-Effect Nucleophile Condensations 
The reactions of carbonyl groups with different nucleophiles have been widely used in organic 
chemistry. In 1964, Jencks reported on this class of transformations and showed that the reaction 
with amine nucleophiles proceeds over a tetrahedral hemiaminal intermediate, which further 
undergoes a dehydration step to yield the final condensed product (Schiff bases).[48] The 
dehydration step was found to be rate-limiting and the whole process is reversible. Amine 
nucleophile condensations are generally slow under neutral conditions and require acid catalysis.  
Nucleophiles with an adjacent heteroatom with unshared electron pairs are called α-nucleophiles. 
Hydroxylamines, hydrazines, the hypochlorite ion and peroxy anions are examples of this type of 
influenced nucleophiles. Certain members of these nucleophiles show higher reactivity compared 
to their non-α-modified versions (e.g. hydroxylamines are more reactive than amines) and are 
therefore termed α-effect nucleophiles.[49] The special properties of these nucleophiles have been 
further investigated in earlier reports.[49,50] We limit the following discussion about α-effect 
nucleophile condensations to the reactions of hydroxylamines, hydrazines and hydrazides with 
carbonyl compounds (aldehydes and ketones). 
Despite the higher nucleophilicity of α-effect nucleophiles, condensation reactions with carbonyl 
compounds are still very slow at neutral conditions. Most attempts on increasing the reaction rate 
have focused on lowering the barrier of the dehydration step. The use of low pH values[51] and the 
addition of aniline derived catalysts to speed up the reactions have been reported.[52–54] Recent 
reports showed that aniline derivatives with ortho proton donors even further increased the 
reaction rates of oxime/hydrazone condensations.[55–57] Interestingly, the attachment of a 
phosphate group in ortho position to an aldehyde also increased the reaction rate with 
hydrazines/hydrazides by an order of magnitude.[58] In a very recent assay, it was also shown that 
the oxime condensation might be accelerated by the increase of the salt (NaCl) concentration in 
the reaction mixture. This is an important finding for modifications of biological systems, since 
increased salt concentrations are easily applicable, whereas complicated catalytic procedures or 
laboriously introduced accelerating groups can show incompatibilities with the biological system 




Figure 10. Overview of the most recent reports about (α-effect) amine nucleophile condensations under neutral 
conditions that do not make use of catalysts or ortho proton-donating groups. a) Ortho-dialdehydes showed to increase 
oxime formation rates due to the formation of a bis-hemiaminal intermediate.[60] b) Gois et al. reported an increased 
stability of imines with ortho-boronate carbonyl compounds.[61] c) Ketone boronic acids displayed highly increased 
reaction rates for oxime and hydrazone formations in a reversible manner.[62] d) Boronic acid aldehydes were found to 
facilitate oxime condensations under neutral conditions with high rate constants.[63] e) Boronic acid carbonyl compounds 
formed a stable, irreversible, aromatic product with hydrazines in a two steps process.[64,65] f) Hydrazides underwent 
condensation with aldehydes to rapidly form a reversible, heterocyclic boron product.[66] BIQ = 4,3-borazaroisoquinoline. 
Several methodologies to improve the formation of imine-type condensations without the need for 
catalysts or proton donating groups have been shown. Our group reported the formation of stable 
oximes with the use of ortho-dialdehydes under neutral conditions (Figure 10a). The intermediate 
bis-hemiaminal structure formed very rapidly with rate constants of approximately 500 M-1s-1. 
While the addition step was very quick, the subsequent dehydration step to form the actual oxime 
was found to be slow (k2 = 1.2 * 10-5 s-1), about two to three orders of magnitude slower than 
typical oxime condensations under equal conditions. Along with the very large overall equilibrium 
constant (>107 M-1), this implied an energetically very stable bis-hemiaminal intermediate. For 
that reason, the nucleophile addition step was found to be practically irreversible, which also 
illustrates a successful bioconjugation. DNA labeling experiments and peptide hydroxylamine test 
reactions with common biological additives rendered this reaction suitable for more advanced 
bioorthogonal transformations.[60]  
In 2012, the Gois group published a procedure for the formation of hydrolytically stable imine 
formations with the potential for selective reversibility. They discovered that  
2-carbonylphenylboronic acids underwent rapid imine formation with primary amines under 
neutral conditions, while the generated iminoboronates showed exceptionally high stability 
towards hydrolysis (Figure 10b). They concluded that an interaction between the imine nitrogen 
and the boron atom is responsible for this high stability. Upon the addition of dopamine, fructose 
or glutathione, compounds that are known to interfere with boronic acids, the hydrolysis rate of 
the iminoboronates highly increased, which supported this assumption.[61] 
Based on these results, our group published almost simultaneously with the Gao group reports 
about oxime and hydrazone formations with 2-carbonylphenylboronic acids. The Gao group 
investigated oxime and hydrazone formations with ketone boronic acids, whereas our group 
focused on the formation of oximes with boronic acid aldehydes (Figure 10c and d).[62,63] While 
both carbonyl functional groups underwent rapid imine-type conjugations with rate constants 
>103 M-1s-1, the ketone Schiff base compounds were highly susceptible to hydrolysis. Aldehyde 
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the addition of a different hydroxylamine or boronic acid aldehyde in excess. Our group also 
successfully showed that common biological additives like glutathione, sucrose, lysozyme and 
human serum did not interfere with Schiff base formation. Only the oxidation of the phenylboronic 
acid to a phenol in human serum was observed as a side reaction, however, the oxime formation 
was determined to be faster than the oxidation process, which ensured a successful conjugation. 
Lysozyme, which was modified with boronic acid aldehydes in previous reports,[61] remained 
unaffected in this assay, showing that hydroxylamines outcompete any nucleophilic amino acid 
moieties.[63] 
In a further report, we showed that the mechanism for boron-assisted oxime formation most likely 
proceeds over the generation of a five-membered hemiaminal boronate. This intermediate 
strongly facilitates the rate limiting dehydration step, due to the elimination of a boronate instead 
of a water molecule. We supported this mechanistic assumption by substrate variation; changing 
the position of the boronic acid from the aldehyde moiety to the hydroxylamine coupling partner 
did not show any acceleration of the condensation compared to uncatalyzed oxime 
condensations under neutral conditions. Additionally, the use of coordinatively saturated 
boronates (trifluoroboronates and MIDA esters) showed a diminished reaction rate enhancement 
in comparison to free boronic acids. We also showed that ketoximes were more susceptible to 
exchange reactions than aldoximes. An X-ray structure of an aldoxime showed no iminoboronate 
formation, which explained the higher hydrolytic stability compared to ketoximes. The latter are 
known to form iminoboronate structures, which act as an activation for hydrolysis.[64]  
The Bane lab and our group published reports about boron-assisted hydrazone formation that 
leads to the generation of an irreversible 4,3-borazaroisoquinoline (BIQ) product (Figure 10e). 
The initial hydrazone formation between hydrazines and ortho-boronate carbonyl compounds 
was found to be very fast (>103 M-1s-1). However, the hydrazone underwent a secondary reaction, 
forming the aromatic, heterocyclic BIQ. This second process proceeded more slowly  
(10-3 - 10-2 s-1), but formed a stable product. We showed that the fused aromatic ring system 
could be used to generate fluorescent molecules by the introduction of electron-donating 
substituents.[64] The Bane lab showed the usefulness of this methodology in orthogonal protein 
labeling.[65] BIQs and their preparation are known since the 1960s,[67,68] but were forgotten until 
the 1990's, when Groziak et al. confirmed the structure of the BIQs and extended the scope of 
this compound class.[69,70] BIQs have been considered as unique pharmacophores, and indeed 
were shown to have growth inhibitory effects against different types of bacteria.[71–74] 
In 2017, the Bane and Gao groups reported the formation of heterocyclic structures upon the 
synthesis of hydrazones with acyl hydrazides (Figure 10f). Unlike hydrazines, these acyl 
hydrazides did not form a stable BIQ, because the B-N bond formation in the heterocyclic 
structure was reversible. Semicarbazides, on the contrary, formed stable compounds and upon 
the introduction of an amine substituent in α-position to a hydrazide, a tricyclic structure was 
generated that was also stable enough for protein modifications.[66,75] 
In summary, iminoboronate, acyl hydrazone and ketoxime formations are rapidly reversible, 
which enables dynamic, covalent modification applications. Aldoxime formation is slowly 
reversible and therefore perfectly suited for targeted slow release and exchange assays. A 
stable, irreversible linkage is obtained upon the treatment of carbonyl boronic acids with 
hydrazines that form stable, heteroaromatic BIQs in a two steps process.[57,64,76] 
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1.3 Fluorescent Molecules in Bioconjugation 
 
Figure 11. Overview of the most important fluorophore classes that are regularly used in chemical labeling of 
biomolecules. BODIPY = Boron-dipyrromethene. 
Fluorophores are one of the most important classes of small molecules for bio-imaging 
techniques. Due to the high sensitivity and selectivity, fast and simple data acquisition, multi-
parametric nature and the spatial and temporal resolution, fluorescent tagging is the method of 
choice for biomolecule labeling and observation of dynamic cellular processes. In contrast with 
radioactivity-based techniques, fluorescence is non-invasive, which makes it safe to use with 
living cells. In principle, fluorescence detection can be achieved down to one single fluorescent 
molecule, owing to its high sensitivity.[77] The biggest problem in biological systems is the intrinsic 
fluorescence of naturally occurring molecules, such as tryptophan, NADH or flavins. For that 
purpose, many different fluorophores have been developed that display different absorption and 
emission spectra. Figure 11 shows the structures of the most important fluorophore classes that 
have been employed for bioorthogonal fluorescence labeling.[78]  
Another advantage of fluorescence imaging over other labeling methods is the potential 
modulation of the signal. A non-fluorescent or only weakly fluorescent molecule can be designed 
in order to increase its fluorescence upon structural alterations or by environmental changes  
(e.g. metal complexation or pH changes).[79] Such structures are called turn-on fluorophores.[80] In 
an ideal case, the turn-on fluorophore displays no fluorescence until a specific modification 
occurs. However, a certain amount of fluorescence is observed with the parent molecule. 
Nevertheless, if the reaction gives a significant signal increase and a shift in emission wavelength 
(for biological applications a red shift is desired due to the biomolecules' intrinsic fluorescence in 
the blue-green), the background signal is not problematic. Boron-containing fluorophores are very 
interesting for the development of such turn-on fluorophores. BODIPY is by far the most widely 
applied boron-based fluorophore and it has been shown that turn-on fluorophores may be 
generated using the BODIPY core structure.[81,82] Other boron-containing heterocycles were 
found to act as fluorophores as well.[83] We and the Gao group published reports about the 




























1.4 Project Description 
After reporting the fast formation of oximes with adjacent boronic acid substituents, we 
emphasized the evaluation of the hydrolytic stability of aldoximes, since ketoximes showed a 
rather low resistance towards hydrolysis.[62] Furthermore, several reversibility assays gave an 
idea about the kinetics of the back reaction and a direct comparison about the preference 
between aldoximes and ketoximes. We also investigated the mechanism of the boron-assisted 
oxime formations by repositioning of the boronic acid in the oxime condensation system and 
masking of the boronic acid by different coordinative saturation methods. This methodology was 
applied to the fluorescent labeling of proteins. 
Another focus was the evaluation of boron-assisted condensation reactions between hydrazines 
and carbonyl boronic acids. The formation of the hydrazone and the subsequent intramolecular 
cyclization reaction were of particular interest along with potential influences on the reaction. For 
the first time, we showed the time-resolved observation of the BIQ formation with NMR 
spectroscopy. We also synthesized a series of BIQs to develop a novel turn-on fluorophore that 
might be used for bioorthogonal fluorescent labeling. 
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2. Boron-Assisted Oxime Condensations 
2.1 Characteristics of Boron-Assisted Oxime Condensations 
Stability and Reversibility 
 
Figure 12. NMR stability measurements of 1-1 at 100 µM concentration over four days. The oxime (black) and benzylic 
(orange) protons are highlighted. The used internal standard was 3-(trimethylsilyl)-2,2',3,3'-tetradeuteropropionic acid 
(TMSP-d4). 
Measurements of the hydrolytic stability of aldoxime 1-1 at a 100 µM concentration in pH 7.2 
phosphate buffer revealed a high resistance against hydrolysis (Figure 12). Over the course of 
three days, we found integration differences of less than 5%, which lies within the margin of the 
integration accuracy. After four days, we found an integration reduction of 15% compared to the 
initial measurement, which indicated a slow hydrolysis of the product (see Figure 23 for detailed 























Figure 13. a) NMR reversibility assay between aldoxime 1-1 and a five-fold excess of methylhydroxylamine (MeONH2). 
The conversion to the new oxime proton Hb is displayed. b) Time-course NMR assay for the reversibility of aldoxime 1-1 
with a five-fold excess of boronic acid aldehyde 1-2. The oxime and aldehyde proton changes are displayed. The assays 
were conducted with 10 mM KPi, pH 7.2 in D2O:CD3CN 4:1. 
To find evidence for the reversibility of oxime formation and to determine the aldoxime hydrolysis 
rate, we conducted two time-course NMR assays, in which we directly observed the generation of 
new aldoxime products. In the first assay (Figure 13a), we treated 1-1 with a five-fold excess of 
methylhydroxylamine (MeONH2). The formation of the new oxime species was clearly observed 
by NMR and we found that equilibrium was established after 10-19 hours. For a final proof of the 
oxime reversibility, we replaced methylhydroxylamine by boronic acid aldehyde 1-2 and again 
observed the formation of a new oxime species with equilibrium established after 10-12 hours. 
This second experiment was necessary to be able to distinguish between hydrolysis and direct 
nucleophilic attack of methylhydroxylamine at the aldoxime 1-1. From these results, we found that 
the oxime formation rate constant must be much larger than the rate constant for aldoxime 
hydrolysis (k1>>k-1). For that reason, we could take the formation of the new product as a direct 
measure of the aldoxime hydrolysis rate. Intermediate hydrolysis products could not be observed 
in any of these assays. The rate constant for this particular aldoxime hydrolysis was calculated to 
be 4.2 ± 0.4 x 10-5 s-1. From the rate constant of oxime formation (11.1 ± 0.3 x 103 M-1s-1), we 
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Figure 14. Time-course NMR assay for the determination of the ketoxime reversibility in the presence of a boronic acid 
aldehyde (2-formylphenylboronic acid, 2-FPBA in this case). 
In earlier reports, it was shown that ketone hydrazones showed fast reversibility in aqueous 
medium.[62] To explore the reversibility of ketoximes in comparison to aldoximes, we prepared 
ketoxime 1-3 and treated it with a five-fold excess of 2-formylphenylboronic acid (2-FPBA). Time-
course NMR analysis revealed that ketoxime hydrolysis and subsequent aldoxime formation 
rapidly occurred (Figure 14). After 15 minutes, about 60% of the ketoxime had been transformed 
to aldoxime 1-1 and after 75 minutes, compound 1-1 was the only detectable oxime species. We 
concluded that the ketoxime nitrogen is more prone to binding to the boron and formation of an 
iminoboronate species. Unlike non-boron containing imines, iminoboronates were reported to be 
activated for hydrolysis.[61] An X-ray structure of our model compound 1-1 revealed no 
iminoboronate interaction in the ground state.[64] We supposed that the energetic reason for this 
difference is related to the hypothesis that the nitrogen basicity of the Schiff base determines the 
stability of oximes and hydrazones.[85] The additional σ-donation form the ketoxime methyl 
substituent should render its nitrogen more basic and therefore more susceptible to protonation 
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Figure 15. Experiments to give insight into the mechanism of oxime formation. All reactions were conducted in pH 7.2 
phosphate buffer at 100 µM (a, c and d) and 1 mM (b) concentrations. a) Putative mechanism of the boron-assisted 
oxime formation. Reaction rates were adapted from our first publication of that topic.[63] b) Prove of the importance of the 
five-membered ring intermediate. An 8-membered intermediate did not promote an efficient coupling. c) Prove of the 
importance for a free boron coordination site. Coordination saturation with trifluoroborates reduces the oxime 
condensation rate. d) MIDA-boronates also slow down the oxime condensation. The reaction supposedly proceeds over 
the same mechanism as for trifluoroborates. 2-FPBA = 2-formylphenylboronic acid, 2-FPTFB = 2-formylphenyl-
trifluoroborate. 
From the initial reports of our group about boron-accelerated oxime condensations, we know that 
the positioning of the boronic acid plays a very important role, thus only ortho-boronic acid 
aldehydes/ketones show increased reaction rates compared to uncatalyzed oxime formations 
under neutral conditions.[63] We hypothesized that the transformation of the aldehyde to the oxime 
proceeds over a five-membered, cyclic boron-hemiaminal intermediate (1-1a in Figure 15a). The 
rate limiting dehydration step further occurs over the elimination of a boronate rather than a water 
molecule. This process should be far more facile since the protonation of the cyclic boron-
hemiaminal intermediate should take place at around neutral pH.[86–88] The shown mechanism 
was also supported by the report about iminoboronate formation of carbonyl boronic acids with 
primary amine sidechains in proteins.[61] A potential interaction of the hemiaminal (1-1a) nitrogen 
with the boron atom could be excluded because such an interaction would lead to an activation of 
the hemiaminal towards hydrolysis (or the backreaction) due to iminoboronate formation.  
The importance of the cyclic intermediate was further proven by the reaction of 
aminooxybenzylboronic acid 1-4 with benzaldehyde (Figure 15b). In that case, the formation of 
the product would proceed over an 8-membered cyclic intermediate. In fact, we found a reaction 
rate that was comparable to oxime condensations at neutral pH without catalysis or substituent-
induced reaction rate enhancement. 
The role of the boronic acid was further elucidated by the use of boron moieties without a free 
coordination site (masking). 2-Formylphenyltrifluoroborate (2-FPTFB) and its corresponding 
MIDA ester (MIDA-boronate) were employed for that purpose (Figure 15c and d). The reaction 
rates were much faster than conventional oxime condensations, however, boronates with a free 
coordination site showed a 2000-4000 times higher reaction rate. We hypothesized that with 
coordinatively saturated boronates the rate-limiting step of the reaction was the hydrolysis of the 
trifluoroborate (or the MIDA ester) prior to the actual oxime condensation. Two reports showed 
that the hydrolysis of the first fluoride (or the B-N interaction in the MIDA-boronate) was rate-
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faster. The reported reaction rates for these processes fit our observations in the oxime forming 
reactions and supported our proposed mechanism.[89,90] 
2.2 Bioorthogonal Labeling of Immunoglobulin G 
 
Figure 16. a) Schematic representation of the IgG modification with a hydroxylamine handle and subsequent fluorescein 
labeling with boronic acid aldehyde 1-7. IgG is represented in cartoon and only one primary amine group is shown for 
simplicity. H = Heavy chain; L = Light chain; F = Full protein. Reaction conditions: a) 50 mM phosphate buffer, 1 mM 
EDTA, pH 7.5, DMSO, 35°C, 30 min. b) NH2OH hydrochloride, 50 mM phosphate buffer, 25 mM EDTA, pH 7.5, 36°C, 
2 h. c) 50 mM phosphate buffer, 1 mM EDTA, pH 7.5, DMSO, 37°C, 80 min. b) 10% SDS-PAGE analysis (200 V, 60 
min) of the IgG fluorescent labeling. Top: Fluorescein excitation; Bottom: Coomassie staining. L1: Protein standards, 
L2: IgG-Fluo, L3: IgG-Fluo reduced, L4: Control experiment 1, IgG-ONH2 + 2-FPBA + 1-7, L5: Control experiment 1, 
IgG-ONH2 + 2-FPBA + 1-7 reduced, L6: Control experiment 2, IgG + 1-7, L7: Control experiment 2, IgG + 1-7 reduced. 
2-FPBA = 2-formylphenylboronic acid. Protein reduction was achieved by treatment with 2-mercaptoethanol (BME). 
Protein modifications are one of the most important tasks in biochemical research. Especially the 
fluorescent labeling of proteins opens up the possibility to directly observe them in cell assays or 
in complex mixtures. The introduction of unique handles creates the desired selectivity.  
IgG is the most abundant class of antibodies in human serum. There are four different subclasses 
of IgG (IgG1-IgG4), of which IgG1 and IgG2 are the most commonly found variants.[91] A 
schematic representation of IgG is depicted in Figure 16a. It has a molecular weight of 146 kD 
(except IgG3 with 170 kD) and consists of two heavy chains (H, ~ 55 kD) and two light chains  
(L, ~25 kD) that are assembled in the typical Y-shape of antibodies.[92] Electrostatic interactions 
and disulfide bridges hold the four chains together. IgG interacts with different antigen classes 
(soluble protein antigens, membrane proteins, bacterial polysaccharides, allergens) and triggers 
the immune response.[91] 
To demonstrate the value of our boron-assisted oxime formation technique, we labeled 
immunoglobulin G (IgG) with the fluorescein-boronic acid aldehyde 1-7. IgG contains about 90 
lysine residues, of which up to 30 are accessible for chemical modification.[93] We used the 
activated succinimidyl ester 1-6 to randomly generate the corresponding amides with the 
accessible primary amines (Figure 16a). The acetone-oxime protecting group was selectively 
removed by the addition of a large excess of hydroxylamine hydrochloride. Treatment of the 


































































desired labeling (Figure 16b, lanes 2 and 3). To exclude random binding of the dye to the 
protein, we ran two control experiments. In a first assay, we treated the hydroxylamine antibody 
(IgG-ONH2) with a large excess of 2-FPBA to selectively block all hydroxylamines (and potential 
remaining amines). Despite treatment with an excess of the fluorescent dye 1-7 for 1 h, we only 
found weakly fluorescent protein bands (Figure 16b, lanes 4 and 5). The remaining fluorescence 
most likely arose from the slow reversibility of the oxime linkage (compare Figure 13b). The 
second control experiment used unmodified IgG, which was treated with dye 1-7. Polyacrylamide 
gel analysis showed very weakly fluorescent bands (Figure 16b, lanes 6 and 7), which most 
likely arose from iminoboronate formation with the accessible lysine residues. As described in 
Chapter 1.2, iminoboronates are relatively unstable modifications. Most of the fluorescent label 
was removed during gel analysis. 
In summary, we showed the successful modification of the IgG antibody with a hydroxylamine 
handle and subsequent fluorescent labeling. The fluorescein compound was selectively attached 
via oxime formation. Due to the reversible nature of the oxime linkage, dynamic covalent 
modifications are possible, while undesired background modifications remain low. 
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3. Boron-Assisted Hydrazone and BIQ Formation 
3.1 Characteristics of Boron-Assisted Hydrazone and BIQ Formation 
After the successful elucidation of the boron-assisted oxime formation characteristics and the 
application in antibody labeling, we turned our attention to boron-assisted hydrazone formations. 
Despite hydrazones show a higher susceptibility to hydrolysis than oximes,[85] we considered the 
boron-assisted hydrazone formation a valuable approach for the development of an irreversible 
bioconjugation. Several reports from the 1960's showed that hydrazones with a boronic acid 
substituent in ortho position undergo an intramolecular cyclization reaction to 4,3-borazaro-
isoquinolines (BIQ).[67,68] The synthesis and the exact BIQ structure had been shown in several 
publications,[69,70,73,74] however, applications in bioconjugation had not been reported up to that 
point. Shortly before our own publication, the Bane group reported their analysis of BIQ formation 
with reaction kinetics and applicability in protein labeling.[65] We were pleased to find that our own 
results on the kinetic parameters fit well with the findings of the Bane lab. We included direct 
observation of BIQ formation by 1H NMR analysis, showing that the cyclization to BIQ was 
irreversible. The influence of pH and additives on the reaction rate was also investigated. 
BIQ Formation and Reversibility 
The first step in the synthesis of a BIQ is the formation of a hydrazone with an adjacent boronic 
acid. We think that the mechanism for this condensation proceeds through the same pathway as 
for boron-mediated oxime formations (Figure 15a). Unlike oximes, hydrazones undergo a 
second, intramolecular cyclization reaction to form the heteroaromatic BIQ. Figure 17 shows a 
reaction example between aldehyde 1-2 and phenylhydrazine to form the BIQ product 1-8. We 
found that hydrazone formation proceeded rapidly at low micromolar concentrations with 
subsequent intramolecular cyclization to the BIQ product. 
 
Figure 17. Two steps formation of BIQs. The hydrazone condensation proceeds rapidly, whereas the cyclization to the 
aromatic BIQ is a slow, intramolecular process. The rate constants were adapted from the kinetic UV measurements 
(Table 2). 
Although BIQ formation is observable by UV spectroscopy and LC-MS analysis, we decided to 
use a time-course NMR assay to show the formation of the BIQ. In Figure 18a, the generation of 
a new proton signal (Hb) right next to the hydrazone proton Ha was observed. Due to the high 
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Figure 18. a) BIQ formation observed by time-course NMR analysis. The detection of the aldehyde and the hydrazine 
starting materials was not possible due to the high reaction rate in hydrazone formation. A complete conversion from the 
hydrazone proton Ha to the BIQ proton Hb was detected. b) NMR reversibility assay of BIQ 1-8. A five-fold excess of  
2-FPBA was added to BIQ 1-8 to potentially form the new BIQ 1-9. 
The high stability of BIQs towards hydrolysis had been shown in earlier reports,[65,67,68] however, 
to the best of our knowledge, a final piece of evidence of the irreversibility of BIQ formation had 
not been shown. For that purpose, we treated BIQ 1-8 with a five-fold excess of 2-FPBA and 
recorded several 1H NMR spectra after various time points (Figure 18b). We observed no 
changes within 24 hours, which led us to the conclusion that the formation of BIQ is irreversible 
under the applied aqueous conditions. An explanation for the high stability is found in the 
aromatic structure of the BIQ, which stabilizes the system and renders the former hydrazone 
carbon atom unsusceptible to the nucleophilic attack of a water molecule. 
Reaction Kinetics, Influence of pH and Biological Additives 
The formation and the structural confirmation of BIQs was shown in several reports (see previous 
section), however, the analysis of the reaction rates for BIQ formation were still unknown until the 
report published by the Bane group.[65] We were pleased to find that their reaction rate 
determinations showed similar results to our own. pH and biological additives were found to 
influence the rate of BIQ formation (Table 2). The time resolution of UV analysis for the formation 
of hydrazone 1-8a was not high enough to enable an accurate determination of the rate constant. 
However, a lower bound of k1 >103 M-1s-1 could be established from the first few seconds of the 
hydrazone UV measurement. The cyclization to the BIQ proceeded much slower and could be 
measured by UV absorption at 340 nm at 10 µM in both starting materials (Figure 19). We chose 
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and the low absorption of the BIQ. In fact, we used the decrease in hydrazone absorption as an 
indirect measurement of the BIQ formation. For accurate rate constant determination, we first 
measured the extinction coefficient ε of the hydrazone intermediate 1-8a, which is also pH 
dependent. We ran these measurements with a 50% excess of hydrazine at a known aldehyde 
concentration. The determined maximum absorption was considered as the point of complete 
conversion to the hydrazone 1-8a. Although BIQ formation immediately starts after mixing the two 
starting materials, the fraction of BIQ at the highest absorption point was negligible due to the 
much higher hydrazone formation rate. 
 
Figure 19. Time-course UV measurements (340 nm) of the BIQ formation. All assays were performed at a 10 µM 
concentration with 1:1 stoichiometry. a) Measurements of the BIQ formation under different pH values. Lowered pH 
increases the BIQ formation rate, increased pH reduces the BIQ formation rate. b) Influence of human serum (HS) and 
glutathione (GSH) on the BIQ reaction rate under neutral conditions. Both additives decreased the BIQ formation 
kinetics. 
As shown in Figure 19 and Table 2, the pH of the buffer influenced the formation rate of the BIQ. 
While the rate constant under neutral (pH 7.20) conditions was found to be 2.6 x 10-3 s-1, a 
decrease to pH 5.50 or an increase to pH 8.50 resulted in a 50% higher or 50% lower reaction 
rate, respectively. Biological additives, such as human serum (HS) and glutathione (GSH) also 
influenced the reaction kinetics. Both rate constants were determined to be in between the pH 
7.20 and pH 8.50 rates. In the case of human serum, a maximum amount of 10% could be 
added, because higher HS concentrations deteriorated the signal-to-noise ratio of the UV signal. 
Table 2. Summary of the measured BIQ reaction rates (k2) dependent on pH and additives. The reaction rates of the 
hydrazone formation (k1) could not be measured with high accuracy, but a lower bound of >103 M-1s-1 could be 
established from the measurement results. 





pH 5.50 ε = 11390 k2 = 3.95 x10-3 1.32 x 10-4 
pH 7.20 ε = 10006 k2 = 2.57 x 10-3 1.19 x 10-4 
pH 8.50 ε = 7810 k2 = 1.32 x 10-3 1.36 x 10-4 
HS (10%) ε = 10006 k2 = 1.68 x 10-3 1.04 x 10-4 
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Reversibility of Hydrazones 
In analogy to boron-assisted oxime condensations, we suspected that hydrazone formation was 
reversible as well. Gao et al. reported the reversibility of hydrazones from the reaction of  
2-acetylphenylboronic acid with acetylhydrazine.[62] The Bane lab also reported the formation of 
BIQ-like heterocycles in the reaction of hydrazides and ortho-carbonyl phenylboronic acids. 
These BIQ-type products formed dimers and showed reversibility dependent on the pH of the 
buffer.[66] We could confirm the reversibility of hydrazides by our own assays with benzhydrazide 
and different boronic acid aldehydes. However, the reversibility of hydrazones from the reaction 
of ortho-carbonyl substituted phenylboronic acids with a hydrazine had not been confirmed yet. 
 
Figure 20. a) UV measurement of BIQ 1-8 formation with the addition of an excess of benzylhydroxylamine after 
3.5 min. The reaction was carried out in 1:1 phosphate buffer/acetonitrile to slow down the BIQ formtion. b) UPLC-MS 
analysis of the reaction products after 13 h. 85% of the BIQ product was found, along with 15% of the corresponding 
oxime product. 
We designed an experiment, in which we could show that the intermediate hydrazone is 
reversible, however, BIQ formation was still found to be faster. Our model aldehyde 1-2 was 
treated with phenylhydrazine at 100 µM and after a few minutes when all of the aldehyde had 
been converted to the hydrazone, a three times excess of benzylhydroxylamine was added to the 
mixture (Figure 20a). Subsequent analysis of the reaction products revealed a BIQ:oxime ratio of 
17:3 (Figure 20b). This result showed that the BIQ formation was faster than the hydrazone 
hydrolysis with subsequent oxime formation and only a minor amount of the hydrazone was 
hydrolyzed during the reaction. In addition, the organic solvent ratio in this assay had to be 
increased to 50% acetonitrile in order to slow down BIQ formation by a factor of 25. Under 
conditions with a lower organic solvent ratio (10%), no oxime product was found at all. With this 
assay, we could demonstrate the reversibility of the intermediate hydrazone boronic acid, along 
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3.2 BIQ Syntheses and Fluorescence Property Analysis 
BIQ Synthesis 
 
Figure 21. a) BIQ series with a B-OH group. b) BIQ series with fused ring systems consisting of three six-membered 
and one five-membered ring. c) A BIQ with a fused ring system consisting of four six-membered rings. d) BIQ that was 
generated from an alkene boronic acid, containing an aliphatic ring. 
After the evaluation of the BIQ formation characteristics, we enlarged the scope of the reaction by 
introducing different substituents (Figure 21a). We synthesized a completely unsubstituted BIQ 
(1-9), as well as compounds with methyl (1-10), alkoxy (1-11 and 1-13) and nitro substituents  
(1-12 and 1-13). Performing the reaction with 2-hydroxyphenylhydrazine yielded a series of BIQs 
with fused ring systems and hydroxy, alkoxy and alkylamino substituents (1-14 - 1-19, Figure 
21b). The aromatic alcohol of the hydrazine coupling partner underwent a dehydration step with 
the boron-hydroxy group to form the five-membered heterocycle. The same process occurred 
with 2-carboxyphenylhydrazine, giving a BIQ with a fused ring system, composed of four six-
membered rings (1-20, Figure 21c). We also showed that the BIQ formation process was not 
restricted to arylboronic acid carbonyls, but an alkeneboronic acid with an aldehyde in the ortho-
position was also suitable for BIQ formation (1-21, Figure 21d). We also considered the 
synthesis of an indole-based BIQ, which we could obtain from the reaction of an indoleboronic 
acid aldehyde and 2-hydroxyphenylhydrazine. However, the compound turned out to be unstable 
in solution. Complete decomposition was observed after a few hours. Moreover, the indole BIQ 
formed dimers over the boron and oxygen atoms instead of the intramolecular cyclization with the 
aromatic hydroxyl group. 
The BIQ synthesis did not require any precautions in terms of inertness. The reaction proceeded 
best in a water:DMSO 4:1 mixture, even though some starting materials and 
intermediates/products were poorly soluble under these conditions. The reaction proceeded to 
completeness within two hours, whereby no side products were observed. Only in the case of 
BIQs with electron-withdrawing nitro-substituents (1-12 and 1-13), prolonged reaction times and 
acidification were necessary to drive the reaction to completion. Figure 21 shows that the BIQs 
were in general obtained in high yields (>75%) with only few exceptions. Loss of product mainly 
occurred during the work-up of the reaction mixtures. 
Fluorescence Property Analysis 
The fused ring structure and modularity of BIQs opens up the potential for the creation of new 
fluorogenic molecules. Especially the de novo construction of the boron-nitrogen aromatic ring 
might enable turn-on fluorescence. The fluorescence potential of boron-heterocycles has been 
shown in previous reports[83,84] and the BODIPY fluorophores, a boron-containing compound 
family, are frequently used for fluorescence assays.[81] 
We initially measured the UV and fluorescence properties of the BIQs without fused ring systems 
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<300 nm, the efficiencies of most of these compounds was not useful for practice. The 
fluorescence emission at higher excitation wavelengths was weak. We expected the B-OH group 
to potentially act as a fluorescence quencher, which is why we synthesized the second series of 
BIQs (Figure 21b) that contained the additional annulation. We also hoped to achieve a 
substantial red shift by this additional annulation and the decoration of the BIQs with different 
substituents. In general, the hydroxyl and alkoxy substituents did not improve the fluorescence 
properties of these molecules (1-15 - 1-18). Incorporation of the electron-rich dimethylamino 
group in the boronic acid component (1-19c), however, created a good blue fluorophore (Figure 
22). 
 
Figure 22. Fluorescence emission spectra of BIQ 1-19 and its precursor aldehyde 1-19c. The spectra were recorded at 
10 µM in DMSO. Excitation wavelength 1-19: 365 nm, excitation wavelength 1-19c: 370 nm. 
The aldehyde precursor 1-19c showed fluorescence in DMSO with a maximum at 502 nm and a 
fluorescence quantum yield (Φ, ratio of fluorescently emitted photons per absorbed photon, value 
between 0 and 1) of 28%. BIQ formation with 1-19c yielded a five-fold increase in fluorescence 
and an improvement in fluorescence quantum yield (Φ = 39%) with maximum emission at 
444 nm. A remarkable finding for BIQ 1-19 and its precursor 1-19c were the large Stokes shifts of 
83 nm and 126 nm, respectively (see Figure 30). The Stokes shift is defined as the difference 
between excitation and emission maximum. A large Stokes shift (>80 nm) is beneficial, due to the 
reduced risk of interferences between the excitation source and the fluorescent emission. This is, 
in particular, important for fluorescent assays with high signal-to-noise ratios.[94] Many common 
fluorophores exhibit rather small Stokes shifts (e.g. fluorescein with 24 nm or BODIPY 505 with 
10 nm Stokes shifts). Protonation of the dimethylamino substituent did not change any 
fluorescence properties. The major drawback of our turn-on fluorophore was the blue shift in the 
emission spectrum upon BIQ formation. For biological applications, a red shift is desirable, 
because in the region of blue fluorophores, many other biological molecules (e.g. tryptophan, 
NADH, flavins) also show fluorescence emission. However, fine-tuning of the substitution pattern 
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4. Conclusions and Perspective 
In bioconjugation techniques, α-effect-amine condensations are frequently used for the 
modification of biomolecules. We showed that the boron-assisted oxime condensation proceeded 
at very high reaction rates, was stable in aqueous solution for more than three days and a slow 
reversibility was found upon the addition of a second aldehyde boronate or hydroxylamine. 
Ketoximes were found to be more susceptible to hydrolysis (and therefore for reversibility) than 
aldoximes. The proposed mechanism, proceeding over an intermediate, cyclic hemiaminal 
boronate, was supported by different experiments. Placing the boronic acid adjacent to the 
hydroxylamine showed little to no enhancement of the reaction rate compared to oxime 
formations under neutral conditions without boronic acid substituent. The reason for this behavior 
was the eight-membered cyclic intermediate, which was much less favorable than the five-
membered ring intermediate. Masking of the boronic acid by covalent saturation with fluorine 
atoms (trifluoroborate) or the MIDA ester also resulted in a diminished reaction rate for boron-
assisted oxime condensations. These results showed the importance of the free coordination site 
at the boron atom for the enhancement of the reaction rate. 
We used the accelerated oxime formation technique to label immunoglobulin G with a fluorescein 
tag. The experimental results revealed a high degree of labeling and a high stability towards 
hydrolysis. The oxime link was found to be stable under the conditions of SDS-PAGE analysis 
with β-mercaptoethanol added as a reducing agent. 
Boron-assisted hydrazone condensations were further explored to determine the characteristics 
of this conjugation type. Hydrazones with adjacent boronic acid substituents undergo a 
cyclization reaction to stable, heteroaromatic compounds, the borazaroisoquinolines (BIQs). We 
showed that BIQs formed much slower than the hydrazone precursors, however, the BIQ 
formation was found to be stable to hydrolysis and irreversible. Influences on BIQ formation by 
pH and additives could be determined as well. An acidic environment enhances the rate of BIQ 
formation, whereas increases in pH value slowed the reaction down. Additionally, high amounts 
of organic solvents decreased the BIQ reaction rate. Biological additives, such as human serum 
and glutathione, were found to have minor influences on BIQ generation. In a competition 
experiment, we found that hydrazones were reversible as well with the addition of a 
hydroxylamine. However, BIQ formation proceeded much faster than the hydrolysis of the 
hydrazone with subsequent oxime formation. Analysis of the reaction products revealed only a 
small amount of the oxime product, despite the excess of added hydroxylamine. 
The remarkable structure of BIQs prompted us to synthesize a series of substituted BIQs with 
fused ring systems for the determination of the fluorescence properties. While most of the 
compounds showed only weak fluorescence at low emission wavelengths, one BIQ, with an 
electron-rich diethylamino substituent, showed good fluorescence properties. Although the 
aldehyde precursor revealed fluorescence in the blue region, upon BIQ formation a five-fold 
enhancement of the fluorescence intensity was found, along with an increase in fluorescence 
quantum yield. This behavior was considered as a turn-on fluorescence event. The fact that the 
turn-on fluorescence, upon BIQ formation, causes a blue-shift of the emission maximum was the 
main drawback due to the intrinsic fluorescence of several biomolecules in this region of the 
electromagnetic spectrum. The fluorescent BIQ and its precursor showed both a large Stokes 
shift (>80 nm), which is beneficial for applications in biochemistry. 
Our findings on boron-assisted oxime and hydrazone/BIQ formations, along with the results from 
other research groups, enabled the construction of a guidebook for α-effect-amine 
condensations. Ketoxime and acylhydrazones were determined to be rapidly reversible and might 
be applied in dynamic covalent chemistry. Aldoximes are slowly hydrolyzed and may find 
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applications for targeted slow release or exchange. Hydrazones lead to the formation of BIQs, 
which are irreversible and might be used for permanent linking applications. 
Boron-mediated Schiff base formations with hydroxylamines and hydrazines may find various 
applications for bioorthogonal labeling. However, the technique might be restricted to in vitro 
applications, since boronic acids interfere with carbohydrates that are found on the surface of 
cells. For that reason, the transport of the boronic acid carbonyl compound into the cell may be a 
big challenge. Masking of the boronic acid by coordination saturation might be considered, 
however, the hydrolytic stability of such boronates is usually not high enough to prevent 
interactions with carbohydrates in a cellular environment and meanwhile slows down the rate of 
the Schiff base formation. 
Boronic acids are prone to oxidation, a property that may be used for targeted release of a cargo 
in close proximity to cancer cells. Boron-mediated oximes might be used as the linker between 
the cargo (e.g. an anti-cancer drug) and a transporter molecule. The prerequisite for such a 
system is that the linker is protected from other nucleophiles by the transporter moiety or by 
encapsulation of the assembly within a vesicle. The transporter molecule ensures the selective 
binding to the target cell proteins and the increased concentration of oxidizing agents near tumor 
cells destroys the boronic acid substituent. This oxidation leads to a destabilization of the oxime 
linkage, which enables the release of the cargo molecule to kill the tumor cell. 
Due to the functionality of boronic acids, a secondary reaction, such as Suzuki-Miyaura cross-
coupling, may also be considered after completed Schiff base formation. This duality of boronic 
acid carbonyl compounds opens up the potential for the creation of new, interesting molecules, 
applicable in early drug-discovery. Due to the high availability of halogenated compounds, large 
combinatorial libraries may be accessible by this technique. 
The BIQ system may be expanded by substituent variation in order to create new, red-fluorescent 
molecules or turn-on fluorophores. The ease of synthesis of this compound class will enable the 
creation of large BIQ collections. However, BIQs are not restricted to the area of fluorescent 




5. Experimental Part Oxime, Hydrazone, BIQ 
5.1 General Information 
Reagents and Solvents 
Reagents and solvents were purchased from Sigma-Aldrich, Alfa Aesar, Apollo Scientific Ltd., 
Fluka, Fluorochem, Fisher Scientific, Enamine, TCI, Bachem, Biosolve or Acros and were used 
as received. 1,4-dioxane was freshly distilled from sodium benzophenone ketyl under dry 
nitrogen prior to use. Buffers and HPLC eluents were prepared with nanopure water (resistivity 
18.2 MΩ). KPi refers to (sodium or potassium) phosphate buffer at the stated concentration and 
pH. 
Chromatographic Purification and Isolation 
Flash chromatography was performed on SilicaFlash® gel P60 40-63 µm (230-400 mesh, 
SiliCycle, Quebec) according to Still[95] or on a Biotage Isolera four with SilicaFlash® gel packed 
cartridges. Reversed phase flash chromatographies were run on a Biotage Isolera four with self-
packed columns (LiChroprep RP-18, 40-63 µM silica from Merck). Preparative RP-HPLC was 
carried out on a Shimadzu Prominence UFLC Preparative Liquid Chromatograph.  
Method A: Gemini NX-C18, 5 µm, 110 Å, 21.2 x 250 mm from Phenomenex with a flow rate of 
20 mL/min, gradient: 1% (3 min)-99% (25 min)-99% (3 min) (B), monitoring and collecting the 
products at 254 nm. Buffer (A): 0.1% TFA (v/v) in H2O, Buffer (B): MeCN.  
The crude compound mixtures were injected as MeCN solutions. Concentration under reduced 
pressure was performed by rotatory evaporation at 40°C water bath temperature. Aqueous 
product fractions were frozen in liquid N2 and lyophilized on a Christ Alpha 2-4 LDplus flask 
lyophilizer at 0.3 mbar or below.  
Chromatographic Analysis 
Analytical TLC was performed on Silica gel 60 F254, 0.25 mm pre-coated glass plates (Merck) 
and visualized by fluorescence quenching under UV light at 254 nm and subsequent KMnO4 
staining.  
ESI-MS and LC-MS 
ESI-MS spectra were recorded on a Bruker Esquire3000 spectrometer by direct injection in 
positive or negative polarity of the ion trap detector. Compounds were injected as MeOH, MeCN 
or H2O solutions. High-resolution mass spectra (HRMS) were recorded by the mass 
spectrometric service of the University of Basel on a Bruker maXis 4G QTOF ESI mass 
spectrometer.  
UPLC-MS was carried out on an Agilent 1290 Infinity system equipped with an Agilent 6130 
Quadrupole ESI-MS using a C18 column (ZORBAX Eclipse Plus RRHD, 
1.8 µm, 2.1 x 50 mm) from Agilent with a flow rate of 0.45 mL/min at 40°C. Buffer (A): 0.1% (v/v) 
formic acid in H2O/1% MeCN (v/v), Buffer (B): 0.1% (v/v) formic acid in MeCN/1% H2O (v/v) using 





Gel electrophoresis was performed with a Bio-Rad PowerPac HV high-voltage power supply. 
Gels were prepared with an area of 83 x 83 mm and a thickness of 1.0 mm with 10 wells.  
Denaturing protein gels were prepared with a 5% stacking gel (approx. 2 cm high) and a 
resolving gel of different percentages (approx. 6 cm). The stacking gel was prepared from 40% 
acrylamide/bis-acrylamide 37.5:1 (Fisher Scientific) with 0.1% (m/v) SDS, 0.2% (v/v) TEMED and 
0.4% (v/v) APS (10% APS solution in H2O) in 125 mM TRIS, pH 6.8. The resolving gel was 
prepared from 40% acrylamide/bis-acrylamide 37.5:1 (Fisher Scientific) with 0.1% (m/v) SDS, 
0.1% (v/v) TEMED and 0.3% (v/v) APS (10% APS solution in H2O) in 375 mM TRIS, pH 8.8. 
Protein samples were treated with 2X loading dye (66 mM TRIS pH 6.8, 2% (m/v) SDS, 
0.01% (m/v) bromophenol blue, 30% (v/v) glycerol) and denatured at 95°C for 5 min prior to gel 
loading. Visualization was achieved with Coomassie Blue staining. Gel imaging and analysis was 
performed on a Bio-Rad ChemiDoc MP system. 
Running buffer: 193 mM glycine, 25 mM TRIS, 0.1% (m/v) SDS.  
Nuclear Magnetic Resonance (NMR) 
1H, 13C and 2D-NMR spectra were acquired on BrukerAvance (250, 400, 500 or 600 MHz proton 
frequency) spectrometers at 298.15 K. Chemical shifts (δ values) are referenced to the solvent’s 
residual peak and reported in ppm. Multiplicities are reported as follows: s = singlet, sbr = broad 
singlet, d = doublet, t = triplet, q = quartet, p = quintet, m = multiplet or unresolved and 
combinations of these multiplicities (e.g. dd, dt, td etc.). Coupling constants J are given in Hz. 
Due to the quadrupole effect, carbon atoms attached to a boron atom are invisible in 13C spectra.  
Special NMR Assays 
NMR experiments were performed at 298 K either on a Bruker Avance III NMR spectrometer 
operating at 600.13 MHz and equipped with a direct observe 5 mm BBFO smart probe or a 
Bruker Avance III HD NMR spectrometer operating at 600.13 MHz equipped with a cryogenic 
5 mm four-channel QCI probe (H/C/N/F). All 1H experiments were recorded using the same 
parameters (256 scans, relaxation delay of 4.0 s and an acquisition time of 2.00 s) and were 
processed using TopSpin software from Bruker. Line broadening of 0.5 Hz and automated 
baseline correction was applied after manual phase correction. Chemical shifts were referenced 
to the residual solvent peak of acetonitrile (1.94 ppm) and TMSP-d4 (3-(trimethylsilyl)-2,2',3,3'-
tetradeuteropropionic acid) was used as an internal standard. The pH (no correction for 
deuterium) was adjusted by addition of concentrated DCl from ABCR (DCl, 38% wt% in D2O, 
99.5% atom%D) measured with a 827 pH Lab - Metrohm equipped with a glass minitrode, which 
was pre-rinsed with D2O. Standard NMR tubes (throw away quality) were rinsed with D2O and 
dried in the oven prior to use. Stock solutions were mixed in the NMR tube, vortexed and 
sonicated before measurement. 
UV Assays for BIQ Experiments 
All measurements were conducted on a Shimadzu UV-1800 UV-Vis spectrophotometer (190-
1100 nm, bandwidth 1 nm) using 10 x 10 mm quartz cuvettes from Hellma Analytics (3500 µL). 
The Human Serum (HS) was of type AB (male). Cuvettes were rinsed with deionized H2O 
followed by technical EtOH and dried under a N2 stream prior to use. For all UV measurements 
the boronic acid was dissolved in the solvent and measured for 10 s. The hydrazine stock 
solution (freshly prepared, could not be used for longer than 1 h) was directly added into the 
cuvette, gently shaken three times and the measurement was continued. Formation of the 
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hydrazone and BIQ were recorded in triplicate at 340 nm. The absorbance was measured every 
0.5 s over a period of about 1500 s. The recorded data was analyzed with MS Excel. Hydrazone 
formation was too fast to determine exact rate constants by the described method. The 
intramolecular BIQ formation showed first order behavior and was measured by the signal 
decrease at 340 nm (only hydrazone visible). Extinction coefficients for the hydrazone 
intermediate at 340 nm were determined by addition of 1.5 equivalents of the corresponding 
hydrazine to a known concentration of aldehyde (typically 10 µM), assuming that the highest 
absorbance is equal to complete conversion to the hydrazone (Lambert-Beer law). 
Fluorescence Measurements 
Fluorescence emission measurements were performed on a Shimaduzu RF-5301PC 
spectrofluoro-photometer with 3 nm spectral bandwidth, using 10 x 10 mm quartz cuvettes from 
Hellma Analytics (3500 µL). Quantum yield measurements were done on a Hamamatsu 
Quantaurus-QY Absolute PL quantum yields measurement system C11347-11 with an integrating 
sphere. All samples were prepared as 10 µM samples in DMSO. UV and fluorescence files were 
processed with MS Excel. 
5.2 Compound Synthesis 
(E)-(2-(((Benzyloxy)imino)methyl)phenyl)boronic acid 1-1 
 
2-Formylphenylboronic acid (50.0 mg, 333.0 µmol, 1.0 eq.) and O-benzylhydroxylamine 
hydrochloride (58.5 mg, 367.0 µmol, 1.1 eq.) were dissolved in MeOH (2 mL) and the mixture 
was stirred at RT for 21 h, after which UPLC-MS analysis showed complete conversion to the 
desired product. The solvent was removed by rotary evaporation and the residue was purified by 
reversed phase flash column chromatography on the ISOLERA (RP-Silica, 25 g, H2O/MeCN, UV) 
to yield the desired product as a white solid (73 mg, 86%). Analytical data was in agreement with 
reported data.[63] 
1H NMR (400 MHz, CD3CN) δ/ppm: 8.50 (s, 1H), 7.76 – 7.70 (m, 1H), 7.62 (dd, J = 7.4, 1.7 Hz, 
1H), 7.46 – 7.36 (m, 5H), 7.34 – 7.26 (m, 2H), 6.48 (s, 2H), 5.17 (s, 2H). 
2-Formyl-4-hydroxyphenylboronic acid pinacol ester 1-2 
 
Under an inert atmosphere, 2-bromo-5-hydroxybenzaldehyde (500.0 mg, 2.5 mmol, 1.0 eq.), 
bis(pinacolato)diboron (821.0 mg, 3.23 mmol, 1.3 eq.), Pd(dppf)Cl2 (182.0 mg, 249.0 µmol, 
10 mol%) and potassium acetate (732.0 mg, 7.5 mmol, 3.0 eq.) were suspended in freshly 
distilled dioxane (10 mL). The mixture was heated to reflux (110°C) for 3 h. After cooling, the 
solvent was removed by rotary evaporation. The residue was diluted with DCM (40 mL) and 
washed with H2O (3 x 40 mL). The combined aqueous layers were extracted with DCM (3 x 
15 mL) and the combined organic layers were washed with brine (40 mL). The organic phase 
was dried over Na2SO4, concentrated by rotary evaporation and the crude was purified by flash 
column chromatography (Silica, 110 g, cyclohexane → 10:1 → 7.5:1 → 5:1 cyclohexane:EtOAc, 
Rf = 0.3, UV/KMnO4). Product containing fractions were combined and concentrated in vacuo to 











1H NMR (400 MHz, DMSO-d6) δ/ppm: 10.45 (s, 1H), 10.26 (s, 1H), 7.68 (d, J = 8.2 Hz, 1H), 7.25 
(d, J = 2.5 Hz, 1H), 7.06 (dd, J = 8.1, 2.5 Hz, 1H), 1.31 (s, 12H). 
(E)-(2-(1-((Benzyloxy)imino)ethyl)phenyl)boronic acid 1-3 
 
2-Acetylphenylboronic acid (50.0 mg, 305.0 µmol, 1.0 eq.) and O-benzylhydroxylamine 
hydrochloride (53.5 mg, 335.0 µmol, 1.1 eq.) were dissolved in MeOH (2 mL) and the mixture 
was stirred at RT for 15 h, after which UPLC-MS analysis showed full conversion to the desired 
product. The solvent was removed by rotary evaporation and the residue was purified by 
preparative RP-HPLC (Method A). Product containing fractions were combined and lyophilized to 
yield the desired product as a white solid (56 mg, 68%). Analytical data was in agreement with 
reported data.[63] 
1H NMR (400 MHz, CD3CN) δ/ppm: 7.47 – 7.40 (m, 4H), 7.40 – 7.31 (m, 4H), 7.31 – 7.24 (m, 
1H), 5.19 (s, 2H), 2.23 (s, 3H). 
2-(N-Boc-aminooxymethyl)phenylboronic acid pinacol ester 1-4a 
 
Under a N2 atmosphere in a dry Schlenk tube, N-Boc-hydroxylamine (33.6 mg, 250.0 µmol, 
1.5 eq.) and 2-bromomethylphenylboronic acid pinacol ester (50.0 mg, 170.0 µmol, 1.0 eq.) were 
dissolved in dry MeCN (0.5 mL) and cooled to 0°C. NaH (9.0 mg, 340.0 µmol, 2.0 eq.) was slowly 
added and the mixture was stirred for 30 min. The cooling bath was removed and the mixture 
was stirred for another 4 h whereupon UPLC-MS analysis showed complete conversion. The 
mixture was diluted with H2O (3 mL) and EtOAc (3 mL) and the layers were separated. The 
aqueous layer was extracted with EtOAc (2 x 5 mL) and the combined organic layers were 
washed with H2O (5 mL), brine (5 mL), dried over Na2SO4 and the solvent was removed by rotary 
evaporation. The residue was purified by preparative RP-HPLC (Method A, no TFA) and product 
containing fractions were combined and lyophilized to yield the desired product as a white solid 
(20 mg, 34%).  
1H NMR (400 MHz, CDCl3) δ/ppm: 7.81 (dt, J = 7.3, 1.0 Hz, 1H), 7.45 – 7.42 (m, 2H), 7.35 – 7.30 
(m, 1H), 7.18 (s, 1H), 5.14 (s, 2H), 1.46 (s, 9H), 1.35 (s, 12H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 156.71, 141.82, 135.98, 131.03, 129.63, 127.72, 83.97, 
81.52, 77.87, 28.37, 25.02.  
HRMS (ESI): C18H29BNO5+ calcd.: 350.2133, found: 350.2137. 
2-Aminooxymethylphenylboronic acid 1-4 
 
1-4a (35.0 mg, 100.0 µmol, 1.0 eq.) was dissolved in CH2Cl2 (0.5 mL) while cooling to 0°C. 
Trifluoroacetic acid (300.0 µL, 3.9 mmol, 39.1 eq.) was added dropwise over 2 min. After 10 min, 
the cooling bath was removed and the mixture was stirred at RT for 20 min. H2O (0.25 mL) and 
MeCN (0.1 mL) were added and the biphasic mixture was stirred at room temperature for 3 h. 
The volatiles were removed by rotary evaporation and the mixture was purified by preparative 













yield the desired product as a white solid (5 mg, 30%). NMR showed a mixture of the free boronic 
acid and pinacol ester in a ratio of 3:2.  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 7.68 – 7.64 (m, 1H), 7.52 – 7.49 (m, 1H, pinacol ester), 
7.22 – 7.18 (m, 2H), 7.17 – 7.13 (m, 2H, pinacol ester), 7.10 – 7.07 (m, 1H), 7.04 – 7.01 (m, 1H, 
pinacol ester), 5.04 (s, 2H), 4.78 (s, 2H, pinacol ester), 1.14 (s, 12H, pinacol ester).  
13C NMR (500 MHz, 2D NMR, DMSO-d6) δ/ppm: 142.64, 138.25, 132.12, 126.29, 126.14, 
124.64, 72.83 (boronic aicd); 140.02, 131.5, 126.13, 126.00, 123.52, 79.22, 71.65, 25.88 (pinacol 
ester). 
HRMS (ESI): C13H21BNO3+ calcd.: 250.1609, found: 250.1611 (pinacol ester). 
 (E)-(2-(((Benzylideneamino)oxy)methyl)phenyl)boronic acid 1-5 
 
1-4 (3.0 mg, 20.0 µmol, 1.0 eq.) and benzaldehyde (2.8 µL, 30.0 µmol, 1.5 eq.) were dissolved in 
MeOH (0.2 mL) and the solution was stirred at RT overnight. The mixture was directly purified by 
preparative RP-HPLC (Method A). Product containing fractions were combined and lyophilized to 
yield the desired product as a white solid (1 mg, 22%).  
1H NMR (500 MHz, CD3CN) δ/ppm: 8.17 (s, 1H), 7.67 – 7.64 (m, 1H), 7.57 – 7.54 (m, 2H), 7.44 – 
7.39 (m, 5H), 7.35 – 7.31 (m, 1H), 6.88 (s, 2H), 5.29 (s, 2H).  
13C NMR (500 MHz, 2D NMR, DMSO-d6) δ/ppm: 150.97, 142.00, 135.17, 132.66, 131.15, 
130.80, 130.65, 129.72, 128.46, 127.92, 76.94.  
HRMS (ESI): C14H14BNNaO3+ calcd.: 278.0959, found: 278.0961. 
2-((Propan-2-ylideneamino)oxy)acetic acid 1-6a 
 
Carboxymethoxylamine hemihydrochloride (500.0 mg, 2.3 mmol, 1.0 eq.) was dissolved in 
acetone (6.6 mL, 89.3 mmol, 39.1 eq.) and H2O (0.5 mL). The solution was stirred at RT for 2 h, 
after which the volatiles were removed by rotary evaporation and the residue was lyophilized to 
yield the desired product as a white solid (543 mg, 91%).  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 12.57 (sbr, 1H), 4.44 (s, 2H), 1.82 (s, 3H), 1.79 (s, 3H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 171.34, 155.35, 69.54, 21.17, 15.50. 
HRMS (ESI): C5H9NNaO3+ calcd.: 154.0475, found: 154.0476. 
Succinimidyl 2-((propan-2-ylideneamino)oxy)acetate 1-6 
 
1-6a (50.0 mg, 381.0 µmol, 1.0 eq.), N-hydroxysuccinimide (65.8 mg, 572.0 µmol, 1.5 eq.) and 
DMAP (4.7 mg, 38.1 µmol, 10 mol%) were dissolved in DCM (3 mL) and the mixture was cooled 
in an ice bath. Diisopropylcarbodiimide (89.6 µL, 572.0 µmol, 1.5 eq.) was added dropwise over 
2 min. The mixture was stirred in the ice bath for 1 h, warmed to RT and continued stirring 
overnight. The precipitate was filtered off and the filtrate was washed with aqueous HCl (50 mM, 
4 x 10 mL), brine (10 mL) and was dried over Na2SO4. The solvent was removed by rotary 
















overnight. The precipitate was filtered off, washed with EtOAc (3 x 2 ml, -20°C) and the combined 
filtrates were concentrated in vacuo to yield the desired product as slightly yellow, thick oil that 
slowly crystallized (90 mg, 99%). The product was used without further purification. 
1H NMR (400 MHz, CDCl3) δ/ppm: 4.90 (s, 2H), 2.84 (s, 4H), 1.92 (s, 3H), 1.88 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 168.86, 165.91, 158.17, 68.07, 25.72, 21.77, 15.93. 
HRMS (ESI): C9H12N2NaO5+ calcd.: 251.0638, found: 251.0640. 
Azidopropyl-(fluoresceinyl)thiourea 1-7a 
 
A solution of fluorescein isothiocyanate (50.0 mg, 128.0 µmol, 1.0 eq.) in DMF (1 mL) was added 
dropwise to a solution of 3-azidopropylamine 2-1 (14.0 mg, 140.0 µmol, 1.1 eq.) in DMF (2 mL) 
under a nitrogen atmosphere. The solution was stirred for 20 h at RT, after which the mixture was 
directly purified by preparative RP-HPLC (Method A). Product containing fractions were 
combined and lyophilized to yield the desired product as an orange solid (30 mg, 48%). Analytical 
data was in agreement with reported data.[97] 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 10.13 (brs, 2H), 9.97 (brs, 1H), 8.22 – 8.15 (m, 2H), 7.73 
(dd, J = 8.2, 4.4 Hz, 1H), 7.18 (d, J = 8.3 Hz, 1H), 6.67 (d, J = 2.2 Hz, 2H), 6.62 (d, J = 1.8 Hz, 
1H), 6.59 (s, 1H), 6.57 (d, J = 2.2 Hz, 2H), 3.59 (t, J = 5.6 Hz, 2H), 3.44 (t, J = 6.7 Hz, 2H), 1.85 
(p, J = 6.8 Hz, 2H). 
2-Formyl-4-(propargyloxy)phenylboronic acid pinacol ester 1-7b 
 
Under a N2 atmosphere 1-2 (50.0 mg, 200.0 µmol, 1.0 eq.) and propargyl bromide (26.9 µL, 
240.0 µmol, 1.3 eq., 80% solution in toluene) were dissolved in DMF (0.5 mL) and K2CO3 
(41.8 mg, 300.0 µmol, 1.5 eq.) was added. The mixture was stirred at room temperature for 21 h, 
after which the mixture was diluted with H2O (15 mL) and EtOAc (15 mL). The layers were 
separated and the aqueous layer was washed with EtOAc (2 x 15 mL). The combined organic 
layers were washed with brine (10 mL), dried over Na2SO4 and the solvent was removed by 
rotary evaporation. The crude product was purified by flash chromatography (Silica, 5 g, 
10:1 cyclohexane/EtOAc, UV/KMnO4, Rf = 0.24) to yield the desired product as a white solid (37 
mg, 64%).  
1H NMR (400 MHz, CDCl3) δ/ppm: 10.67 (s, 1H), 7.89 (d, J = 8.3 Hz, 1H), 7.57 (d, J = 2.7 Hz, 
1H), 7.19 (dd, J = 8.3, 2.7 Hz, 1H), 4.77 (d, J = 2.4 Hz, 2H), 2.53 (t, J = 2.4 Hz, 1H), 1.37 (s, 
12H).  
13C NMR (101 MHz, CDCl3) δ/ppm: 194.72, 159.92, 143.64, 138.11, 120.66, 111.63, 84.38, 
77.89, 76.23, 55.94, 25.02.  















Fluorescein boronic acid aldehyde 1-7 
 
In a 1.5 mL Eppendorf tube 1-7a (25.0 mg, 51.1 µmol, 1.0 eq.), 1-7b (16.1 mg, 56.2 µmol, 
1.1 eq.) and sodium ascorbate (6.1 mg, 30.6 µmol, 0.6 eq.) were dissolved in t-BuOH:H2O (1:1, 
310 µL each). CuSO4 pentahydrate (3.8 mg, 15.3 µmol, 0.3 eq.) was added and the mixture was 
agitated at RT for 21 h, after which UPLC-MS analysis showed complete conversion of the 
starting material. The mixture was diluted with MeCN (1 mL) and purified by preparative  
RP-HPLC (Method A). Product containing fractions were combined and lyophilized to yield the 
product as an orange solid (11 mg, 31%).  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 10.20 (s, 1H), 10.12 (brs, 2H), 9.97 (brs, 1H), 8.31 (s, 1H), 
8.24 – 8.13 (m, 3H), 7.76 – 7.71 (m, 1H), 7.61 (d, J = 8.2 Hz, 1H), 7.50 (d, J = 2.6 Hz, 1H), 7.30 
(dd, J = 8.2, 2.7 Hz, 1H), 7.19 (d, J = 8.3 Hz, 1H), 7.09 – 7.01 (m, 1H), 6.67 (d, J = 2.3 Hz, 2H), 
6.59 (s, 1H), 6.57 (d, J = 2.3 Hz, 1H), 5.24 (s, 2H), 4.46 (t, J = 7.0 Hz, 2H), 3.58 – 3.52 (m, 2H), 
2.16 (p, J = 7.1 Hz, 3H). 
13C NMR (500 MHz, 2D NMR, DMSO-d6) δ/ppm: 193.83, 159.18, 158.33, 151.53, 142.04, 
141.02, 140.87, 135.19, 131.37, 129.36, 128.72, 126.20, 124.36, 123.77, 119.43, 116.36, 113.33, 
112.25, 109.39, 101.93, 82.72, 60.93, 47.02, 40.80, 28.88. 
HRMS (ESI): C35H31BN5O9S+ calcd.: 708.1930, found: 708.1932 (mono-methyl boronate). 
General Procedure for the Synthesis of 4,3-Borazaroisoquinolines (BIQ) 
Boronic acid aldehyde (1.0 eq.) and phenylhydrazine (1.4 eq.) were suspended in DMSO/H2O 
(1:4) and the suspension was stirred at room temperature for 2 h. The mixture was diluted with 
MeCN until a clear solution was obtained. The product was purified by preparative RP-HPLC 
(Method A) and the product-containing fractions were lyophilized. 
2-Phenylbenzo[d][1,2,3]diazaborinine-1,6(2H)-diol 1-8 
 
1-8 was synthesized according to the general procedure. 1-2 (20.0 mg, 80.6 µmol, 1.0 eq.) and 
phenylhydrazine (11.1 µL, 113.0 µmol, 1.4 eq.) were mixed in the solvent (1 mL). The product 
was isolated as a white solid (18 mg, 94%).  
1H NMR (400 MHz, CD3CN) δ/ppm: 8.06 – 8.02 (m, 1H), 8.01 (s, 1H), 7.54 – 7.50 (m, 2H), 7.45 – 
7.40 (m, 2H), 7.29 – 7.24 (m, 1H), 7.17 – 7.13 (m, 1H), 7.12 – 7.10 (m, 1H).  
13C NMR (500 MHz, 2D NMR, CD3CN) δ/ppm: 160.63, 147.20, 140.05, 138.50, 134.04, 129.37, 
126.33, 125.90, 119.23, 112.15.  






















1-9 was synthesized according to the general procedure. 2-Formylphenylboronic acid (2-FPBA) 
(5.0 mg, 33.3 µmol, 1.0 eq.) and phenylhydrazine (4.6 µL, 46.7 µmol, 1.4 eq.) were mixed in the 
solvent (1 mL). The product was isolated as a white solid (4 mg, 54%). Analytical data was in 
agreement with reported data.[68] 
1H NMR (400 MHz, CD3CN) δ/ppm: 8.19 (d, J = 7.6 Hz, 1H), 8.14 (s, 1H), 7.82 – 7.74 (m, 2H), 
7.68 (ddd, J = 8.2, 4.9, 3.5 Hz, 1H), 7.57 – 7.51 (m, 2H), 7.49 – 7.41 (m, 2H), 7.32 – 7.26 (m, 1H), 
6.32 (s, 1H). 
4-Methyl-2-phenylbenzo[d][1,2,3]diazaborinin-1(2H)-ol 1-10 
 
1-10 was synthesized according to the general procedure. 2-Acetylphenylboronic acid (5.0 mg, 
30.5 µmol, 1.0 eq.) and phenylhydrazine (4.2 µL, 42.7 µmol, 1.4 eq.) were mixed in the solvent 
(250 µL). The product was isolated as a yellow solid (6 mg, 83%). 
1H NMR (400 MHz, CD3CN) δ/ppm: 8.21 – 8.17 (m, 1H), 7.95 – 7.91 (m, 1H), 7.82 – 7.77 (m, 
1H), 7.70 – 7.65 (m, 1H), 7.56 – 7.51 (m, 2H), 7.47 – 7.41 (m, 2H), 7.30 – 7.24 (m, 1H), 2.58 (s, 
3H).  
13C NMR (500 MHz, HMQC, HMBC, CD3CN) δ/ppm: 147.01, 144.40, 136.10, 132.29, 132.00, 
129.78, 129.38, 126.44, 126.33, 126.04, 20.27.  
HRMS (ESI): C14H14BN2O+ calcd.: 237.1194, found: 237.1198. 
2-Phenyl-6-(propargyloxy)benzo[d][1,2,3]diazaborinin-1(2H)-ol 1-11 
 
19 was synthesized according to the general procedure. 1-7b (5.0 mg, 17.5 µmol, 1.0 eq.) and 
phenylhydrazine (2.4 µL, 24.5 µmol, 1.4 eq.) were mixed in the solvent (250 µL). The product was 
isolated as a white solid (4 mg, 83%).  
1H NMR (400 MHz, CD3CN) δ/ppm: 8.14 – 8.11 (m, 1H), 8.08 (s, 1H), 7.55 – 7.51 (m, 2H), 7.46 – 
7.41 (m, 2H), 7.32 – 7.29 (m, 2H), 7.29 – 7.27 (m, 1H), 6.25 (s, 1H), 4.89 (d, J = 2.4 Hz, 2H), 2.86 
(t, J = 2.3 Hz, 1H).  
13C NMR (500 MHz, HMQC, HMBC, CD3CN) δ/ppm: 160.83, 147.03, 139.86, 138.27, 133.82, 
129.29, 126.56, 125.91, 119.21, 110.93, 79.23, 77.11, 56.59.  


















2-Formylphenylboronic acid (10.0 mg, 66.7 µmol, 1.0 eq.) and 4-nitrophenylhydrazine (22.0 mg, 
93.4 µmol, 1.4 eq., 65% in H2O) were dissolved in the solvent (1.0 mL). The suspension was 
acidified with aqueous HCl (100 µL, 1N) and stirred for 32 h at RT. Purification was performed 
according to the general procedure. The product was isolated as a yellow solid (14 mg, 79%).  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 9.64 (s, 1H), 8.44 (d, J = 7.4 Hz, 1H), 8.33 – 8.27 (m, 3H), 
8.03 – 7.97 (m, 2H), 7.88 – 7.78 (m, 2H), 7.71 (td, J = 7.1, 1.5 Hz, 1H).  
13C NMR (101 MHz, DMSO-d6) δ/ppm: 152.28, 143.52, 140.86, 134.70, 132.00, 131.97, 129.63, 
127.40, 123.96, 123.81.  
HRMS (ESI): C13H11BN3O3+ calcd.: 268.0888, found: 268.0893. 
2-Nitro-4-methoxyphenyhydrazine 1-13a 
 
4-Methoxy-2-nitroaniline (5.0 g, 29.7 mmol, 1.0 eq.) was suspended in HCl (35%, 12.5 mL) and 
H2O (12.5 mL). The mixture was cooled in an ice/salt bath to -10°C. A solution of NaNO2 (2.3 g, 
32.7 mmol, 1.1 eq.) in H2O (5 mL) was added dropwise over 10 min, keeping the temperature 
between -10°C and -5°C (no gas evolution). The dark solution was stirred for 10 min, after which 
it was slowly transferred to a solution of SnCl2 (16.9 g, 89.2 mmol, 3.0 eq.) in HCl (35%, 20 mL) 
while cooling in an ice/salt bath. The suspension was stirred for 1 h in the cooling bath and was 
then warmed to RT in the course of 45 minutes. The precipitate was filtered off and dissolved in 
H2O (180 mL). NaOAc (15 g) was added, whereby a dark red precipitate formed. The solid was 
filtered off, washed with H2O (15 mL) and was dried in vacuo overnight. The crude product was 
recrystallized in cyclohexane:EtOH (1:1, 80 mL) with hot filtration over G4. The desired product 
was isolated as a dark red solid (853 mg, 16%). Analytical data was in agreement with the 
reported data.[98] 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.99 (s, 1H), 7.61 (d, J = 9.5 Hz, 1H), 7.40 (d, J = 2.9 Hz, 
1H), 7.29 (ddd, J = 9.5, 3.0, 0.7 Hz, 1H), 4.66 (s, 2H), 3.74 (s, 3H). 
2-(4-Methoxy-2-nitrophenyl)benzo[d][1,2,3]diazaborinin-1(2H)-ol 1-13 
 
2-Formylphenylboronic acid (10.0 mg, 66.7 µmol, 1.0 eq.) and 1-13a (17.1 mg, 93.3 µmol, 
1.4 eq.) were dissolved in the solvent (1.0 mL). The suspension was acidified with aqueous HCl 
(100 µL, 1N) and was stirred for 67 h at 70°C. Purification was performed according to the 
general procedure. The product was isolated as a brown solid (12 mg, 61%).  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 9.12 (sbr, 1H), 8.36 – 8.31 (m, 1H), 8.15 (s, 1H), 7.84 – 
7.76 (m, 2H), 7.70 – 7.65 (m, 1H), 7.57 (d, J = 9.0 Hz, 1H), 7.51 (d, J = 3.1 Hz, 1H), 7.35 (dd, J = 
8.9, 3.0 Hz, 1H), 3.89 (s, 3H).  
13C NMR (101 MHz, DMSO-d6) δ/ppm: 157.19, 145.62, 139.74, 135.16, 132.07, 131.67, 131.65, 
130.25, 129.28, 127.26, 119.17, 109.03, 56.12.  

















2-Hydroxyphenylhydrazine pTsOH salt 1-14a 
 
2-Hydroxyaniline (3.0 g, 27.5 mmol, 1.0 eq.) was suspended in EtOH (22 mL) and concentrated 
HCl (35%, 2.4 mL, 27.5 mmol, 1.0 eq.) was added. The mixture was cooled in an ice/salt bath. 
Isopentylnitrite (4.1 mL, 30.2 mmol, 1.1 eq.) in EtOH (13 mL) was slowly added, keeping the 
temperature between -5°C and 0°C. The solution was stirred for 45 min, after which it was slowly 
transferred to a cooled solution of SnCl2 (10.4 g, 55.0 mmol, 2.0 eq.) and pTsOH monohydrate 
(5.2 g, 27.5 mmol, 1.0 eq.) in EtOH (35 mL), keeping the temperature between 0°C and 10°C. 
The suspension was stirred in the ice bath for 30 min and was them warmed to RT over the 
course of 30 min. Et2O (70 mL) was added and the suspension was stirred for another 10 min. 
The solid was filtered off and washed with Et2O (4 x 25 mL). The obtained material was 
suspended in cyclohexane (20 mL) and heated to reflux. EtOH (50 mL) was added portionwise to 
obtain a clear solution. The solution was slowly cooled down to RT and was then left in the fridge 
(5°C) overnight. The precipitate was filtered off, washed with cyclohexane (3 x 15 mL) and dried 
in vacuo to yield the desired product as white plates (4.4 g, 54%). Analytical data was in 
agreement with the reported data.[99] 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 9.97 (s, 1H), 9.66 (s, 3H), 7.49 – 7.45 (m, 2H), 7.11 (d, J = 
7.9 Hz, 2H), 6.92 (dd, J = 7.6, 1.5 Hz, 1H), 6.88 – 6.82 (m, 2H), 6.79 (ddd, J = 7.6, 6.5, 2.3 Hz, 
1H), 2.29 (s, 3H). 
Benzo[d]benzo[4,5][1,3,2]oxazaborolo[3,2-b][1,2,3]diazaborinine 1-14 
 
1-14 was synthesized according to the general procedure. 2-Formylphenylboronic acid (10.0 mg, 
66.7 µmol, 1.0 eq.) and 1-14a (27.7 mg, 93.4 µmol, 1.4 eq.) were mixed in the solvent (1.0 mL). 
The product was isolated as a white solid (14 mg, 95%).  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.73 (s, 1H), 8.34 (d, J = 7.4 Hz, 1H), 8.18 (d, J = 7.9 Hz, 
1H), 7.96 (td, J = 7.3, 1.4 Hz, 1H), 7.88 (td, J = 7.4, 1.1 Hz, 1H), 7.82 (dd, J = 7.5, 1.3 Hz, 1H), 
7.62 (dd, J = 8.0, 0.9 Hz, 1H), 7.35 (td, J = 7.5, 1.3 Hz, 1H), 7.29 (td, J = 7.7, 1.5 Hz, 1H).  
13C NMR (101 MHz, DMSO-d6) δ/ppm: 148.12, 144.64, 135.75, 134.35, 131.99, 130.62, 130.37, 
129.49, 123.17, 122.89, 113.69, 110.35.  
HRMS (ESI): C13H10BN2O+ calcd.: 221.0881, found: 221.0883. 
Benzo[d]benzo[4,5][1,3,2]oxazaborolo[3,2-b][1,2,3]diazaborinin-3-ol 1-15 
 
1-15 was synthesized according to the general procedure. 1-2 (15.0 mg, 60.5 µmol, 1.0 eq.) and 
1-14a (25.1 mg, 84.6 µmol, 1.4 eq.) were mixed in the solvent (1.0 mL). The product was isolated 
as a white solid (13 mg, 91%).  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 10.56 (sbr, 1H), 8.55 (s, 1H), 8.16 (d, J = 8.3 Hz, 1H), 7.75 
(dd, J = 7.5, 1.1 Hz, 1H), 7.55 (dd, J = 7.8, 1.1 Hz, 1H), 7.43 (d, J = 2.1, Hz, 1H), 7.35 – 7.27 (m, 
2H), 7.24 (td, J = 7.7, 1.4 Hz, 1H).  
13C NMR (101 MHz, DMSO-d6) δ/ppm: 160.75, 148.19, 144.37, 138.17, 134.51, 132.44, 122.92, 
















HRMS (ESI): C13H10BN2O2+ calcd.: 237.0830, found: 237.0832. 
2-Formyl-5-hydroxyphenylboronic acid pinacol ester 1-16a 
 
Under an Ar atmosphere, 2-bromo-4-hydroxybenzaldehyde (250.0 mg, 1.2 mmol, 1.0 eq.), 
bis(pinacolato)diboron (410.6 mg, 1.6 mmol, 1.3 eq.), Pd(dppf)Cl2 (91.0 mg, 120 µmol, 10 mol%) 
and KOAc (366.2 mg, 3.7 mmol, 3.0 eq.) were suspended in freshly distilled dioxane (5 mL). The 
mixture was heated to reflux (100°C) for 16 h. After cooling, the solvent was removed by rotary 
evaporation. The residue was diluted with CH2Cl2 (20 mL) and was washed with H2O (3 x 20 mL) 
and brine (20 mL). The organic layer was dried over Na2SO4, concentrated by rotary evaporation 
and purified by flash column chromatography (10:1→ 5:1→ 3:1 cyclohexane:EtOAc, Rf = 0.33, 
UV/KMnO4) to yield the desired product as a slightly orange solid (141 mg, 46%).  
1H NMR (400 MHz, CDCl3) δ/ppm: 10.33 (s, 1H), 7.89 (d, J = 8.5 Hz, 1H), 7.23 (d, J = 2.6 Hz, 
1H), 6.96 (dd, J = 8.5, 2.6 Hz, 1H), 1.39 (s, 12H).  
13C NMR (101 MHz, CDCl3) δ/ppm: 193.13, 160.16, 134.78, 132.52, 131.34, 121.89, 117.64, 
84.71, 25.00.  
HRMS (ESI): C13H17BNaO4+ calcd.: 271.1112, found: 271.1114. 
Benzo[d]benzo[4,5][1,3,2]oxazaborolo[3,2-b][1,2,3]diazaborinin-3-ol 1-16 
 
1-16 was synthesized according to the general procedure. 1-16a (15.0 mg, 60.5 µmol, 1.0 eq.) 
and 1-14a (25.1 mg, 84.6 µmol, 1.4 eq.) were mixed in the solvent (1.0 mL). The product was 
isolated as a white solid (13 mg, 91%).  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 10.63 (sbr, 1H), 8.54 (s, 1H), 8.02 (d, J = 8.3 Hz, 1H), 7.77 
(dd, J = 7.5, 1.2 Hz, 1H), 7.58 (dd, J = 7.8, 1.0 Hz, 1H), 7.55 (d, J = 2.6, Hz, 1H), 7.38 – 7.29 (m, 
2H), 7.26 (td, J = 7.8, 1.5 Hz, 1H).  
13C NMR (101 MHz, DMSO-d6) δ/ppm: 159.48, 148.06, 144.41, 134.58, 132.09, 128.91, 122.97, 
122.90, 121.27, 114.07, 113.69, 110.35.  
HRMS (ESI): C13H10BN2O2+ calcd.: 237.0830, found: 237.0832. 
3-(Propargyloxy)benzo[d]benzo[4,5][1,3,2]oxazaborolo[3,2-b][1,2,3]diazaborinine 1-17 
 
1-17 was synthesized according to the general procedure. 1-7b (15.0 mg, 52.4 µmol, 1.0 eq.) and 
1-14a (21.7 mg, 73.4 µmol, 1.4 eq.) were mixed in the solvent (1.0 mL). The product was isolated 
as a white solid (12 mg, 84%).  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.65 (s, 1H), 8.28 (d, J = 8.5 Hz, 1H), 7.79 (dd, J = 7.5, 
1.3 Hz, 1H), 7.75 (d, J = 2.4 Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.51 (dd, J = 8.5, 2.5, 1H), 7.33 (td, 

















13C NMR (101 MHz, DMSO-d6) δ/ppm: 159.93, 148.20, 144.24, 137.78, 134.39, 132.33, 123.15, 
122.90, 120.13, 113.69, 112.76, 110.28, 78.92, 78.77, 55.79.  
HRMS (ESI): C16H12BN2O2+ calcd.: 275.0986, found: 275.0989. 
2-Formyl-5-methoxyphenylboronic acid pinacol ester 1-18a 
 
Under a N2 atmosphere 1-16a (70.0 mg, 282.0 µmol, 1.0 eq.) was dissolved in DMF (1 mL) and 
K2CO3 (58.5 mg, 423.0 µmol, 1.5 eq.) was added. MeI (21.1 µL, 339 µmol, 1.2 eq.) was added 
dropwise and the mixture was stirred at room temperature overnight. The mixture was diluted 
with H2O (15 mL) and extracted with EtOAc (3 x 15 mL). The combined organic layers were 
washed with H2O (2 x 15 mL) and brine (15 mL). The organic layers were concentrated by rotary 
evaporation and the residue was purified by flash column chromatography (cyclohexane→ 20:1→ 
10:1→ 5:1 cyclohexane:EtOAc, Rf = 0.26, UV/KMnO4) to yield the desired product as slightly 
yellow oil (18 mg, 24%). Analytical data was in agreement with reported data.[100] 
1H NMR (400 MHz, CDCl3) δ/ppm: 10.37 (s, 1H), 7.94 (d, J = 8.6 Hz, 1H), 7.29 (d, J = 2.6 Hz, 
1H), 7.03 (ddd, J = 8.6, 2.7, 0.6 Hz, 1H), 3.90 (s, 3H), 1.40 (s, 12H). 
2-Methoxybenzo[d]benzo[4,5][1,3,2]oxazaborolo[3,2-b][1,2,3]diazaborinine 1-18 
 
1-18 was synthesized according to the general procedure. 1-18a (16.0 mg, 61.0 µmol, 1.0 eq.) 
and 1-14a (25.3 mg, 85.5 µmol, 1.4 eq.) were mixed in the solvent (1.0 mL). The product was 
isolated as a white solid (10 mg, 66%).  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.62 (s, 1H), 8.11 (d, J = 8.8 Hz, 1H), 7.80 (dd, J = 7.7, 
1.3 Hz, 1H), 7.74 (d, J = 2.7 Hz, 1H), 7.60 (dd, J = 7.8, 1.0 Hz, 1H), 7.52 (dd, J = 8.7, 2.7, 1H), 
7.34 (td, J = 7.6, 1.2 Hz, 1H) 7.28 (td, J = 7.7, 1.6 Hz, 1H), 3.98 (s, 3H).  
13C NMR (101 MHz, DMSO-d6) δ/ppm: 160.57, 148.02, 144.12, 134.44, 131.65, 129.96, 123.03, 
122.86, 120.96, 113.60, 111.48, 110.37, 55.68.  
HRMS (ESI): C14H12BN2O2+ calcd.: 251.0986, found: 251.0989. 
2-Bromo-5-(dimethylamino)phenylmethanol 1-19a 
 
In a Schlenk tube under an inert atmosphere, 3-(dimethylamino)benzyl alcohol (142.0 µL, 
992.0 µmol, 1.05 eq.) was dissolved in MeCN (4 mL). NBS (168.0 mg, 942.0 µmol, 1.0 eq.) was 
added portionwise over 10 min, keeping the temperature at RT with a water bath. After 17 h, 
NMR analysis showed no more conversion to the product. The solvent was removed by rotary 
evaporation and the residue was purified by flash column chromatography (Silica, 40 g, 
5:1→3:1→2:1 cyclohexane:EtOAc, Rf = 0.43, UV/KMnO4). Product-containing fractions were 
combined and concentrated in vacuo to yield the desired product as a white solid (162 mg, 75%). 
Analytical data was in agreement with the reported data.[101] 
1H NMR (400 MHz, CDCl3) δ/ppm: 7.35 (d, J = 8.8 Hz, 1H), 6.87 (s, 1H), 6.66 – 6.49 (m, 1H), 
















Under an argon atmosphere, oxalyl chloride (45.8 µL, 535.0 µmol, 1.2 eq.) was dissolved in DCM 
(2.2 mL) and cooled to -70°C in dry ice/acetone bath. A solution of DMSO (80.3 µL, 1.1 mmol, 
2.6 eq.) in DCM (1.1 mL) was added dropwise over 5 min, while keeping the temperature below  
-63°C. The mixture was stirred for 15 min. A solution of 1-19a (100.0 mg, 435.0 µmol, 1.0 eq.) in 
DCM (1.1 mL) was added over 5 min and the mixture was stirred for 15 min. Triethylamine 
(242.0 µL, 1.7 mmol, 4.0 eq.) was added dropwise and the yellow solution was stirred for 15 min. 
The cooling bath was removed and the solution was stirred at RT for 30 min, after which TLC 
showed complete conversion. The solution was washed with H2O (5 x 10 mL) and the combined 
aqueous layers were extracted with DCM (3 x 5 mL). The combined organic layers were washed 
with brine (15 mL), dried over Na2SO4 and were concentrated by rotary evaporation. The residue 
was purified by flash column chromatography (Silica, 13 g, cyclohexane→20:1 
cyclohexane:EtOAc, Rf = 0.3, UV/KMnO4). Product-containing fractions were combined and 
concentrated in vacuo to yield the desired product as a yellow solid (76 mg, 77%). Analytical data 
was in agreement with reported data.[101] 
1H NMR (400 MHz, CDCl3) δ/ppm: 10.32 (s, 1H), 7.50 (d, J = 8.8 Hz, 1H), 7.32 (d, J = 3.3 Hz, 
1H), 7.03 (d, J = 8.4 Hz, 1H), 3.02 (s, 6H). 
2-Formyl-4-(dimethylamino)phenylboronic acid pinacol ester 1-19c 
 
Under an argon atmosphere, 1-19b (50.0 mg, 219.0 µmol, 1.0 eq.), bis(pinacolato)diboron 
(72.4 mg, 285.0 µmol, 1.3 eq.), Pd(dppf)Cl2 (16.0 mg, 21.9 µmol, 10 mol%) and KOAc (64.5 mg, 
658.0 µmol, 3.0 eq.) were suspended in freshly distilled dioxane (1.5 mL). The mixture was 
heated to reflux for 3 h. After cooling, the solvent was removed by rotary evaporation and the 
residue was diluted with CH2Cl2 (20 mL). The solution was washed with H2O (3 x 20 mL), 
followed by brine (20 mL), was dried over Na2SO4 and concentrated by rotary evaporation. The 
residue was purified by flash column chromatography (Silica, 13 g, cyclohexane→20:1 
→15:1→10:1 cyclohexane:EtOAc, Rf = 0.27, UV/KMnO4). Product-containing fractions were 
combined and concentrated in vacuo to yield the desired product as a yellow solid (43 mg, 71%). 
Analytical data was in agreement with reported data.[102] 
1H NMR (400 MHz, CDCl3) δ/ppm: 10.70 (s, 1H), 7.88 (d, J = 8.1 Hz, 1H), 7.49 (s, 1H), 7.21 (s, 
1H), 3.08 (s, 6H), 1.36 (s, 12H). 
N,N-dimethylbenzo[d]benzo[4,5][1,3,2]oxazaborolo[3,2-b][1,2,3]diazaborinin-3-amine 1-19 
 
1-19 was synthesized according to the general procedure. 1-19c (15.0 mg, 54.5 µmol, 1.0 eq.) 
and 1-14a (22.6 mg, 76.3 µmol, 1.4 eq.) were mixed in the solvent (1.0 mL). The product was 
isolated as a white solid (11 mg, 77%).  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.52 (s, 1H), 8.11 – 8.06 (m, 1H), 7.72 (dd, J = 7.7, 1.2 Hz, 















13C NMR (101 MHz, DMSO-d6) δ/ppm: 152.54, 148.19, 145.00, 137.87, 134.57, 131.32, 122.57, 
122.49, 116.18, 113.35, 109.77, 109.70, 39.50.  
HRMS (ESI): C15H15BN3O+ calcd.: 264.1303, found: 264.1305. 
14H-benzo[d]benzo[4,5][1,2,3]diazaborinino[3,2-b][1,3,2]oxazaborinin-14-one 1-20 
 
1-20 was synthesized according to the general procedure. 2-FPBA (11.0 mg, 73.4 µmol, 1.0 eq.) 
and 2-hydrazinobenzoic acid (19.4 mg, 103.0 µmol, 1.4 eq.) were mixed in the solvent (1.0 mL). 
The product was isolated as a white solid (18 mg, 99%).  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.42 (s, 1H), 8.20 – 8.15 (m, 1H), 8.13 – 8.05 (m, 2H), 
7.90 – 7.85 (m, 1H), 7.83 – 7.76 (m, 2H), 7.74 (td, J = 7.4, 1.1, 1H), 7.30 – 7.24 (m, 1H).  
13C NMR (101 MHz, DMSO-d6) δ/ppm: 160.75, 145.82, 142.16, 135.38, 133.87, 131.50, 130.31, 
130.25, 130.15, 127.62, 122.77, 115.14, 114.42.  
HRMS (ESI): C14H10BN2O2+ calcd.: 249.0830, found: 249.0832. 
2-Bromocyclohex-1-ene-1-carbaldehyde 1-21a 
 
In a dry 100 mL flask under an inert atmosphere DMF (3.6 mL, 45.9 mmol, 3.0 eq.) was dissolved 
in DCM (50 mL) and cooled in an ice bath to 0°C. PBr3 (3.6 mL, 38.2 mmol, 2.5 eq.) was slowly 
added and the mixture was stirred while cooling for 1 h. A solution of cyclohexanone (1.6 mL, 
15.3 mmol, 1.0 eq.) in DCM (5 mL) was slowly added to the suspension while cooling. The 
mixture was slowly warmed to RT and stirred for 22 h. The reaction was quenched with H2O 
(50 mL) while cooling at 0°C. The mixture was neutralized by addition of solid NaHCO3 in small 
portions. The biphasic mixture was separated and the aqueous layer was extracted with DCM 
(3 x 50 mL). The combined organic layers were washed with brine (50 mL), dried over Na2SO4 
and concentrated by rotary evaporation. The residue was purified by flash column 
chromatography (Silica, 250 g, 2%→3%→5% EtOAc in cyclohexane, Rf= 0.21 in 
2% EtOAc/cyclohexane, UV, KMnO4 or DNP stain) to yield the desired product as yellow liquid 
(1.4 g, 49%).  
1H NMR (400 MHz, CDCl3) δ/ppm: 10.02 (s, 1H), 2.75 (tt, J = 6.3, 2.3 Hz, 2H), 2.28 (tt, J = 5.8, 
2.3 Hz, 2H), 1.80 – 1.73 (m, 2H), 1.72 – 1.65 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 193.90, 143.75, 135.42, 38.98, 25.14, 24.41, 21.24. 
HRMS (ESI): C7H10BrO+ calcd.: 188.9910, found: 188.9913. 
2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-1-ene-1-carbaldehyde 1-21b 
 
In a dry 50 mL flask under an Ar atmosphere, 1-21a (256.0 mg, 1.4 mmol, 1.0 eq.) was dissolved 
in dioxane (7 mL), followed by bis(pinacolato)diboron (378.0 mg, 1.5 mmol, 1.1 eq.) and 
potassium acetate (266.0 mg, 2.7 mmol, 2.0 eq.). The mixture was degassed by bubbling argon 
through the mixture for 10 min. Pd(dppf)Cl2 (49.5 mg, 67.7 µmol, 5 mol%) was added and the 
mixture was heated to 80°C for 2 h, after which UPLC-MS analysis showed full conversion to the 











dissolved in EtOAc (40 mL) and was washed with H2O (2 x 20 mL). The combined aqueous 
layers were extracted with EtOAc (2 x 20 mL) and the combined organic layers were washed with 
brine (20 mL), dried over Na2SO4 and were concentrated by rotary evaporation. The crude was 
purified by flash column chromatography (Silica, 33 g, cyclohexane:EtOAc 10:1, Rf = 0.24, 
UV/KMnO4/DNP). Product-containing fractions were combined and concentrated in vacuo to yield 
the desired product as yellow oil (258 mg, 81%).  
1H NMR (400 MHz, CDCl3) δ/ppm: 9.96 (s, 1H), 2.42 – 2.37 (m, 2H), 2.28 – 2.22 (m, 2H), 1.62 (p, 
J = 3.2 Hz, 4H), 1.31 (s, 12H). 
13C NMR (126 MHz, CDCl3) δ/ppm: 194.71, 149.31, 84.27, 29.72, 24.78, 22.60, 21.96, 21.23. 
HRMS (ESI): C13H22BO3+ calcd.: 237.1657, found: 237.1653. 
2-Phenyl-5,6,7,8-tetrahydrobenzo[d][1,2,3]diazaborinin-1(2H)-ol 1-21 
 
1-21b (32.0 mg, 135.5 µmol, 1.0 eq.) was dissolved in DMSO (1.4 mL) and H2O (1.6 mL). 
Phenylhydrazine (18.7 µL, 190.0 µmol, 1.4 eq.) was added and the suspension was stirred at RT 
for 10 min. For better solubility, MeCN (1 mL) was added and the mixture was stirred at RT for 
another 2 h. UPLC-MS analysis showed 50% BIQ product and 50% Pin protected hydrazone 
intermediate. TFA (3 drops) was added, followed by MeCN (500 µL). The solution was purified by 
preparative RP-HPLC (Method A). Product-containing fractions were combined and lyophilized to 
yield the desired product as a white solid (16 mg, 52%).  
1H NMR (500 MHz, DMSO-d6) δ/ppm: 7.83 (s, 1H), 7.49 – 7.43 (m, 2H), 7.40 (s, 1H), 7.39 – 7.33 
(m, 2H), 7.23 – 7.17 (m, 1H), 2.48 – 2.41 (m, 4H), 1.74 – 1.67 (m, 2H), 1.67 – 1.61 (m, 2H). 
13C NMR (126 MHz, DMSO-d6) δ/ppm: 146.18, 141.95, 139.52, 128.06, 125.02, 124.37, 26.85, 
25.26, 21.70. 







5.3 Stability and Reversibility of Boron-Assisted Oxime Formations 
NMR Oxime Stability Assay 
 
Stock solutions: 
- Phosphate buffer: 12.8 mM potassium phosphate (K3PO4) in D2O, pH 7.2, adj. with DCl 
- Oxime: 500.0 µM 1-1 in CD3CN 
- Internal Standard: 275.0 µM TMSP-d4 in D2O 
Procedure: 
Phosphate Buffer (430 µL) was mixed inside the NMR tube with the oxime 1-1 (110 µL) and the 
internal standard (10 µL). The final volume was 550 µL with the following final 
concentrations: 100 µM oxime 1-1, 10 mM phosphate buffer and 5 µM TMSP-d4 with a ratio of 4:1 
phosphate buffer: CD3CN. The sample was locked to the CD3CN residual peak and shimmed 
before recording the first 1H NMR spectrum. 
The stability of oxime 1-1 was determined by recording 1H NMR spectra every 7 h for the first day 
and then one spectrum per day for another three days. The integration of the oxime proton 






10 mM KPi, pH 7.2




Figure 23. NMR stability assay over four days. TMSP-d4 was used as internal standard. In the first three days a 
concentration difference of <5% was observed, which was attributed to errors in integration. After 96 h a concentration 
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First NMR Reversibility Assay Aldoxime 
 
Stock solutions: 
- Phosphate buffer: 13.1 mM potassium phosphate (K3PO4) in D2O, pH 7.2, adj. with DCl 
- Oxime: 500.0 µM 1-1 in CD3CN 
- Hydroxylamine: 27.5 mM methoxylamine hydrochloride in D2O 
- Internal Standard: 275.0 µM TMSP-d4 in D2O 
Procedure: 
Phosphate Buffer (420 µL) was mixed inside the NMR tube with the oxime 1-1 (110 µL), the 
hydroxylamine (10 µL) and the internal standard (10 µL). The final volume was 550 µL with the 
following final concentrations: 100 µM oxime 1-1, 500 µM hydroxylamine, 10 mM phosphate 
buffer and 5 µM TMSP-d4 with a ratio of 4:1 phosphate buffer:CD3CN. The sample was locked to 
the CD3CN residual peak and shimmed before recording the first 1H NMR spectrum. 
The reversibility of oxime 1-1 was determined by recording 1H NMR spectra every 2 h for a total 
of 60 h. The oxime protons are indicated with an arrow (Figure 24). A zoom-in of the NMR 














Figure 24. NMR assay for the reversibility of aldoxime 1-1 with an excess of methylhydroxylamine. NMR spectra were 
recorded over the course of 60 h. Complete formation of a new oxime species was observed within 10-19 h. 
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Second NMR Reversibility Assay Aldoxime 
 
Stock solutions: 
- Phosphate buffer: 13.1 mM potassium phosphate (K3PO4) in D2O, pH 7.2, adj. with DCl 
- Oxime: 550.0 µM 1-1 in CD3CN 
- Aldehyde boronic acid: 27.5 mM 1-2 in CD3CN 
- Internal Standard: 275.0 µM TMSP-d4 in D2O 
Procedure: 
Phosphate Buffer (430 µL) was mixed inside the NMR tube with the oxime 1-1 (100 µL), the 
aldehyde boronic acid (10 µL) and the internal standard (10 µL). The final volume was 550 µL 
with the following final concentrations: 100 µM oxime 1-1, 500 µM aldehyde boronic acid, 10 mM 
phosphate buffer and 5 µM TMSP-d4 with a ratio of 4:1 phosphate buffer:CD3CN. The sample 
was locked to the CD3CN residual peak and shimmed before recording the first 1H NMR 
spectrum. 
The reversibility of oxime 1-1 was determined by recording 1H NMR spectra every 2 h for a total 
of 28 h. The stacked NMR spectra are found in Figure 13b.  
NMR Reversibility Assay of Ketoximes  
 
Stock solutions: 
- Phosphate buffer: 13.1 mM potassium phosphate (K3PO4) in D2O, pH 7.3  
- Ketoxime: 550.0 µM 1-3 in CD3CN 
- Aldehyde boronic acid: 27.5 mM 2-FPBA in CD3CN 
- Internal Standard: 275.0 µM TMSP-d4 in D2O 
Procedure: 
Phosphate Buffer (430 µL) was mixed inside the NMR tube with the ketoxime 1-3 (100 µL), the 
aldehyde boronic acid (10 µL) and the internal standard (10 µL). The final volume was 550 µL 
with the following final concentrations: 100 µM ketoxime 1-3, 500 µM aldehyde boronic acid, 
10 mM phosphate buffer and 5 µM TMSP-d4 with a ratio of 4:1 phosphate buffer:CD3CN. The 
sample was locked to the CD3CN residual peak and shimmed before recording the first 1H NMR 
spectrum. 
Reversibility measurements were conducted every 30 min for a total of 26 h. The integrals were 
compared to the signal of TMSP-d4. After 75 min the equilibrium was almost reached. 





































Figure 25. NMR assay for the determination of the ketoxime reversibility with an excess of 2-FPBA. Four traces (out of 
52) are shown. The equilibrium was reached after 75 min.  
  



































































5.4 HPLC Assays on Oxime Formation Mechanism 
Oxime Formation with 1-4 
 
Stock solutions: 
Benzaldehyde: 50 mM in HPLC grade MeCN 
1-4: 5 mM in HPLC grade MeCN 
Phosphate buffer (KPi): 100 mM in dd H2O, pH 7.2 
Procedure: 
Phosphate buffer (156 µL), benzaldehyde (4 µL) and 1-4 (40 µL) were mixed in a PP HPLC vial 
to obtain a final concentration of 1 mM.  
Sample and references were analyzed by RP-HPLC on an Agilent 1100 LC system equipped with 
a YMC-Gel ODS-A 10 µm 4.6 x 150 mm column from Dr. Maisch GmbH at 25°C. Buffer A (A): 
0.1% TFA (v/v) in H2O/1% MeCN (v/v), Buffer B (B): 0.1% TFA (v/v) in MeCN/1% H2O (v/v). 
Gradient: 1% (2 min) - 99% (24 min) - 99% (2 min) (B). Samples were measured after 1 min, 30 
min, 60 min, 90 min and 15 h with injection volumes of 20 µL and UV absorption detection at 254 
nm. Conversions were calculated according to the peak area change of the benzaldehyde signal. 
New peaks at 17.522 min and 19.295 min of the 15 h run were collected and analyzed by UPLC-
MS (Table 3 and Figure 26). 
Table 3. Conversion of 1-4 and benzaldehyde to the oxime product 1-5. Percentages were calculated by the peak area 
change of the benzaldehyde signal. 
Time Conversion to 1-5 
1 min < 1% 
30 min <1% 
60 min 1% 
90 min 2% 




















Figure 26. a) HPLC trace of 1 mM benzaldehyde. b) HPLC trace after 60 min reaction time. c) HPLC trace after 15 h 
reaction time. The peaks at 17.522 and 19.295 min were collected and analyzed by UPLC-MS. d) ESI-MS spectra of the 
collected peaks. The desired product was found in the 17.522 min fraction, the oxidized product (MS trace inset) was 
found in the 19.295 min fraction. 
We proved the formation of the desired product 1-5 by LC-MS analysis of the newly formed 
peaks. Oxidation of the boronic acid (1-5ox) was also observed in a substantial amount. 
  
















































































































































Oxime Condensation with Triply Coordinated Boronates 
 
Stock solutions: 
Boronate 1: 5 mM potassium 2-formylphenyltrifluoroborate (2-FPTFB) in HPLC grade MeCN 
Boronate 2: 5 mM 2-formylphenylboronic acid MIDA ester in HPLC grade MeCN 
Benzylhydroxylamine (BnONH2): 5 mM in HPLC grade MeCN 
Phosphate buffer: 100 mM in dd H2O, pH 7.2 
Procedure: 
Phosphate buffer (192 µL), boronate 1 or 2 (4 µL) and BnONH2 (4 µL) were mixed in a PP HPLC 
vial to obtain a final concentration of 100 µM.  
Samples and references were analyzed by RP-HPLC on an Agilent 1100 LC system equipped 
with a Zorbax Eclipse XDB-C8 5 µm 4.6 x 150 mm column from Agilent at 25°C. Buffer A (A): 
H2O/1% MeCN (v/v), Buffer B (B): MeCN/1% H2O (v/v). Gradient: 1% (2 min) - 99% (24 min) - 
99% (2 min) (B). The samples were measured after 1 min, 30 min, 60 min and 90 min with 
injection volumes of 20 µL and UV absorption detection at 254 nm. For 2-FPTFB, conversions 
were calculated according to the area increase of the oxime 1-1 product signal compared to a 
100 µM product reference sample. For the MIDA boronate the area increase of the oxime 1-1 
product signal or the area decrease of the starting material could be used for conversion 
calculations (Table 4 and Figure 27). 
Table 4. Conversion of the triply coordinated boronates to the oxime product 1-1. Percentages were calculated by the 
peak area changes of the product or the starting material. 
Time 2-FPTFB MIDA boronate 
1 min 5% 12% 
30 min 51% 26% 
60 min 76% 46% 














Figure 27. HPLC chromatograms of the oxime conversion assays with triply coordinated boron species. a) Oxime 
condensation with 2-FPTFB after 1 min reaction time. b) Oxime condensation with 2-FPTFB after 90 min reaction time. 
c) Oxime condensation with MIDA boronate after 1 min reaction time. d) Oxime condensation with MIDA boronate after 
90 min reaction time. e) Oxime 1-1 product reference chromatogram. 
  








































































































5.5 Fluorescent Labeling of Immunoglobulin G 
 
Stock solutions: 
Phosphate Buffer:  50 mM Na2HPO4, 1 mM EDTA in dd H2O, adjusted to pH 7.5 
Hydroxylamine: 500 mM NH2OH hydrochloride in 50 mM NaHPO4/25 mM EDTA, pH 7.5 
buffer 
Antibody IgG:  0.96 mg/ml IgG in phosphate buffer. Concentration measured by the 
Nanodrop at 280 nm (MW = 146'000 g/mol, ε = 210'000 M-1cm-1) 
Active ester 1-6: 65 mM 1-6 in DMSO 
Fluorophore 1-7: 10 mM 1-7 in DMSO 
Hydroxylamine incorporation: 
A solution of 1-6 (10.0 µL, 650.0 nmol, 99.4 eq.) was added to the antibody solution (1.0 mL, 
6.5 nmol, 1.0 eq.) and the mixture was agitated at 35°C for 30 min. Purification was achieved by 
dialysis against phosphate buffer (2 x 1 L) at 4°C for 6 h and 18 h, respectively. For the oxime 
deprotection, hydroxylamine hydrochloride solution (80.0 µL, 40.0 µmol, 6115.2 eq.) was added 
to the antibody and the mixture was agitated at 36°C for 2 h. The modified antibody was dialyzed 
against phosphate buffer (2 x 1 L) at 4°C for 6 h and 18 h, respectively, to yield a final 
concentration of 0.742 mg/ml. 
Fluorescent Labeling: 
An aliquot of the modified IgG solution (50.0 µL, 254.1 pmol, 1.0 eq.) was treated with the 
fluorophore 1-7 solution (10 µL, 100.0 nmol, 393.5 eq.). The mixture was agitated at 37°C for 
80 min. The success of the labeling was controlled by SDS-PAGE analysis (200 V, 60 min) and 
fluorescent bands analysis in the gel imager. Final protein staining was performed with 
Coomassie Blue. 
1. Control experiment: 
An aliquot of the modified IgG solution (25.0 µL, 127.1 pmol, 1.0 eq.) was treated with 2-FPBA 
(2.0 µL, 25.0 mM in DMSO, 50.0 nmol, 393.4 eq.) at 37°C for 45 min. Then, fluorophore 1-7 
solution (5 µL, 50.0 nmol, 393.4 eq.) was added and the reaction mixture was agitated at 37°C for 
1 h. The reaction was analyzed by SDS-PAGE separation (200 V, 60 min) and fluorescent bands 
analysis in the gel imager. Final protein staining was performed with Coomassie Blue. 
2. Control experiment: 
An aliquot of the native IgG solution (25.0 µL, 163.5 pmol, 1.0 eq.) was diluted with phosphate 
buffer (7 µL) and was mixed with the fluorophore 1-7 solution (6.4 µL, 64.0 nmol, 391.4 eq.). The 
mixture was agitated at 37°C for 1h. The reaction was analyzed by SDS-PAGE separation 
(200 V, 60 min) and fluorescent bands analysis in the gel imager. Final protein staining was 
performed with Coomassie Blue. 



















31. 1-6, KPi, EDTA, DMSO, pH 7.5, 35°C, 30 min
2. NH2OH * HCl, KPi, EDTA, pH 7.5. 36°C, 2 h
3. 1-7, KPi, EDTA, DMSO, pH 7.5, 37°C, 80 min
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5.6 NMR Assay for BIQ Formation 
Stock solutions: 
207.5 µM 1-2 in CD3CN 
5.5 mM phenylhydrazine in CD3CN 
275 µM TMSP-d4 in D2O 
20.75 mM potassium phosphate buffer in D2O, pH 7.25 
The stock solutions were mixed in a NMR tube with the following final concentrations: 100 µM  
1-2, 100 µM phenylhydrazine, 5 µM TMSP-d4, 10 mM potassium phosphate buffer with a final 
volume of 550 µL and a ratio of 1:1 KPi in D2O/CD3CN. The sample was locked to the residual 
CD3CN peak and shimmed prior to the first measurement. BIQ formation measurements were 
conducted every 30 min over 23 h. The integrals were compared to the signal of TMSP-d4. After 
8.5 h the reaction was complete (Figure 28). 
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Figure 28. Time-course NMR of the BIQ formation over 23 hours. The reaction was carried out at 100 µM concentration 
in 1:1 KPi:CD3CN. The hydrazone proton (Ha) and the BIQ proton (Hb) are specified. The peak at -0.1 ppm corresponds 

































5.7 NMR Assay for BIQ Reversibility 
 
Stock solutions: 
207.5 µM 1-8 in CD3CN 
27.5 mM 2-FPBA in CD3CN 
275 µM TMSP-d4 in D2O 
20.75 mM potassium phosphate buffer in D2O, pH 7.25 
The stock solutions were mixed in a NMR tube with the following final concentrations: 100 µM  
1-8, 500 µM 2-FPBA, 5 µM TMSP-d4, 10 mM potassium phosphate buffer with a final volume of 
550 µL and a ratio of 1:1 KPi in D2O/CD3CN. The sample was locked to the residual CD3CN peak 
and shimmed prior to the first measurement. BIQ reversibility measurements were conducted 
every 30 min over 24 h, starting with the first measurement after 10 min. The integrals were 
compared to the signal of TMSP-d4. After 24 h no changes were observed. The comparison of 
the NMR spectra is found in Figure 18b. 
5.8 pH Effects on BIQ Formation 
 
Stock solutions: 
10.04 µM 1-2 in 100 mM potassium phosphate buffer pH 5.50/MeCN 9:1 
10.04 µM 1-2 in 100 mM potassium phosphate buffer pH 7.20/MeCN 9:1 
10.04 µM 1-2 in 100 mM potassium phosphate buffer pH 8.50/MeCN 9:1 
2.5 mM phenylhydrazine in dd H2O/MeCN 1:1 
2490 µL of the 1-2 stock solution was measured for 10 s, after which 10 µL of the 
phenylhydrazine stock solution was added and measured. Result analysis and calculations were 
performed with MS Excel. The accuracy of the calculated reaction kinetics is given by the 
calculated standard deviation (SD). The UV traces and the rate constant calculations are shown 




































KPi, MeCN, pH? KPi, MeCN, pH?
1-2 1-81-8a
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5.9 Effects of Glutathione and Human Serum on BIQ Formation 
 
Stock solutions: 
10.04 µM 1-2  in 100 mM potassium phosphate buffer pH 7.20/MeCN/HS 8:1:1 
10.04 µM 1-2 in 100 mM potassium phosphate buffer pH 7.20 with 5 mM GSH/MeCN 9:1 
2.5 mM phenylhydrazine in MeCN 
2490 µL of 1-2 stock solution was measured for 10 s, after which 10 µL of the phenylhydrazine 
stock solution was added and measured. Result analysis and calculations were performed with 
MS Excel. The accuracy of the calculated reaction kinetics is given by the calculated standard 
deviation (SD). The UV traces and the rate constant calculations are shown in Figure 19b and 
Table 2. 
5.10 Hydrazone Reversibility Assay 
 
Stock solutions: 
100.4 µM 1-2 in 100 mM potassium phosphate buffer pH 7.20/MeCN 1:1 
25 mM phenylhydrazine in MeCN 
25 mM benzylhydroxylamine in MeCN 
2490 µL of 1-2 stock solution was measured for 10 s, after which 15 µL (1.5 eq.) of the 
phenylhydrazine stock solution was added and measured. After 3.5 min 30 µL (3 eq.) of the 
hydroxylamine stock solution were added. BIQ formation turned out to be much slower compared 
to previous results even though a ten times higher concentration was used. This showed the 
decelerating effect of higher organic solvent concentrations. The kinetic results were analyzed 
and processed with MS Excel. After 13 h, the mixture was analyzed by UPLC-MS. About 15% of 
the corresponding oxime product was observed, proving that the BIQ formation was faster than 















































KPi:MeCN 1:, pH 7.2 KPi:MeCN 1:, pH 7.2
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Figure 29. a) UPLC chromatogram of the hydrazone reversibility assay after 13 hours reaction time. Approximately 15% 
oxime was found next to the BIQ 1-8 product. b) MS trace of the BIQ product. c) MS trace of the oxime product. Due to 
peak overlap, the BIQ ion is found as the most intense signal. In contrast to the BIQ, the oxime also showed a 
dehydration ion. 
  















































































































5.11 Fluorescence Measurements 
 
Figure 30. UV and fluorescence spectra of 1-19 and 1-19c in DMSO at 10 µM concentration. Arrows indicate the Stokes 
shift. For additional fluorescence properties, see Figure 22. 
Quantum yields were determined at 10 µM concentration in DMSO with excitation wavelengths 
370 nm and 365 nm for 1-19c and 1-19 respectively. 
Φ(370 nm) = 0.279 (1-19c) 
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Part II: DNA-Encoded Chemical Libraries 
6. Introduction to DNA-Encoded Chemical Libraries 
The development of DNA-encoded libraries is the focus of this part with an emphasis on the 
development of a natural product-like encoded macrocycle library. Library assembly, properties 
evaluation and protein affinity screening results are presented. Before the discussion of the 
experimental assays, a detailed introduction to the main concepts of combinatorial chemistry and 
encoding of chemical libraries is given. 
6.1 Combinatorial Chemistry and High-Throughput Screening 
The discovery of new lead compounds for drug development is an essential task for modern 
pharmaceutical research. The generation of large molecule collections is very tedious and costly 
due to the synthesis, purification and characterization of each substance. Combinatorial 
chemistry offers the potential to simultaneously generate large compound collections within a 
relatively short time.[103] These libraries usually range from several thousands to up to billions of 
different members. Library assembly is often performed by the chemical linkage of available 
building blocks in a repetitive manner.[104] Screening of these compound collections against 
biological targets (e.g. proteins) may lead to the discovery of new and interesting binders that are 
then further optimized with medicinal chemistry tools, often with the help of combinatorial 
methodologies. The concepts of combinatorial chemistry were developed in the 1980's when, for 
the first time, hundreds of peptides were synthesized in parallel on a solid support.[105,106] In the 
following decade, a large number of new library technologies were evolved, such as one-bead-
one-compound (OBOC) libraries,[107] phage display technology[108] and DNA-encoded chemical 
libraries.[109] 
 
Figure 31. Overview of the different types of combinatorial chemistry libraries. Orange/black boxes show the 
combinatorial technique, blue indicates the type of the chemical library and green shows the screening assay type.[104] 
Reprinted with permission.a 
Figure 31 shows an overview of the different types of combinatorial libraries. While most library 
types have the potential to generate compound collections of over a million members, parallel 
synthesis libraries and microarray libraries are much more focused (black boxes) and usually 
smaller. In the maturation process of the combinatorial chemistry technique, computational 
                                            
a Elsevier, License Number: 4526970559050, 13.02.2019 
 -62- 
chemistry evolved as an essential tool for the in silico creation and analysis of combinatorial 
libraries as well as for the handling of large screening data sets.[104] Computer-assisted library 
design contributes to the improvement of the chemical structure of building blocks and library 
members to cover a broader chemical space[110] or to create more specific variants of a known 
target binder.[111] Although combinatorial chemistry has opened a vast potential for the 
development of new drug substances, the drawbacks of this technology soon emerged. New 
strategies for library design were required for the identification of single compounds in large 
mixtures. Moreover, to create one member of every theoretically possible molecule with a 
molecular mass below 500 Da only using the common atoms of organic structures would exceed 
the number of atoms available in the universe.[103] After the initial enthusiasm about the new 
technologies, combinatorial chemistry was relegated for a long time to the creation of focused 
libraries for hit optimization whereas high-throughput screening (HTS) of compound collections 
was employed for the de novo discovery of drug compounds. Advances in combinatorial 
chemistry, especially the successful encoding of library members, led to the revival of these 
technologies and is nowadays re-employed in drug discovery and optimization by academic and 
industrial researchers. 
In the early days, companies performed HTS with randomly assembled compound collections 
from previous activities in dye and fine chemical synthesis.[112] Combinatorial methodologies 
enlarged those compound collections, using a few simple chemical reactions without paying too 
much attention to diversity issues. Owing to the huge chemical space, one might think that testing 
large numbers of molecules should increase the chance of finding new hits. However, it is more 
important to screen compound collections with a high diversity rather than large numbers.[113] An 
improved hit rate is often found with structurally diverse libraries in comparison to large, 
structurally more similar compound collections. This factor is why large pharmaceutical 
companies have invested a lot of money in maintaining and improving their libraries, with a focus 
on variety rather than size. Such collections typically consist of several hundred thousand to a 
few million compounds. HTS almost never delivers high affinity hits that fulfill all the criteria for 
drug market release in first instance.[113] Usually, the found hits become lead structures, which 
are further optimized by computational and combinatorial methodologies.[112] The limiting aspect 
of HTS screening libraries is that every library member needs to be acquired or synthesized, 
stored, dispensed and screened individually. These operations require large financial 
investments, equipment, space and people, which define the boundaries of the screening assay. 
With the technological progress in process automation, screening campaigns have become 
automated.[114] However, a screening campaign with about 1 million compounds lasts up to 
several months. Most often several rounds of screening are required to minimize the rate of false 
positive and false negative results. Biochemical methods are routinely used in in vitro HTS but 
cellular screening assays are also employed for lead discovery and optimization due to the higher 
physiological relevance. Fluorescence, luminescence and absorbance measurements are the 
most common detection methods for those operations. The measurable signal is either generated 
by direct enzyme of interest targeting (and thereby start or stop the generation of a luminescence 
signal) or by targeting the enzyme/protein to indirectly (de)activate a secondary process for the 
termination or release of a measurable signal by a second, unaffected enzyme.[114] Luciferase[115] 
and GFP[116] proteins are often found in these kinds of assays.[113] 
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6.2 Phage Display Libraries 
In 1985, Smith[108] described, for the first time, a system in which a filamentous bacteriophage  
(a virus that can infect bacteria) was used for the expression of peptides and proteins on its 
surface, induced by a previously cloned vector.[117] This method enabled the construction of 
phage libraries, in which every virus expressed a different peptide or protein. Most commonly 
filamentous E. coli bacteriophages (f1, fd, M13) are used for the generation of such libraries. 
Figure 32a shows the schematic setting of a phage display library. The expressed 
protein/peptide is usually displayed as a fusion protein with the phage pIII protein. The phage 
pVIII protein is alternatively used for the generation of such fusion proteins, however, only short 
peptides may be expressed with this system in order to retain phage functionality.[118] The 
expressed protein on the surface (phenotype) is physically connected to the viral DNA (genotype) 
inside the phage capsule. 
 
Figure 32. a) Schematic representation of a phage display library with an example of a displayed antibody. The library is 
divided into a phenotype part (antibody or protein/peptide) and a genotype part (DNA strand inside the viral cage).[119]  
b) Schematic description of the selection procedure (biopanning) with phage display libraries in vitro, in vivo and ex vivo. 
Several rounds of selections are usually conducted to find high affinity ligands.[120] Reprinted with permission.bc 
This technique allows the construction of libraries containing up to 1010 different variants, which 
are simultaneously screened against the target. DNA sequencing identifies all binders obtained 
after a selection round (biopanning) due to the genetic code inside the phage capsule. This is a 
big contrast to the libraries described in the previous section, where no compound encoding was 
applied. Phage display technology improves studies of protein-ligand interactions, receptor and 
antibody-binding site characterizations, screening of cloned antibody collections, search for 
enzyme substrates and display of epitopes for monoclonal antibodies. There are fewer limitations 
in terms of length and size of the expressed peptides and proteins compared to conventional 
synthetic peptide libraries.[120] Phage display libraries are highly efficient, inexpensive and even 
commercially available. In vitro, as well as in vivo assays, have been conducted with this library 
type (Figure 32b). Since bacteriophages can only express linear peptides, Heinis et al. 
successfully introduced post-translational bridging moieties to generate macrocyclic peptide 
libraries for an improved scaffold diversity.[121,122] The technology's main drawbacks are its almost 
exclusive applicability to binding assays and the expressed peptides and proteins only consist of 
the proteinogenic L-amino acids. Typical screening procedures for ligands with this library type 
are illustrated in Figure 32b. Biopanning starts with a first round of selections of the library 
against the targets. Weak or non-binding members are simply washed away and the remaining 
                                            
b Annual Reviews, License Number: 4527170686357, 13.02.2019 
c Elsevier, License Number: 4527140523283, 13.02.2019 
a) b) 
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binders are eluted and amplified in bacteria. In vitro, in vivo or ex vivo procedures, as well as 
combinations thereof, are possible depending on the assay requirements. Several rounds of 
target testing are often conducted to increase the enrichment of tight binders. The development 
of human monoclonal antibodies is a field in which phage display technology has been 
successfully applied.[117] 
6.3 DNA-Encoded Chemical Libraries 
Inspired by the success of monoclonal antibody development with phage display libraries, 
Brenner and Lerner proposed an encoded chemical library technique in 1992.[109] Their system 
used a solid support (beads) to immobilize each screening compound along with an encoded 
DNA strand on the same bead. This assembly allowed the synthesis of identifiable small 
molecules in a combinatorial way, giving access to very large libraries. The attached DNA strands 
carry unique "barcodes" for the different molecules, which allows testing the complete set of 
encoded molecules at once. This strategy was considered as a combination of the traditional 
high-throughput screening of compound collections and the encoded screening from phage 
display.[109,119,123] Only one year later, two groups published reports on the synthesis of bead-
immobilized peptide libraries with attached "barcode" oligonucleotide strands for peptide 
sequence encoding.[124,125] A few years later, three groups reported new concepts for the design 
of encoded small molecule libraries without the need of a solid support.[126–128] These findings led 
to the development of several different construction strategies for DNA-encoded chemical 
libraries (DECL).[126,127] This technology opened up the possibility to simultaneously screen very 
large numbers (up to billions) of small molecules in a time- and cost-efficient manner, which 
makes it affordable for smaller companies and academia. 
Types of DNA-Encoded Chemical Libraries 
There are two main DECL types that differ in the type of small molecule attachment. Single-
pharmacophore libraries (Figure 33a) consist of a double-stranded DNA with the small molecule 
attached to one of the strands (usually at the 5' end). This is the most frequently found library 
type in literature. Single-pharmacophore libraries are further subdivided in different types, 
depending on their encoding scheme (see next section).[129] The second, less commonly used 
library type is the dual-pharmacophore library (Figure 33b). In this setup, two pools of encoded 
small molecules are combined to form the final library. Both pools contain single-stranded DNAs 
that are complementary to each other. The small molecules are attached to the 5'- or the 3'- end 
of the oligonucleotides. Upon hybridization of the sub-libraries, a large combinatorial diversity is 
achieved and the ligand pairs end up at the same extremity of the duplex DNA strand. This library 
design is often referred to as encoded self-assembling chemical (ESAC) library technology and 
was introduced by researchers from the Neri group in 2004.[127] 
 -65- 
 
Figure 33. Schematic design of a) single-pharmacophore libraries and b) dual-pharmacophore libraries. The library 
types are drawn in a double helix DNA structure and in a linear structure.[119] 
Single-Pharmacophore Libraries: DNA-Templated Synthesis 
One variant of single-pharmacophore libraries was pioneered by the Liu group as early as 
2001.[130] In this approach, a preformed library of long DNA strands (templates), which carry the 
molecular scaffold (and/or the first building blocks) subsequently reacts with a set of building 
blocks, encoded by complementary DNA strands. Prior to the synthesis of the actual 
pharmacophore, the DNA template library is preassembled by a split-and-pool technology.[131] 
The added oligonucleotides carrying the new building blocks must be highly specific for annealing 
with certain regions of the longer DNA strand. The high specificity of the encoded building blocks 
is essential to correctly bring them in close proximity to its reaction partner. This assembly 
increases the local molarity of the reagents, which is very advantageous for the synthesis of 
encoded libraries. After successful coupling of the new building block with the scaffold moiety, the 
linker between the building blocks and their directing DNA strands are cleaved and the redundant 
DNA is removed to prepare the library for the next round of synthesis (Figure 34a). 
 
Figure 34. a) Schematic representation of the assembly of a DNA-templated library. The encoded building blocks 
specifically anneal with the template DNA strand to enable the chemical reaction. After the chemical reaction, linker 
cleavage and oligonucleotide removal are necessary to enable the next round of synthesis. b) A variation of the DNA-
templated synthesis method. The template DNA strand is replaced with a DNA strand carrying poly inosine (IN) stretches 
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With that method, the Liu group has created several different DNA-templated macrocycle 
libraries.[132–134] Li and co-workers reported a variation of this technology in 2013. A simple DNA 
strand containing poly-inosine stretches instead of predefined codons was used as the template 
DNA strand (Figure 34b).[135] Since poly-inosine stretches can undergo base-pairing with any 
codon segments, the combinatorial pre-assembly of the template DNA strands is unnecessary. 
Further variations have been developed, such as the Yocto reactor from the Danish company 
Vipergen.[136] This technology uses hairpin loops with attached building blocks that are annealed 
and ligated, so the reaction can be carried out in the thereby formed yoctoliter reactor. Repetition 
of this assembly yields a library of compounds with attached double-stranded DNAs that carry all 
necessary information. DNA routing is another type of DNA-templated synthesis and was 
reported by the Harbury group in 2004.[128] Long, preformed DNA strands are annealed to 
complementary strands that are attached to different solid supports. Only the oligonucleotides 
with the correct annealing site are retained on the support by hybridization, the excess DNA is 
washed away and transferred to another solid support with a different annealing oligonucleotide. 
Every solid support is then used for the reaction with a specific building block. This setup allows a 
library construction in a templated fashion, using several rounds of hybridization to the solid 
supports and chemical reactions with the building blocks. The technique is strongly dependent on 
a high fidelity in the hybridization step and, due to the complicated setting for library generation, 
may quickly turn out to be impractical for the synthesis of big and complex DECLs. 
Single-Pharmacophore Libraries: DNA-Recorded Synthesis 
DNA-recorded synthesis refers to an encoding strategy in which newly attached building blocks 
are subsequently encoded by DNA fragments bearing the codons for those building blocks 
(Figure 35a). This leads to a continuous elongation of the DNA chain while "recording" the 
introduced chemical moieties by DNA codons. This technique is presently the most popular 
encoding strategy.[119] 
 
Figure 35. a) Schematic representation of a DNA-recorded library. Encoded building blocks are modified with new 
chemical moieties, followed by an encoding step with another DNA fragment. In the shown case a single-stranded sub-
library is chemically modified, followed by encoding with a second, partially complementary single-stranded DNA. This 
yields a duplex DNA after enzymatic polymerization. The same type of library can also be obtained by sequential 
encoding with duplex DNA fragments. b) Representation of a library using duplex DNA fragments encoding whereby the 
“headpiece” covalently connects the forward and reverse DNA strands. 
As outlined in Figure 35a, the construction of this library type begins with a set of encoded 
chemical moieties for which either single- or double-stranded DNAs can be used. The encoding 
of a single-stranded sub-library often proceeds by splint ligation and Klenow fill-in techniques.[137] 
During this process, the single-stranded DNA is converted into double-stranded oligonucleotides 
which bear the codon and anticodon regions. There is no limit to the number of diversity elements 
that can be introduced since several consecutive splint ligation steps or repetitive 
restriction/ligation procedures with the duplex DNA can be performed.[138] Another encoding 
possibility is to directly start from a duplex DNA fragment, which is chemically modified and 
continuously encoded by duplex DNA ligations. Researchers from GlaxoSmithKline (GSK) 








































strands with each other using the so-called “headpiece” (Figure 35b). This part consists of a 
phosphorylated and PEGylated branched amine, which carries complementary short DNA 
strands (six and eight bases) at each end of the two PEG linker chains. This assembly creates a 
3' two base overhang that serves as the "sticky end" for consecutive duplex DNA encoding with 
short duplex DNA fragments.[139] The GSK researchers created a library of several hundred 
million members, applying four cycles of chemical modifications and subsequent encoding. 
Dual-Pharmacophore Libraries: Encoded Self-Assembling Chemical (ESAC) Libraries 
Dual-Pharmacophore libraries consist of complementary DNA strand pairs, which possess 
chemical moieties at their extremity.[140] This type of library, designed in 2004 by the Neri 
group,[127] was initially used for decoding with oligonucleotide microarrays.[141] A modified 
approach was introduced in 2015, which allowed for decoding of the library after affinity 
selections by high-throughput sequencing.[142] The first set of building blocks is coupled to a non-
coding oligonucleotide containing an abasic stretch that is further encoded by splint ligation to 
generate sub-library A. This library contains DNA strands with the codons for all the used building 
blocks along with the abasic site that is necessary for hybridization with the second sub-library. 
Sub-library B consists of building blocks that are directly coupled to their encoding DNA strands. 
 
Figure 36. a) Schematic assembly of an ESAC library. Two sets of encoded building blocks containing complementary 
DNA regions are annealed and subsequently encoded by polimerization. One set (building blocks A) contains an abasic 
site (grey zig-zag line), which can anneal with any codon from the second set of building blocks. b) A variation of the 
technique uses DNA strands as templates, which can anneal with PNA-encoded sub-libraries. 
Hybridization of the two sub-libraries yields all possible combinations in a double-stranded format. 
Subsequent polymerization copies the code from sub-library A onto the sub-library B DNA strand 
(Figure 36a). This arrangement generates one DNA strand with the codons for the building block 
pair, which is analyzable by high-throughput DNA sequencing. The chemical building blocks need 
to end up at the same side of the DNA duplex for application in protein affinity selections. 
Therefore, the building blocks must be connected to the 3'-end of one sub-library and to the  
5'-end of the other sub-library.  
Researchers from the Winssinger lab presented a similar approach, using peptide nucleic acids 
(PNAs) as encoding tags.[143] The PNA-encoded sub-libraries were hybridized with a pool of 
complementary DNA template strands to generate the dual-pharmacophore library (Figure 36b). 
PNAs were found to be more stable towards certain chemical reaction conditions compared to 
DNA, which creates the possibility to use chemical modifications of the building blocks, unknown 
to DNA-encoded library synthesis. Although PNAs can be chemically encoded during library 
assembly, an amplification procedure, such as PCR, known from DECLs, is not possible. That 
prevents an amplification of the PNA code for protein binders and renders decoding procedures 
very difficult. This is the reason why the PNA-encoded sub-libraries are hybridized with 
complementary DNA strands containing the building block codes in every possible combination.  
Another very interesting approach is the encoded dynamic combinatorial chemical libraries 
(EDCCL) methodology. This technology uses dual-pharmacophore libraries that are 












annealing stretches, induces this instability. Upon strong binding of a building block pair to the 
protein substrate, the thermodynamic equilibrium is shifted such as to generate higher amounts 
of the strong binder pair due to the dynamic recombination of the library. Repeating the 
procedure results in a high enrichment of the potent building block pair. 
6.4 Chemical Requirements and Hit Validation 
The main advantage of DECLs, compared to conventional libraries (compound collections), is 
that every single member is linked to a unique DNA codon. This phenotype (small-molecule) - 
genotype (DNA tag) connection is the key for successful hit identification, even though the 
biologically more interesting part consists of the small-molecules collection. Since most libraries 
are assembled in a split-and-pool synthesis manner,[131] chemical reactions need to be conducted 
in the presence of the DNA tag. For this purpose, the applied chemical reactions need to be 
oligonucleotide-compatible.[145] As we know from the research of Watson and Crick in the 1950s, 
DNA consists of a phosphoribose diester backbone with four different nucleobases (two purine 
and two pyrimidine bases).[6] This setup shows many potential modification sites for reactive 
chemicals. Predominantly, the phosphate backbone and the bases are susceptible to chemical 
modifications. Such alterations of the DNA tag in a DECL bear the risk that the DNA cannot be 
correctly amplified by PCR. Furthermore, lack of amplifiable DNA or read-out errors during 
oligonucleotide sequencing might result in the loss of potential target hits.  
Most standard chemical reactions are conducted at relatively high concentrations (10 mM - 1 M 
concentrations). For modifications of chemical entities attached to a DNA strand, however, the 
reactions need to be performed at much lower concentrations (1 µM - 1 mM concentrations). 
Stoichiometric increase of reagents (up to several thousand equivalents) forces reactions to 
proceed under pseudo-first-order conditions. This is why reactions that usually require millimolar 
concentrations are possible to be carried out with one reagent (such as the DNA-tagged building 
block) present at micromolar concentrations. The risk of random modifications to the DNA tag 
increases with the amount of added reagents. Additionally, only reactions and reagents 
compatible with the aqueous conditions, necessary for solubilizing the DNA, are useful for DECL 
construction. Therefore, highly reactive chemicals, such as organo-lithium compounds, most 
hydrides, anhydrides, acyl chlorides or very sensitive transition metal catalysts, may not be used 
since they react (violently) with water. Routinely-used reactions for the construction of DECLs 
include amide bond formation[146,147], copper-catalyzed click reaction[137,144], reductive 
amination[146,148], Suzuki reaction[42,145,148], Wittig-type reactions[132,134], Diels-Alder 
reaction[138,149,150], Staudinger reduction[137] and certain transition metal-catalyzed reactions.[151–
155] Even though there is a good set of chemical transformations that have been successfully 
applied for DECL construction, there are still major limitations to the methods due to the 
dependence of certain building blocks on special reaction conditions (organic solvents, high 
temperatures, additives, acidic pH). Immobilizing the DNA on a solid support helps overcome the 
DNA incompatibility with high levels of organic solvents. Although such a technique allows the 
use of special chemical transformations, the immobilizing strategy also complicates library 
synthesis because of extensive solid support handling and might lead to undesired DNA 
damage.[138] A recent publication from Paegel investigated the effects of a series of reactions on 
the amplification performance of a DNA strand after the chemical reaction.[145]  
In general, double-stranded DNA is less susceptible to undesired modifications due to the 
shielding properties of the Watson-Crick base pairing (also see results in Chapter 8.3). This is 
why researchers from GSK preferred to develop the "headpiece" duplex DNA-encoding system 
for the generation of their 800 million member library (description in Chapter 6.3).[139]  
Such limitations clearly specify the need for new DNA-compatible reactions to generate new and 
more diverse libraries by reactions currently unknown in DECL assembly.[156–158] 
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For the construction of a successful library, there are several properties that need to be fulfilled 
by the building blocks themselves. The DNA-compatibility and the reactivity under the aqueous 
conditions were mentioned before, but the size and shape of the building blocks also need to be 
considered. Depending on the number of used building blocks, the molecular weight of the 
individual blocks is limited. Additionally, functional groups, heteroatoms and chiral centers play a 
very important role since they define most of the properties of the final compound library. 
Creating drug-like molecules is only possible by taking the proposed physicochemical guidelines, 
such as the rule-of-five defined by Lipinski, into account.[159] For a detailed discussion on the 
properties of conventional small molecules and macrocycles, see Chapter 8.1.  
In the simplest implementation, chemical building blocks with one reactive functional group (most 
often amines or carboxylic acids) are coupled in a single step to the encoding DNA strand. Such 
encoded compound collections (sub-libraries) are commonly used in dual-pharmacophore 
libraries (see previous section). More complicated libraries are created by the subsequent 
attachment of two or more building blocks to the same encoding oligonucleotide (most often 
employed in single-pharmacophore libraries). For this purpose, the building blocks and/or the 
library scaffold require at least two sites with reactive functional groups to conduct the building 
block connections. For linear compounds, amino acids (such as alanine, proline or serine) and 
amino acid derivatives are very well suited. It is often desirable to also obtain branched or cyclic 
molecules, which demand a combination of building blocks with two or three modification sites 
(e.g. lysine, cysteine or aromatic derivatives). 
 
Figure 37. Representation of selected DECL examples with various types of building blocks. The exact encoding 
scheme with codon coloring was neglected for simplicity. a) A linear encoded library consisting of amino acids (blue), 
formyl acids (pink) and amines (green).[160] b) A branched DECL using a trifunctional linker basic scaffold (black). The 
diversity was introduced with amino acids (red), amine modifiers (like carboxylic acids or sulfonyl chlorides, blue) and 
maleimides (green).[138] c) A four building blocks library using 1,3,5-triazine as the central scaffold trifunctional linker. 
Diversity was introduced with amino acids (pink), bifunctional acids (green) and amines (red and blue).[139] 
d) A macrocyclic library consisting of coupled amino acids. The central scaffold (blue) consisted of an amino acid with an 
alkyne sidechain for click macrocyclization.[161] 
Figure 37a shows a typical example for a library that was designed in a linear fashion. The DNA 
strand was modified with a set of amino acids that were further coupled to a collection of formyl 
acid building blocks. The sub-library was finally modified with a series of amines by reductive 
amination to yield a 110 million member DECL.[160] A branched approach was shown by the Neri 
group for the discovery of carbonic anhydrase inhibitors from a one million compound library.[138] 
They used a modified hydroxyproline central scaffold, which connected the DNA strand with three 
different sets of building blocks (Figure 37b). Aromatic (or heteroaromatic) rings are very well 
suited for the construction of non-linear encoded libraries. In the previously mentioned GSK 800 
million members library[139], 1,3,5-triazine (from cyanuric chloride) was used as the central 
scaffold to connect the DNA codons with the building blocks (Figure 37c). In their approach, they 
used bifunctional building blocks (amino acids and bifunctional acids), as well as monofunctional 
building blocks (two sets of amines) for library construction. Another approach from GSK 
researchers was reported in 2018, showing a collection of 2.4 trillion macrocyclic peptides 
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which was macrocyclized in the last step using the Click reaction. For this purpose, an amino 
acid-derived trifunctional linker with an alkyne sidechain was used. 
The selection of a DNA-encoded chemical library against the target proteins of interest 
represents the most important step for the discovery of strong protein binders or enzyme 
inhibitors. In contrast to conventional high-throughput screening, no selection-related absorption 
or luminescence events are necessary to detect binding of the ligand to the target. The most 
common approach used for these selections is to immobilize the target on a solid support and 
perform an affinity screen with the DECL. Commonly used solid supports include functionalized 
magnetic beads[162] or cyanogenbromide-modified sepharose.[163] Such particles, especially 
magnetic beads, allow very simple bind, wash and elute procedures. Furthermore, they enable 
automation of the affinity screenings, which results in a faster screening of multiple target 
selections in parallel.[164] qPCR was shown to be a reliable tool for selection quality estimations 
before DNA sequencing. With this relatively simple quality control, potentially tricky selections are 
optimized to improve the enrichment factor of the binding molecules.[165]  
Selection strategies that do not make use of solid support immobilization have also been 
proposed. Capillary electrophoresis might be applied to separate protein-ligand complexes from 
the remaining library with subsequent DNA sequencing.[166,167] Interaction-dependent PCR is 
another option for affinity selections. A library of DNA-tagged proteins is screened with a DECL in 
the presence of a polymerase. In the event of a ligand binding to the protein, the DNA-tag from 
the protein anneals with the ligand DNA strand and serves as primer for the polymerase DNA 
chain extension (PCR).[168] Owing to this PCR step, the code from the protein is copied to the 
ligand DNA strand, which is further analyzed by DNA sequencing. The technique allows the 
screening of protein collections with a DECL in a single step. The technology has been further 
improved by using interaction dependent PCR in unpurified protein mixtures from cell lysates.[169] 
Direct crosslinking of the encoded ligand and the target protein enables the selection of strong 
and weaker ligands. Upon binding of the ligand to the protein target, a crosslinking unit attaches 
the encoded compound to the protein. The crosslink moiety is separately introduced into the 
selection mixture as a DNA-tagged reactive molecule, which undergoes a hybridization with the 
DECL to trigger the crosslinking of the ligand with the protein. This procedure stabilizes the 
protein-ligand complex and helps to enrich the binders more strongly.[170] A similar variation of 
this method has also been applied to generate a covalent link between the target protein and the 
DNA codon of the ligand by a photo cross-linking method.[171] 
High-throughput sequencing has revolutionized the use of encoded chemical libraries. Decoding 
the eluted binders from the affinity selections identifies the molecules and yields a relative 
quantification by comparing the presence of the found molecules in the library before and after 
protein selection (enrichment factor).[172] For the determination of the absolute binding properties, 
the ligands identified need to be individually tested. This is particularly important for the exclusion 
of false positive results, which often result from unspecific (random) binding to the protein, the 
solid support, or from systematic difficulties.  
A series of hits is frequently chemically resynthesized and tested against the protein target with 
biochemical or biophysical methods.[119] Isothermal titration calorimetry (ITC) is very well suited 
for this task since the binding constant (KD) of the ligand to the protein target is directly 
determined from the measurement. Nevertheless, this methodology exhibits several limitations, 
most notably the requirement for a certain minimal amount of chemical and protein. This is the 
limiting factor for proteins, which are often only available in very low quantities. Furthermore, the 
solubility of the tested ligands might cause problems during affinity measurements. ITC accepts a 
certain percentage of organic solvents but the protein must be stable under these conditions. In 
this prospect, lipophilic compounds most often cannot be tested with this method.  
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For difficult cases, it may be beneficial to resynthesize the compounds with a fluorophore tag to 
perform fluorescence polarization measurements.[172] On-DNA resynthesis ensures the solubility 
of the compound in the aqueous environment, which is especially advantageous for lipophilic 
molecules. Additionally, the synthesis of the compound is simplified due to the straightforward 
DNA purification techniques (such as ethanol precipitation). Researchers from the Neri group 
have recently shown methodologies to quickly assess the binding properties of DNA-tagged 
ligands by fluorescence and chemoluminescence methods.[173] However, care must still be taken 
in the application of such methods, since the DNA strand can potentially have an influence on the 
binding affinity of the small molecule to the protein target. In DECL technology, there is a certain 
chance to miss potentially good target binders due to the changes in binding, induced by the 
oligonucleotide tag. 
 
Figure 38. Selected examples for tight binders against various protein targets. a) A binder from GSK against neurokinin 
3 (NK3) based on their "headpiece" encoded single-pharmacophore library technique with 41 million library 
members.[174] b) A binder from the Neri research group against tankyrase-1 (TNKS-1) from a two building blocks 
recorded library consisting of 103'200 library members.[175] c) A 334 million membered library from a recorded library 
with triazole connected oligonucleotide codons. The library was tested against soluble epoxide hydrolase (sEH) and 
revealed the shown binder.[176] d) The shown α-1-acid glycoprotein (AGP) binder was identified from a 235'400 members 
dual-display library, developed by the Neri lab.[177] 
A few binders found against different target proteins are shown in Figure 38. All of these hits 
were discovered using the encoded chemical libraries technology with various types of library-
encoding procedures. All of these binders showed very tight binding properties with binding 
affinities in the nanomolar range. The AGP binder (Figure 38d) was identified from an ESAC 
library, whereas all other shown binders were found from single-pharmacophore libraries. The 
soluble epoxide hydrolase (sEH) binder in Figure 38c was generated with a library approach that 
used copper-catalyzed click reactions to connect the encoding DNA fragments by triazole units. 
No enzymatic encoding was necessary for the generation of this library and the codon connecting 
units were well tolerated by the polymerases for affinity selection analyses.[176] 
6.5 Description of our Natural Product-like DNA-Encoded Macrocycle Library 
The number of publications about DNA-encoded small molecule libraries has vastly increased in 
the last 15 years. Due to new encoding strategies, along with high-throughput DNA sequencing, 
the technology has become very interesting for industry and academia. Most of the reported 
libraries use linear or branched chemical moieties, often consisting of peptidic fragments. The 
number of encoded macrocycle libraries, however, is low; predominantly the Liu research group 
has developed DNA-encoded macrocycle libraries with their DNA-templated library synthesis 
approach. Their earliest report from 2004 generated a DNA-templated library with 65 
macrocycles.[132] A few years later, they reported the development of a new macrocyle library 
consisting of 13'000 members.[133] From this library, several protein inhibitors were found.[178,179] 
In 2018, they published the synthesis of a new library with 256'000 macrocyclic members.[134] 
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macrocycle libraries. GSK showed the assembly of a peptide macrocycle library with 2.4 x 1012 
members. The Neri group published a 35 million macrocycle-containing library, based on a 
peptide macrocycle scaffold with large sidechain diversity (Figure 40d). Macrocycles, as a 
structural class, are still under-represented in drug discovery despite their special properties 
concerning oral bioavailability (see Chapter 8.1 for a detailed description of the physicochemical 
properties of macrocycles).[180] 
We envisioned the design of a new DNA-encoded macrocycle library (DEML) comprising of 
mixed peptide-polyketide and polyene moieties that resemble natural product macrocycles.  
 
Figure 39. Structures of macrocyclic natural-products and drugs. Polyene, polyketide and special peptidic moieties are 
highlighted. a) Macbecin an antitumor antibiotic isolated from Nocardia bacteria.[181] b) Patellamide A an anticancer 
therapeutic agent isolated from Lissoclinum patella, an ascidian.[182] c) Everolimus is an immunosuppressant agent used 
in transplantation. It is also known as Afinitor from Novartis.[183] 
A few examples of such natural product-like macrocycles are shown in Figure 39. Our main 
focus during library development was the structural diversity of our macrocyclic scaffold. We 
included natural product-like moieties at two distinct positions in the ring, along with other 
hydrophobic elements to increase the number of different ring sizes and shapes. Figure 40a 
shows the schematic construction of our library. We used an ethylene diamine-modified 
terephthalic acid as the core structure for the further attachment of the building blocks and the 














































Figure 40 a) Schematic representation of the macrocycle library presented in this work. The library contains three 
building blocks, which are encoded by the attached DNA strand. A total of approximately 1.4 x 106 library members were 
generated during the assembly of the DEML. The structure part underneath displays the exact linkage between DNA 
strand and the macrocycle. b) Representative building block examples from the three diversity elements.  
c) The reported DNA-templated macrocycle library from the Liu lab.[134] It contains four diversity elements, which 
generate high scaffold diversity. d) The recently reported library from the Neri group.[137] The basic scaffold is decorated 
with three sets of diversity elements to generate deep sidechain variation. 
Two sets of building blocks were incorporated within the ring scaffold for ring diversity 
enhancement (giving up to 2'142 macrocycle scaffolds) and a third set was attached at the ring 
periphery to generate a high number of library members (approx. 1.4 x 106 members). The 
building blocks of the first diversity element were designed to mainly incorporate natural product-
like moieties and comprised of alkenes, dienes and alkyl chains, but also aromatic, 
heteroaromatic and etheral moieties were introduced (Figure 40b).  
The second diversity element was mainly derived from amino acids. We used L- and D- amino 
acids, along with several unnatural modifications thereof. A bunch of elements were specifically 
designed and synthesized to further incorporate natural product elements and to vary the size 
and rigidity of the macrocyclic ring.  
The last diversifying element was a large series of terminal alkynes, which were attached after 
macrocyclization. This set diversified the library with a broad range of functional groups and 
structural elements, highly varying in size, shape and lipophilicity.  
The reported macrocycle library from the Liu group (Figure 40c) showed a high diversity of the 
ring scaffold but contained mostly peptidic moieties. In comparison to our work, they did not 
include larger hydrophobic moieties based on pure carbon frameworks. Furthermore, the 
peripheric diversity of their macrocycles was much lower compared to other macrocycle libraries. 
The setup of the Neri library showed a constant peptide macrocycle scaffold with three 
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Figure 41. Split-Pool synthesis scheme. For combinatorial library assembly the compounds pool is divided into several 
vessels (split), coupled with the next building blocks, encoded with a DNA codon and finally pooled to get to the next 
step of the library construction. Three split-and-pool steps were necessary for the synthesis of the DEML, whereby the 
DE-1 introduction did not proceed in a parallel manner, as was it the case for DE-2 and DE-3 couplings, but in single 
steps with HPLC purification. Labeled spheres represent the complete building block pool of the corresponding diversity 
element. Unlabeled spheres represent single building blocks. 
For the construction of our macrocycle library, we used the split-and-pool technique to synthesize 
our compound collection in a combinatorial manner.[131] The first diversity elements (21 building 
blocks) were introduced off-DNA and were subsequently coupled to the DNA codon, and followed 
by HPLC purification. The collection of these encoded compounds was pooled and used for the 
simultaneous introduction of the trifunctional linker. For the modification with the amino acid sub-
library, we split the DE-1 pool into 102 vessels, performed the reactions with all DE-2 building 
blocks, followed by encoding and pooling again (second split-pool event in Figure 41). This sub-
library consisting of all DE-1/DE-2 combinations was cyclized to generate the first macrocycle 
sub-library (2'142 macrocycles). It was then divided into 663 vessels and reacted with the alkyne 
building blocks (DE-3). After encoding and pooling, we obtained the final macrocycle library 
comprised of 1'420'146 members.  
We then tested our DEML against human serum albumin (HSA), α-1-acid glycoprotein (AGP) and 
carbonic anhydrase 9 (CA9). HSA is the most abundant protein in the human blood serum and 
carries mostly acidic ligands, which are otherwise insoluble in blood serum.[184,185] Many 
commercial drugs (e.g. warfarin or ibuprofen) are transported by HSA [186,187]. AGP is a second, 
less abundant transport protein in the human blood serum, which carries mainly neutral and basic 
(drug) molecules, such as the macrocyclic polymyxins (e.g. Colistin).[188] These plasma proteins 
are of major importance for the development of new drug candidates, which might be bound and 
transported by those carrier proteins. CA9 is one of the isoforms of the zinc-containing 
transmembrane enzyme, carbonic anhydrase.[189] It is involved in tumor acidification by hydration 
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as a marker for tumor hypoxia and acts as a prognostic factor for several human cancers.[189] 
Owing to these properties, CA9 has gained a lot of attention in drug research. 
The first version of the DNA-encoded macrocylce library (see next Chapter) was initially 
developed in a Sinergia project (Engineering the targeted drugs of the future: A general 
approach, number: 160699) in collaboration with the Schneider and Neri research groups from 
the ETH Zürich. From this work, two macrocycle libraries were published, each from the Neri[137] 
and the Gillingham group.[190] The Schneider research group focused on the development of 






7. Assembly of a DNA-Encoded Macrocycle Library 
7.1 Chemical Library Designs 
First Design of the DNA-Encoded Macrocycle Library 
 
Figure 42. Synthetic scheme of the first library design. The initial scaffold was modified by boron-assisted oxime 
condensations, followed by Suzuki-Miyaura cross-coupling with a set of bromoazides. After DNA linkage, the third 
diversity element consisting of iodopropargyl amino acids was introduced, continued by copper-catalyzed click 
macrocyclization. The final diversification was achieved by Suzuki-Miyaura cross-coupling with a boronic acids sub-
library. Detailed DNA encoding is omitted for clarity. The test macrocycle synthesis was performed off-DNA. Estimated 
library size: 4.3 x 107 members. 
The first attempt to build a macrocycle library was based on the subsequent modification of a 
linker-modified 4-amino-2-formylphenylboronic acid subunit. Inspired by the very successful 
boron-assisted oxime condensation methodology (described in Chapter 2), we initially envisioned 
the synthesis of several oximes with a selection of hydroxylamines. Subsequent modification of 
the oxime boronates with a set of commercial or synthesized bromoazides in Suzuki-Miyaura 
reactions would deliver the azido-acids sub-library. Figure 42 shows an overview of the library 
design. The azido-acids sub-library would be treated like a single diversity element since we 
anticipated synthesizing all members individually with separate purification steps. After DNA-
encoding, the third diversity element consisting of iodopropargyl amino acids would be introduced 
by amide couplings, followed by CuAAC-mediated macrocyclization and a final diversification 
step with a large set of boronic acids. Given the high synthetic effort to generate the azido-acids 
and the modified amino acids sub-libraries, we sought to end up with a forty- to fifty-million 
macrocycle library.  
The actual synthesis of this library turned out to be tricky. We tested the chemistry without the 
introduction of any DNA strands to be able to use all analytical methods for small molecule 
characterization and we focused on reaction conditions that were potentially compatible to on-
DNA synthesis. Oxime formation (with aminooxyacetic acid) showed to be the simplest step of all 
and the reaction proceeded with full conversion. The Suzuki-Miyaura cross-coupling revealed a 
high intolerance towards the oxime. Only very low quantities of the desired azido-acid product 
could be generated, with mostly deborylation products found. A swap in assembling order yielded 
a much higher amount of product. The Suzuki-Miyaura reaction of the azido-bromide  
(4-azidophenylbromide was used as test substrate) with the aldehyde subunit yielded >60% 
product. Oxime generation was then achieved by acid-catalyzed oxime condensation with near 
quantitative yields. Due to the swap of the reaction order, the advantageous boronic acid-assisted 
oxime condensation was not possible anymore. In the fourth step (the DNA encoding was 
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whereby the amino acid was modified beforehand according to a literature procedure.[191] The 
fifth step of the trial macrocycle assembly turned out to be the final step of the synthesis. Even 
though reports of very successful copper-catalyzed iodoalkyne-azide click reactions were 
published,[192] we could not achieve the desired macrocyclization along with a conserved iodo-
triazole moiety. The main side products found, were alkyne and triazole deiodinations. Linear, 
dimeric structures with intact iodotriazoles could also be identified. Swapping the reaction order, 
like in the case of the first two steps, was not possible either, because the click reaction between 
the azido-acid and the alkyne-amino acid yielded very low amounts of the target iodotriazole. 
Second Design of the DNA-Encoded Macrocycle Library 
 
Figure 43. Synthetic strategy of the second macrocycle library attempt. The building blocks displayed in the box were 
used for strategy validation on-DNA and off-DNA. The strategy included three amide coupling steps, two cross-
couplings, one CuAAC and one SN2 reaction along with protection-deprotection chemistry. The exact DNA-small 
molecule linkage and the detailed enzymatic encoding are omitted for clarity. 
Due to the synthetic difficulties of the first library strategy, we developed a new library assembly 
procedure. We only included chemical transformations that were known for DECL compatibility, 
along with readily available building block collections. The strategy is outlined in Figure 43. We 
started with 2-bromo-5-hydroxyaniline as modular scaffold with three diversification sites. The 
hydroxy group was used for the attachment of an azido linker by nucleophilic substitution for the 
later connection of the small molecule to the DNA strand. Under common SN2 reaction conditions 
at elevated temperatures, the substitution selectively occurred with the aromatic alcohol. For the 
protection of the aromatic amine, we considered TFA as suitable for our needs due to the simple 
installment with trifluoroacetic anhydride and its stability during library assembly.[193]  
The first diversity element was introduced by Suzuki-Miyaura cross-coupling in an aqueous 
environment. We used 3-(2-carboxyvinyl)phenylboronic acid (see the black box in Figure 43) as 
building block for the strategy validation. The encoding step was skipped in the first attempt to 
prove the suitability of the chemistry off-DNA. For a trifunctional linker, we chose  
4-bromophenylalanine, which connected the two ring diversity elements and provided the 
coupling site for the final peripheral diversification. We also considered 3-bromo-5-aminobenzoic 
acid as a potential linker, which would keep the third diversity element closer to the ring scaffold, 
but this molecule turned out to be very inefficient in standard amide couplings. Subsequent ester 
hydrolysis was performed using lithium hydroxide. It was important to use a final concentration of 
5 mM LiOH to ensure efficient ester hydrolysis, while keeping the TFA protecting group 
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test macrocycle assembly by the introduction of L-alanine under standard amide coupling 
conditions. The following deprotection step (ester and trifluoroacetamide) was achieved by an 
increased LiOH concentration (50 mM) at slightly elevated temperatures (45°C). The 
macrocyclization step again turned out to be the bottleneck of this synthetic approach. We tested 
several conditions by exchanging coupling reagents and solvents/bases to achieve 
macrocyclization, but at best, we found 8% conversion of starting material to the desired 
macrocycle. We tried to determine whether the geometry or flexibility of the macrocycle was 
unfavorable for the cyclization to proceed. For this purpose, we attached glycine after the second 
diversity element, which should act as a very flexible three-atom spacer. While the attachment of 
the glycine was successfully achieved, the macrocyclization failed again. Incorporation of a three-
atom spacer, containing a more reactive primary alkylamine (2-bromoethylamine), by nucleophilic 
substitution with the aniline nitrogen was achieved in very low amounts.  
The described synthesis was repeated on-DNA as well, which was successfully conducted up to 
the macrocyclization step (amide coupling conditions were adopted from literature 
procedures).[147] We obtained the desired macrocycles neither on-DNA nor as small molecule. 
With the linear on-DNA macrocycle precursor, we also tested Suzuki-Miyaura cross-couplings to 
validate this diversification step under DNA-compatible conditions. The desired cross-coupled 
product was not clearly identified, but we saw a strong peak broadening, which was a hint that 
potential DNA damage had occurred.  
Concluding, we realized that the presented strategy was in principle suitable for synthesis on 
DNA and the amide and protection/deprotection steps worked with the developed conditions. The 
reactivity of the aniline moiety was the limiting factor for the synthesis. Alternative strategies with 
acyl chlorides, that should be more reactive towards amide bond formation with anilines, were not 
tested since acyl chlorides are incompatible with the aqueous conditions required for on-DNA 
synthesis. 
Final Design of the DNA-Encoded Macrocycle Library 
Based on the results from the design of the second library, we developed a new but similar 
strategy to achieve successful macrocyclization. We excluded the set of boronic acids as DE-3 
building blocks due to difficult transformations and the potential for DNA damage by the palladium 
catalysts. We instead considered copper-catalyzed click reactions (CuAAC) with terminal alkynes 
more suitable for DE-3 incorporation. These reactions are routinely used in biological 
environments since they work at low concentrations with high efficiencies.[97,194–196] The 
development of a new central scaffold with a more reactive amine for the macrocyclization step 
was the main focus of this new approach. We considered 2-bromo-5-hydroxybenzaldehyde (A) 
as a valuable candidate for the generation of the natural product-like DEML. The aldehyde gives 
the opportunity to incorporate chemically interesting moieties via a set of different chemical 
transformations. Most importantly, Wittig-type reactions were selected for the generation of 
polyolefin structures. Unfortunately, modifications of this compound turned out to be tedious and 
impractical for the synthesis of a larger set of scaffold-DE-1 blocks. 
 
Figure 44. Four commercially available central scaffold units that were evaluated for macrocycle library synthesis. 
B could be modified with 3-azidopropanol as the DNA linker in a nucleophilic aromatic 
substitution, but the aldehyde needed acetal protection. The isolated product was a mixture of 
para (desired) and ortho (undesired) substitution to the aldehyde in a 2:1 ratio. The most similar 
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amine with a carboxylic acid that was further modified with Nosyl-protected ethylenediamine  
(2-3). The limiting step in this approach was the introduction of a linker for DNA attachment (we 
used the same linker from step 1 in Figure 43). The hydroxy group and the sulfonamide of the 
Nosyl protecting group were both modified by nucleophilic substitution. This led to the 
development of a strategy, based on a 2-iodoterephthalic acid core structure (D).  
3-Azidopropylamine 2-1 was coupled with the terephthalate derivative D and further modification 
with the Nosyl-protected diamine 2-3 yielded the basic structure for the assembly of the first 
building block set (2-4 in Figure 45). The diversification element was introduced by cross-
coupling reactions (see Chapter 7.4 for further details). 
 
Figure 45. Synthetic scheme for the synthesis of the diversity elements 1 sub-library. a) HATU, DIPEA, THF/DMF, RT, 
2 h, 95%. b) LiOH, H2O/MeCN 1:1, RT, 4 h, 98%. c) HATU, DIPEA, DMF, RT, 3 h, 92%. 
We synthesized a set of 21 building blocks, which were further used for the assembly of the DNA-
encoded macrocycle library. A detailed synthetic outline is shown in Figure 46. The first set of 
building blocks was encoded with a short DNA strand, pooled and modified with the trifunctional 
linker 2-5. The second diversity element (102 amino acid building blocks) was introduced in a 
split synthesis step by amide coupling (compare Figure 41 for details about the split- and pool 
synthetic steps). These building blocks were encoded and combined to yield the DE-1/DE-2 pool. 
After full deprotection of the ester and the Nosyl group, the DE-1/DE-2 pool was macrocyclized to 
yield the DEML sub-library (smDEML), which was modified by click reaction with 663 terminal 
alkyne building blocks in a split synthesis step. Encoding and pooling of the vessels yielded the 












































Figure 46. DEML synthesis overview. The individual steps are given with optimized reaction conditions. Split- and pool 
steps are not especially marked. a) Cu-TBTA, NaOAsc, TEAA buffer pH 7.2, DMSO, RT, 20 h. b) DMTMM-BF4, NMM, 
MOPS buffer pH 8.2, DMSO, RT, 24 h. c) LiOH, H2O/MeCN 3:1, RT, 2.5 h. d) DMTMM-BF4, NMM, MOPS buffer pH 8.2, 
DMSO, RT, 20 h or EDC*HCl, HOAt, DIPEA, MOPS buffer pH 8.2, DMSO, RT, 20 h. e) Klenow Polymerase, NEBuffer 
2, dNTPs, 25°C, 30 min. f) 2-Mercaptoethanol, DBU, MOPS buffer pH 8.2, DMSO, RT, 6 h. g) DMTMM-BF4, NMM, 
MOPS buffer pH 8.2, DMSO, RT, 18 h. h) BamHI-HF, CutSmart buffer, 37°C, 30 min. i) Cu-TBTA, NaOAsc, TEAA buffer 
pH 7.2, DMSO, RT, 16 h. j) T4 DNA ligase, NEB ligase buffer, ATP, 16°C, 16 h. k) Klenow Polymerase, NEB ligase 
Buffer, dNTPs, 25°C, 30 min. 
The enzymatic encoding of our library was the key for successful evaluation of potent protein 
binders. Every building block from each diversity element was encoded by a unique DNA coding 
sequence (codon). We decided to encode our library by a Klenow polymerization-restriction-
ligation methodology. Since the first diversity elements were encoded individually and then 
pooled, the schematic representation of the encoding in Figure 47 starts after the introduction of 
the DE-2 elements. A single-stranded DNA with the according DE-2 codon was annealed to the 
DNA strands of the former DE-1 pool. The formed partially double-stranded DNA was filled in with 
the Klenow fragment polymerase to yield the coding DNA in duplex format. After the 
macrocyclization step, the duplex DNA was cut at two specific sites (restriction) on opposite sides 
of the DNA duplex to yield a 5'- four base overhang (sticky end). This overhang was used for 
encoding of the last chemical step. We introduced a pre-annealed, partially double-stranded DNA 
fragment by T4 ligation using the sticky ends for annealing. The final stage consisted of another 
Klenow fill-in step to generate a DEML with a fully duplex oligonucleotide strand. The presented 








































































































Figure 47. Schematic representation of the library encoding. The scheme was adapted from the overview Figure 46. 
Chemical transformation steps are omitted for clarity. A Klenow polymerization-restriction-ligation procedure was used 
for library encoding. The shown encoding steps start at the second split synthesis step (amino acids coupling). 
7.2 Library Validation off-DNA 
Before we started the library synthesis with DNA-encoding, we synthesized a model macrocycle 
to make sure that our chemical strategy was valuable. We used 3-(2-carboxyvinyl)phenylboronic 
acid in a Suzuki-Miyaura cross-coupling to generate NP01, which was further modified by the 
trifunctional linker 2-5 (Figure 48). After basic hydrolysis of 2-6, the free acid 2-7 was modified 
with L-alanine methyl ester (AA001) to obtain the linear macrocycle precursor 2-8. This 
compound was transformed to its free "amino-acid" form 2-9, which was used for subsequent 
macrocyclization, followed by peripheral modification with ethyl propiolate to the final macrocycle 
2-11. Since macrocycle 2-10 contained two azide groups at different positions, the final 
macrocycle contained two triazole units. In the on-DNA synthesis, the propylazide linker will be 
used for DNA attachment prior to incorporation of the trifunctional azide linker 2-5. The success 
of this synthesis with acceptable yields (>60% per step) laid the foundation for further 

















1. Annealing 2. Klenow Fill-in 
3. BamHI  
restriction 
digest 
4. T4 Ligation 5. Klenow Fill-in 
 -83- 
 
Figure 48. Synthetic scheme of the off-DNA macrocycle synthesis. a) Pd (π-cinnamyl) chloride dimer, K3PO4, 
ETOH/H2O 2:1, 50°C, 1 h, 63%. b) HATU, DIPEA, DMF, RT, 1 h, 75%. c) LiOH, MeCN/H2O 1:1, RT, 2 h, 74%.  
d) HATU, DIPEA, DMF, RT, 2 h, 62%. e) PhSH, DIPEA, DMF, 40°C, 3 h, then LiOH, H2O, 30 min, RT, 78%. f) HATU, 
DIPEA, DMF, RT, 1 h, 63%. g) Ethyl propiolate, Cu-TBTA, NaOAsc, DMSO, H2O, MeCN, RT, 2 h, 68%. 
7.3 Library Validation on-DNA 
 
Figure 49. a) Schematic representation of the macrocycle synthesis on DNA in seven steps. Encoding of DE-2 and DE-
3 was not performed. Reaction steps and conditions are outlined in detail in Figure 46. b) Denaturing PAGE gel of the 
synthetic steps during on-DNA macrocycle synthesis validation. 
After successful synthesis of the small-molecule macrocycle, we also validated and optimized the 
strategy in the presence of a DNA strand. Figure 49a shows the simplified synthetic procedure in 
which we started from an alkyne-modified DNA strand to synthesize the final encoded 
macrocycle 2-12 in seven synthetic steps (for a detailed synthetic outline, see Figure 46). We 
included the diversity elements NP01, AA001 and TA641, but skipped the encoding of these 
elements for simplicity. At a later stage, we saw that the encoding steps and the chemical 
transformations did not affect each other. The effect of the chemical synthesis is shown in Figure 
49b. The mass increase (or decrease) during the synthesis along with the temporary generation 
of ionizable groups was observed by slight band shifts over the course of the synthesis. The last 
two bands with the attached macrocycles are less pronounced compared to the linear precursors. 
Since the assembly contains a big hydrophilic DNA part with a partially polar, but rather 
hydrophobic small-molecule attached, we assumed that the exceptional physicochemical 
properties of macrocycles cause interactions with the DNA. Polyacrylamide effects on the DNA-
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7.4 Assembly of the Macrocycle Library 
Diversity Element 1 Sub-Library 
The most challenging part for the development of a natural product-like macrocycle library was 
the incorporation of typical elements, such as polyketides, polyolefins or heteroaromatic building 
blocks. The first set of diversity elements was the ideal position for mostly carbon framework 
building blocks. The members of this diversity element had to be created individually from the 
common scaffold 2-4.  
 
Figure 50. a) General assembly of the DE-1 elements with subsequent DNA encoding. b) The aldehyde intermediate for 
the synthesis of polyolefin building blocks. c) Desired structural elements, which were not accessible. 
Palladium-catalyzed cross-coupling reactions such as the Suzuki-Miyaura and Negishi couplings 
turned out to be ideal for this task (Figure 50). We found a set of commercially available boronic 
acids and zinc reagents that were valuable for the construction of these building blocks. Due to 
the high synthetic effort to create such elements, we limited the number of elements to about 20 
(in the end 21!). With an operationally simple procedure for the Suzuki cross-coupling, we could 
rapidly create nine building blocks from commercial sources with substituted aromatic and 
heteroaromatic moieties (NP01-NP09, Table 5). Furthermore, commercially available zinc 
reagents allowed the incorporation of alkyl moieties and a furanyl group (NP12-NP16). All cross-
couplings were carried out with the palladium (π-cinnamyl) chloride dimer catalyst. Due to the 
presence of an azido group, the use of phosphine-based catalysts was not possible because of 
potential Staudinger reduction. The employed catalyst showed good compatibility with the 
functional groups, no need of highly inert reaction conditions and it yielded enough material 
(typically 50-90% isolated yield) to proceed with the library synthesis.  
For the generation of polyolefin moieties (NP17-NP21) or non-commercial cis-olefins (NP11), we 
used Wittig-type reactions (Horner-Wadsworth-Emmons reaction and Still-Gennari variant) in 
combination with the successfully obtained aldehyde 2-13. The majority of the shown building 
blocks were comprised of biaryl structures. The direct incorporation of polyolefins without the 
need for biaryl moieties (Figure 50c) would have been very desirable, but we could not achieve 
this goal. The direct coupling of olefinic boronic acids, carbonylation or Negishi couplings with an 
acetal-protected aldehyde zinc reagent with precursor 2-4 for subsequent Wittig-olefination were 
unsuccessful. Neither the generation of a Grignard species with subsequent quenching with 
aldehyde precursors, such as the Vilsmeier reagent, DMF, paraformaldehyde or 
triethylorthoformate, nor the introduction of a vinyl group for olefin metathesis were successful. All 
the mentioned attempts were repeated with precursors of 2-4 or with a different protecting 
scheme, however, the desired products could not be obtained.  
The difficulty of the described carbonyl-introducing reactions became clear after the synthesis of 
the benzylic alcohol 2-16 (Figure 51). Lactone 2-15 was opened with nosylethylenediamine 2-3 

























































observed. However, the aldehyde underwent a further cyclization step with the sulfonamide group 
(2-18). This cyclic hemiaminal could neither be transformed back to the aldehyde nor directly 
used in Wittig-type reactions. 
 
Figure 51. Aldehyde synthesis from lactone 2-15. Reaction conditions: a) K2CO3, THF, 65°C, 23 h, 62%. b) DMP or IBX, 
(additives), THF, RT, 15 min, 0%. 
Due to these difficulties, we continued with the shown building blocks in Table 5. New strategies 
for the incorporation of polyolefin moieties without the need of an aryl core would be highly 
desirable. Furthermore, polyketide moieties should be taken into account, even though the 
synthetic effort for this complicated building block type will limit the number of obtainable 
compounds to only a few members. 
Table 5. Structures of the set of diversity element 1 building blocks. R indicates the constant terephthalate scaffold. 



















NP11  NP18  
NP05[a] 
 
NP12[b]  NP19  
NP06[a]  NP13




NP14[b]  NP21  
[a] Commercially available as boronic acid derivatives. [b] These elements were synthesized by Negishi cross-coupling 
with the corresponding commercial zinc reagents. 
For the generation of the DE-1 sub-library, all building blocks depicted in Table 5 were coupled 
by the copper-catalyzed click reaction (CuAAC) to the corresponding 5'-alkyne modified 39-mer 
oligonucleotides. The DNA tags were comprised of two primer annealing sites (for all building 
blocks the same) and individual three base codons in the middle of the strands. These 
transformations were carried out with high yields (approx. 80%), even though some part of the 
DNA was always found to be unreacted, originating from alkyne oxidations during DNA synthesis. 
The DNA side products were successfully separated from the DE-1 DNAs by reverse-phase 


































































Trifunctional Linker Synthesis and Coupling with the DEML 
 
Figure 52. a) Scheme for the trifunctional linker coupling with the DE-1 sub-library pool. Reaction conditions:  
a) DMTMM-BF4, NMM, MOPS buffer pH 8.2, DMSO, RT, 24 h. b) The influence of methylene spacers in β- and γ-azido 
amino acid linkers under basic conditions. c) Structure of the unstable α-azido-β-amino acid. 
The incorporation of a trifunctional linker (TFL) into the library was a very important task because 
it connects the three diversity elements. The TFL strongly influences the final structure of the 
macrocycle, and it may influence the interplay between the diversity elements. While the 
geometry of the macrocyclic scaffold is largely dependent on the structures of DE-1 and DE-2, 
the trifunctional linker defines the proximity of the peripheral diversification site. Depending on the 
interaction mode of a macrocycle with a certain protein, it may be beneficial to keep the overall 
structure compact and get the building blocks in close relation with each other, so that the 
macrocycle may fit into the binding pocket of the protein. Alternatively, large peripheral groups 
might improve binding to several locations on the protein surface, which also generates high 
affinity. We decided to keep the peripheral modification close to the macrocyclic scaffold.  
At first, we tried to synthesize a β-amino acid with an azido group attached to the α-carbon 
(Figure 52c). This compound would generate the shortest possible triazole linkage to the DE-3 
elements. The synthesis of this compound turned out to be possible up to its Fmoc-protected 
precursor. Upon protecting group removal, the desired compound could be detected in solution, 
but it rapidly decomposed upon isolation.  
In further attempts, we turned to azido-modified α-amino acids (Figure 52b), which are 
commercially available or could be synthesized in a one-step procedure by copper-catalyzed 
amine-azide transfer from commercial precursors. The simplest representative is L-azido-alanine 
(n=1), which we could successfully introduce into DNA-encoded macrocycle precursors. While 
amide couplings with this azido-amino acid worked relatively well, treatment with strong basic 
conditions (such as those used for ester hydrolysis) led to a substantial amount of azide 
elimination to form dehydroalanine (see Figure 52b). This elimination product cannot be used for 
the incorporation of the third diversity element, but dehydroalanine is an interesting building block 
for future encoded-libraries. Finally, we ended up using a trifunctional linker with two methylene 
spacers (2-5, n=2), which was resistant to azide elimination.  
The amide coupling with encoded DE-1 elements was found to be possible with EDC/HOAt or 
DMTMM-BF4 as coupling reagents with similarly high efficiencies. For library construction with the 
complete pool, we decided to use the DMTMM conditions because we found a decreased 
amount of DNA-damage under these conditions (see Chapter 8.3 for qPCR experiments). Test 
assays with eight representative DE-1 building blocks showed full conversion to the desired 
product, except for NP07. We also carried out LC-MS analysis of the coupled pool (20 BBs) and 
identified all coupling products while no traces of the starting materials were observed. NP07 was 
treated twice with the coupling solution to achieve full conversion and was then combined with 










































Figure 53. Ester deprotection of the library sub-pool. Reaction conditions: a) LiOH monohydrate, H2O,/MeCN 2:1, RT, 
2.5 h. 
For the hydrolysis of the ester, lithium hydroxide was used in the presence of about 30% organic 
solvent (usually acetonitrile). Unlike in amide coupling, where at least 1000 equivalents of the 
reagents were necessary, ester hydrolysis always proceeded within a few hours with only 100-
150 equivalents of LiOH. Except for elimination reactions with azido-alanine, we never came 
across any undesired side reactions in this deprotection step. 
DE-2 Screening and Coupling with the DE-1 Pool 
The second diversity element consisted of a collection of amino acids. We included L- and D- 
amino acids, modified amino acids, unnatural amino acids with pure alkyl sidechains, but also 
with various functional groups (hydroxy, pyridine, thiazole, quinoline, sulfoxide). We also selected 
cyclic, spirocyclic, bridged and strained amino acids to introduce some rigidity into the 
macrocycle scaffold. The length and sizes of the building blocks were very diverse, ranging from 
small glycine up to a very long mini-PEG or the very bulky adamantyl-containing amino acid. High 
commercial availability along with easy synthetic procedures rendered this diversity element ideal 
to expand the diversity of our ring scaffold. We synthesized several olefinic (alkene and diene) 
amino acids to expand the number of natural product-like building blocks in our library. 
 
Figure 54. a) Schematic representation of the DE-2 test assay with 126 amino acids. We used trifunctional linkers with 
one or two methylene spacers. Reaction conditions: a) DMTMM-BF4, NMM, MOPS buffer, DMSO, RT, 24 h or EDC*HCl, 
HOAt, DIPEA, MOPS buffer, DMSO, RT, 24 h. b) α,α-disubstituted amino acids showed no coupling. c) N-methylated 
amino acids showed no coupling. d) Homoprolines showed no coupling. e) Tyrosine and its derivatives showed good 
couplings with EDC/HOAt conditions. f) β-substituted β-amino acids showed very low efficiencies with non-aromatic 
sidechains. 
Prior to the introduction of the second diversity element, we screened our collection of 126 amino 
acids to explore the reactivity of these compounds towards amide coupling with the DE-1-TFL 
pool. For this purpose, we took a model precursor (NP01-TFL), screened it against all amino 
acids (DMTMM coupling conditions) and analyzed the results with LC-MS detection. In the case 
of unsuccessful couplings, we repeated the reaction under EDC/HOAt conditions to find potential 
improvements in coupling efficiency. We set the limit of usefulness for library construction at 























































































We found several trends in reactivity depending on the amino acid structure. In general, α,α-
disubstituted amino acids (Figure 54b) did not couple (AA093 in combination with the 
EDC/HOAt/DIPEA system was the exception) and neither did N-methylated amino acids (Figure 
54c). Sarcosine (N-methylglycine) was the only exception. Cyclic amino acids also showed a 
reactivity trend depending on the nature of the ring scaffold. The 4-membered ring amino acid 
AA094, as well as proline derivatives, worked well under the tested reaction conditions, whereas 
homoprolines (Figure 54d) did not work at all. Interestingly, β- and  
γ-homoprolines yielded a good amount of the desired product, which led to the conclusion that 
the arrangement of the functional groups in cyclic amino acids has a big influence on their 
reactivity. A very important, but difficult, group of compounds were linear β-amino acids. In the 
case of α-substituted β-amino acids, the couplings proceeded with good conversions and purities, 
whereas with β-substituted β-amino acids (Figure 54f), only the members with flat, aromatic 
sidechains gave acceptable yields. The special case amino acids with electron-withdrawing 
substituents, good leaving groups, a hydroxylamine or a thiazoline ring scaffold generally showed 
no conversion to the desired products at all. Due to the reactivity of aromatic alcohols with 
DMTMM-BF4, tyrosine derivatives (Figure 54e) were only successfully coupled under 
EDC/HOAt/DIPEA conditions. Apart from the previously mentioned dehydroalanine side product 
(we included successful coupling to this moiety in the coupling efficiency), we also identified the 
two major side products that we observed during the test assay by LC-MS (Figure 55). The 
complete list of amino acids with coupling efficiency results are found in Table 12 in the 
experimental. A more detailed discussion about the occurrence of the identified side products will 
be held in the section about the Nosyl deprotection (Page 90). 
 
Figure 55. Proposed structure of found common side products. a) Elimination product to the dehydroalanine species. b) 
Terminal amide product. c) Dihydrotriazinone product. 
The results from this screening were used for the assembly of the final library. Taking into 
account our cut-off limits (>80% conversion, ≥50% product purity), we included 102 amino acids 
for the actual synthesis. This was performed in a split procedure, whereby the DE-1-TFL pool 
was split into 102 vessels and every vessel was reacted with one amino acid under the 
elaborated coupling conditions.  
 
Figure 56. DE-2 coupling of the DE1-TFL pool with the selected 102 amino acids. Coupling conditions matched the 
conditions described in Figure 54a. 
Encoding of the Second Diversity Elements 
After the introduction of the DE-2 sub-library, we encoded the new building blocks with a 40-mer 
DNA strand (Figure 57a). This DNA strand consisted of an 18-base annealing site, 
complementary to the DE-1 coding DNA, the four bases codon for the specific DE-2 building 
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Figure 57. a) Schematic representation of the DE-2 encoding. b) Exact sequences for the annealing and Klenow fill-in 
during encoding. c) 12% DNA polyacrylamide gel, SYBR gold staining. L1: Low MW DNA ladder, L2: DNA-DE-1 pool, 
L3: DE-2 coding DNA strand, L4: Annealing of DNA-DE-1 pool and DE-2 coding DNA strand, L5: Klenow extension. 
The exact DNA sequence for the encoding of the amino acids is shown in Figure 57b. The 
codons are represented as XXX (for DE-1) and YYYY (for DE-2). Underlined bases indicate the 
BamHI restriction site. Annealing of the coding DNA created an 18-base duplex strand with long 
5' overhangs. The large Klenow fragment subsequently polymerized the two strands to create a 
61-base pair long duplex DNA. During this procedure, the reverse complementary codons of the 
DE-1 and DE-2 building blocks were incorporated into the complementary oligonucleotide 
strands. The conditions for the encoding step were adapted from the manufacturer's published 
procedure. We did not see any undesired side product formation, nor the truncation of DNA 
strands due to exonuclease activity of the Klenow fragment. The detailed annealing and encoding 
results are presented in the gel picture (Figure 57c). After the encoding of all building blocks, the 
















































Nosyl and Ester Deprotection Screening and Application with the DE-1/DE-2 Pool 
 
Table 6. Nosyl deprotection screening and optimization.  
Entry Thiol Base Temperature Time Nosyl Deprotection Ester Hydrolysis 
1 PhSH DIPEA 60°C 6 h Yes No 
2 BME DBU 60°C 6 h Yes Yes 
3 MPAA DIPEA 60°C 6 h Incomplete No 
4 NaTG[a] DIPEA 60°C 6 h No No 
5 PhSH DBU 60°C 2 h Incomplete Incomplete 
6 PhSH DBU 60°C 4 h Yes Yes 
7 PhSH DBU 60°C 6 h Yes Yes 
8 BME DBU RT 2 h Yes Yes 
9 BME DBU RT 4 h Yes Yes 
10 BME DBU RT 6 h Yes Yes 
11[b] MPAA DBU 60°C 6 h Incomplete Incomplete 
12 BME DIPEA RT 6 h Incomplete No 
13 BME NMM RT 6 h No No 
[a] Stock solution 1:1 H2O:DMSO. [b] Reagent concentrations: 200 mM. 
Prior to the macrocyclization step, we needed to generate the free amine and the free carboxylic 
acid by Nosyl and ester deprotection. This procedure could be done in a tandem reaction or in 
two consecutive steps. We first analyzed the influence of the sulfur nucleophile in combination 
with different bases at variable temperatures on product and side product (mainly terminal amide, 
see Figure 55b) formation. Only thiophenol (PhSH) and β- mercaptoethanol (BME) completely 
removed the Nosyl group. Ester deprotection was uniquely achieved in combination with DBU. 
The mildest conditions with the least side product formation were BME/DBU at room temperature 
(Table 6, Entry 10). These findings were well in accordance to a published procedure on Nosyl 
deprotection with DNA-encoded amino acids on a solid support.[197] Ester hydrolysis (with LiOH) 
prior to Nosyl removal made the latter reaction very inefficient and led to a high amount of the 
undesired side product.  
We further investigated the influence of the diversity element 2 structure on deprotection 
efficiencies. For this purpose, we synthesized a series of encoded macrocycle precursors with 
constant DE-1 (NP19) and 20 diverse DE-2 elements (Figure 58a). The best protecting group 
removal was achieved with proline derivatives (AA049/053/106), however the common 
proteinogenic amino acids Gly, Val and Phe (AA009/010/012/056/058) also showed good 
deprotection efficiencies (Figure 58c). The size and bulkiness of the amino acids seemed to 
have a big influence on the deprotection, because the sterically hindered dicyclohexylalanine 
(AA008) and the adamantyl amino acid (AA101) showed little to no conversion to the desired 
product, but the formation of a substantial amount of side product was observed. Despite 



























100 mM Thiol, 100 mM Base,
100 mM MOPS buffer, 
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 -91- 
and serine (AA025) were amongst the members with the highest side product formation of all 
tested compounds. L-Asparagine (AA047), with its nucleophilic amide sidechain, underwent an 
intramolecular cyclization reaction with the adjacent ester to form the corresponding cyclic imide 
(Figure 58b).  
 
Figure 58. a) Schematic representation of the deprotection test assay. b) The found cyclic imide side product with  
L-asparagine (AA047). c) Nosyl deprotection results with 20 representative DE-2 building blocks, including the most 
special amino acids in terms of size and structure. The amounts of desired products are shown with black pillars, the 
undesired terminal amide side product is represented in red.[198] 
The optimized reaction conditions were then applied to the DE-1/DE-2 sub-library to generate the 
pool of free "amino acids", ready for macrocyclization. In a future attempt, several building blocks, 
including AA008, AA047 and AA101, should be excluded from the library assembly due to the 
high amounts of side product and the low reactivity in macrocyclization. 
 
 
Figure 59. Proposed mechnism for the generation of the terminal amide side product during amide coupling and Nosyl 
deprotection. In the first step the azide attacks the amide bond of the trifunctional linker and the DE-2 (a). The formed 
five-membered intermediate b eliminates the DE-2 element followed by a base-induced nitrogen loss in c. In the final 
step 2H-pyrrol-2-one is generated to yield the final terminal amide side product (e). 
During the validation of the reactions and the compatibility of the building blocks, we often came 
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building blocks. From the mass spectrum, we proposed a DE-1 terminal amide structure  
(an example is shown in Figure 55b and a general structure is shown in Figure 59). We came 
across this particular side product after DE-2 amide coupling and Nosyl deprotection. We could 
demonstrate that the azide from the trifunctional linker is involved in terminal amide generation, 
because the resynthesis of two test molecules with an alkyne trifunctional linker in combination 
with AA008 and AA018, respectively, showed no terminal amide formation. We also determined 
that the structure of the DE-2 element dictated the amount of the formed terminal amide (Figure 
58c). A dependency on the structure of the DE-1 moiety was not observed.  
We proposed that the azido group attacks the amide bond between the trifunctional linker and the 
DE-2 building block to form a five-membered ring intermediate (b in Figure 59), which further 
eliminates the DE-2 amino acid. This proposed step is supported by the fact that five-membered 
structures are kinetically favored. Moreover, the influence of the DE-2 structure supports such an 
assumption, since very bulky amino acid sidechains showed reduced reactivity in the 
deprotection, as well as side product formation (see Figure 58, AA008 and AA101). It may be 
assumed that the large substituents shielded the adjacent groups, resulting in lowered terminal 
amide formation. Compound c can further lose a nitrogen molecule, which is likely the driving 
force for this side reaction. The dihydro-2H-pyrrole-2-one intermediate further undergoes the 
elimination of a 2H-pyrrol-2-one molecule, however, this process could also stem from the 
compound ionization in the ESI-MS. It is still unclear which compound we kept in solution after 
the reaction (compound d or e), but we could only identify the terminal amide e in the mass 
analysis. An alternative mechanism, involving going over a six-membered ring intermediate in the 
first step (reaction with the DE-1 amide), is also possible, but we considered it to be less likely, 
because it did not explain the influence of the DE-2 sidechain structure. However, the proposed 
mechanism does not explain why this side reaction only occurs during amide coupling and Nosyl 
deprotection, whereas ester hydrolysis with lithium hydroxide did not yield any side products. 
Perhaps, activating species, such as the coupling reagents for amide couplings, promote the 
generation of the undesired side product, although their direct influence is unclear. 
Macrocyclization of the DE-1/DE-2 Sub-library 
We tested the influence of various coupling reagents on the efficiency of the macrocyclization 
reaction. DMTMM-BF4 was superior to all other reagents tested (see Table 7). In contrast to 
intermolecular amino acid couplings, the macrocyclizations performed well with fewer equivalents 
of the reagents (250-500 eq.). We could reduce the coupling reagent amount to as low as 100 eq. 
for the cyclization reaction to occur within the tested time frame, albeit with more side products. 
We think this is a result of slower kinetics in the cyclization reaction, which consequently 
increased side product formation. Optimal conditions were found with 250-500 equivalents of 
coupling reagent and 1000 equivalents of base. The DNA concentration in the final mixture was 




Table 7. Efficiency of the macrocyclization with different coupling reagents and amounts. A model compound was used 
for the optimization (Scheme). 
 
Entry Coupling Reagent Equivalents Base Macrocyclization 
1 DMTMM-BF4 500 NMM Yes 
2 EEDQ 500 - No 
3 EDC*HCl/sulfo-NHS 500 DIPEA very little 
4 DMTMM-BF4 250 NMM Yes 
5[a] DMTMM-BF4 100 NMM Yes 
[a] Larger amount of side product formation. 
We further investigated the influence of the DE-2 elements for macrocyclization reactions. As 
shown in Figure 60, the majority of the tested compounds showed cyclization ratios of >60%. 
Only amino acids that also caused difficulties during the preceding Nosyl deprotection (AA008, 
AA047 and AA101) did not macrocyclize with this method. For AA008 and AA101, the bulky and 
sterically hindered sidechains influenced the deprotection reaction, giving a small amount or even 
no unprotected species. Moreover, the bulky groups of these members potentially inhibited the 
activation of the carboxylic acid and/or prevented the amine from the nucleophilic attack. The 
asparagine macrocycle (AA047) was not accessible because the asparagine sidechain fully 
underwent the imide side product formation (Figure 58b). 
 
Figure 60. Schematic representation of the efficiency evaluation during macrocycle formation. We used the same 
precursors as for the full deprotection.[198] 
For the test macrocyclization (as was the case for the previous deprotection), we chose the most 
difficult and representative amino acid building blocks in combination with a rather rigid DE-1 
moiety. This setup should ensure that we would find potential difficulties with those building 
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Figure 61. Schematic representation of the library macrocyclization. Reaction conditions: a) DMTMM-BF4, NMM, MOPS 
buffer, DMSO, RT, 18 h. 
With the certainty that the macrocyclizations should work well, we treated our precursor library 
with the established DMTMM conditions (300 eq.). Careful analysis of a reference sample 
indicated incomplete macrocyclization. We treated the library and the test sample with another 
portion of coupling reagent and were happy to find no additional side reactions, along with full 
conversion to the macrocyclic products. The macrocycle library (smDEML) was purified by 
reversed-phase chromatography. Some residual DE-2 encoding DNA could not be removed due 
to co-elution with the product. Nevertheless, the purity was high (>80% estimated from gel 
analysis, Figure 64c) and some of this library was kept for protein affinity testing. Comparison of 
the protein affinity results from this batch and the final library will give an idea about which part(s) 
of the molecules bound to the protein. If a macrocycle (without DE-3) and its DE-3 modification(s) 
both show high affinity, then the macrocyclic core is responsible for the protein-small molecule 
interactions. If the binder only shows up in the final macrocycle library, but not in the smDEML, 
then it is almost certain that the contribution to binding was due to the peripheral moiety and not 
due to the macrocyclic core. 
Restriction Digest 
For the last encoding step, we needed to generate 5' overhangs for the ligation with the DE-3 
coding DNA strands. We chose to achieve this by BamHI restriction digest since we deliberately 
included the corresponding restriction site (see Figure 47 for the schematic representation of the 
library encoding). In order to efficiently restrict the library, we preferred to perform this 
transformation in a pooled step, rather than in a split synthesis step with more than 600 vessels. 
 
Figure 62. a) Schematic representation of the restriction digest. Reaction conditions: a) BamHI-HF, CutSmart buffer, 
37°C, 30 min. b) Restriction scheme. Underlined bases indicate the recognition site for the BamHI-HF enzyme, the 
arrows show the restriction sites. c) Native PAGE gel of several restriction samples. L1: Low MW DNA ladder, L2: small 
DEML before restriction, L3-L7: Restricted samples. 
The BamHI restriction enzyme cuts double-stranded oligonucleotides between the two guanines 
of the palindromic GGATCC restriction site to generate a four base 5' overhang, a so-called sticky 
end (Figure 62b). We performed a deep evaluation of potential reaction condition improvements 


































































but always with only about 80% overall restriction. Approximately 20% of the DNA stayed in its 
undigested form. Reference tests with unmodified duplex DNA strands with different lengths 
showed the same results. Therefore, we conducted the restriction digest with the library, taking 
into account that a certain percentage of our library would remain uncut. Figure 62b shows the 
successful restriction of the library. The loss in DNA length is displayed along with the remaining 
native DNA strands (grey blurry band above the restricted DNA band). 
Introduction of the DE-3 Sub-Library by Click Reaction 
 
Figure 63. a) Schematic representation of the DE-3 coupling. Reaction conditions: a) Cu-TBTA, NaOAsc, TEAA, DMSO, 
RT, 16 h. b) A few representative examples of the diverse set of terminal alkyne building blocks. 
The introduction of a 663-member terminal alkyne sub-library by copper-catalyzed click reaction 
represented the last chemical diversification step of the DEML (Figure 63a). The majority of the 
building blocks were commercially available and only a few very specific members had to be 
specifically synthesized. We tried to include a very diverse set of building blocks, covering a 
broad range of chemical space. We incorporated a vast set of functional groups such as amines, 
amides, ureas, sulfonamides, sulfonic acids, alcohols, esters, imides, halides and many more 
(Figure 63b). We also chose members with very different structures, shapes and stereochemical 
arrangements. Short linear aliphatic alkynes, branched functionalized or small cyclic members 
were included as well as large aromatic, heteroaromatic and complex alkyl-aryl framework 
structures. We did not assay the coupling efficiencies of each building block as was done for the 
DE-2 amino acids, but random sampling demonstrated that the CuAAC click reaction was very 
tolerant towards the incorporation of all building blocks tested in the course of library assembly 
and validation. Therefore, we considered this reaction to be the most reliable and least building-
block dependent transformation of all chemical steps used during the DEML synthesis.  
The only limitation of this chemical step turned out to be the reactants' concentration. While for 
the assembly of the encoded DE-1 sub-library only a few equivalents of the reactants and 
catalysts with a high DNA concentration were necessary, in this step, it was vital to perform the 
reaction at a single digit micromolar concentration. For this purpose a pseudo-first-order reaction 
was required. We discovered that the reaction performed very well with a few hundred 
equivalents of the reactants and catalyst, which is in sharp contrast to the amide couplings, 
where thousands of equivalents are necessary for a clean reaction.  
We split the previously restricted smDEML pool into 663 vessels and carried out the click 
reactions with the complete set of terminal alkynes. Ethanol precipitation was utilized for cleanup 


























































Encoding of the DE-3 Building Blocks 
 
Figure 64. a) Schematic representation of the terminal alkyne encoding. Reaction conditions: a) T4 DNA ligase, NEB 
ligase buffer, ATP, 16°C, 16 h. b) Klenow Polymerase, NEB ligase Buffer, dNTPs, 25°C, 30 min. b) Details for the 3rd 
diversity element encoding steps. Coding regions are colored according to the diversity elements. Underlined bases 
show the Bam-HI-HF restriction site. c) Full synthesis native DNA polyacrylamide gel (10%, TBE). L1: Low MW DNA 
ladder, L2: DNA alkyne, L3: DE-1 click reaction, L4: Trifunctional linker coupling, L5: Trifunctional linker ester hydrolysis, 
L6: DE-2 amide coupling and Klenow encoding, L7: Ester hydrolysis + Nosyl deprotection. L8: Macrocyclization (small 
DEML), L9: BamHI-HF restriction digest, L10: Click reaction with DE-3 and subsequent encoding by T4 ligation and 
Klenow fill-in. 
In the last step of the DEML synthesis, we encoded the building blocks from the previous 
synthetic step. A detailed encoding scheme is displayed in Figure 64b. We used the previously 
generated "sticky ends" to ligate partially double-stranded DNA fragments containing the six-
bases codons. The encoding DNA fragments consisted of 41-mer oligonucleotides with the 
coding information and a pre-annealed 5'-phosphorylated 21-mer oligonucleotide. This created a 
sub-library of 5'-phosphorylated four-base overhang DNAs complementary to the restricted 
DEML. Annealing with subsequent T4 ligation resulted in the generation of a predominantly 
double-stranded, encoded macrocycle library, in which the unmodified DNA strands contained 
the complete set of codons. Final Klenow fill-in copied the reverse complementary codons onto 
the macrocycle-modified DNA strands and rendered the DEML fully double-stranded.  
We chose this encoding strategy, because in that case, we only needed to acquire one 
phosphorylated oligonucleotide along with the 663 unmodified coding DNA strands. In an 
alternative approach, one might use 5'-phosphorylated codon containing DNA strands and anneal 
it with an unmodified primer. In that case, the codon was directly introduced onto the macrocycle-
modified DNA strand and the Klenow fill-in step was not necessary (nor possible) anymore. The 
coding sequence for DE-3 would, in that case, remain single-stranded. We excluded this 
encoding variant due to financial considerations. Figure 64c shows a polyacrylamide gel with the 
complete library assembly. Synthetic steps, but especially the enzymatic encodings, are easily 
recognized by large band shifts. The DEML band appeared as a weak, rather broad band at 
around 100 bp length (DEML DNA length: 95 bp). We assumed that the high diversity of the 
attached macrocycles, along with some DNA damage during library synthesis, was responsible 
for the blurry band. Additionally, we already showed in Figure 49b that macrocyclization in 






















































Figure 65. The purified DEML in comparison with self-ligated library or insert DNA strands. L1: Low MW DNA ladder, 
L2: Purified DEML, L3: DEML self-ligation assay, L4: Insert DNA self-ligation assay, L5: Insert DNA self-ligation assay 
after Klenow extension. 
The palindromic nature of the BamHI binding and restriction site made it possible for the 
restricted oligonucleotides with "sticky ends" to undergo ligation reactions with each other or with 
itself (self-ligation). The self-ligation of the DEML was particularly critical because, in that case, 
the last diversity element was not correctly encoded for and both DNA strands of the duplex 
would carry the macrocycle. To overcome this issue, we used an excess of insert DNA to prevent 
DEML self-ligation. Comparison of lanes 2 and 3 in Figure 65 led to the conclusion that DEML 
self-ligation did not occur during DE-3 encoding. On the other hand, the insert DNA formed its 
self-ligation product in good amount due to the excess in the mixture. Lanes 4 and 5 show the 
behavior of this excess during the DEML encoding steps. Surprisingly, the Klenow fragment 
seemed to truncate the self-ligated DNA to some part (new band at approx. 45 bp in lanes 2 and 
5) rather than just turn it into a full duplex DNA. Completely double-stranded insert DNA (that was 
not ligated before) might appear at the same position, however, the intensity of this band is too 
high to completely stem from that reaction. These short oligonucleotide fragments were the main 
DNA impurity in our library, which we could not completely remove.  
DEML purification was conducted by semi-preparative HPLC (Figure 94a) to remove enzyme, 
buffer and excess DNA leftovers. Since the purification step was not completely successful, we 
still see bands for short DNA fragments in the final PAGE analysis (Figure 94b). However, we 
considered the library useful without further cleanup because the HPLC chromatogram (Figure 
94b) showed no potential purification improvement by the applied methods. The short DNA 
strands should not contain any attached small molecules and were not coding for the complete 
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8. Properties Evaluation and DNA Damage Analysis of the DEML 
8.1 Introduction to Physicochemical Properties of Macrocycles 
Lipinski and Veber Rules for the Bioavailability of Small Molecules 
The discovery of new, drug-like molecules is a very important task and can be achieved through 
the screening methods described in Chapter 6. Although theoretical chemical space is huge, only 
a tiny fraction of chemical structures possess drug-like activities. This subset of molecules is 
confined by suitable ADME (absorption, distribution, metabolism, excretion) and toxicity 
properties, enabling them to pass human phase 1 clinical trials.[159] Drugs and their targets are 
spread out over chemical space, making their discovery difficult and laborious.  
In a thought experiment, Lipinski defined the success of a truly diverse chemical library in finding 
a protein target hit as almost zero, taking into account certain assumptions. If a 100 kg human 
was completely composed of drug targets with molecular weights >500 Da, there would be about 
1026 different druggable molecules. With the lower estimate of 1040 different compounds in 
chemical space, the chance of finding a drug against a target would require a diverse library with 
at least 1014 members. In reality, most drug receptors are much bigger than 500 Da and a human 
does not entirely consist of druggable moieties. For that reason, the number of drug targets is 
much smaller than 1026 and along with the fact that the chemical space must be assumed to be 
much larger (estimations range from 1040 to 10100), the chance of finding drug molecules is even 
much smaller.[159]  
Very large, diverse libraries (1014 or more members) are theoretically possible with encoded 
library technologies, but are neither practical nor reliable because they suffer from combinatorial 
and synthetic deficiencies (e.g. a too low number of molecules per compound structure, building 
block availability or incompatibility of the building blocks with the reaction conditions). As 
presented in Chapter 6, many drug candidates with high affinity have been found with much 
smaller libraries containing several thousand up to a few million members. This implies that drug 
candidates are not distributed randomly throughout chemical space but are rather located within 
a well-defined (but still large) area. In addition, many drug targets might bind several different 
molecules with high affinity, which simplifies the search for good drug candidates. From this fact, 
libraries that cover well-defined areas of chemical space are preferred (so-called focused libraries 
that were specifically designed with respect to physicochemical properties or taking into account 
certain drug target specifications). Truly diverse libraries, as mentioned at the beginning of this 
section, can be created in silico, but in an experimental setup are not practical due to the 
limitations of chemical library assembly.[159]  
In addition to these limitations, drug candidates not only need to be active in target binding but 
they also need to possess the correct physicochemical properties to make them orally 
bioavailable.[199] Compounds with many very polar groups may display extraordinary solubility 
properties in a biological environment but membrane permeability will decrease with higher 
polarity. In contrast, high lipophilicity makes a compound more permeable across the membrane 
of a cell, but decreases aqueous solubility. These competing factors lead to difficulties for the 
administration of the drug and might influence the drug uptake into the cell. Based on these 
findings and in comparison with successfully developed remedies, Lipinski defined a catalogue of 
physicochemical properties that small molecule drug candidates should fulfill to be considered as 
lead compounds in pharmaceutical medicine discovery. This property-set is called the (Lipinski) 
rule-of-five (Ro5) because the cutoffs for all parameters were close to five or a multiple of five. He 
defined that the molecular weight of a drug candidate should be ≤500 Da, the partition coefficient 
logP should be ≤5, the number of hydrogen bond donors should not exceed five and the number 
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of hydrogen bond acceptors should be maximum 10 (see Table 8).[159,200] However, the Ro5 are 
not strict. Violation of one of the parameters might still deliver reasonable drug candidates but 
upon violation of two or more parameters the compound becomes very unlikely to be drug-
like.[199] Nevertheless, oral bioavailability measurements with more than a thousand compounds 
on a rat model showed that the proposed properties of the Ro5 are insufficient to fully describe 
the drug-likeness of a molecule. The rigidity of a compound, measured by the number of rotatable 
bonds as well as the polar surface area must also be included in the physicochemical properties 
analyses. LogP and molecular mass are usually used for the analysis of a compound's 
lipophilicity, however these descriptors do not take into account structure-specific properties that 
influence the lipophilicity of the drug candidate. The number of rotatable bonds in combination 
with the polar surface area complements these properties. Veber et al. proposed to include 
cutoffs for the polar surface area at ≤140 Å2 and for the number of rotatable bonds at ≤10.[201] 
Despite these guidelines, supported by oral bioavailability measurements and calculated 
physicochemical properties with a large set of compounds, several molecule classes violate 
these rules, yet still are orally bioavailable.[202,203] Among these classes are antibiotics, 
antifungals, vitamins and macrocycles.[199,204] 
Macrocycle Properties and Features Defined by Whitty 
As described in the previous section, macrocycles often violate the Lipinski and Veber rules but 
still operate as bioavailable, potent drugs. Macrocycles are defined as cyclic molecules consisting 
of 12 or more ring atoms, which provides the compound a certain degree of structural pre-
organization.[204] To address the binding features to proteins of this compound class, Whitty et al. 
analyzed the binding modes and the structural conformations of 22 X-ray protein-macrocycle 
complexes consisting of 19 distinct macrocycles and 13 different proteins.[205]  
It was found that macrocycles interact with proteins in fundamentally different binding modes 
compared to linear small molecules. Macrocycles can interact with the protein in a face-on 
binding mode, which means that the core ring structure is in contact with the protein surface 
along with a set of the ring substituents. The edge-on binding mode describes a macrocycle 
sitting almost perpendicular on the protein, whereby only one side of the ring is in direct protein 
contact while the outer part of the ring scaffold is exposed to the solvent. Macrocycles with the 
edge-on binding mode usually adopt a flattened conformation that allows additional interactions 
of substituents located on the solvent-exposed part with the protein. Some macrocycles also 
adopt very compact, almost globular geometries to interact with the protein in a cleft or a 
pronounced depression.  
The Whitty group could also show that the peripheral atoms (atoms connected with one covalent 
bond to the ring scaffold, e.g. methyl groups, carbonyl or hydroxy groups) interacted the most 
with the protein. Larger substituent interactions were still pronounced whereas the actual ring 
atoms showed the least interactions with the protein target. Due to the, in general, larger 
structure of macrocycles, they can interact with more and farther distributed binding spots on the 
protein than is the case with conventional small molecules. Even if the binding energy of a distinct 
spot on the protein with the macrocyclic ligand is much lower compared to small molecules, the 
overall binding energy may be higher because often a larger number of such spots can be 
simultaneously occupied by the macrocycle. This feature renders macrocycles capable of 
drugging proteins that were considered undruggable with conventional small molecules. Deriving 
from the results of this protein-macrocycle binding evaluation, the authors proposed a set of 
physicochemical properties guidelines in analogy to the Lipinski rules (see Table 8). In addition to 
good binding properties, macrocycles also need to show high metabolic stability as well as good 
solubility and membrane permeability, which are key features for orally bioavailable drugs.[205] 
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A conventional small molecule drug with MW <500 Da, for example, contains about 25% polar 
heavy atoms to maintain aqueous solubility along with good membrane permeability. Such a 
molecule usually fulfills the physicochemical properties guidelines from Lipinski and Veber. For a 
compound with MW = 1000 Da, about 25% polar heavy atoms are also required for water-
solubility. Consequently, the small and the big molecule will have the same octanol-water 
partition coefficient (logP). However, the larger compound will most probably not be orally 
bioavailable due to the violation of the Ro5 in terms of mass, hydrogen bond donors, hydrogen 
bond acceptors and polar surface area. The energetic penalty of desolvation and transfer into a 
nonpolar environment increases with the absolute number of polar groups. With increasing 
molecular weight it becomes more difficult for a compound to show high solubility in polar and 
nonpolar environments.[206]  
Large molecules (such as certain macrocycles) possess "chameleonic" properties to achieve 
good oral bioavailability.[206,207] These properties result from conformational changes dependent 
on the environment. In an aqueous environment the macrocycle is in equilibrium between an 
"open" conformation whereby the polar groups are exposed into the aqueous environment and a 
"closed" conformation with partially shielded polar groups within the compound along with 
intramolecular hydrogen bonds (Figure 66). Upon permeation through the membrane of a cell, 
only the "closed" form is present, shielding the polar groups within the compound and exposing 
the nonpolar groups to ensure sufficiently high lipophilicity. When the macrocycle reaches the 
inside of the cell it readopts the conformational equilibrium for the aqueous environment. Such 
equilibria render strong solvating interactions with the water low to reduce the energetic cost 
upon desolvation and membrane permeation while maintaining aqueous solubility. For high 
molecular weight compounds it is a prerequisite to show a certain degree of "chameleonic" 
behavior in order to be orally bioavailable.[206,207] 
 
Figure 66. Cartoon explanation of chameleonic properties. Macrocycles in aqueous solution are in equilibrium between 
an "open" (upper structure) and "closed" (lower structure) form. Upon membrane permeation only the "closed" 
conformation is adopted to shield the polar groups within the molecule. Upon resolvation in the aqueous environment the 
polar groups are exposed to the solvent again and the macrocycle readopts the conformational equilibrium.[206] 
Reprinted with permission.d 
  
                                            
d Elsevier, License Number: 4537081008616, 27.02.2019. 
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Macrocycle Properties Requirements by Kihlberg 
Kihlberg et al. reported another set of macrocycle design guidelines in 2016, which were based 
on experimentally determined physicochemical properties.[208] They selected a set of 214 non-
peptidic macrocycles from a >100'000 compounds high-throughput screening library. This set 
consisted of three main types (different macrocyclization reactions) and a few miscellaneous 
macrocycles. These substances were used for solubility, lipophilicity, pKa and permeability 
measurements across Caco-2 cell monolayers. From these empirical results Kihlberg et al. 
identified structural motifs that influenced cell permeability. Phenyl, pyridyl, isoxazole and tertiary 
amines were found to improve cell permeability whereas ureas, carbonyl groups, sulfonamides 
and secondary amines were unfavorable. Furthermore, stereo- and regiochemistry was shown to 
potentially have a big influence on cell permeability, while no substantial effects on aqueous 
solubility were observed. They further demonstrated that unfavorable functional groups in 
combination with favorable groups might exhibit synergistic cell permeability improvements. The 
opposite was observed as well, whereby antagonistic effects even further reduced cell uptake 
than what was expected for the functional groups alone. With their assay, they showed that 
predictions for oral bioavailability are achieved in a more reliable form, if the three-dimensional 
compound structure and certain higher energy conformations are also taken into account. From 
these results they generated a set of physicochemical properties guidelines,[209] which are 
depicted in Table 8. 
8.2 Evaluation of the Physicochemical Properties of the DEML 
The building blocks that were used for the construction of the DEML had all been manually 
selected with an emphasis on including natural product-like moieties and covering a broad range 
of chemical space in terms of functional groups, size and structure. We did this without the use of 
informatics tools that could predict the suitability of building blocks for the construction of drug-like 
molecules. For that reason, we analyzed the physicochemical properties of the final macrocycle 
library to get an idea of whether our macrocycle collection occupied a favorable chemical space 
for oral bioavailability. Based on this analysis, we will be able to optimize the building blocks for 
future libraries. For this purpose we developed an in-house software to construct the full library 
from its fragments (see Chapter 13.15) and subsequently calculate chemical properties with 
open-source software.[210] The software suite is available on https://github.com/Gillingham-
Lab/DECL-Gen and was developed in Python 3.6 with the following packages: Biopython[211], 
RDKit[212], NumPy[213], SciPy[214], pandas[215] and Matplotlib.[216] 
The following properties were calculated with RDKit for the macrocycle library: Molecular weight, 
TPSA (calculated surface sum of all polar atoms), AlogP (logarithmic value of an atom-based 
calculation of a compound's partition coefficient between a polar/nonpolar mixture), number of 
hydrogen bond donors, number of hydrogen bond acceptors, number of rotatable bonds and size 
of the biggest ring.e We compared these calculated results with the guidelines from Whitty[205] and 
Kihlberg[209], which gave us an estimate of the potential (oral) bioavailability of our macrocycles. 
  
                                            
e We also calculated the quantitative estimation of drug-likeness (QED), number of heteroatoms, number of 
N,O,NH,OH, number of rings, number of sp3 carbons and number of heavy atoms. 
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Table 8. Comparison of the proposed guidelines from Whitty, Kihlberg and Lipinski. MW = molecular weight, AlogP = 
atom based partition coefficient (logP) calculation, TPSA = topological polar surface area, HBDs = hydrogen bond 
donors, HBAs = hydrogen bond acceptors, RotBs = rotatable bonds. 
 MW [g/mol] AlogP TPSA [Å2] No. HBDs No. HBAs No. RotBs 
Whitty[a] 600 ≤ x ≤1200 -2 ≤ x ≤6 180 ≤ x ≤ 320 ≤ 12 12 ≤ x ≤ 16 ≤ 15 
Kihlberg ≤ 1000 -2 ≤ x ≤ 10 ≤ 250 ≤ 6 ≤ 15 ≤ 20 
Lipinski ≤ 500 ≤ 5 ≤ 140[b] ≤ 5 ≤ 10 ≤ 10[b] 
[a] Proposed physicochemical guidelines for oral macrocyclic drugs. [b] From the enhanced rules for conventional small 
molecule drugs by Veber.[201] 
As previously explained, the common rule-of-five (Ro5) from Lipinski[159][200] cannot be applied to 
macrocycles since their occupied chemical space mostly lies beyond the Ro5 region. In that 
sense these compounds are pharmacologically uninteresting from a common small molecule 
perspective. However, as discussed in Chapter 8.1, macrocycles behave very differently than 
small molecules, making them suitable drug candidates despite their Ro5 violation. Comparing 
our results with the reported guidelines from Table 8 we directly saw that our macrocycle library 
fit well to the Whitty and the Kihlberg rules (Figure 67). 
 
 
Figure 67. The most important calculated physicochemical properties of the macrocycle collection. Coloring shows the 
comparison of the calculated properties with the guidelines from Whitty (blue) and Kihlberg (orange) for potential 
macrocyclic drugs beyond the rule-of-five chemical space.f  
We found that the largest deviation from the Whitty parameters lies with the number of hydrogen 
bond acceptors (HBAs). The majority of our macrocycles possessed 9-12 HBAs, which was too 
low of a number by the Whitty definition. In contrast, the Kihlberg parameters that arose from 
direct macrocycle measurements state that 15 or less HBAs is suitable for a macrocyclic drug. A 
similiar but less pronounced picture was found with the topological surface area (TPSA). For both 
                                            
f Analysis plots were generated by B. Sauter with the described software suite. Coloring and modification of the plot 
representation was performed by C. Stress. 
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guidelines a fraction of our library lay outside the ideal parameters, although both rule sets 
seemed to cover about 75% of our structures. We analyzed the distribution of the macrocycle ring 
sizes to further highlight the diversity and potential applicability of the DEML in drug discovery 
(top left graph in Figure 67). Most of the ring scaffolds contained 16 to 23 ring atoms with a few 
outliers having up to 33 ring atoms. From this analysis we felt confident that we had generated a 
diverse natural product-like macrocycle library that mostly fulfilled the reported criteria for drug-
likeness. 
8.3 Quantitative PCR (qPCR) 
An encoded chemical library is only successful if the coding DNA strand remains intact and 
amplifiable. Therefore, not every chemical transformation may be conducted in the presence of a 
DNA strand due to incompatibility with the aqueous environment or chemical modification of the 
oligonucleotide. Malone and Paegel from the Scripps Research Institute Florida showed a set of 
DNA-compatible reactions and assayed the viability of the DNA strands by qPCR.[145] They 
defined that reactions were useful for DECL synthesis if >30% viable DNA remained after the 
chemical transformation. For that reason, we assessed the DNA damage that occurred 
throughout the synthesis of our library.  
We tested the potential DNA damage on a reference DNA strand without an attached small 
molecule. qPCR of the purified DNA strand revealed the remaining amount of fully intact DNA. 
Unsurprisingly, we observed that double-stranded DNA was more resistant to chemical 
modifications than single-stranded DNA (Figure 68). This implies that the Watson-Crick base 
pairing[6] shields the nucleobases from the reactive species and predominantly backbone 
modifications occur. In the case of the click reaction, containing approximately 200 eq. of 
copper(I), much more single-stranded DNA (89% damage) was damaged than double-stranded 
oligonucleotides (26% damage).  
For amide couplings, we first tested the coupling conditions that were used for the DEML 
assembly. Since in our DEML assay the carboxylic acid was located on the DNA, the amine 
coupling partner was added in a huge excess. Good results were observed in the DMTMM 
couplings (DMTMM Amine) in which about 30% of the single-stranded and more than 75% of the 
double-stranded DNA were recovered intact. These were the conditions most often applied for 
amide couplings in our DEML assembly. On the other hand, we found troubling results for the 
EDC coupling with amines, where >99% of the DNA (single-stranded or double-stranded) was 
damaged. In previous reports on DNA damage during chemical synthesis, peptide coupling 
conditions showed a certain oligonucleotide damage potential (up to 80% damage), but never in 
such a huge amount.[145] However, most DECL assemblies use the amine located on the DNA 
strand[137,147] and perform the reactions with a large excess of activated carboxylic acid. Under 
our reaction conditions >99% of the coupling reagents and the amine did not react with the DNA-
attached carboxylic acid, but were available for undesired oligonucleotide damaging reactions. 
This seemed to be particularly disadvantageous for the EDC coupling conditions. Luckily, we only 
used these conditions for a small number of amino acid couplings (e.g. tyrosine DE-2 building 
blocks). For comparison, we investigated the DNA damage of reported amide coupling 
conditions, where the amine moiety was located on the DNA strand and treated it with a huge 
excess of activated carboxylic acids. The DNA damage with DMTMM was similar as in the first 
assay (slightly less DNA damage with single-stranded DNA). In contrast to the first peptide 
couplings with EDC, in the control approach we obtained amplifiable DNA in a useful range 
(>30% for single- and double-stranded DNA).  
The deprotection steps (ester hydrolysis and Nosyl) seemed to be the mildest conditions for 
single-stranded DNA, even though more than 50% damage was observed in both cases. Taking 
into account the determined DNA damage ratios, only 0.1% of our library DNA was left fully intact 
 -105- 
(calculated from the stated percentages in Figure 68 in respect to the synthesis scheme, Figure 
46). Yet, this does not take into account the amount of DNA modifications that might have been 
removed again during the synthesis like activated phosphate backbone hydrolysis. DMTMM is 
known to modify DNA, but these modifications can be removed again by base treatment of the 
DNA.[155] Moreover, DNA backbone modifications may not be problematic for the successful use 
of the DECL.[217,218] Furthermore, some polymerases might even accept certain modifications of 
the DNA template for PCR replication.[219,220] 
 
Figure 68. qPCR results from all tested reaction conditions with single- or double-stranded DNA. Not all of these 
conditions were applied during DEML assembly, but several of them have also been routinely used in DECL synthesis 
(e.g. EDC acid coupling). 
In addition to the shown reaction conditions, we also investigated on the DNA damage of BIQ 
formation on DNA (reaction conditions from Part I, see Chapter 3). These conditions revealed a 
recovery rate of intact DNA of >40% for single-stranded and >60% for double-stranded DNA. In 
conclusion, BIQ formation on DNA may be very interesting as it fulfills all criteria for the use in 
DNA-encoded libraries in terms of DNA and reaction conditions compatibility as well as novelty of 




















































9. Protein Affinity Selections, Sequencing and Data Analysis 
9.1 Protein Affinity Selections 
 
Figure 69. Schematic representation of protein affinity selections. The DEML was tested against the protein of interest 
(POI) to find enriched protein binders. Elution of these binders with subsequent PCR amplification delivered the binder 
DNA in sufficient quantities for DNA sequencing. For simplicity a binding event of a single binder is displayed. Usually 
series of binders are identified after sequencing with different relative abundances. 
The synthesized DNA-encoded macrocycle library (DEML) and its precursor macrocycle library 
(smDEML, DE-3 missing) were tested for binding affinities (Figure 69) to human serum albumin 
(HSA), α-1-acid glycoprotein (AGP) and carbonic anhydrase 9 (CA9). In a first step, HSA and 
AGP were biotinylated according to a published procedure with an activated biotin derivative.[164] 
The unspecificity of this procedure ensured a protein display on the streptavidin-coated magnetic 
beads in all possible orientations. The success of the biotinylation was confirmed by a band-shift 
assay with avidin. CA9 is commercially available with a C-terminal polyhistidine tag (His-tag). For 
this reason, we used magnetic nickel beads for His-tag CA9 immobilization. Blockage of the 
unoccupied protein binding sites was achieved with D-biotin (streptavidin) and imidazole (nickel 
beads). After protein immobilization, we incubated the two libraries with the protein beads, 
followed by several washing steps to remove weak and unspecific binding. Random DNA binding 
of the library to the beads or the proteins was minimized by the addition of sheared salmon sperm 
DNA, blocking unspecific DNA interaction sites. The remaining binders were eluted from the 
beads by heat denaturation of the proteins. For control experiments, we used dummy samples 
(beads with biotin-blocked or imidazole-blocked protein binding sites), which did not contain the 
target protein. Along with the library fingerprint, these reference selections were later used for 
data evaluation.  
We conducted the affinity assays in duplicates with freshly prepared library solutions, whereby 
the same assays were performed on two consecutive days. For the CA9 assays, we included in 
one of the two selections a positive control spike-macrocycle with the known acetazolamide 
binder TA664. DNA amplification by PCR yielded the required oligonucleotide amounts for 
sequencing, whereby the selection specific identification barcodes, along with the Illumina 
primers were incorporated on both ends of the duplex DNA strands. We purified the PCR 
products with DNA column purification kits and agarose gel electrophoresis (after the 2nd PCR). 
Details on the selection protocols, PCR amplification and purification gels are presented in 
Chapters 13.7 - 13.9. 
DEML 
POI 
Protein Affinity Selection 
POI 
Elution and  
PCR Amplification 
Amplified Binder DNA 
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9.2 Next Generation Sequencing (NGS) 
Introduction 
Sequencing of the amplified DNA after protein affinity screening is the most important step for the 
evaluation of target binders. This is the major difference between high-throughput screening and 
encoded library technologies. Traditional DNA sequencing such as radioactive sequencing by 
Maxam and Gilbert[221] or sequencing with fluorescently labeled dideoxynucleoside triphosphates 
in chain terminating reactions by Sanger[222] have been used for many years to determine DNA 
sequences from genomic DNA. While Sanger sequencing is still a popular method for certain 
oligonucleotide sequencing applications, the Maxam-Gilbert method has mostly vanished.[223] The 
main disadvantage of those methods is the rather low throughput of the sequencing, along with 
labor-intensive procedures.  
In 2004, the first machines were released that used completely new techniques for high-
throughput parallel DNA sequencing. The data output and speed outperformed state-of-the-art 
Sanger sequencing tremendously and thus coined the term "next generation sequencing".[224] 
This improvement caused a strong decrease in sequencing costs. Since then, many different 
techniques have been established. All of them have in common, that they can produce large, 
genome-scale datasets. Many of these modern techniques are limited by read length, which 
requires the preparation of a so-called DNA library. Long DNA sequences are enzymatically 
restricted into shorter strands, which are then ligated to specific adapters, amplified and purified. 
After the DNA sequencing, bioinformatics tools reassemble the genome from the short 
oligonucleotide reads. In the case of DECLs the eluted DNA strands are usually short enough to 
be directly used for the adapter ligation, amplification and sequencing (see Chapter 9.1).  
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Figure 70. a) Schematic representation of the emulsion PCR amplification. A primer modified solid bead anneals with a 
specific DNA strand and gets amplified to immobilize the reverse complementary sequence on the bead. The process is 
repeated several times to cover the solid bead with a single DNA sequence. b) Schematic representation of the bridge 
amplification. The surface of a flow cell is covered with two different primers. A complementary oligonucleotide anneals 
and further adopts a bridge structure to anneal with the second primer. This induces the generation of the covalently 
attached reverse complementary sequence. Repetition of this procedure generates clusters of DNA with identical 
sequence. 
A certain amount of identical DNA is a prerequisite to generate a detectable signal for the DNA 
sequencing reaction. For this purpose, the DNA library is amplified again using two major 
methodologies. Emulsion PCR uses tiny water droplets in oil as micro reactors (Figure 70a). In 
addition to the necessary reagents and primers for PCR amplification, every micro reactor 
contains one solid bead with an attached primer that is complementary to a DNA strand from the 
DNA library. With this method, single beads carrying identical DNA strands are generated.[225] 





















not always perfectly achieved. This leads to sequencing data that has to be filtered from the 
reliable data.  
Another methodology (the so-called bridge amplification) uses immobilized DNA primers on a 
glass plate (Figure 70b). The DNA molecules from the DNA library specifically bind to these 
primers. PCR amplification then generates colonies of identical DNA strands. The amplification is 
achieved since both primers (forward and reverse) are located on the glass plate. The DNA 
adopts a bridged shape for priming with the complementary primer to generate colonies in which 
the forward and the reverse oligonucleotide strands are present.[223] 
The actual sequencing is performed after the amplification by several different procedures. In the 
Roche 454 pyrosequencing the generated DNA beads (from emulsion PCR with biotinylated 
primers) are placed in a picotiter-plate. Non-biotinylated complementary DNA strands are washed 
away and the nucleotide building blocks are washed over the plate one at a time. The sequencing 
method is based on the DNA synthesis from the single-stranded oligonucleotides attached to the 
beads in the plate. The incorporation of a nucleotide generates a molecule of pyrophosphate, 
which is used for the generation of ATP. In a coupled luciferin-luciferase reaction the generated 
ATP induces the emission of light, which is recorded by a camera. The amount of emitted light is 
proportional to the number of incorporated nucleotides. [224] 
The SOLiD (Sequencing by Oligonucleotide Ligation and Detection) system uses ligation 
reactions for DNA sequencing. After emulsion PCR the DNA strands are treated with a primer, 
followed by the ligation of different fluorescently labeled di-nucleotides (pre-defined nucleotide 
combinations). The fluorophore is cleaved off, which generates the detection signal and the next 
round of di-nucleotides is incorporated. After completion of the first cycle of ligation, dye cleavage 
and detection the generated complementary strand is removed and a new cycle starts with a one 
base longer primer. After six cycles of this ligation series, all nucleotides have been read in 
duplicates. The detection signals of the dyes can then be transformed into the DNA sequence 
with bioinformatics tools.[224] 
Ion Torrent technology uses semiconductors to detect tiniest pH changes. During the synthesis of 
a DNA strand, protons are released, which induces measurable acidity changes. The number of 
released protons is proportional to the number of incorporated nucleotides. After emulsion PCR 
the beads are placed in microwells and then stepwise flooded with single nucleotide solutions. 
This technology generates large datasets within short time and low cost. However, the accuracy 
of the method is only at about 98%.[224] 
The Illumina platform uses the described bridge amplification for DNA immobilization and 
generation of the required clusters. The sequencing is performed by DNA synthesis with 
reversibly blocked dye nucleotides. The nucleotides are stepwise incorporated, the dye cleaved 
off and detected by a camera. This enables the next cycle of nucleotide incorporation. With this 
technology all DNA strands are elongated simultaneously one nucleotide per step. This method 
generates a high output per run at a reduced price.[224] 
Further techniques have evolved over time and there is a lot of research focusing on new 
procedures for DNA sequencing. An example is in situ sequencing (ISS) that enables the 
sequencing of the genome and transcriptome of whole tissue samples.[226] 
Sequencing of the DEMLs 
We equipped our eluted binders from the protein affinity assays during the two PCR steps with 
the necessary primers for Illumina sequencing. Each sample was given a unique index primer 
sequence and all samples were pooled together. The sequencing of that pool was performed with 
a target read count of 240 million reads and paired-end 150 sequencing (reading 150 bases from 
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both ends of the DNA) by Novogene. From the generated sequencing data, we analyzed the 
results with the DECL-Gen.[227] The theoretical DNA strands were aligned with the obtained 
sequencing results and the codons were extracted. DNA strands with damaged or missing 
codons were discarded, as well as reads where the codon on both strands was read differently. 
Sequences that displayed gaps or errors in the constant regions of the DNA strand with intact 
codons were also included to improve the number and quality of the data set. Detailed statistics 
about the sequencing data are displayed in Table 13.  
For the smDEML assays we had a very high coverage of several thousand reads per codon, 
whereas for the DEML we achieved coverage of 5-7 reads per codon. That is explicable by the 
much bigger library size of the DEML versus the smDEML at a comparable sequencing depth. 
The coverage gives an estimate of the expected number of reads per codon in an equally 
distributed sample. This is never the case in enrichment assays where the highly enriched 
sequences appear much more frequently than those of the weak binders. The invalid codon 
content was in all samples below 7% with a trend that the smDEML showed significantly less 
invalid codons than the DEML. This indicated a lower purity of the DEML codons, which may 
stem from the last encoding step or the additional chemical transformation, leading to more DNA 
damage. We were happy to find 100% of all codons in the smDEML fingerprint and about 93% of 
all codons in the DEML. This stated that above 90% of all codon combinations had been 
generated during library assembly. 
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9.3 NGS Results Analysis 
Hit Identification (smDEML) 
 
Figure 71. Scatterplots for the selections of the smDEML, presented in 2D (upper) and 3D (lower) plots. For clarity, only 
the 100 most abundant compounds are shown. a) smDEML fingerprint. b) smDEML dummy selection (streptavidin 
beads only). c) smDEML selection against AGP. d) smDEML selection against HSA. Coloring and scale bar according 
to a-c. e) smDEML CA9 dummy selection (nickel beads only). Coloring and scale bar according to f. f) CA9 selection.[227] 
Potential binders were identified by comparison of the found hits in the protein selections to the 
dummy selections and the fingerprint. Hits containing the DE-1 elements NP09, NP18, NP19 and 
NP20 were directly excluded, since these compounds were highly overrepresented in the 
fingerprint and/or the dummy selections. Those moieties seemed to favor binding to the magnetic 
beads (perhaps streptavidin or nickel), which led to the conclusion that these compounds were 
false positives. Macrocycle NP07-AA001 was found to be the most abundant compound in the 
fingerprint and reappeared in high amounts in all other selections, which required its exclusion 
from the analysis (Figure 71). The AGP selection did not reveal any potentially interesting protein 
binders. For HSA we found only one enriched compound (MC NP01-AA001, 2-18) that seemed 
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blocks that also appeared in the CA9 selections, we found macrocycle 2-18 in these selections as 
well, but this time highly enriched in the dummy and the protein selections (Figure 71e and f). 
We speculated that this compound might also be a good binder for nickel. We created a list of the 
remaining potential macrocyclic protein binders (see Table 9) from which we chose the 
compounds for synthesis and binding affinity measurements. Only the top hit in the HSA selection 
was finally considered valuable for binding affinity tests. 
Hit Identification (DEML) 
 
Figure 72. Scatterplots for the selections of the DEML in 3D. For clarity, only the 100 most abundant compounds are 
shown for the selections, 1000 compounds for the fingerprint plot. a) DEML fingerprint. b) DEML dummy selection 
(streptavidin beads only). c) DEML selection against AGP. d) DEML selection against HSA. Scale bar and coloring 
according to a-c. e) DEML CA9 dummy selection (nickel beads only). Coloring and scale bar according to f.  
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As with the smDEML, potential binders were identified by comparison of the found hits in the 
protein selections to the dummy selections and the fingerprint. Hits containing the DE-1 elements 
NP09, NP18, NP19 and NP20 were excluded again, since these compounds were highly 
overrepresented in the fingerprint and dummy selections. The compound group  
MC NP07-AA001-TAX was highly overrepresented in the fingerprint, resulting from the same 
high abundance of macrocycle MC NP07-AA001 (compare to smDEML selection analysis). For 
the carbonic anhydrase 9 selections we found MC NP07-AA001-TA001 to be even more 
enriched than in the HSA and AGP selections. We proposed that the pyridyl moiety in 
combination with a triazole and a urea could form complexes with the nickel (or other metals) 
from the beads. As a positive control we spiked the library for the CA9 selections with the 
individually synthesized macrocycle NP01-AA001-TA664 that contained the azolamide building 
block, a known carbonic anhydrase 9 binder.[228] However, an enrichment compared to the 
dummy selection was not observed. Either the spike concentration was too high in the assays, so 
that we could not see enrichment differences between the sample and dummy, or no protein 
binding took place (which might be an indication of unsuccessful protein immobilization).  
A summary of the top hits of these selections is shown in Table 9. We chose four compounds 
from the AGP selection and one macrocycle from the HSA selection (see Figure 72 and Table 9 
for the details) for protein binding affinity evaluations. In the case of macrocycles  
MC NP02-AA058-TA229 and MC NP13-AA070-TA333 the first diversity element was changed to 
NP01 and NP12 respectively. These changes were done due to the high similarity of these 
elements and to simplify the macrocycle resyntheses (see the structures of 2-21 and 2-23). From 
the CA9 results we did not choose any compounds for resynthesis because of the high 
uncertainty level in the selection data. 
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Table 9. Results for the different library-protein selections. The compounds were ranked after comparison of the protein 
selection with the dummy selection experiment and the fingerprint. Only the top 6 compounds are listed, the rest was 
considered too little enriched. Compounds in bold face and grey coloring were chosen for resynthesis and binding 
affinity measurements. 
Small DEML selection against AGP DEML selection against AGP 
Rank DE-1 DE-2 Number Rank DE-1 DE-2 DE-3 Number 
1 NP20 AA069 NP20-AA069 1 NP07 AA026 TA256 NP07-AA026-TA256  2-19 
2 NP19 AA088 NP19-AA088 2 NP14 AA020 TA607 NP14-AA020-TA607 2-20 
3 NP19 AA117 NP19-AA117 3 NP13[b] AA070 TA333 NP13-AA070-TA333 2-21 
4 NP18 AA053 NP18-AA053 4 NP12 AA118 TA622 NP12-AA118-TA622 2-22 
    5 NP21 AA125 TA412 NP21/AA125/TA412 
    6 NP09 AA029 TA443 NP09/AA029/TA443 
Small DEML selection against HSA DEML selection against HSA 
Rank DE-1 DE-2 Number Rank DE-1 DE-2 DE-3 Number 
1 NP01 AA001 NP01-AA001 2-18 1 NP21 AA026 TA423 NP21-AA026-TA423 
2 NP18 AA034 NP18-AA034 2 NP14 AA086 TA621 NP14-AA086-TA621 
3 NP17 AA070 NP17-AA070 3 NP02[a] AA058 TA229 NP02-AA058-TA229 2-23 
4 NP20 AA069 NP20-AA069 4 NP15 AA020 TA459 NP15-AA020-TA459 
5 NP19 AA029 NP19-AA029 5 NP19 AA039 TA357 NP19-AA039-TA357 
6 NP20 AA072 NP20-AA072 6 NP12 AA029 TA553 NP12-AA029-TA553 
Small DEML selection against CA9 DEML selection against CA9 
Rank DE-1 DE-2 Number Rank DE-1 DE-2 DE-3 Number 
1 NP10 AA026 NP10-AA026 1 NP01 AA006 TA316 NP01-AA006-TA316 
2 NP02 AA069 NP02-AA069 2 NP08 AA042 TA519 NP08-AA042-TA519 
3 NP05 AA026 NP05-AA026 3 NP08 AA018 TA410 NP08-AA018-TA410 
4 NP09 AA019 NP09-AA019 4 NP06 AA072 TA589 NP06-AA072-TA589 
5 NP10 AA107 NP10-AA107 5 NP19 AA102 TA429 NP19-AA102-TA429 
6    6 NP05 AA032 TA430 NP05-AA032-TA430 
[a] Due to the high similarity and ease of chemical synthesis, NP02 was replaced by NP01 for off-DNA macrocycle 




Figure 73. Top 100 AGP binders ranking. Molecules with the 2-chlorophenyl β-amino acid are highlighted in red. 
From the results of the smDEML and DEML affinity selections (Figure 71 & Figure 72) we could 
not directly see any trends concerning enrichment of diversity elements or diversity element 
combinations. The found top hits all seemed to be singleton hits except for the bead binders, 
which all showed the same or very similar diversity elements. For that reason we looked at the 
distribution of the second diversity elements among the top 100 hits in the DEML versus AGP 
selections. The most abundant element that we found was building block AA001 (L-alanine), 
followed by the 2-chlorophenyl-β-amino acid (AA118) element. However, AA001 was also the 
most abundant building block in the dummy samples, whereas the AA118 did not show up 
among the top 10 binders in the dummy selections. This comparison showed a clear enrichment 
of building block AA118 in the selections against AGP. We noticed similar behavior for only one 
other building block. AA029 (L-tryptophan) was also slightly enriched but to a lesser extent than 
AA118 (5 appearances in the top 100 hits). Figure 73 displays the locations of the AA118 
containing macrocycles among the top 100 AGP binders. We found it as the fourth highest 
































10. Macrocycle Resynthesis and Protein Binding Affinity Measurements 
10.1 Resynthesis of the Macrocycles 
 
Figure 74. Schematic description of the macrocycle resynthesis for protein binding affinity assays. Z is the place holder 
for the macrocyles defined in Table 9. DE-1: NP01, NP07, NP12, NP14. DE-2: AA001, AA020, AA026, AA058, AA070, 
AA118. DE-3: TA229, TA256, TA333, TA607, TA622. Reaction conditions: a) HBTU, DIPEA, THF, RT, 2 h, 94%.  
b) Pd (π-cinnamyl) chloride dimer, K3PO4, EtOH, H2O, 50°C 1 h or Pd(dppf)Cl2, NEt3, methoxyethanol, 100°C, 4 h or Pd 
(π-cinnamyl) chloride dimer, THF, 0°C → RT, 1 h, 53-82%. c) LiOH * H2O, MeCN, H2O, RT, 2.5 h, 49-99%. d) HBTU, 
DIPEA, THF, RT, 1.5 h, 96-99%. e) LiOH*H2O, MeCN, H2O, RT, 1.5 h, 73-99%. f) HATU, DIPEA, THF, RT, 1 h, 66-94%. 
g) 1. PhSH, DIPEA, MeCN, RT, 2 h; 2. LiOH*H2O, MeCN, H2O, RT, 1.5 h, 76-99%. h) HATU, DIPEA, THF, RT, 2 h,  
5-89%. i) CuSO4, NaOAsc, DMSO, H2O, RT, 2-14 h, 35-93%. 
In order to perform quantitative protein affinity measurements we synthesized the most promising 
macrocycles from the DEML enrichments (see Table 9) as small molecules. In comparison to the 
macrocycle validation synthesis (see Figure 48) we eliminated the DNA attachment site. We 
started with the nosylethylenediamine (2-3) coupling with iodobenzoic acid and subsequent DE-1 
cross coupling reactions (Suzuki-Miyaura and Negishi couplings). Following the established 
deprotection and amide coupling procedures we introduced the trifunctional linker 2-5 along with 
a set of six different amino acid building blocks. During these amide couplings we encountered 
10-20% epimerization of the azidoethyl sidechain of the trifunctional linker. In the case of AA118 
(compound 2-22d) we found a mixture of four diastereomers in a 7:36:42:15 ratio. AA118 was 
not available as an enantiomerically pure compound, just as a racemate, which explains the 
generation of four diastereomers at an estimated epimerization of approximately 10%.  
The Nosyl deprotection was performed with thiophenol and subsequent ester hydrolysis. The 
macrocyclization turned out to be the most difficult step and seemed dependent on the rigidity of 
the precursor. The employed DE-2 elements were all very similar in structure (α-and β-amino 
acids), so the differences mostly arose from the DE-1 building block shapes and the linear 
precursor chemical properties (e.g. solubility). While the flexible alkyl based DE-1 elements 
(NP12 and NP14) gave medium yields of 40-70%, the more rigid aryl based DE-1 elements 
(NP01 and NP07) delivered rather low yields (<35%). Dimerization was not a substantial problem 
since the reactions were performed at concentrations of 1-2 mM. However, macrocycles 2-18 and 
2-23f in particular (both contained NP01) caused separation problems in combination with 
reduced solubility. 2-18 had to be purified by reversed phase and normal phase column 
separations to obtain pure material. 2-23f reacted under the same conditions as the rest of the 
macrocycles to give a larger set of (side) products. Isolation in pure form was not possible at this 
step, but could be achieved after the subsequent click reaction. In order to generate pure material 
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precursor (2-23e) on a small scale with slightly altered reaction conditions (89% product were 
isolated with this approach).  
Click reactions generally performed well with medium to high yields. Only the synthesis of 2-23 
was low yielding (35%) due to the removal of a high amount of undesired side products from the 
previous macrocyclization step. All six chosen macrocycles were successfully synthesized along 
with their macrocyclic precursors, yielding a total of 11 macrocycles for binding affinity 
measurements. Every compound (except from 2-18 and 2-23; isolated yield: 5 and 37 mg, 
respectively) was obtained in amounts ranging from 60 to several hundred milligrams of pure 
material.  
10.2 Differential Scanning Fluorimetry (DSF) 
Introduction 
For the quantitative measurement of ligand-protein binding interactions, biophysical methods 
such as isothermal titration calorimetry (ITC) are inevitable. However, some of these methods 
may become very laborious and time-consuming for larger numbers of ligands and proteins that 
need to be assayed. Differential scanning fluorimetry (DSF) is a biophysical method that is based 
on the thermal denaturation of a protein. Protein binders are assumed to stabilize the three-
dimensional structure of the protein, which results in a shift of the melting temperature of the 
protein (thermal shift) compared to its unbound state. The melting temperature is defined as the 
halfway transition point during protein denaturation.[229]  
DSF is a semi-quantitative method that usually does not deliver exact binding constants, but 
depending on the ligand affinity, different thermal shifts can be observed within a series of ligands 
versus a single protein. In general, the higher the ligand affinity, the more intensive the thermal 
shift. The most important prerequisite for DSF measurements is, that ligands still show good 
affinity at the melting temperature of the unbound protein. Ligands that stabilize the folded state 
of the protein give shifts to higher melting temperatures, whereas ligands that preferentially bind 
to unfolded states (destabilize) yield negative thermal shifts. Nonetheless, destabilizing ligands 
are still interesting because they might also bind to the folded form of the protein or a pseudo-
unfolded form (exposure of some hydrophobic protein areas), which are masked by the higher 
(negative) thermal shift at the melting point.  
In practice, this technique is simple and allows high-throughput parallel screening with a low 
consumption of resources. The thermal shifts are measured by the detection of fluorescence 
emission changes of the protein. This can be either UV excitation of aromatic amino acids (Trp, 
Tyr, Phe) enabling the fluorescence detection, or alternatively the addition of a fluorescent dye 
that binds to the protein. In any case, the structural rearrangement of the protein during 
denaturation exposes hydrophobic regions to the aqueous environment and induces a change in 
the fluorescence properties of the amino acids or the dye.[229] This technique has been 
successfully applied to the parallel screening of ligand collections to a set of proteins[230,231] with 
even in-cell measurements being possible.[232] 
DSF was chosen to be the first step for the quantitative binding assessment of our identified 
potential ligands from Table 9. To the best of our knowledge, this is the first time that DSF has 




The six potential hits and their macrocyclic precursors (missing DE-3, five compounds) were 
tested for thermal shifts with AGP and HSA. In contrast to the results from the DEML selections 
(two HSA binders and four AGP binders) we assayed all macrocycles versus both proteins in 
triplicate measurements. 
 
Figure 75. Normalized first derivatives of the DSF measurements. Compounds 2-23 and 2-23f are not shown as they 
yielded no thermal shifts because of high insolubility. a) Measurements of AGP with MC ligands in PBS buffer.  
b) Measurement of AGP with MC ligand 2-21f in 5% DMSO in PBS. c) Measurements of AGP with MC ligands in 25% 
DMSO in PBS. d) Measurements of HSA with MC ligands in PBS buffer. e) Measurement of HSA with MC ligand 2-21f 
in 5% DMSO in PBS. f) Measurements of AGP with MC ligands in 25% DMSO in PBS.g 
Thermal shift data for our synthesized macrocycles is presented in Figure 75 as normalized first 
derivative curves. The protein denaturation halfway transition point was determined by the first 
derivative of the melting curve. Minima/maxima of these first derivatives show the melting 
temperature of the protein-ligand complexes. Five macrocycles showed good solubility in PBS 
and could be measured without the need for organic solvents. In the AGP assays especially MC 
2-22 and its precursor 2-22f showed large thermal shifts. The other potential AGP binders 2-19, 
2-20 as well as 2-21f showed much smaller shifts, as was the case for the corresponding 
precursors (see Figure 75 and Table 10). Macrocycle 2-21 could not be measured due to its very 
fluorescent DE-3 moiety that interfered with the thermal shift assay. Interestingly, 2-20 displayed 
a negative thermal shift of -1.2°C that implies a protein destabilization (preferred binding to the 
unfolded or a pseudo-unfolded protein form). AGP without a ligand in pure PBS showed a 
broadened melting curve first derivative. Addition of 5% DMSO improved the curve shape, 
however, there were no significant changes in the measured thermal shifts (Table 10). As 
expected from the DEML affinity assays macrocycle 2-18 showed no binding to AGP.  
In the HSA binding assays none of the tested macrocycles showed strong binding that resulted in 
a large thermal shift (>3°C). The potential HSA binder 2-18 showed a melting shift with a high 
difference (9.5°C), however, this value was not trustworthy due to the bad shape of the melting 
curve and its first derivative. The other binder from the DEML-HSA assay, 2-23 and its precursor 
2-23f, were not measurable because the compounds were too insoluble to achieve the necessary 
concentrations. As a consequence the thermal shift was not determined for these molecules. 
                                            
g Normalized thermal shift plots were generated by Dr. Timothy Sharpe from the Biozentrum, University of Basel. 





































































































































a) b) c) 
d) e) f) 
 -120- 
Table 10. Measured ΔTm shifts during macrocycle-protein binding events. Positive ΔTm values imply stabilization of the 
protein structure, negative ΔTm values imply a destabilization of the protein structure. Macrocycles 2-23f and 2-23 are 
not shown in this analysis due to their poor solubility, which resulted in 0°C shift of the protein melting temperature. h 
Compound ΔTm for AGP [°C] ΔTm for HSA [°C] % DMSO Comments 
2-18 0.32 9.47[a] 25 Bad peak shape 
2-19 0.32 8.65[a] 25 Bad peak shape 
2-19f 1.37 -0.07 0  
2-19f[b] 1.38	 - 5  
2-20 -1.21 1.27 0  
2-20[b] -0.78	 - 5  
2-20f 0.49 0.83 0  
2-20f[b] 0.37 - 5  
2-21f 1.16 -0.44 5  
2-22 4.32 0.67 0 AGP Binder 
2-22f 5.94 N/A[c] 0 AGP Binder 
[a] Unreliable data. Curve shape is too unsteady for accurate meting temperature shift measurements. [b] Due to a 
broadened peak shape of pure AGP in PBS the assay was repeated in 5% DMSO in PBS which showed a sharper 
melting peak. [c] Peak is too broad to determine a ΔTm value. 
From the found temperature shifts we chose 2-20, 2-21 (no DSF measurements possible), 2-22 
and 2-22f for ITC measurements with AGP and 2-18, 2-20 and 2-22 for ITC measurements with 
HSA. 
10.3 Isothermal Titration Calorimetry (ITC) 
Introduction 
Isothermal titration calorimetry is a very important method for the direct measurement of a 
reaction's thermodynamic parameters in solution. It is most widely employed to study 
macromolecular processes such as protein-protein, DNA-protein or antibody-antigen interactions 
as well as affinity determinations of small molecules with macromolecular systems. In a single 
experiment the association constant, binding enthalpy and stoichiometry are measured.[233] The 
setup of an ITC machine is based on measuring the power input changes caused by enthalpy 
changes during the reactions in solution while maintaining a constant reaction temperature. An 
ITC machine consists of two identical cells made of highly thermal conductive materials with an 
adiabatic jacket. Sensitive thermophile/thermocouple circuits detect any temperature changes 
between the two cells. One cell is used as reference cell and is filled with buffer whereas the 
second cell contains the sample. The titrant is slowly added to the sample cell by a syringe with 
gentle mixing. Depending on the thermodynamics of the reaction, heating or cooling of the 
sample cell is required to maintain a constant temperature in both cells. The required time-
dependent power input is the actual measure. For exothermic reactions the power input has to be 
lowered and for endothermic reactions an increased power input is necessary. The heat changes 
                                            
h Data was generated by Dr. Timothy Sharpe from the Biozentrum, University of Basel during thermal shift plot 
generation. 
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are directly proportional to the fraction of bound ligand. Over time a saturation curve is obtained 
that determines the thermodynamic parameters. It is important to accurately measure the protein 
and titrant concentrations for precise determination of the parameters. That is why reference 
titrations, lacking the macromolecule in the sample cell, are vital to identify the heat of dilution 
portion, which is then subtracted from the actual titration.[233] ITC measurements are not ideal for 
high-throughput assays because of the required large amounts of protein and ligand, along with a 
time-consuming measurement. Moreover, the assay is very sensitive to slightest changes in 
buffer composition and environmental influences. In comparison to DSF, the parallelization of ITC 
measurements is much more difficult. 
Results 
From the semi-quantitative protein binding assays we first started with the exact measurement of 
the potential AGP binders 2-22 and 2-22f by ITC. Both compounds directly showed a good 
binding affinity in the one digit micromolar range (Figure 76). While 2-22f showed an exothermic 
binding, which revealed an enthalpy driven (negative ΔH value) interaction, the bigger 
macrocycle 2-22 bound the protein in an endothermic process, implying entropy change as the 
main driving force for the protein-ligand complexation (positive ΔH value). To obtain an 
appropriate signal for the differential power changes with 2-22 we lowered the measurement 
temperature to 10°C, whereas the assays with 2-22f could be easily conducted at 25°C. These 
measurements clearly showed that the DSF assay correctly predicted good binding to the 
proteins with a stronger binding of 2-22f (thermal shift 5.9°C and KD= 4.1 µM) than 2-22 (thermal 
shift 4.3°C and KD= 7.0 µM). Since both compounds contained the same ring structure, we 
concluded that the macrocylic core was responsible for the protein binding, not the sidechain 
diversity element. 
The question, why we did not find 2-22f as a hit in the smDEML/AGP enrichment assays came 
up at this point. This was a clear false negative result from the smDEML enrichments. And why 
did we not find a series of macrocycles with the 2-22f scaffold to show up as binders in the DEML 
enrichments? To answer the later question, we can only make assumptions. The largest 
difference between the DEML selections and the binding constant evaluations was the attached 
DNA strand. In the DEML selections, DNA is considered to have no or only very low interactions 
with the protein due to the addition of salmon sperm DNA. However, the DNA represents a much 
bigger part of the encoded molecule than the actual ligand. Steric interferences of the DNA with 
the protein might reduce the binding affinity. Furthermore, interactions of the macrocycle with the 
oligonucleotide tail could lead to a coiled structure that shields the less polar macrocycle from the 
aqueous environment by interactions with the nucleobases. This is a possible explanation why  
2-22f did not show up as a binder. In contrast, 2-22 possesses a sidechain with a tertiary amine 
that is protonated at physiological pH, which makes the compound more water-soluble and 
perhaps more accessible for protein binding. However, such an assumption does not explain why 
we only found singleton hits in the DEML enrichment assays.  
In Figure 73 we showed that the 2-chlorophenyl-β-amino acid was the most abundant DE-2 
element in the top 100 enriched binders of the AGP assay. Therefore, we can state that this 
element is most probably responsible for AGP binding. However, it cannot be the only part of the 
molecule that causes the binding affinity to AGP, otherwise we would find a larger series of 
molecules containing the AA118 element among the top hits. Supposedly, the interplay between 
certain diversity element building blocks combinations may influence the binding affinity. All these 
findings and conclusions complicate a careful discussion of the results along with suspected 
imperfect DEML enrichments and DNA sequencing. Finally, we also found that only about 50% of 
the AGP were involved in ligand binding (molar ratios in both measurements approximately 0.5). 
This is an indication that only certain isoforms of AGP bind the ligands.[188]  
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The Neri group has published several reports about other, small molecule binders from encoded 
libraries that showed single-digit nanomolar binding affinities. However, their binding affinities 
were determined by on-DNA fluorescence polarization measurements, which usually give much 
stronger binding than confirmation by ITC. Their DNA-free small molecule AGP binders showed 
single-digit micromolar affinities, comparable to our hits. In the case of their macrocyclic binders, 
even on-DNA fluorescence polarization only showed single-digit micromolar binding affinities to 
AGP.[137,142,177]  
 
Figure 76. a) Overlay of the triplicate ITC measurements of 2-22f versus AGP after data processing with heat of dilution 
subtraction. The binding affinity constant KD and the binding enthalpy ΔH were calculated after data fitting with 
specialized software. b) Overlay of the triplicate ITC measurements of 2-22 versus AGP after data processing with heat 
of dilution subtraction. The binding affinity constant KD and the binding enthalpy ΔH were calculated after data fitting with 
specialized software.i 
We conducted further ITC measurements with 2-20 and 2-21 versus AGP but none of these 
compounds showed strong binding to the protein. We did not exactly evaluate any binding 
constants, but from the behavior during ITC measurements we could estimate a binding constant 
of >100 µM for 2-21 and no detectable binding for 2-20 (see Figure 104). All assayed HSA 
binders showed weak binding interactions with binding constants in the several hundred 
micromolar range (see Figure 105). We did not further optimize these assays. 
We clearly showed that the majority of the identified binders from the DEML enrichments were 
false positives that actually possessed rather weak or even no binding affinity to AGP and HSA. 
Only macrocycle 2-22 showed binding to AGP in all of the used affinity assays. Furthermore, we 
found 2-22f to possess even better binding properties for AGP despite little enrichment in the 
smDEML selection, a clear false negative result. 
  
                                            
i Graph generation, data fitting and parameter determinations were conducted by Dr. Timothy Sharpe from the 

















































































































KD= 4.1 ± 2.0 µM 
ΔH= -20.0 ± 3.1 kJ/mol 
KD= 7.0 ± 3.7 µM 
ΔH= 11.4 ± 1.8 kJ/mol 
a) b) 
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11. Conclusions and Perspective 
We have developed and assembled a DNA-encoded macrocycle library based on the 
incorporation of natural product-derived building blocks in a split-and-pool synthetic procedure. 
The library design focused on the generation of highly diverse macrocycle scaffolds that covered 
a broad area of chemical space in terms of structure, ring size and polarity. The scaffold ring 
composed of two sets of building blocks along with a trifunctional linker and the basic core, 
responsible for attachment of the DNA strand and macrocyclization. The first set of diversifying 
elements was designed and individually synthesized to incorporate natural product motifs. The 
majority of these elements contained alkyl chains, polyolefin moieties and heteroaromatic parts. 
Polyketide-like structures were not included due to the disproportional synthetic effort to create 
such elements.  
The second set of building blocks contained highly diverse amino acids. Along with the common 
D- and L-amino acids, we incorporated unnatural α- and β-amino acids with alkyl, aryl and 
heteroaromatic substituents. For a high structural diversity we also included diverse olefinic and 
cyclic amino acids, which introduced a certain degree of conformational rigidity due to bridged 
and spirocyclic structures. Prior to the incorporation of the DE-2 building blocks we conducted a 
thorough compound and conditions screening in which the low yielding elements were removed 
from the compounds set. We generated 21 x 102 = 2'142 linear macrocycle precursors from 
those building block collections. The trifunctional linker that was integrated to connect all three 
diversity elements, influenced many of the reactions and required careful design. Due to synthetic 
difficulties as well as undesired elimination processes we were forced to include a C2 spacing unit 
between the macrocycle scaffold and the DE-3 attachment site. The azide moiety of the 
trifunctional linker turned out to be the critical spot because it caused the formation of a terminal 
amide side product under certain reaction conditions.  
To the best of our knowledge we are the first to successfully use the nosyl protecting group in 
DNA-encoded chemical library synthesis. Nosyl deprotection was a vital step to generate the 
reactive amine essential for macrocyclization. While nosyl deprotection efficiency was strongly 
dependent on the reaction conditions and the structure of the DE-2 building blocks, the 
macrocyclization step turned out to be very efficient with all individually tested compounds. The 
final diversification of the sub-library was achieved by click (CuAAC) reaction with a collection of 
663 diverse terminal alkynes to generate the 1'420'146 member library (DEML). From the 
building block screenings, we concluded that most effort must be taken in design and evaluation 
of the trifunctional linker along with the amino acids collection during DE-2 amide coupling and 
nosyl deprotection.  
The library was encoded consecutively after each diversifying chemical step. Every building block 
was encoded with a unique oligonucleotide "barcode". We chose a polymerization-restriction-
ligation strategy to modify the DNA tag in a consecutive manner. The selected BamHI restriction 
process turned out to be the bottleneck in this encoding strategy, since the restriction did not 
proceed to completion, thereby generating some left-over DNA. Library purification turned out to 
be particularly tricky because of the co-elution of undesired oligonucleotide strands.  
We performed affinity selections of the DEML and the precursor library (lack of DE-3, smDEML) 
with AGP, HSA and CA9. While we found several singleton hits for AGP and HSA that were 
promising for resynthesis, the CA9 selections were very unreliable due to supposed interactions 
of the macrocycles with the nickel beads. We finally selected two compounds for affinity 
measurements with HSA and four compounds for AGP. To the best of our knowledge, we were 
the first to use differential scanning fluorimetry (DSF) for semi-quantitative protein affinity 
measurements with potential binders from DECL selections. We treated both proteins with all the 
resynthesized compounds to screen for potential false positive and false negative hits. The 
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sidechain and macrocycle ring influences on protein binding were evaluated by inclusion of the 
precursor macrocycles (without DE-3). From the thermal shift results we identified one 
macrocycle and its precursor as potentially good binders to AGP. Isothermal titration calorimetry 
(ITC) measurements yielded binding constants (KD) of 4.1 µM (small macrocycle) and 7.0 µM 
(large macrocycle). While all other tested ligands showed very weak or no binding affinity (false 
positive results from the DEML enrichments), discovery of the small macrocycle's high AGP 
binding affinity represented a clear false negative smDEML selection result. The DNA tag 
potentially changes or even inhibits protein binding, which might be a drawback of the encoded 
libraries selection procedure. The newly discovered AGP binders hold a high potential for further 
optimizations to increase protein affinity.  
The structure of our library was developed in a way to further modify and diversify the 
macrocycles for future attempts. In order to improve hit rates in enrichment assays, the structures 
should display a high similarity to natural macrocycles. In Figure 77 we show potential 
modification sites and new building block types that might be incorporated. The first set of 
building blocks (DE-1, ①  in Figure 77) has the highest potential to create new macrocyclic 
scaffolds. Increasing the number of building blocks in this diversity element seems to be a simple 
task, because many boronic acids are commercially available. However, bifunctional boronic 
acids, displaying natural product features, are rare and their creation might require laborious 
procedures. Polyolefinic moieties directly attached to the basic scaffold would be highly desirable, 
a task that could not be achieved in the first DEML generation. Even more interesting would be 
the use of polyketide parts in the library (see structures in ① ). Such building blocks are very 
common in natural macrocycles, but their synthesis in high purity and well-defined 
stereochemistry is extremely challenging. New methods to have quick access to such complex 




Figure 77. Schematic overview of the potential modification and improvement sites. New building blocks might be 
designed, synthesized and evaluated along with an improved encoding strategy. 
As we have realized from the DEML construction, the trifunctional linker (➁ ) played a very 
important role during the chemical synthesis of our library. The azide seemed to be responsible 
for the increased amount of terminal amide side product. Exchanging the azide with an alkyne 
overcomes this problem as we have shown in separate assays. Even though, the azide may also 
be considered as an amine protecting group, not as the actual functional substituent. Staudinger 
reduction, which is compatible with aqueous conditions, reliably yields the desired amine that is 
then further modified with carboxylic acids (amide coupling), isocyanates (ureas) or aldehydes 
(reductive amination, ③ ). A very simple approach might be the use of a carboxylic acid 
trifunctional linker (e.g. aspartic acid) to take advantage of the very large set of available amine 
and amino acid building blocks. In any case, the trifunctional linker is a key structure that needs a 
thorough consideration and design, but might also act as a diversity element itself.  
Diversity element 2 (DE-2) consisted of a collection of amino acids, a type of molecule that is 
readily available from commercial sources in large numbers or can often be synthesized in a few 
steps (④ ). Uninteresting compounds should be exchanged for more fancy building blocks, 
featuring novel structural moieties (spirocyclic parts, branched or bridged structures with chiral 
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successful incorporation of novel amino acids into the library is a thorough assessment of the 
coupling efficiencies of the building blocks and their influence on the succeeding chemical steps.  
In our library design we used an ethylene diamine spacer for macrocyclization (⑤ ). Many 
diamines are commercially available such as cyclic primary and secondary diamines as well as 
linear compounds with chiral centers. This element could be used to generate several individual 
libraries in which the influence of this part of the macrocycle is investigated. However, an even 
more fruitful approach might be to consider this linker as a third ring diversity element. The 
synthetic effort to create all combinations of the 21 (or more) DE-1 elements with all diamines and 
subsequent coupling to the DNA strands (as we did it for the DEML synthesis with only one 
diamine linker) would exceed a reasonable timeframe for DECL construction. Incorporation of the 
diamines set would be performed in a combinatorial step with subsequent encoding. This goal is 
achieved if the terephthalate core remained on one site as a methyl ester during tBu-protected 
trifunctional linker coupling. Methyl ester hydrolysis, followed by diamine incorporation and 
encoding, would yield the desired products (see Figure 78). Careful temperature and pH control 
during deprotection makes the terephthalate core's methyl ester and the trifunctional linker's tert-
butyl ester orthogonal.[193] 
 
Figure 78. Proposed synthetic strategy for the incorporation of a set of diamine building blocks. Temperature and pH 
control make the two different esters orthogonal. Encoding steps were omitted for simplicity. 
The last improvement of the DEML strategy should be applied to the encoding procedure. As we 
have seen, the restriction digest of double-stranded DNA yielded unsatisfactory results, which 
produced undesired DNA impurities in the final encoded library. We propose to use splint ligation 
and Klenow polymerization strategies for the encoding of future libraries (⑥ ). Splint ligations are 
repeated for the encoding of several subsequent diversifications. Klenow fill-in represents the 
encoding step of choice for the last diversity element. 
Design and validation of a DNA-encoded library are the foundation for its successful construction. 
Nevertheless, there are three main considerations to render a DECL valuable for drug discovery. 
Library size matters! Large libraries are desirable since they can cover a broad range of chemical 
space. However, large libraries (>109 members) come with the bias that many theoretical building 
block combinations are not generated during the library assembly. Furthermore, at some point 
the number of molecules per library member drops to a level, where an efficient enrichment with 
the protein cannot be achieved anymore. To overcome this issue, larger amounts of library need 
to be synthesized, which quickly becomes impractical and higher library concentrations are 
necessary for protein selections with the risk of more random DNA-protein interactions. We think 
that the ideal library size ranges from 105 to 106 members in focused libraries. Secondly, prior to 
the construction of a library or the incorporation of new building blocks, in silico properties 
calculations should be performed to check whether the generated set of compounds fulfills the 
required physicochemical properties (see Table 8).  
The last consideration should include strategies for library purification. Left-over DNA influences 
the quality of the protein selections and may generate higher rates of false positives. 
Chromatographic procedures are inevitable for good library quality, especially size-exclusion 




























12. DNA-Encoded Small Molecule Library 
12.1 Introduction 
From the lessons learned during the design, synthesis, evaluation and testing of the encoded 
macrocycle library we intended to create a novel small molecule library based on the synthesized 
and acquired building blocks and DNA strands from the previous library. We tried to keep the 
library design simple, in principle a connection of two different building blocks. The novelty in this 
approach was to use building blocks off-the-shelf with different reactive groups that were 
attached to the same scaffold modification site with a versatile substituent (see purple circle in 
Figure 79).  
 
Figure 79. Schematic representation of the small molecule library design. Two diversity elements were connected by a 
simple trifunctional linker with the DNA strand. The purple circle stands for a series of chemical connection possibilities 
to attach different DE-2 sub-libraries. This connection scheme is encoded by a third DNA codon (indexing). 
An azido group seemed best suited as versatile functional group for this library, since it 
undergoes click reactions with our alkyne building block library, and can be transformed to an 
amine, which reacts with several electrophilic moieties (e.g. isothiocyanates, aldehydes). We also 
introduced a new concept that we called reaction indexing. The notion behind this method is to 
use a set of DNA strands to encode different reactions with different building blocks. 
Conventional encoding uses X DNA strands to encode X building blocks. With our reaction 
indexing strategy, we use n+X DNA strands to encode nX (n>1) building blocks. This is achieved 
by additional DNA incorporation after encoding of the building block (see purple DNA codon in 
Figure 79). For example, 300 DNA strands can encode sub-libraries of 300 alkynes, 300 
carboxylic acids and 300 isocyanates. All these types of molecules react with an azide or the 
amine, generated by azide reduction. To distinguish the connection type (triazole, amide, 
thiourea), three additional coding DNA strands (indexing codons) are incorporated after building 
block encoding. The different building blocks and their connection types are unambiguously 
reidentified by the combination of building block codon and indexing codon. With this method, 
only 303 unique DNA strands are required to encode 900 building blocks that were attached via 
three different chemical transformations. An example of this indexing strategy is outlined in 
Figure 80c with two building block types (alkynes and carboxylic acids) at the same 
diversification spot. 
12.2 Design and Assembly of the Small Molecule Library 
Design 
The detailed design and synthesis overview of the small molecule library is depicted in Figure 80. 
The scaffold was synthesized from tert-butyl modified glutamic acid, which was transformed to 
the desired azido trifunctional linker in three consecutive steps. After DNA attachment, we 
diversified the linker (2-26) with two sets of building blocks. The first set consisted of amino acids 
and amines (primary and secondary). We used in total 150 compounds for this diversification site. 
The second set of building blocks consisted of 664 terminal alkynes and of 89 carboxylic acids. 
The alkynes were introduced by copper-catalyzed click reaction (CuAAC) and the carboxylic 
acids were incorporated by amide coupling after Staudinger reduction of the azide to the amine. 
Encoding of the library was performed by splint mediated T4 ligation (see Figure 77, ⑥  first step 











sub-libraries were further encoded by indexing, to use the same codon DNA strands for different 
building block types. In principle the index codon represents the connection type of the DE-2 
element (triazole or amide bond). The size of the final library was 150 x 753 = 112'750 members 
(Figure 80b). We employed an encoding strategy that resulted in a purely single-stranded DNA-
encoded library. This left the possibilities of combining this library with other libraries and potential 
further modification or application in an interaction-dependent PCR protein screening assay 
(description of this technique in Chapter 6.4). 
 
Figure 80. a) Chemical synthesis of the trifunctional linker to connect the DNA strand with the two diversity elements.  
b) Examples of the used building blocks. For DE-1 we employed amino acids, primary and secondary amines. For the 
DE-2 we used alkynes and carboxylic acids. c) Synthetic overview of the chemical synthesis of the library and the 
encoding steps. Dashed arrows indicate reaction steps that had not yet been accomplished when the author stopped 
working on this project. Reaction conditions: a) CuSO4 pentahydrate, K2CO3, MeOH, RT, 2 h, 98%. b) TMS-
diazomethane, MeOH, RT, 17 h, 95%. c) Formic acid, RT, 17 h, 78%. d) EDC hydrochloride, HOAt, DIPEA, MOPS 
buffer, DMSO, RT, 22 h. e) LiOH monohydrate, H2O, MeCN, RT, 5 h. f) DMTMM-BF4, NMM, MOPS buffer, DMSO, RT, 
20 h or EDC hydrochloride, HOAt, DIPEA, MOPS buffer, DMSO, RT, 20 h. g) Splint DNA, T4 PNK, T4 DNA ligase, 10X 
ligase buffer, H2O, ATP. h) Cu-TBTA, NaOAsc, TEAA buffer, DMSO, RT, 21 h. k) TCEP, TEAA buffer, RT, 16 h. l) EDC 


























































































































































Scaffold Synthesis and DNA Attachment 
We synthesized the scaffold for the small molecule library from H-Glu(OtBu)-OH in three steps 
with high yields (Figure 80a). In the first transformation we used copper-catalyzed amine-azide 
transfer for the introduction of the azido group at the α-position of the glutamic ester (2-26a).[236] 
After methyl ester formation with TMS-diazomethane (2-26b) the tert-butyl ester was selectively 
deprotected under acidic conditions to yield the final scaffold linker 2-26 with the free γ-carboxylic 
acid. A single 5'-hexylamine modified DNA strand was attached by EDC/HOAt mediated amide 
coupling. We designed the sequence of this DNA strand in a way to enable splint ligation 
encoding, but we also left a three base coding site (in this approach with an AAA sequence) in 




Figure 81. Validation compounds. Both DE-2 reactions, click and amide coupling, were tested prior to the assembly of 
the final library. Reaction conditions were according to the stated conditions in Figure 80. 
We validated the chemistry of the small molecule library with three different building blocks. For 
the DE-1 modification we chose cyclohexylalanine (AA006) that was coupled under DMTMM 
coupling conditions. For the DE-2 click reaction we chose the tetrazole-alkyne TA662 that yielded 
perfect conversions and high purity. We also validated that the Staudinger reduction of the azide 
worked well using tris(2-carboxyethyl)phosphine (TCEP) with subsequent 2,4-pentadienoic acid 
(CA001) modification under EDC/HOAt coupling conditions. In terms of DNA damaging 
conditions, this amide coupling step should not be more harmful to the oligonucleotide strand 
than any of the other reaction conditions applied (compared to our own qPCR results for DNA 
viability after chemical transformations in Figure 68). 
Validation and Introduction of the DE-1 Building Blocks 
 
Figure 82. Introduction of the first diversity element. Reaction conditions: a) DMTMM-BF4, NMM, MOPS buffer, DMSO, 
RT, 20 h or EDC hydrochloride, HOAt, DIPEA, MOPS buffer, DMSO, RT, 20 h. 
After successful validation of the chemistry for the library assembly, we screened 126 amino 
acids, 26 primary and 26 secondary amines for their reactivity towards amide coupling with the 
DNA-modified linker scaffold. All building blocks were selected from existing sub-libraries and off-
the-shelf compounds. The screening conditions were similar to the screening in the macrocycle 
library. We employed the DMTMM conditions except for the known building blocks that required 
the EDC/HOAt coupling conditions (tyrosine and its derivatives). We set a threshold of 80% 
product purity. 153 building blocks fulfilled this condition, while 25 compounds were not suitable 
for library assembly (Table 14). The majority of the building blocks showed purities of >90%  
(134 building blocks). Interestingly, several amino acids that were tricky or even unsuitable for the 
synthesis in the macrocycle library showed good to excellent conversions in this assay. In 
general N-methylated amino acids were unsuitable along with some of the special case amino 
acids (good leaving groups, hydroxylamine, thiazoline sidechain) known from the previous 
macrocycle library screening. Fortunately, homoprolines and α,α-disubstituted amino acids now 

































modification with the exception of tert-butyl amine, which appeared to be too bulky to undergo an 
efficient coupling. Secondary amines, on the contrary, were more difficult to couple. Cyclic 
secondary amines showed good conversions unless both positions ortho to the amine were 
substituted (steric hindrance, e.g. 2,6-dimethylpiperidine). Linear secondary amines were the 
trickiest coupling partners. Only short linear secondary amines (N-methyl-N-propargylamine, N-
(2-hydroxyethyl)-N-methylamine) showed high enough conversions and purities for library build-
up. From the set of suitable building blocks we chose 150 for library construction. After ester 
hydrolysis of the scaffold linker we introduced the building blocks by the evaluated DMTMM and 
EDC/HOAt coupling conditions in a combinatorial split synthesis step. 
Encoding of the DE-1 Building Blocks by Splint Ligation 
 
Figure 83. a) Schematic procedure of the splint ligation. Reaction conditions: a) T4 PNK, ligase buffer, ATP, 37°C, 
30 min. b) T4 DNA ligase, ligase buffer, ATP, 4°C, 16 h. b) Detailed splint ligation with the exact DNA sequences.  
c) 12% denat. PAGE analysis, SYBR gold staining. L1: Low MW DNA ladder, L2: Scaffold DNA before DE-1 coupling & 
encoding, L3: sample DE-1 DNA strand, L4: Splint DNA, L5-L9: Random sampling of different encoded DE-1 reactions 
from the well plates. d) The identified diketopiperazine side product. 
The individual amide coupling reactions were encoded by splint ligation with 5'-phosphorylated 
DNA strands (Figure 83a). We used the same oligonucleotides as we had used for the amino 
acid encodings in the macrocycle library. The scaffold DNA strand and the DE-1 encoding strand 
did not contain any complementary regions so that annealing with a third oligonucleotide  
(the splint) could be performed. This splint DNA was designed in a way to linearly align the two 
other oligonucleotides by partial annealing with both strands (for detailed DNA sequences see 
Figure 83b). The connection between the aligned coding oligonucleotides was established by 
DNA ligation. For that reaction, the DE-1 DNA strand required a 5'-phosphate group, which we 
introduced by in situ phosphorylation with the T4 polynucleotide kinase (PNK). We optimized the 
phosphorylation-ligation procedure prior to library encoding. Figure 83c shows the very 
successful encoding of a randomly selected set of amide couplings. After encoding, we pooled 
the 150 reactions and purified them by chromatographic separation. However, as we figured out 
soon after the encoding, the azido group that we needed for diversification with the terminal 
alkyne sub-library, had been reduced to the amine during the encoding and work-up process. 
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was capable of reducing the azido group, at the α-position to the amide, to the amine, which was 
supported by elevated temperatures (we concentrated the library samples in the SpeedVac at 
45°C or 60°C). That was in sharp contrast to the azido group of the DEML trifunctional linker, 
which was not located in close proximity to any functional groups. Control experiments proved 
that the DEML alkyl azide was not reduced under these conditions. We repeated the library 
construction steps and splint ligation encoding with DTT-free buffer. Optimization experiments 
showed that DTT was not a necessary additive for the phosphorylation or the ligation step. 
Finally, we ended up with two sub-libraries, one with the clickable azide and the other with an 
amine, that we initially intended to generate by TCEP-mediated azide reduction. 
Screening of a Carboxylic Acids Sub-Library for DE-2 Introduction 
For the second diversification site we aimed to introduce different types of building blocks. Next to 
the 664 terminal alkyne sub-library that we had used and evaluated in the macrocyle library, we 
envisioned to use carboxylic acids as a second set of building blocks. We assembled in total 108 
diverse carboxylic acids off-the-shelf (many more would be commercially available). We used 
aliphatic and aromatic carboxylic acids, which allowed us to include many structural features such 
as branched chains, polyolefins, bridged cyclic structures and even a very large lipophilic 
structure with the steroid fused ring scaffold (cholic acid). We also employed many different 
functional groups such as alcohols, sulfonamides, ketones, substituted aromatic and 
heteroaromatic structures as well as nucleobase-derived carboxylic acids. For simplicity, the 
structures were grouped according to their structural and electronic features and 39 
representative members of this collection were tested to find trends in reactivity.  
Anthracene derivatives and many hydroxyl groups containing compounds were low yielding. 
Electron withdrawing groups (especially the nitro group) at the aromatic ring or halogenated 
acetic acids showed low or even no conversion. Aldehydes were unsuitable because they 
reacted in unwanted side reactions, most likely imine formations, which left the amine coupling 
partner inaccessible for the activated ester. Steric influences from large or hindered groups were 
observed as well, but the effect was not strongly pronounced. For example tert-butyl carboxylic 
acid and adamantyl carboxylic acid showed >80% purity. In the end we set the cut-off at >50% 
purity, which delivered 89 carboxylic acids. The majority of these compounds (those that were 
evaluated) showed >80% purity, only a small set of building blocks that gave lower yields were 
included. Side products were not commonly observed during the reactions and in most cases 
unreacted starting material was the main impurity. However, we figured out that the free amine 
(after azide reduction) was capable of diketopiperazine (DKP) formation with some DE-1 amino 
acid esters (Figure 83d). A side reaction that could be prevented by reduced temperatures 
during azide reduction. All of the DKP amount seemed to stem from the azide reduction step and 
not from the DE-2 introduction. The detailed list of the used building blocks is shown in Table 15. 
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Screening of Other DE-2 Building Blocks 
 
Figure 84. a) Nickel click reaction to yield 1,5-disubstituted triazoles. b) Reductive amination with aldehydes to yield 
secondary amines. c) Reaction with iso(thio)cyanates to yield (thio)ureas. d) Two different methods to introduce a 
boronic acid ester for further modifications. 
The strength of our newly developed indexing strategy was the capability to incorporate different 
sets of building blocks using the same oligonucleotide strands. In the simplest implementation we 
would use our large terminal alkyne sub-library with two different connection methodologies. A 
report from 2017 showed that 1,5-disubstituted 1,2,3-triazoles were accessible in nickel-catalyzed 
cycloaddition reactions (NiAAC) under aqueous conditions.[237] A reaction that had so far only 
been accessible with moisture sensitive ruthenium catalysts. Implementation of this reaction type 
would yield the small molecule library with the terminal alkynes attached in the conventional  
1,4-disubstituted 1,2,3-triazole connection from the CuAAC as well as in the isomeric  
1,5-disubstituted form from the NiAAC reaction (Figure 84a). We tried to implement this reaction 
into our library with a screening for potential condition optimizations. Unfortunately, we did not 
succeed in generating the desired 1,5-disubstituted products. In fact, in most attempts with 
various nickel precatalysts, we did not see any transformation at all. Only with the Ni-TBTA 
complex (analog to the Cu-TBTA complex) we found conversion of the starting material to several 
unidentified reaction products. 
Another frequently used reaction in DECL assembly is reductive amination of aldehydes (Figure 
84b). We tested this reaction type and found that in principle it worked, however the purities were 
very low. We found the desired products of the tested compounds along with a majority of 
unidentified side products. For this reason, we concluded that reductive amination was unsuitable 
for diversification of our library. 
Isocyanates and isothiocyanates are not as readily available in larger collections, as is the case 
for the very common building blocks (amines, carboxylic acids, aldehydes, boronic acids). 
However, we considered this type of functional groups, because they had been used for the 
modification of biomolecules under aqueous conditions before (see Chapter 2.2 for an example 
with a protein). Unfortunately, we could not find any of the desired products, instead the 
diketopiperazine side product formation was strongly favored (Figure 84c). 
From the very beginning of our research in DECL construction we envisioned to use boronic acid 
building blocks for the construction of encoded chemical libraries. Boronic acids are commercially 
available in large collections and they have been used in many reaction types for decades.[238,239] 
The versatility of this functional group is unquestioned and the most important transformation still 
remains the Suzuki-Miyaura cross-coupling reaction. In the early stages of the DEML assembly 
we were not successful in employing this chemistry with the macrocycle library construction. 
Based on our more recent developments, we envisioned attaching a boronic acid to a DNA 
strand and using a set of modification reactions and compound classes to introduce diversity 
(Figure 84d). We tried to incorporate a MIDA protected boronic acid alkyne by click reaction.  
LC-MS analysis showed a very small amount of the desired product, however, the majority of the 
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promoted a hydrogen insertion reaction with the carbon-boron bond. In a second attempt we 
explored the amide coupling with a MIDA-protected borylated benzoic acid. A small amount 
(approx. 10%) of the desired product was formed, whereas the remaining material underwent 
undesired side reactions. The incorporation of boronic acids (protected as MIDA esters) seemed 
to work to some extent, though the yields were not high enough for efficient library generation. 
12.3 Perspective 
Further construction of the small molecule library with the final diversification, encoding and 
subsequent protein binding assays were taken over by Basilius Sauter. For that reason the 
construction of this library and its application is not further discussed herein. The author showed 
the construction of a relatively simple library from available building blocks sets. Validation 
assays revealed high yields and purities with a diverse collection of compounds. Furthermore, the 
already available oligonucleotides were employed in a completely different encoding type 
compared to the macrocycle library. Only a few new DNA strands were redesigned and acquired 
from commercial sources. In situ enzymatic phosphorylation of oligonucleotides was proven to be 
very efficient, a factor that reduces the cost of commercial oligonucleotides. New building block 
types were tested, yet more reaction condition screenings and improvements are necessary to 
establish the use of those moieties. 
Small molecule libraries with sizes of 105-106 members are probably the most promising attempts 
for drug discovery. The introduction of new building block types (such as boronic acids) will be 
challenging, but might change the type of libraries that will be accessible in future. Searches for 
new DNA-compatible reaction conditions are highly desirable to get access to a broader selection 
of commercially available building block collections. Our newly established index DNA encoding 
might vastly reduce the cost for DECL construction. Smaller numbers of oligonucleotides will be 
required to encode for several sets of different building blocks. In our opinion, splint ligation 
should be the main encoding type for the construction of this DECL type because it showed high 
efficiency, high versatility and low side product formation. Klenow polymerization is an additional 
encoding reaction of choice due to its high reliability. Traditionally, mostly double-stranded DNA-
encoded libraries have been used for enrichments with protein targets. However, the 
development of new screening assays, such as the interaction-dependent PCR[168], will change 
the way of library construction. Several purely single-stranded DNA-encoded libraries may be 
screened simultaneously against a collection of different DNA-tagged proteins. These libraries 
use the same coding DNA strands but the index codons uniquely identify every single building 
block from each library. After interaction-dependent PCR, binders will contain all the information 
about chemical structure, connection type of the building blocks (depicted by the indexing codon) 
and bound protein on the same oligonucleotide strand. This methodology combines the 
advantages of smaller libraries (high purity) with the advantages of large libraries (high diversity) 





13. Experimental Part DNA-Encoded Libraries 
13.1 General Information 
Reagents, Solvents, Oligonucleotides 
See Chapter 5.1 for information about reagents and solvents. Enzymes and their buffers were 
purchased from New England Biolabs (NEB). Oligonucleotides were purchased from Microsynth 
in desalted or HPLC purified form as lyophilized material or dissolved in H2O as 100 µM stock 
solutions. MOPS buffer refers to a solution of 50 mM MOPS and 500 mM NaCl in H2O at pH 8.2. 
Chromatographic Purification and Isolation 
Flash chromatography was performed on SilicaFlash® gel P60 40-63 µm (230-400 mesh, 
SiliCycle, Quebec) according to Still[95] or on a Biotage Isolera four with SilicaFlash® gel packed 
cartridges. Reversed phase flash chromatographies were run on a Biotage Isolera four with self-
packed columns (LiChroprep RP-18, 40-63 µM silica from Merck). Preparative RP-HPLC was 
carried out on a Shimadzu Prominence UFLC Preparative Liquid Chromatograph.  
Method A: Gemini NX-C18, 5 µm, 110 Å, 21.2 x 250 mm from Phenomenex with a flow rate of 
20 mL/min, gradient: 1% (3 min)-99% (25 min)-99% (3 min) (B), monitoring and collecting the 
products at 254 nm. Buffer (A): 0.1% TFA (v/v) in H2O, Buffer (B): 0.1% TFA (v/v) in MeCN.  
Method B: Gemini NX-C18, 5 µm, 110 Å, 21.2 x 250 mm from Phenomenex with a flow rate of 
20 mL/min, gradient: 1% (3 min)-80% (25 min)-99% (0.1 min)-99% (3 min) (B), monitoring and 
collecting the products at 254 nm. Buffer (A): 50 mM TEAA in H2O, pH 7.2, Buffer (B): MeCN.  
Method C: Jupiter C4, 5 µm, 300 Å, 10 x 250 mm from Phenomenex with a flow rate of 
10 mL/min, gradient: 0% (3 min)-30% (17 min)-30% (2 min) (B), monitoring and collecting the 
products at 254 nm. Buffer (A): 50 mM TEAA in H2O, pH 7.2, Buffer (B): MeCN.  
The crude compound mixtures were injected as H2O, MeCN, MeOH or DMSO solutions. Buffers 
and HPLC eluents were prepared with nanopure water (resistivity 18.2 MΩ). Concentration under 
reduced pressure was performed by rotatory evaporation at 40°C water bath temperature. 
Aqueous product fractions were frozen in liquid N2 and lyophilized on a Christ Alpha 2-4 LDplus 
flask lyophilizer at 0.3 mbar or below.  
Chromatographic Analysis 
Analytical TLC was performed on Silica gel 60 F254, 0.25 mm pre-coated glass plates (Merck) 
and visualized by fluorescence quenching under UV light at 254 nm and subsequent KMnO4 or 
ninhydrin staining.  
HPLC analysis was performed on an Agilent 1100 system equipped with Jupiter C4, 5 µm, 300 Å, 
2 x 50 mm or 2 x 150 mm columns with a flow rate of 0.6 ml/min. Gradients: 0% (1.8 min)-30% 
(3.2 min)-90% (2.2 min)-90% (1.8 min) (B) or 0% (1.8 min)-30% (12.2 min)-90% (4 min)-90% 
(2 min) (B), Buffer (A): 50 mM NH4OAc in H2O, pH 7.2, Buffer (B): MeCN.  
ESI-MS and LC-MS 
For information about ESI-MS and UPLC-MS measurements, see Chapter 5.1. 
LC-MS spectra were recorded on a hyphenated system, consisting of the previously described 
Agilent 1100 HPLC and the Bruker Esquire3000 ESI-MS with a direct connection tube between 
the devices (no flow splitter). The ESI-MS was run at 350°C with a N2 flow of 10.5 L/min and 
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35 psi pressure in positive ionization mode. Tuning ranges were 500 - 1400 or 1000 - 1800 m/z. 
Control software for the ESI-MS was Esquire Control and for the hyphenated system HyStar 3.1 
was used. 
Nuclear Magnetic Resonance (NMR) 
See Chapter 5.1 for detailed information. 
DNA Purification/Handling 
0.2, 0.5, 1.5 and 2.0 ml tubes were centrifuged in an Eppendorf Centrifuge 5418R with a FA-45-
18-11 rotor at max. speed (14'000 rpm). 5, 15 and 50 ml tubes were centrifuged in an Eppendorf 
Centrifuge 5804R with the S-4-72 rotor at max. speed (4'200 rpm). 96-well plates were 
centrifuged with an A-2-DWP rotor at max. speed (3'700 rpm). DNA and protein sample heating 
or cooling was performed with a BIOER Mixing Block MB-102. Vacuum centrifugation was 
performed with an Eppendorf Concentrator 5301. DNA and protein concentrations were 
measured on a Nanodrop 2000 from Thermo Scientific via absorption at 260 nm and 280 nm, 
respectively.  
Gel Electrophoresis 
Gel electrophoresis was performed with a Bio-Rad PowerPac HV high-voltage power supply. 
Gels were prepared with an area of 83 x 83 mm and a thickness of 1.0 or 1.5 mm with 10 or 15 
wells.  
Native DNA polyacrylamide gels were prepared from 40% acrylamide/bis-acrylamide 19:1 (Fisher 
Scientific) with TBE (TRIS-Borate-EDTA) buffer with 0.1% (v/v) TEMED (N,N,N',N'-
Tetramethylethylene-1,2-diamine) and 0.1% (v/v) APS (25% ammonium persulfate in H2O 
solution). Loading dye: Gel loading dye purple (6X), no SDS from NEB. To improve loading, the 
dye was used as 3X.  
For denaturing DNA polyacrylamide gels the same recipe was used with the addition of urea 
(final concentration: 7 M). The DNA sample was treated with 2X formamide loading dye  
(95% formamide, 5 mM EDTA, pH 8, 0.025% (m/v) bromophenol blue) and denatured at 95°C for 
2 min prior to loading onto the gel. Visualization was achieved with SYBR gold dye staining and 
blue LED fluorescence with a 530/28 filter. 
DNA agarose gels were prepared by heat dissolving agarose (Fisher Scientific) in 1X TBE (50 ml 
per gel) and cooling to room temperature. SYBR gold dye for visualization was directly mixed with 
the warm agarose solution. Loading dye: 0.025% (m/v) bromophenol blue in 30% (v/v) glycerol in 
TE buffer, pH 8.  
Denaturing protein gels were prepared with a 5% stacking gel (approx. 2 cm high) and a 
resolving gel of different percentages (approx. 6 cm). The stacking gel was prepared from 40% 
acrylamide/bis-acrylamide 37.5:1 (Fisher Scientific) with 0.1% (m/v) SDS, 0.2% (v/v) TEMED and 
0.4% (v/v) APS (10% APS solution in H2O) in 125 mM TRIS, pH 6.8. The resolving gel was 
prepared from 40% acrylamide/bis-acrylamide 37.5:1 (Fisher Scientific) with 0.1% (m/v) SDS, 
0.1% (v/v) TEMED and 0.3% (v/v) APS (10% APS solution in H2O) in 375 mM TRIS, pH 8.8. 
Protein samples were treated with 2X loading dye (66 mM TRIS pH 6.8, 2% (m/v) SDS, 0.01% 
(m/v) bromophenol blue, 30% (v/v) glycerol) and denatured at 95°C for 5 min prior to gel loading. 
Visualization was achieved with Coomassie Blue staining.  
Running buffer for DNA gels: 1X TBE. Running buffer for protein gels: 193 mM glycine, 25 mM 
TRIS, 0.1% (m/v) SDS.  
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Gel imaging and analysis was performed on a Bio-Rad ChemiDoc MP system. 
PCR and qPCR 
PCR was performed in 0.2 ml PCR tubes in a Bio-Rad T100 Thermal cycler. qPCR was 
performed in a StepOnePlus real-time PCR system from Applied Biosystems using StepOne v2.3 
software. qPCR samples were set up in 96-well plates. 
Differential Scanning Fluorimetry (DSF) and Isothermal Titration Calorimetry (ITC) 
Thermal denaturation experiments were performed with a Nanotemper Prometheus NT.48 
instrument using standard quality capillaries. All samples were subjected to continuous ramping 
from 20-95°C at a rate of 1.5°C/min. The thermal denaturation was monitored by the intrinsic 
fluorescence emission at 330/350 nm after excitation at 285 nm. The data was processed using a 
beta-version of the Nanotemper PR.Analysis software and Graphpad Prism v7. 
ITC experiments were performed on an ITC200 instrument from Malvern Panalytic. Protein 
samples were degassed prior to ligand binding assays. The ligand solution in the syringe was 
added stepwise to the protein solution in the sample cell at 10 or 25°C. 300 s initial delay with 
stirring was followed by 17 syringe injections (1 x 0.5 µL, 16 x 2.3 µL). The baseline subtraction 
and integration of the differential power vs. time was performed using NITPIC[240] and data fitting 
was performed using Sedphat.[241] 
DNA Ethanol Precipitation 
DNA samples were treated with 3 M NaOAc pH 5.2 buffer (10% of DNA sample volume) and 
mixed with EtOH (300-400% of DNA sample volume). The mixture was kept on ice for 2 h (unless 
otherwise stated). The DNA suspension was centrifuged (4°C, max. speed, 30 min) and the 
supernatant was discarded. The obtained pellet was washed twice with cold EtOH and 
centrifuged again (4°C, max. speed, 2 x 15 min). The supernatants were discarded and the 
washed pellet was dried in the air for 30 min. Purified pellets were redissolved in H2O or the 
appropriate buffer for continued synthesis. 
Cu(II)-TBTA Stock Solution, 10.0 mM in 55% DMSO 
The Cu(II)-TBTA stock solution was prepared according to a published procedure for click 
modifications of oligonucleotides found on the Lumiprobe webpage (https://www.lumiprobe.com/ 
protocols/click-chemistry-dna-labeling). 
A solution of copper(II) sulfate pentahydrate (50.0 mg, 200.0 µmol 1.0 eq.) in distilled H2O 
(10 mL) was mixed with a solution of TBTA (116.0 mg, 219.0 µmol, 1.1 eq.) in DMSO (11 mL). 
The dark blue solution was stored at room temperature for months without any observed loss of 
catalytic activity in copper-catalyzed click reactions. 
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13.2 LC-MS Analysis of DNA-tagged Small Molecules 
 
Figure 85. Example of an encoded macrocycle precursor LC-MS analysis with the found ion fragments.[242] 
Chemical modifications of DNA-tagged small molecules were analyzed with the previously 
described LC-MS system. DNA-encoded compounds could be analyzed due to the specific 
fragmentation of the molecules. Therefore, no multiply charged species needed to be 
deconvoluted, which made it possible to easily detect 1 Da modifications of the attached small 
molecule. The accuracy of this method was determined to be ≤ 0.3 Da. In Figure 85 an example 
of an encoded macrocycle precursor is shown. The MS trace analysis clearly shows the 
proposed fragments. The major fragment consists of the small molecule with the phosphate and 
the ribose (now as furyl group) of the first nucleotide. The rest of the DNA strand has been 
eliminated during ionization.[242] A second, less abundant fragment has the same structure, but 
the elimination has occurred at the second nucleotide whereby the first nucleotide (in our case G) 
stayed intact. Sodium (M + Na+) and potassium (M + K+) adducts were often found along with the 
protonated species. 
13.3 Off-DNA Macrocycle Synthesis 
Synthesis of 3-azidopropan-1-amine 2-1 
 
3-Bromopropan-1-amine hydrobromide (5.0 g, 22.8 mmol, 1.0 eq.) and sodium azide (4.5 g, 
68.5 mmol, 3.0 eq.) were dissolved in H2O (20 mL) and heated to 80°C for 22 h. After cooling a 
solution of KOH (6.0 g, 106.9 mmol, 4.7 eq.) in H2O (10 mL) was added while cooling in an ice 
bath. The solution was extracted with DCM (4 x 50 mL) and the combined organic layers were 
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250 mbar) to yield the desired product as slightly yellow liquid (2.0 g, 87.4%). Analytical data was 
in agreement with reported data.[243] 
1H NMR (400 MHz, CDCl3 ) δ/ppm: 3.42 (t, J = 6.6 Hz, 2H), 2.89 (t, J = 6.8 Hz, 2H), 2.79 (s, 2H), 
1.81 (p, J = 6.8 Hz, 2H). 
Synthesis of methyl 4-((3-azidopropyl)carbamoyl)-2-iodobenzoate 2-2 
 
3-Iodo-4-methoxycarbonylbenzoic acid (1.0 g, 3.3 mmol, 1.0 eq.), 2-1 (491.0 mg, 4.9 mmol, 
1.5 eq.), HATU (1.9 g, 4.9 mmol, 1.5 eq.) and DIPEA (1.7 mL, 9.8 mmol, 3.0 eq.) were dissolved 
in THF (30 mL) and DMF (7 mL). The mixture was stirred at RT for 2 h, after which UPLC-MS 
analysis showed complete conversion to the desired product. The volatiles were removed by 
rotary evaporation, the residue was dissolved in EtOAc (100 mL) and washed with half-saturated 
NH4Cl solution (3 x 80 mL) and H2O (80 mL). The combined aqueous layers were extracted with 
EtOAc (100 mL). The combined organic layers were washed with brine (50 mL), dried over 
Na2SO4 and concentrated in vacuo. The crude product was purified by flash column 
chromatography (Silica, 150 g, cyclohexane:EtOAc 2:1, Rf= 0.28, UV). Product-containing 
fractions were combined and concentrated in vacuo to yield the desired product as yellowish oil 
(1.2 g, 95%).  
1H NMR (400 MHz, CDCl3 ) δ/ppm: 8.34 (d, J = 1.7 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.77 (dd, 
J = 8.1, 1.7 Hz, 1H), 6.41 (s, 1H), 3.95 (s, 3H), 3.56 (td, J = 6.6, 5.8 Hz, 2H), 3.47 (t, J = 6.4 Hz, 
2H), 1.92 (p, J = 6.6 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 166.51, 165.27, 139.77, 138.11, 137.85, 131.11, 126.49, 
94.24, 52.91, 49.78, 38.31, 28.77. 
HRMS (ESI): C12H14IN4O3+ calcd: 389.0105, found: 389.0109. 
N-(2-aminoethyl)-2-nitrobenzenesulfonamide 2-3 
 
A solution of 2-nitrobenzenesulfonyl chloride (25.0 g, 113.0 mmol, 1.0 eq.) in DCM (250 mL) was 
added dropwise to a cooled solution of ethylenediamine (75.4 mL, 1.1 mol, 10.0 eq.) in DCM 
(250 mL) over 1.5 h. The mixture was stirred at RT for 3 h. The yellow mixture was washed with 
H2O (3 x 200 mL) and brine (150 mL), the organic layer was dried over Na2SO4 and concentrated 
(residual ethylenediamine was removed by high vacuum drying) to yield the desired product as a 
thick yellow oil (12.2 g, 44%). The material was used without further purification for the next step. 
Analytical data was in agreement with reported data.[244] 
1H NMR (400 MHz, CDCl3 ) δ/ppm: 8.17 – 8.12 (m, 1H), 7.88 – 7.84 (m, 1H), 7.75 (m, 2H), 3.12 
(dd, J = 6.5, 5.0 Hz, 2H), 2.87 (dd, J = 6.5, 4.9 Hz, 2H). 
Synthesis of 4-((3-azidopropyl)carbamoyl)-2-iodobenzoic acid 2-4a 
 
2-2 (1.2 g, 3.1 mmol, 1.0 eq.) was dissolved in MeCN (10 mL) and a solution of LiOH hydrate 
(646.0 mg, 15.4 mmol, 5.0 eq.) in H2O (10 mL) was added. The solution was stirred at RT for 4 h, 
after which UPLC-MS analysis showed complete conversion to the desired product. The reaction 
















chromatography on the ISOLERA (RP-Silica, 100 g, H2O/MeCN + 0.1% TFA, UV, 2 runs). 
Product-containing fractions were combined and lyophilized to yield the desired product as a 
white solid (1.1 g, 98%).  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 13.54 (s, 1H), 8.72 (t, J = 5.6 Hz, 1H), 8.38 (d, J = 1.6 Hz, 
1H), 7.90 (dd, J = 8.0, 1.6 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 3.41 (t, J = 6.7 Hz, 2H), 3.32 (q, J = 
6.5 Hz, 2H), 1.78 (p, J = 6.8 Hz, 2H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 168.02, 164.17, 138.70, 137.16, 129.56, 126.94, 93.82, 
48.50, 36.80, 28.22. 
HRMS (ESI): C11H11IN4NaO3+ calcd: 396.9768, found: 396.9769. 
Synthesis of (Nosyl)ethyl-4-((3-azidopropyl)carbamoyl)-2-iodobenzoic amide 2-4 
 
2-4a (1.1 g, 3.0 mmol, 1.0 eq.), 2-3 (1.1 g, 4.5 mmol, 1.5 eq.), HATU (1.4 g, 3.6 mmol, 1.2 eq.) 
and DIPEA (1.6 mL, 9.0 mmol, 3.0 eq.) were dissolved in DMF (12 mL) and stirred at RT for 3 h, 
after which UPLC-MS analysis showed complete conversion of the starting material. The volatiles 
were removed in vacuo and the residue was dissolved in EtOAc (90 mL). The organic layer was 
washed with saturated NH4Cl (3 x 80 mL) and H2O (80 mL) and the combined aqueous layers 
were extracted with EtOAc (100 mL). The combined organic layers were washed with brine 
(50 mL), dried over Na2SO4 and concentrated by rotary evaporation. The crude was purified by 
flash column chromatography (Silica, 180 g, 1:4 cyclohexane:EtOAc, Rf = 0.2, UV) to yield the 
desired product as a yellow solid (1.6 g, 92%).  
1H NMR (400 MHz, CD3CN) δ/ppm: 8.25 (d, J = 1.6 Hz, 1H), 8.08 (dd, J = 5.9, 3.4 Hz, 1H), 7.89 – 
7.85 (m, 1H), 7.84 – 7.76 (m, 3H), 7.37 (d, J = 7.9 Hz, 1H), 7.16 (s, 1H), 6.95 (s, 1H), 6.19 (s, 
1H), 3.49 – 3.43 (m, 2H), 3.43 – 3.36 (m, 4H), 3.27 (t, J = 6.0 Hz, 2H), 1.83 (t, J = 6.7 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 169.91, 166.24, 148.14, 144.06, 138.37, 136.61, 133.90, 
133.63, 133.06, 131.15, 127.77, 126.70, 92.40, 49.58, 43.39, 40.13, 39.11, 28.75. 
HRMS (ESI): C19H20IN7NaO6S+ calcd: 624.0133, found: 624.0144. 
Imidazole-1-sulfonyl azide hydrochloride 2-5a 
 
Synthesis according to a literature reported procedure.[236]  
Under an inert atmosphere NaN3 (3.9 g, 60.0 mmol, 1.0 eq.) was suspended in MeCN (60 mL) 
and cooled to 0°C in an ice bath. Sulfuryl chloride (4.9 mL, 60.0 mmol, 1.0 eq.) was added 
dropwise over 10 min and the mixture was stirred at RT for 18 h. After that, the mixture was 
cooled in an ice-bath and imidazole (7.8 g, 114.0 mmol, 1.9 eq.) was added portionwise. 
Hereafter, the mixture was stirred at RT for another 3 h. EtOAc (120 mL) was added, the mixture 
was washed with H2O (2 x 120 mL) and saturated NaHCO3 (2 x 120 mL), dried over Na2SO4 and 
filtered. A solution of HCl in EtOH (prepared by the addition of AcCl (6.42 mL, 90 mmol) to dry 
EtOH (22.5 mL) while cooling) was added dropwise to the filtrate. The mixture was cooled in an 
ice bath and stirred for 1 h. The formed solid was filtered off, washed with EtOAc (3 x 10 mL) and 
dried at high vacuum to yield the desired product as white solid (9.1 g, 72%). Analytical data was 
















1H NMR (400 MHz, D2O) δ/ppm: 9.44 (t, J = 1.4 Hz, 1H), 8.06 (dd, J = 2.2, 1.6 Hz, 1H), 7.65 (dd, 
J = 2.2, 1.2 Hz, 1H). 
Boc-Dab(N3)-OH 2-5b 
 
The compound was synthesized according to a modified procedure by E.D. Goddard-Borger and 
R.V. Stick.[236] Compound is also commercially available as CHA salt. 
Under an inert atmosphere Boc-Dab-OH (5.9 g, 27.2 mmol, 1.0 eq.) and 2-5a (6.8 g, 32.7 mmol, 
1.2 eq) were dissolved in MeOH (140 mL) and potassium carbonate (10.2 g, 73.5 mmol, 2.7 eq.) 
was added, followed by CuSO4 pentahydrate (68.0 mg, 272 µmol, 1 mol%). The blue mixture was 
stirred at RT for 2 h, after which TLC (5% MeOH in DCM, Ninhydrin) showed complete 
consumption of the starting material. The solvent was removed and the crude was dissolved in 
EtOAc (150 mL) and H2O (150 mL). The biphasic mixture was acidified with concentrated HCl to 
pH 1-2. The biphasic mixture was separated and the aqueous layer was extracted with EtOAc 
(2 x 150 mL) and the combined organic layers were washed with H2O (2 x 150 mL) and brine 
(150 mL), dried over Na2SO4 and concentrated by rotary evaporation to yield the desired product 
as slightly yellow oil (7.9 g, >100%). NMR analysis showed some unidentified peaks. The 
material was used as obtained without further purification.  
1H NMR (400 MHz, DMSO-d6) δ/ppm 12.60 (s, 1H), 3.96 (ddd, J = 9.9, 8.2, 4.5 Hz, 1H), 3.42 
(ddd, J = 12.4, 7.2, 5.4 Hz, 1H), 3.34 (ddd, J = 12.3, 8.0, 6.5 Hz, 1H), 1.97 – 1.84 (m, 1H), 1.85 – 
1.71 (m, 1H), 1.38 (s, 9H). 
H-Dab(N3)-OMe 2-5 
 
Under an inert atmosphere 2-5b (7.9 g, 32.5 mmol, 1.0 eq.) was dissolved in MeOH (150 mL) 
and cooled in an ice bath. Thionyl chloride (19.0 mL, 260.0 mmol, 8.0 eq.) was added dropwise 
and the solution was stirred at 0°C for 15 min. The cooling bath was removed and the solution 
was stirred at RT for 24 h, after which TLC (BAW, Ninhydrin, Rf= 0.58) and NMR showed 
complete conversion to the desired product. The solvent was removed by rotary evaporation and 
the residue was dissolved in half-saturated NaHCO3 solution (200 mL). The aqueous solution 
was extracted with EtOAc (10 x 100 mL), the combined organic layers were dried over Na2SO4 
and concentrated to yield the desired product as a yellow liquid, which solidified over time in the 
fridge (3.4 g, 66%).  
1H NMR (400 MHz, CD3OD) δ/ppm: 3.74 (s, 3H), 3.55 (dd, J = 7.5, 5.6 Hz, 1H), 3.45 (td, J = 6.6, 
1.5 Hz, 2H), 1.98 (dddd, J = 14.0, 7.3, 6.8, 5.6 Hz, 1H), 1.81 (ddt, J = 14.0, 7.5, 6.4 Hz, 1H). 
13C NMR (101 MHz, CD3OD) δ/ppm: 176.65, 52.75, 52.60, 49.85, 34.47. 







Synthesis of Nos-Sc(N3)-NP01-TFL(N3)-OMe 2-6 
 
In a 2 mL Eppendorf tube NP01 (24.0 mg, 38.6 µmol, 1.0 eq.), TFL 2-5 (9.2 mg, 57.9 µmol, 
1.5 eq.), HATU (22.0 mg, 57.9 µmol, 1.5 eq.) and DIPEA (33.6 µL, 193.0 µmol, 5.0 eq.) were 
dissolved in DMF (300 µL) and agitated at RT for 1 h, after which UPLC-MS analysis showed 
complete conversion to the desired product. The mixture was purified by reversed-phase 
preparative HPLC (Method A) to yield the desired product as white solid (22 mg, 75%). 
1H NMR (500 MHz, CDCl3 ) δ/ppm: 8.06 – 8.00 (m, 1H), 7.86 – 7.81 (m, 1H), 7.77 – 7.73 (m, 2H), 
7.72 – 7.68 (m, 1H), 7.66 – 7.60 (m, 1H), 7.54 (d, J = 15.6 Hz, 1H), 7.42 (d, J = 8.1 Hz, 2H), 
7.40 – 7.28 (m, 5H), 6.60 (s, 1H), 6.47 (d, J = 15.7 Hz, 1H), 5.89 (s, 1H), 4.80 (td, J = 7.7, 5.0 Hz, 
1H), 3.75 (s, 3H), 3.58 (q, J = 6.5 Hz, 2H), 3.45 (t, J = 6.6 Hz, 4H), 3.35 – 3.21 (m, 2H), 3.00 (d, 
J = 5.8 Hz, 2H), 2.20 (dtd, J = 14.0, 6.9, 5.0 Hz, 1H), 2.08 (dq, J = 14.1, 6.9 Hz, 1H), 1.94 (p, J = 
6.6 Hz, 2H). 
13C NMR (500 MHz, 2D NMR, CDCl3) δ/ppm: 172.03, 169.77, 167.27, 166.09, 147.77, 141.10, 
139.42, 139.20, 139.10, 137.69, 135.68, 135.00, 133.86, 132.89, 130.94, 130.10, 129.17, 129.12, 
129.06, 128.48, 126.32, 125.99, 125.33, 120.88, 52.62, 50.31, 49.33, 47.70, 42.67, 39.65, 37.96, 
31.31, 28.52. 
HRMS (ESI): C33H35N11NaO9S+ calcd: 784.2232, found: 784.2237. 
Synthesis of Nos-Sc(N3)-NP01-TFL(N3)-OH 2-7 
 
A solution of 2-6 (22.0 mg, 28.9 µmol, 1.0 eq.) in MeCN (578 µL) and a solution of LiOH 
monohydrate (2.9 mg, 69.4 µmol, 2.4 eq.) in H2O (678 µL) were mixed in an Eppendorf tube and 
the reaction was agitated at RT for 2 h. The mixture was purified by reversed-phase preparative 
HPLC (Method A) to yield the desired product as white solid (16 mg, 74%). 
1H NMR (500 MHz, CDCl3 ) δ/ppm: 7.95 – 7.89 (m, 1H), 7.77 – 7.72 (m, 2H), 7.72 – 7.69 (m, 1H), 
7.70 – 7.63 (m, 2H), 7.54 – 7.48 (m, 2H), 7.45 (d, J = 15.7 Hz, 1H), 7.36 (ddd, J = 5.1, 3.9, 
1.7 Hz, 1H), 7.35 – 7.30 (m, 2H), 6.49 (d, J = 15.5 Hz, 1H), 4.61 (dt, J = 7.9, 3.6 Hz, 1H), 3.41 (t, 
J = 6.8 Hz, 2H), 3.39 – 3.30 (m, 4H), 3.20 (dd, J = 6.6, 5.0 Hz, 2H), 2.91 – 2.83 (m, 2H), 2.13 
(dtd, J = 14.0, 7.1, 5.0 Hz, 1H), 1.98 – 1.89 (m, 1H), 1.82 (p, J = 6.7 Hz, 2H). 
13C NMR (500 MHz, 2D NMR, CDCl3) δ/ppm: 173.20, 170.33, 167.46, 166.22, 147.60, 140.67, 
139.72, 139.13, 138.00, 135.72, 134.75, 133.67, 132.90, 132.59, 130.61, 129.77, 128.97, 128.77, 
128.08, 127.99, 127.08, 126.06, 125.03, 120.65, 49.92, 49.02, 47.66, 42.13, 39.44, 37.35, 30.91, 
28.31. 





























Synthesis of Nos-Sc(N3)-NP01-TFL(N3)-AA001-OMe 2-8 
 
Precursor 2-6 (16.0 mg, 21.4 µmol, 1.0 eq.), AA001 (4.5 mg, 32.1 µmol, 1.5 eq.), HATU (12.2 mg, 
32.1 µmol, 1.5 eq.) and DIPEA (18.6 µL, 107.0 µmol, 5.0 eq.) were dissolved in DMF (700 µL) 
and stirred at RT for 2 h, after which UPLC-MS analysis showed complete conversion to the 
desired product. The mixture was purified by reversed-phase preparative HPLC (Method A) to 
yield the desired product as white solid (11 mg, 62%). 
1H NMR (500 MHz, CD3CN) δ/ppm: 8.03 – 7.95 (m, 1H), 7.88 – 7.84 (m, 1H), 7.84 – 7.78 (m, 
4H), 7.57 (s, 1H), 7.55 – 7.46 (m, 3H), 7.42 – 7.34 (m, 2H), 7.32 (t, J = 5.9 Hz, 1H), 7.15 (d, J = 
7.1 Hz, 1H), 7.09 (d, J = 8.0 Hz, 1H), 6.72 (t, J = 6.0 Hz, 1H), 6.62 (d, J = 15.7 Hz, 1H), 6.06 (t, 
J = 6.0 Hz, 1H), 4.57 (td, J = 8.3, 5.4 Hz, 1H), 4.37 (p, J = 7.2 Hz, 1H), 3.66 (s, 3H), 3.47 – 3.38 
(m, 6H), 3.23 (q, J = 6.2 Hz, 2H), 2.95 (q, J = 6.2 Hz, 2H), 2.07 (dtd, J = 14.3, 7.3, 5.3 Hz, 1H), 
1.87 (dp, J = 29.7, 6.7 Hz, 3H), 1.32 (d, J = 7.3 Hz, 3H). 
13C NMR (500 MHz, 2D NMR, CD3CN) δ/ppm: 173.82, 171.86, 170.23, 167.04, 166.24, 148.79, 
141.19, 140.75, 140.17, 139.59, 137.00, 135.98, 135.14, 133.87, 133.50, 131.40, 130.84, 129.83, 
129.56, 129.03, 128.66, 128.25, 127.23, 126.01, 122.47, 52.69, 51.56, 49.79, 49.05, 48.58, 
43.51, 40.00, 37.84, 32.15, 29.29, 17.40 
HRMS (ESI): C36H40N12NaO10S+ calcd: 855.2603, found: 855.2607. 
Synthesis of NH2-Sc(N3)-NP01-TFL(N3)-AA001-OH 2-9 
 
Precursor 2-8 (11.0 mg, 13.2 µmol, 1.0 eq.) was dissolved in DMF (400 µL) and rendered inert 
with N2. DIPEA (23.0 µL, 132.0 µmol, 10.0 eq.) and thiophenol (6.7 µL, 66 µmol, 5.0 eq.) were 
added subsequently and the solution was stirred at 40°C for 3 h, after which UPLC-MS analysis 
showed full conversion to the Nosyl-deprotected intermediate. The yellow solution was cooled to 
RT and a solution of LiOH monohydrate (5.5 mg, 132.0 µmol, 10.0 eq.) in H2O (264 µL) was 
added. The mixture was stirred at RT for 30 min, after which UPLC-MS analysis showed 
complete conversion to the desired product. The mixture was purified by reversed-phase 
preparative HPLC (Method A) to yield the desired product as white solid (7 mg, 78%). 
1H NMR (500 MHz, CD3OD) δ/ppm: 7.96 – 7.89 (m, 2H), 7.68 (dd, J = 7.7, 0.7 Hz, 1H),  
7.66 – 7.62 (m, 2H), 7.60 (d, J = 15.8 Hz, 1H), 7.53 – 7.47 (m, 2H), 6.74 (d, J = 15.8 Hz, 1H), 
4.62 (dd, J = 8.5, 5.6 Hz, 1H), 4.37 (q, J = 7.3 Hz, 1H), 3.54 – 3.45 (m, 4H), 3.44 – 3.38 (m, 4H), 
2.88 (td, J = 6.8, 1.4 Hz, 2H), 2.13 (dtd, J = 13.0, 7.3, 5.6 Hz, 1H), 2.01 – 1.93 (m, 1H), 1.90 (p, 
J = 6.7 Hz, 2H), 1.43 (d, J = 7.3 Hz, 3H). 
13C NMR (500 MHz, 2D NMR, CD3OD) δ/ppm: 175.74, 172.90, 172.69, 168.76, 168.00, 141.66, 
141.27, 140.62, 139.41, 137.15, 136.07, 131.01, 130.08, 129.81, 129.07, 129.04, 128.13, 127.38, 
121.88, 52.12, 49.98, 49.42, 48.74, 39.72, 38.31, 38.21, 32.30, 29.42, 17.28. 

































Synthesis of MC(N3)-NP01-AA001 2-10 
 
Under an inert atmosphere precursor 2-9 (6.5 mg, 10.3 µmol, 1.0 eq.) was dissolved in DMF 
(6.5 mL) and HATU (5.9 mg, 15.4 µmol, 1.5 eq.) and DIPEA (8.9 µL, 51.3 µmol, 5.0 eq.) were 
added successively. The yellow solution was stirred at RT for 1 h, after which UPLC-MS analysis 
showed complete conversion to the desired product. The solvent was removed by rotary 
evaporation and the residue was purified by reversed-phase preparative HPLC (Method A) to 
yield the desired product as white solid (4 mg, 63%). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.69 (t, J = 5.6 Hz, 1H), 8.56 (t, J = 5.4 Hz, 1H), 8.36 (d, 
J = 7.6 Hz, 1H), 8.00 (d, J = 1.8 Hz, 1H), 7.88 (dd, J = 7.9, 1.7 Hz, 1H), 7.71 (t, J = 6.0 Hz, 1H), 
7.68 (d, J = 8.7 Hz, 1H), 7.67 – 7.64 (m, 1H), 7.60 – 7.57 (m, 1H), 7.55 (d, J = 7.4 Hz, 1H), 7.51 
(d, J = 7.9 Hz, 1H), 7.47 (d, J = 1.7 Hz, 1H), 7.41 (d, J = 15.8 Hz, 1H), 6.55 (d, J = 15.8 Hz, 1H), 
4.27 – 4.19 (m, 2H), 3.51 – 3.46 (m, 1H), 3.44 – 3.42 (m, 2H), 3.40 – 3.35 (m, 2H), 3.30 – 3.26 
(m, 1H), 3.15 – 3.08 (m, 2H), 2.92 – 2.84 (m, 1H), 1.90 (dq, J = 13.8, 6.9 Hz, 2H), 1.81 (p, J = 
6.8 Hz, 3H), 1.18 (d, J = 7.0 Hz, 3H). 
13C NMR (500 MHz, 2D NMR, DMSO-d6) δ/ppm: 172.28, 170.91, 169.52, 166.12, 165.58, 
140.32, 139.73, 138.25, 135.52, 135.20, 129.38, 129.20, 129.11, 129.08, 127.60, 127.14, 126.19, 
124.54, 123.01, 53.09, 48.64, 48.62, 47.68, 39.28, 38.38, 36.51, 29.72, 28.09, 17.34. 
HRMS (ESI): C29H34N11O5+ calcd: 616.2739, found: 616.2737. 
Synthesis of MC(N3)-NP01-AA001-TA641 2-11[198] 
 
Under a N2 atmosphere MC 2-10 (19.0 mg, 30.9 µmol, 1.0 eq.), NaOAsc (3.7 mg, 18.5 µmol, 
0.6 eq.) and ethyl propiolate TA641 (6.6 µL, 64.8 µmol, 2.1 eq.) were dissolved in DMSO (3 mL), 
H2O (550 µL) and MeCN (550 µL). Cu(II)-TBTA complex solution (926.0 µL, 9.3 µmol, 0.3 eq.) 
was added and the mixture was stirred at RT for 2 h. The mixture was purified by reversed-phase 
preparative HPLC (Method A) to yield the desired product as a white solid (17 mg, 68%). 
1H-NMR (600 MHz, DMSO-d6) δ/ppm: 8.83 (s, 1H), 8.80 (s, 1H), 8.72 (t, J = 5.7 Hz, 1H), 8.57 (t, 
J = 5.7 Hz, 1H), 8.44 (d, J = 7.5 Hz, 1H), 8.01 – 7.98 (m, 1H), 7.89 – 7.86 (m, 1H), 7.72 – 7.69 
(m, 2H), 7.67 – 7.64 (m, 1H), 7.60 – 7.58 (m, 1H), 7.57 – 7.55 (m, 1H), 7.52 – 7.50 (m, 1H), 7.48 
– 7.45 (m, 1H), 7.41 (d, J = 15.7 Hz, 1H), 6.54 (d, J = 15.7 Hz, 1H), 4.55 (t, J = 7.1 Hz, 2H), 4.50 
(t, J = 6.9 Hz, 2H), 4.34 – 4.27 (m, 4H), 4.24 – 4.19 (m, 1H), 4.10 – 4.04 (m, 1H), 3.33 – 3.28 (m, 
2H), 3.14 – 3.08 (m, 2H), 2.92 – 2.85 (m, 1H), 2.34 – 2.28 (m, 1H), 2.28 – 2.20 (m, 1H), 2.18 – 
2.12 (p, J = 7.1 Hz, 2H), 1.30 (q, J = 6.8 Hz, 6H), 1.17 (d, J = 7.0 Hz, 3H). 
13C-NMR (151 MHz DMSO-d6) δ/ppm: 172.2, 170.5, 169.3, 166.0, 165.6, 160.3, 160.3, 140.0, 
139.9, 139.9, 138.7, 138.7, 138.1, 135.2, 135.0, 129.4, 129.4, 129.3, 129.2, 129.2, 127.8, 127.2, 
126.4, 124.8, 123.1, 60.5. 60.5, 53.1, 48.7, 47.8, 46.9, 39.6, 38.5, 36.5, 30.9, 29.5, 17.5, 14.2 
(2x). 






























13.4 Test Macrocycle Synthesis on DNA 
Synthesis of the Encoded Macrocycle Precursor 2-12a by Click Reaction with Alkyne-
Modified DNA 
 
In a 1.5 mL Eppendorf tube a 5'-alkyne-DNA strand (1.0 mM in H2O, 44.0 µL, 1.0 eq.) of the 
sequence 5'-hexyne-GGA GCT TGT GAA TTC TGG ATG GGA CGT GTG TGA ATT GTC-3’, DE-
1 azide NP01 (10.0 mM in DMSO, 8.8 µL, 2.0 eq.), sodium ascorbate (5.0 mM in H2O, 44.0 µL, 
5.0 eq.), TEAA buffer (1.0 M, pH 7.2, 88.0 µL), DMSO (198 µL) and H2O (35 µL) were mixed. N2 
was bubbled through the solution for 30 s. The Cu(II)-TBTA solution (10.0 mM in 55% DMSO, 
22.0 µL, 5.0 eq.) was added and the solution was degassed again for 30 s. The mixture was 
agitated at RT for 20 h, after which HPLC showed 88% conversion to the desired product. The 
mixture was purified by preparative HPLC (Method B). The product containing fractions were 
combined and lyophilized to yield the desired product 2-12a as a white solid. The DNA was 
dissolved in MOPS buffer (161 µL) to yield a clear solution (140 µM, 51%). 
 
Figure 86. LC-MS chromatogram of the purified encoded compound 2-12a. 
TFL 2-5 Amide Coupling with 2-12a 
 
In a 1.5 mL Eppendorf tube the DNA-carboxylic acid 2-12a (140.0 µM in MOPS buffer, 21.4 µl, 
1.0 eq.) was mixed with the trifunctional linker 2-5 (0.5 M in DMSO, 6.0 µL, 1000.0 eq.), DMTMM-
BF4 (400.0 mM in DMSO, 7.5 µL, 1000.0 eq.) and NMM (400.0 mM in DMSO, 15.7 µL, 
2100.0 eq.). The mixture was agitated at RT for 24 h. The reaction was purified by EtOH 
precipitation and the clean DNA pellet was dissolved in H2O (25 µL) to yield the desired product 
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Figure 87. LC-MS chromatogram of the purified encoded compound 2-12b. 
Ester Hydrolysis of 2-12b 
 
In a 1.5 mL Eppendorf tube 2-12b (130.0 µM in H2O, 25.0 µL, 1.0 eq.), LiOH monohydrate 
(100.0 mM in H2O, 4.9 µL, 150.0 eq.) and MeCN (15 µL) were mixed and agitated at RT for 3 h. 
The reaction was purified by EtOH precipitation and the clean DNA pellet was dissolved in MOPS 
buffer (28 µL) to yield the desired product 2-12c as a clear solution (100 µM, 86%). 
 
Figure 88. LC-MS chromatogram of the purified encoded compound 2-12c. 
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Amide Coupling with AA001, Introduction of the 2nd Diversity Element 
 
In a 1.5 mL Eppendorf tube 2-12c (90.0 µM in MOPS buffer, 29.0 µL, 1.0 eq.) was mixed with  
L-alanine methyl ester hydrochloride AA001 (500.0 mM in DMSO, 5.2 µL, 1000.0 eq.), DMTMM-
BF4 (150.0 mM in DMSO, 17.4 µL, 1000.0 eq.) and NMM (250.0 mM in DMSO, 36.5 µL, 
3500.0 eq.) and the solution was agitated at RT for 20 h. The mixture was purified by EtOH 
precipitation and the clean DNA-pellet was dissolved in H2O (135 µL) to yield the desired product 
2-12d as a clear solution (20 µM, quant.).  
 
Figure 89. LC-MS chromatogram of the purified encoded compound 2-12d. 
Ester Hydrolysis and Nosyl Deprotection of 2-12d 
 
In a 0.5 mL Eppendorf tube 2-12d (50.0 µM in 300.0 mM MOPS/500.0 mM NaCl pH 8.2 buffer, 
15.0 µL, 1.0 eq.) was mixed with DBU (300.0 mM in DMSO, 15.0 µL, 6000.0 eq.) and BME 
(300.0 mM in DMSO, 15.0 µL, 6000.0 eq.). The mixture was degassed with N2 for 30 s and 
agitated at RT for 6 h. The reaction was purified by EtOH precipitation and the clean DNA pellet 
was dissolved in MOPS buffer (20 µL) to yield the desired product 2-12e as a clear solution 
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Figure 90. LC-MS chromatogram of the purified encoded compound 2-12e. 
Macrocyclization of 2-12e 
 
In a 0.5 mL Eppendorf tube 2-12e (25.0 µM in MOPS buffer, 13.0 µL, 1.0 eq.) was mixed with 
MOPS buffer (2.0 µL), DMSO (4.6 µL), DMTMM-BF4 (25.0 mM in DMSO, 3.9 µL, 300.0 eq.) and 
NMM (50.0 mM in DMSO, 6.5 µL, 1000.0 eq.). The mixture was agitated at RT for 18 h and the 
reaction was purified by EtOH precipitation. The reaction was set up again with above stated 
reagent amounts. After EtOH precipitation the clean DNA pellet was dissolved in H2O (15 µL) to 
yield the desired product 2-12f as a clear solution (24 µM, quant.). Note: The macrocyclization 
was repeated once because LC-MS showed incomplete conversion. Increase of the coupling 
reagent amount (up to 500 eq.) and DMSO amount (>55%) should yield full macrocyclization in 
one step. 
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Figure 91. LC-MS chromatogram of the purified encoded compound 2-12f. 
Diversity Element 3 Introduction by Click Reaction 
 
In a 0.5 mL Eppendorf tube, 2-12f (10.0 µM in 500.0 mM TEAA pH 7.2, 26.4 µL, 1.0 eq.) was 
mixed with ethyl propiolate TA641 (1.0 mM in DMSO, 26.4 µL, 100.0 eq.), sodium ascorbate 
(3.0 mM in H2O, 17.6 µL, 200.0 eq.) and DMSO (17.5 µL) and the mixture was degassed with N2 
for 30 s. Copper(II)-TBTA complex (3.0 mM in 55% DMSO, 17.6 µL, 200.0 eq.) was added and 
the solution was degassed with N2 again. The solution was agitated at RT for 16 h. The reaction 
was purified by EtOH precipitation and the clean DNA pellet was dissolved in H2O (15 µL) to yield 
the final product 2-12 as a clear solution (14 µM, 80%). 
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Figure 92. LC-MS chromatogram of the purified encoded compound 2-12. 
13.5 DNA-Encoded Library Assembly, Synthetic Procedures 
Encoding of DE-1 with Alkyne-Modified DNA (21 elements) 
 
In a 1.5 mL Eppendorf tube the alkyne-DNA strand (1.0 mM in H2O, 1.0 eq.) of the sequence  
5'-hexyne-GGAGCTTGTGAATTCTGGXXXGGACGTGTGTGAATTGTC-3’, DE-1 azide (NP01 - 
21, 10.0 mM in DMSO, 2.0 eq.), sodium ascorbate (5.0 mM in H2O, 5.0 eq.), TEAA buffer (1.0 M, 
pH 7.2), DMSO and H2O were mixed. N2 was bubbled through the solution for 30 s. Cu(II)-TBTA 
complex (10.0 mM in 55% DMSO, 5.0 eq.) was added, N2 was bubbled through the solution 
again and the mixture was shaken at RT overnight (20 h). The final concentrations of the 
reagents were as follows: 100.0 µM DNA, 200.0 µM DE-1 azide, 500.0 µM Cu(II)-TBTA complex, 
500.0 µM sodium ascorbate, 200.0 mM TEAA, 50% DMSO. Typical DNA amounts: 30 nmol. 
Conversion and purity of the product was measured by HPLC. The mixture was directly purified 
by prep. HPLC (Method B). Product-containing fractions were combined and lyophilized. The 
isolated product was dissolved in MOPS buffer to yield a 140 µM solution. Typical conversions: 
80-90%. XXX represents the three-base codon for the diversity element 1. This procedure was 
repeated for all DE-1 building blocks (Table 11). 
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Table 11. Masses found from the DE-1 encoding by LC-MS. 
No. Mass calc. Mass found No. 
Mass calc. 
Mass found No. 
Mass calc. 
Mass found 



































Trifunctional Linker Coupling with DNA-DE-1 Pool  
 
20 encoded DE-1 DNA strands (NP01-06 and NP08-21; 21.5 µL, 3.0 nmol each, 50.0 mM MOPS 
buffer) were pooled in a LowBind 1.5 mL Eppendorf tube and NMM (315.0 µL, 400.0 mM in 
DMSO, 2100.0 eq.) was added. The trifunctional linker (2-5, 120.0 µL, 500.0 mM in DMSO, 
1000.0 eq.) was added, followed by DMTMM-BF4 (150.0 µL, 400.0 mM in DMSO, 1000.0 eq.). 
The solution was agitated at RT for 24 h. The mixture was purified by ethanol precipitation and 
the pool was dissolved in H2O (540 µL) to yield a 130 µM solution. Success of the coupling was 
checked by HPLC analysis. Building block NP07 was coupled independently since 2 coupling 
steps were necessary to achieve full conversion to the desired product. The procedure was 
conducted at the same reagent concentrations as with the pooled elements. Element NP07 was 
pooled with the other 20 elements after successful modification to form the DNA-DE-1 pool. 
Ester Hydrolysis of the DNA-DE-1 Pool 
 
In a LowBind 1.5 mL Eppendorf tube the DNA-DE-1 pool (130.0 µM in H2O, 564.0 µL, 1.0 eq.) 
was mixed with MeCN (340 µL) and LiOH monohydrate (100.0 mM in H2O, 110.0 µL, 150.0 eq.). 
The solution was shaken at RT for 2.5 h, followed by ethanol precipitation. HPLC analysis 
showed full conversion of the starting material (peak shift). The pool was dissolved in MOPS 

















































Amino Acid Test Couplings for Usage in the DEML Synthesis 
 
In a PCR tube the encoded NP01-TFL (74.0 µM, MOPS buffer, 2.0 µL 1.0 eq.), NMM (250.0 mM, 
DMSO, 2.0 µL, 3378.0 eq.), the amino acid (500.0 mM, DMSO, 0.3 µL, 1014.0 eq.) and DMTMM-
BF4 (75.0 mM, DMSO, 2.0 µL, 1014.0 eq.) were mixed. The reaction was left standing at RT for 
19 h and then purified by EtOH precipitation. The DNA was dissolved in H2O (6 uL) and analyzed 
by HPLC (2 uL) and LC-MS (4 uL). 126 amino acids were tested with these conditions. Low 
yielding or non-converting building blocks were repeated with EDC/HOAt conditions (NMM was 
replaced by DIPEA, DMTMM-BF4 was replaced by EDC hydrochloride (150.0 mM, 1.0 µL) and 
HOAt (150.0 mM, 1.0 µL)). In the case of the TFL with n = 1 the dehydroalanine side product 
(see Figure 55a) was found along with the desired products. These eliminated species were 
included in the conversion and purity yields of the amide coupling reaction. 
Table 12. DE-2 amino acids screening results. 126 building blocks were tested for their reactivity in amide coupling. 
Unless stated otherwise the screening was performed with the short trifunctional linker (n = 1). Red coloring indicates 
the building blocks that were excluded from the final DEML assembly due to insufficient conversion and purity. Cutoff: 

























AA002  1077.3 1077.3 100% (92%) AA065  1119.4 1119.4 100% (76%) 
AA003  1077.3 1077.3 100% (66%) AA066  1119.4 1119.4 100% (71%) 
AA004 
 
1111.3 1032.2[a] 100% (0%) AA067  1105.4 1105.4 100% (80%) 







1192.4 1092.4[g] 94% (69%) 
AA006 
 
1159.4 1159.4 100% (75%) AA069 
 










1206.4 1106.4[g] 95% (72%) 
AA008 
 
1241.5 1241.4 100% (90%) AA071  1091.3 879.3
[b] 100% (<5%) 
AA009  1105.4 1105.3 100% (83%) AA072  1091.3 1091.4 100% (72%) 
AA010  1105.4 1105.3 100% (82%) AA073  
1101.3 1101.4 100% (66%) 
AA011 
 
1119.4 1074.3[f] 100% (0%) AA074  1119.4 1119.3 90% (60%) 
AA012  1063.3 1063.3 100% (92%) AA075  1091.3 1091.4 100% (72%) 
AA013  1077.3 1077.3 100% (82%) AA076  
1119.4 1119.4 94% (79%) 



























































































































1177.4 1177.3 100% (73%) AA080 
 
1119.4 1119.4 100% (73%) 
AA018 
 
1157.4 1157.3 100% (91%) AA081  1133.4 1133.4 95% (32%) 
AA019 
 








AA083  1102.3 1031.3








1170.3 1170.3 100% (69%) 
AA022 
 
1183.4 1138.3 100% (0%) AA085  1159.3 879.3






AA086  1087.3 1087.4 93% (72%) 
AA024  1134.4 1134.3 100% (89%) AA087  1089.3 1089.4 100% (69%) 
AA025 
 
1093.3 1093.3 100% (86%) AA088  1089.3 1089.4 100% (75%) 
AA026 
 
1093.3 1093.3 100% (89%) AA089 
 
1129.4 1129.4 100% (75%) 
AA027  1119.4 1119.4 100% (72%) AA090  
1117.4 1117.4 97% (54%) 
AA028 
 
1133.4 1088.3[f] 100% (0%) AA091 
 
1131.4 1131.4 92% (78%) 
AA029 
 
1192.4 1192.3 100% (71%) AA092 
 
1131.4 1131.4 88% (65%) 
AA030 
 














1107.3 1107.3 100% (88%) AA095 
 
1159.4 879.3[b] 100% (0%) 
AA033 
 
1107.3 1107.3 100% (90%) AA096  1103.3 1103.4 
90% (37%) 
100%(24%)[d] 
AA034  1107.3 1107.3 100% (90%) AA097  
1143.4 1143.3 98% (58%) 
AA035 
 


































































































































1207.4 1207.4 100% (86%) AA099 
 
1193.4 1193.3 100% (71%) 
AA037 
 
1207.4 1207.4 100% (89%) AA100 
 
1181.3 949.3[a] 56% (0%) 
AA038 
 
1220.4 1120.4[g] 94% (74%) AA101  1225.5 1225.4 95% (85%) 
AA039 
 
1119.4 1119.3 100% (72%) AA102  1143.4 1143.4 100% (60%) 
AA040 
 
1119.4 1119.4 100% (71%) AA103 
 
1159.4 1159.4 89% (43%) 
AA041 
 
1234.4 1134.4[g] 98% (75%) AA104  1148.3 910.2
[f] 95% (0%) 
AA042 
 
1268.4 1268.4 100% (85%) AA105 
 
1167.3 879.3[b] 100% (0%) 
AA043 
 
1234.4 1134.4[g] 23% (13%) AA106 
 
1240.4 1240.4 93% (76%) 
AA044 
 
1137.3 1137.3 100% (76%) AA107 
 
1160.3 1160.3 93% (66%) 
AA045 
 
1137.3 1137.3 100% (78%) AA108 
 
1204.4 1204.4 100% (71%) 
AA046  1191.4 1191.4
[h] 100% (73%) AA109 
 
1251.4 1251.4 100% (73%) 
AA047 
 
1120.3 1120.3 100% (80%) AA110 
 
1203.4 1203.4 87% (71%) 
AA048  1103.3 1103.3 95% (72%) AA111  1167.4 1167.4 100% (63%) 
AA049  1103.3 1103.3 100% (82%) AA112 
 











1185.4 1185.4 95% (60%) 
AA051 
 
1117.4 1117.3 100% (<5%) AA114 
 
1179.4 1179.4 100% (50%) 
AA052 
 
1119.3 1119.3 100% (75%) AA115 
 
1197.4 1197.4 95% (73%) 
AA053 
 
1119.3 1119.3 100% (83%) AA116 
 
1181.4 1181.4 93% (51%) 
AA054  1101.3 1101.3 100% (82%) AA117 
 

































































































































AA055  1153.4 1153.3 100% (75%) AA118  
1187.3 1187.4 93% (50%) 
AA056 
 
1153.4 1153.3 100% (78%) AA119 
 
1229.4 1229.4 94% (58%) 








1217.4 1217.4 94% (65%) 
AA058 
 
1198.3 1198.3 100% (74%) AA121 
 
1145.3 1145.3 95% (64%) 
AA059 
 
1198.3 1198.3 100% (57%) AA122 
 






100% (<5%) AA123 
 
1247.4 1247.4 100% (76%) 
AA061 
 
1185.4 1185.4 100% (79%) AA124 
 
1143.4 1143.4 100% (74%) 
AA062 
 
1171.4 1171.4 100% (76%) AA125  1129.4
[e] 1129.3 100%(69%) 
AA063 
 
1171.4 1171.4 100% (76%) AA126 
 
1174.3[e] 1174.3 100%(77%) 
[a] Elimination reaction(s) to dehydroalanine species. [b] Terminal amide side product. [c] Dihydrotriazinone. [d] 
EDC/HOAt/DIPEA reaction conditions. [e] Trifunctional linker with n = 2 [f] unknown species [g] Boc removal under ESI-
MS conditions [h] tBu ester hydrolysis in ESI-MS also observed 
Amino Acid Couplings, DE-2 Attachment by Split Synthesis  
 
The amide coupling reactions were performed in U-shaped 96 well-plates (Eppendorf Microplate 
96/U-PP, white border, PCR clean, 250 µL well-volume). The stated reagent amounts apply per 
well. 
The DNA-DE-1 pool (90.0 µM in MOPS buffer, 6.5 µL, 1.0 eq.) was distributed in 102 wells on 
2 plates. NMM (250.0 mM in DMSO, 8.2 µL, 3500.0 eq.) was added, followed by the 102 amino 
acids (500.0 mM in DMSO, 1.2 µL, 1000.0 eq.). DMTMM-BF4 (150.0 mM in DMSO, 3.9 µL, 
1000.0 eq.) was added and the solutions were thoroughly mixed. The plates were slowly agitated 
at RT for 20 h. NaOAc buffer (3.0 M, pH 5.20, 2.5 µL) was added, followed by EtOH (75 µL). The 
plates were placed in the fridge overnight. The plates were centrifuged (3700 rpm, 4°C, 60 min) 
and the supernatant was discarded. The DNA pellets were washed with EtOH (75%, 2 x 50 µL) 
and the plates were centrifuged (3700 rpm, 4°C, 2 x 40 min). The purified pellets were air-dried 
for 20 min. The DNA pellets were dissolved in H2O (20 µL) to yield 18-20 µM solutions (average 
of 9 measurements). For Amino Acids AA007, AA016, AA020, AA021, AA023, AA093 and 
AA094 NMM was replaced by DIPEA (250.0 mM in DMSO, 8.2 µL, 3500.0 eq.) and the coupling 
reagents were changed to EDC hydrochloride (300.0 mM in DMSO, 2.0 µL, 1000.0 eq.) and 























































































Klenow Encoding of the Coupled DE-2 Building Blocks 
 
The encodings were performed in PCR tube 96 well-plates (Eppendorf twin.tec PCR Plate 96 
LoBind, semi-skirted, 250 µL well-volume). The amino acid coupling products (20.0 µM in H2O, 
20.0 µL) were transferred to the PCR 96 well-plates and diluted with H2O (146 µL) and 
10X NEBuffer 2 (20 µL). The DE-2-encoding DNA strand (100.0 µM in H2O, 8.0 µL, 2.0 eq.) with 
the general sequence 5'-GTAGTTGGATCCGCACACYYYYGACAATTCACACACGTCC-3’ was 
added and the solution was annealed by heating to 65°C for 5 min. YYYY represents the coding 
sequence for the DE-2 amino acids and the underline shows the BamHI restriction site. The used 
annealing gradient was: 65°C(5 min)-50°(0.5 min)-40°(0.5 min)-25°C. The dNTPs mixture 
(10.0 mM in H2O each dNTP, 4.0 µL, 100.0 eq.) was added, followed by the Klenow polymerase 
(5000 U/ml, 2.0 µL, 10.0 Units). The reaction was incubated at 25°C for 30 min while shaking 
(150 rpm). To stop the reaction, EDTA (500.0 mM, 5.0 µL) was added and the mixture was 
incubated at 75°C for 20 min. The 102 encoded wells were combined in Eppendorf tubes (2 ml 
tubes, 14 pcs) and were concentrated to 8 ml by SpeedVac (45°C, 6 h). NaOAc buffer (3.0 M, 
pH 5.2, 960.0 µL) was added, followed by EtOH (28.8 mL). The mixture was left in the fridge 
(4°C) overnight. Hereafter, the suspension was centrifuged (4200 rpm, 4°C, 60 min) and the 
supernatant was discarded. The pellet was suspended in EtOH (75%, 2 x 8 ml) and centrifuged 
(4200 rpm, 2 x 30 min, 4°C). The clean pellet was air-dried for 20 min. The DNA was dissolved in 
MOPS buffer (300.0 mM, 500.0 mM NaCl, pH 8.2, 800.0 µL) to yield a 200 µM solution. Success 
of the encoding was checked by native DNA polyacrylamide gel electrophoresis (12%, TBE, 
150 V, 75 min, SYBR Gold staining). 
Optimization of the Ester and Nosyl Deprotection 
 
Stock solutions: DNA test sample (87.0 µM in 300.0 mM MOPS 500.0 mM NaCl buffer, 2.0 µL, 
1.0 eq.), thiol (300.0 mM in DMSO, 2.0 µL, 3448.0 eq.), base (300.0 mM in DMSO, 2.0 µL, 
3448.0 eq.).  
In a PCR tube all stock solutions were mixed and the solution was degassed with N2 for 30 s, 
followed by incubation according to Table 6. The sample was purified by ethanol precipitation, 
dissolved in H2O (6 µL) and further analyzed by HPLC and LC-MS.  
Ester and Deprotection of the DE-1/DE-2 sub-library 
 
In a 5 mL Eppendorf tube the encoded library (800.0 µL in 300.0 mM MOPS, 500.0 mM NaCl 
buffer), DBU (300.0 mM in DMSO, 800.0 µL) and BME (300.0 mM in DMSO, 800.0 µL) were 
mixed. The mixture was degassed with N2 for 30 s, followed by agitating at RT for 6 h. A white 
precipitate formed after BME addition. The suspension was treated with NaOAc buffer (3.0 M, 
pH 5.2, 250.0 µL) and EtOH (8.1 ml) and was placed in the fridge (4°C) overnight. The mixture 
was centrifuged (4200 rpm, 4°C, 60 min) and the supernatant was discarded. The pellet was 

























































100 mM Thiol, 100 mM Base,
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air for 30 min. The DEML was dissolved in MOPS buffer (700 µL) to yield a 79 µM solution. 
Success of the transformation was checked by HPLC (peak shift). 
Macrocyclization of the Encoded DE-1/DE-2 Pool 
 
In a 5 mL Eppendorf tube the DEML (900.0 µL, 56.0 µM in MOPS buffer) was diluted with MOPS 
buffer (1.4 mL) and DMSO (637 µL). NMM (50.0 mM in DMSO, 1.0 mL, 1000.0 eq.) and 
DMTMM-BF4 (25.0 mM in DMSO, 605.0 µL, 300.0 eq.) were mixed and agitated at RT for 18 h. 
NaOAc buffer (3.0 M, pH 5.2, 450.0 µL) was added, followed by EtOH (15 mL). The suspension 
was placed on ice for 2 h, followed by centrifugation (4200 rpm, 4°C, 60 min) and the supernatant 
was discarded. The DNA pellet was washed with EtOH (75%, 2 x 4 mL), centrifuged (4200 rpm, 
4°C, 2 x 30 min) and air-dried for 30 min. The DEML pellet was dissolved in H2O (800 µL). The 
coupling was repeated once more. The DEML was purified by ssDNA digestion in 8 batches, 
followed by reversed phase preparative column chromatography. The library (100 µL) was diluted 
with nuclease-free H2O (770 µL) and exonuclease 1 buffer (100 µL) was added, followed by the 
exonuclease 1 (E. coli) enzyme (20000 U/mL, 30 µL, 600.0 U). The solution was incubated at 
37°C for 40 min and the enzyme was deactivated by heating to 80°C for 20 min. The crude 
material was directly purified by preparative reversed phase HPLC (Method B). Product-
containing fractions were combined, lyophilized and dissolved in nuclease-free H2O (1.2 mL, 
26 µM). 100 µL of the DEML solution was diluted with TRIS (10.0 mM, pH 8.0) to 1.0 µM final 
concentration. The library was aliquoted (10 µL aliquots) and stored in the freezer (-20°C) for 
protein selection experiments (small DEML). 
Note: The macrocyclization was repeated once, because the reference sample, which was 
synthesized simultaneously, showed incomplete conversion. Increase of the coupling reagent 
amount (up to 500 eq.) and DMSO amount (>55%) should yield full macrocyclization in a single 
step. 
 
Figure 93. Left: Preparative HPLC chromatogram at 254 nm for the purification of the DEML. Blue indication shows the 
DEML containing fractions. Right: HPLC chromatogram at 254 nm of the purified small DEML. The large peak at 4.568 
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BamHI-HF Restriction Digest 
 
The restriction digest of the DEML was performed in 20 batches; amounts per batch. 
In an Eppendorf tube, DEML (55.0 µL, 26.0 µM in H2O) was mixed with 10X CutSmart buffer 
(75 µL) and diluted with H2O (565 µL). BamHI-HF (55.0 µL, 1100.0 U, 20000 U/mL) was added 
and incubated at 37°C for 30 min. The success of the reaction was checked by native 
polyacrylamide gel electrophoresis (12%, TBE, 150 V, 70 min). A solution of 
phenol:chloroform:isoamylalcohol 24:24:1 (740 µL) was added to the reaction and the mixture 
was vortexed for 2 min (phenol-chloroform extraction). The biphasic mixture was centrifuged 
(16900 g, RT, 5 min) and the aqueous layer was carefully removed. The aqueous phase was 
washed with chloroform (740 µL), vortexed for 2 min and centrifuged (16900 g, RT, 5 min). The 
aqueous layer was carefully removed and concentrated in the SpeedVac (45°C, 4 h). The 20 
combined samples were diluted with H2O to 4 mL total volume. NaOAc buffer (3.0 M, pH 5.2, 
400.0 µL) was added, followed by EtOH (13.2 mL). The mixture was placed on ice for 1 h and in 
the freezer at -80°C for 1 h. The suspension was centrifuged (4200 rpm, 4°C, 1 h) and the 
supernatant was removed. The pellet was washed with EtOH (75%, 2 x 4 mL) and centrifuged 
(4200 rpm, 4°C, 2 x 20 min). The restricted DNA was dried in the air for 30 min. The DNA pellet 
was dissolved in TEAA buffer (500.0 mM, pH 7.2, 2.3 mL) to yield a 10.5 µM solution. The 
restricted library was used as obtained for further experiments. 
Click Reactions, DE-3 Incorporation by Split Synthesis  
 
The reactions were performed in U-shaped 96 well-plates (Eppendorf Microplate 96/U-PP, white 
border, PCR clean, 250 µL well-volume). Columns 1 and 12 were left empty, 80 reactions per 
plate. 663 reactions were performed in 9 plates. The stated reagent amounts are given per well. 
Addition of the catalyst and the reducing agent was performed in a glove bag under an inert 
atmosphere (N2). 
The restricted DEML (3.5 µL, 10.5 µM in 500.0 mM TEAA buffer, pH 7.2) was mixed with the DE-
3 alkyne (3.7 µL, 1.0 mM in DMSO, 100.0 eq.) and DMSO (2.5 µL). Under an inert atmosphere 
degassed NaOAsc solution (2.5 µL, 3.0 mM in H2O, 200.0 eq.) was added, followed by Cu(II)-
TBTA complex solution (2.5 µL, 3.0 mM in 55% DMSO/H2O, 200.0 eq.). The plates were sealed 
(Starlab StarSeal sealing tape polyolefin) and left standing in the glove bag at RT for 16 h. 
NaOAc buffer (3.0 M, pH 5.2, 2.5 µL) was added, followed by EtOH (65 µL). The plates were 
placed in the fridge over the weekend. The 96-well plates were centrifuged (3700 rpm, 4°C, 
60 min) and the supernatant was removed. The DNA was washed with EtOH (75%, 2 x 50 µL) 
and centrifuged (3700 rpm, 4°C, 2 x 30 min). The DNA pellet was dissolved in nuclease-free H2O 






























































TEAA, DMSO, RT, 16 h
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Encoding of DE-3 by T4 Ligation and Klenow Fill-in 
 
The encoding was performed in V-shaped 96 well-plates (Eppendorf twin.tec PCR Plate 96 
LoBind, semi-skirted, 250 µL well-volume). The given amounts and volumes are valid per well. 
DE-3 encoding DNA strands (called insert DNA) consisted of a partially double-stranded DNA 
piece, that was preformed by the annealing of the coding strand with the sequence  
5'-GTTCAAGCCACTTACCTZZZZZZTGATGCCTACCTATGAGA-3' and a 5'- phosphorylated 
strand with the sequence 5'-P-GATCCAAGTTCGGTGAATGGA-3'. ZZZZZZ stands for the coding 
sequence of the DE-3 building blocks. 
The DEML (10.0 µL, approx. 3.7 µM) was diluted with nuclease-free H2O (15.3 µL) and mixed 
with the insert DNA (2.2 µL, 50.0 µM in H2O, 3.0 eq.). 10X ligase buffer (3.5 µL) and T4 DNA 
ligase (4.0 µL, 80.0 U, 20000 U/mL) were added. The 96-well plates were incubated at 16°C for 
16 h and hereafter the reaction was stopped by heating to 65°C for 10 min. dNTPs solution 
(3.7 µL, 1.0 mM in H2O, 100.0 eq.) was added, followed by Klenow polymerase (4.0 µL, 2.0 U, 
500 U/mL) and incubated at 25°C for 30 min. The reaction was stopped by the addition of EDTA 
(125.0 mM in H2O, 4.0 µL) and heating to 75°C for 20 min. All 663 reactions were pooled in 
2.0 mL Eppendorf tubes and were concentrated in the SpeedVac at 60°C. The concentrates were 
mixed with NaOAc buffer (3.0 M, pH 5.2, 840 µL), followed by EtOH (28 mL). The mixture was 
put on ice for 3 h and kept in the fridge overnight. The suspension was centrifuged (4200 rpm, 
4°C, 60 min) and the supernatant was discarded. The precipitate was washed with EtOH (75%, 
2 x 8 mL) and centrifuged (4200 rpm, 4°C, 2 x 20 min). The DNA pellet was air-dried for 1 h and 
was dissolved in H2O (1 mL). The encoded macrocycle library was purified by semi-preparative 
reversed phase HPLC (Method C). The product-containing fractions were combined, lyophilized 
and dissolved in 10 mM TRIS buffer pH 7.42 to a final concentration of 9.4 µM (3890 µL). The 
library was aliquoted (10 µL) and stored in the freezer (-20°C). 
 
Figure 94. a) DEML purification on the semi-preparative column. Blue indication shows the library containing fractions. 

































1. T4 Ligase, 10X Ligase buffer,
1.  16°C, 16 h
2. Klenow polymerase, dNTPs,
2. 25°C, 0.5 h
min
mV




































13.6. Quantitative PCR (qPCR) of Chemical Reactions on DNA 
General Procedure 
DNA damage evaluations were made with representative DNA strands, based on the same 
structure as the coding DNA strands of the DEML. For the evaluation of chemical modifications 
on a single-stranded DNA, we used DNA with the sequence 5'-GGAGCTTGTGAATTCTGGATG 
GGACGTGTGTGAATTGTCTTTTGTGTGCGGATCCAAGTTCGGTGAATGGATTTTTTACTACG
GATGGATACTCT-3' (DNA1).  
Chemical modifications on a double-stranded system were evaluated on a DNA pair consisting of 
DNA1 annealed to its reverse complementary strand with the sequence 5'-AGAGTATCCATCCG 
TAGTAAAAAATCCATTCACCGAACTTGGATCCGCACACAAAAGACAATTCACACACGTCCCAT
CCAGAATTCACAAGCTCC-3' (DNA2).  
The annealing of DNA1 and DNA2 was performed with the following gradient: 95°C(1 min)-
70°C(2 min)-45°C(2 min) to yield the double-stranded DNA3. DNA1 and DNA3 were diluted with 
H2O to a final concentration of 0.45 ng/µL. Primer1 had the following sequence:  
5'-AGAGTATCCATCCGTAGT-3' and Primer2: 5'-GGAGCTTGTGAATTCTGG-3'.  
For the qPCR assay the following solutions were mixed in a 96-well plate: DNA1 or DNA3 
(3.0 µL, 0.45 ng/µL in H2O), Primer1 (0.5 µL, 2.5 µM in H2O), Primer2 (0.5 µL, 2.5 µM in H2O), 
H2O (3.5 µL) and SYBR Green Master Mix (5.0 µL). After mixing and centrifugation of the plate, 
the PCR was run according to the following program: 95°C(2 min)-40 x (95°C(15 s)-60°C(1 min)). 
The progress of the DNA amplification was observed by fluorescence emission of the DNA-SYBR 
complex formed during the PCR. All assays were performed with three or more valid replicates 
that were further processed. Standard curves with unmodified DNA1 or DNA3 at four 
concentrations (1X, 10X, 100X, 1000X dilutions) were generated as well as dummy samples  
(no primers and primer only). The quantity of remaining intact DNA could be calculated by the 
number of PCR cycles necessary for complete consumption of the primers of each assay relative 
to the generated standard curves. For this purpose the standard curves were fitted with 
logarithmic trendlines in Excel. For single-stranded assays we calculated the following trendline: 𝑦 = −4.384𝑙𝑛(𝑥) + 7.4961,𝑅! = 0.99126, with y= the number of PCR cycles and x= the remaining 
intact DNA quantity. For double-stranded DNA we calculated the trendline: 𝑦 = −3.421𝑙𝑛(𝑥) +11.458,𝑅! = 0.98647. 
Ester Deprotection Conditions 
In a PCR tube DNA1 (3.0 µL, 110.0 µM in H2O, 1.0 eq.) was mixed with H2O (2 µL), MeCN 
(3.5 µL) and a solution of LiOH monohydrate (1.65 µL, 100.0 mM in H2O, 500.0 eq.). The mixture 
was left standing at RT for 16 h, followed by EtOH purification. The washed DNA pellet was 
dissolved in H2O (30 µL) and further diluted to the desired concentration for qPCR. 
Click Reaction Conditions 
In a PCR tube DNA1 (3.0 µL, 110.0 µM in H2O, 1.0 eq.) was mixed with TEAA (1.0 M, pH 7.2, 
3.0 µL), DMSO (7 µL), a solution of TA662 (3.3 µL, 10.0 mM in DMSO, 100.0 eq.) and a solution 
of sodium ascorbate (3.3 µL, 20.0 mM in H2O, 200.0 eq.). The mixture was degassed for 30 s by 
bubbling a stream of N2 gas through the solution. Cu(II)-TBTA complex solution (6.6 µL, 10.0 mM 
in 55% DMSO, 200.0 eq.) was added and the mixture was degassed again for 30 s. The mixture 
was left standing at RT for 16 h, followed by EtOH purification. The washed DNA pellet was 
dissolved in H2O (30 µL) and was further diluted to the desired concentration for qPCR. For the 
double-stranded assay DNA1 was replaced by DNA3 (6.0 µL, 50.0 µM, 1.0 eq.) 
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DMTMM Coupling with Excess Amine Conditions 
In a PCR tube DNA1 (3.0 µL, 110.0 µM in H2O, 1.0 eq.) was mixed with MOPS buffer (300.0 mM, 
pH 8.2, 0.5 µL), NMM (2.2 µL, 300.0 mM in DMSO, 2000.0 eq.), AA001 (3.3 µL, 100.0 mM in 
DMSO, 1000.0 eq.) and DMTMM-BF4 (1.7 µL, 200.0 mM in DMSO, 1000.0 eq.). The mixture was 
left standing at RT for 16 h, followed by EtOH purification. The washed DNA pellet was dissolved 
in H2O (30 µL) and further diluted to the desired concentration for qPCR. For the double-stranded 
assay DNA1 was replaced by DNA3 (6.0 µL, 50.0 µM, 1.0 eq.) 
DMTMM Coupling with Excess Acid Conditions 
In a PCR tube DNA1 (3.0 µL, 110.0 µM in H2O, 1.0 eq.) was mixed with MOPS buffer (300.0 mM, 
pH 8.2, 0.5 µL), NMM (2.2 µL, 300.0 mM in DMSO, 2000.0 eq.), 1-H-indazole-3-carboxylic acid 
(3.3 µL, 100.0 mM in DMSO, 1000.0 eq.) and DMTMM-BF4 (1.7 µL, 200.0 mM in DMSO, 
1000.0 eq.). The mixture was left standing at RT for 16 h, followed by EtOH purification. The 
washed DNA pellet was dissolved in H2O (30 µL) and further diluted to the desired concentration 
for qPCR. For the double-stranded assay DNA1 was replaced by DNA3 (6.0 µL, 50.0 µM, 
1.0 eq.) 
EDC/HOAt Coupling with Excess Amine Conditions 
In a PCR tube DNA1 (3.0 µL, 110.0 µM in H2O, 1.0 eq.) was mixed with MOPS buffer (300.0 mM, 
pH 8.2, 0.5 µL), DIPEA (3.7 µL, 180.0 mM in DMSO, 2000.0 eq.), AA001 (3.3 µL, 100.0 mM in 
DMSO, 1000.0 eq.), EDC hydrochloride (1.7 µL, 200.0 mM in DMSO, 1000.0 eq.) and HOAt 
(1.7 µL, 200.0 mM in DMSO, 1000.0 eq.). The mixture was left standing at RT for 16 h, followed 
by EtOH purification. The washed DNA pellet was dissolved in H2O (30 µL) and further diluted to 
the desired concentration for qPCR. For the double-stranded assay DNA1 was replaced by 
DNA3 (6.0 µL, 50.0 µM, 1.0 eq.) 
EDC/HOAt Coupling with Excess Acid Conditions 
In a PCR tube DNA1 (3.0 µL, 110.0 µM in H2O, 1.0 eq.) was mixed with MOPS buffer (300.0 mM, 
pH 8.2, 0.5 µL), DIPEA (3.7 µL, 180.0 mM in DMSO, 2000.0 eq.), 1-H-indazole-3-carboxylic acid 
(3.3 µL, 100.0 mM in DMSO, 1000.0 eq.), EDC hydrochloride (1.7 µL, 200.0 mM in DMSO, 
1000.0 eq.) and HOAt (1.7 µL, 200.0 mM in DMSO, 1000.0 eq.). The mixture was left standing at 
RT for 16 h, followed by EtOH purification. The washed DNA pellet was dissolved in H2O (30 µL) 
and further diluted to the desired concentration for qPCR. For the double-stranded assay DNA1 
was replaced by DNA3 (6.0 µL, 50.0 µM, 1.0 eq.) 
Nosyl Deprotection Conditions 
In a PCR tube DNA1 (3.0 µL, 110.0 µM in H2O, 1.0 eq.) was mixed with MOPS buffer (600.0 mM, 
pH 8.2, 3.0 µL), DBU (6.0 µL, 300.0 mM in DMSO, 5455.0 eq.) and BME (6.0 µL, 300.0 mM in 
DMSO, 5455.0 eq.). The mixture was degassed by bubbling N2 through the solution for 30 s and 
then left standing at RT for 16 h, followed by EtOH purification. The washed DNA pellet was 
dissolved in H2O (30 µL) and further diluted to the desired concentration for qPCR.  
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13.7 Protein Biotinylation of HSA and AGP 
Protein biotinylation was performed according to a modified procedure from Scheuermann et 
al.[164] The given procedure below was applied for HSA and AGP modifications. 
In a 1.5 mL Eppendorf tube the protein (1.0 mg/ml in PBS buffer, 1.0 ml) was mixed with NHS-
LC-Biotin (10.0 mM in DMSO, 20.0 eq.) and the solution was incubated at 4°C for 3 h (Thermo 
Block, 500 rpm shaking). The reaction was quenched by the addition of TRIS hydrochloride buffer 
(1.0 M, pH 7.42, 66.0 eq.) and was incubated at 4°C for another 1 h. PBS buffer (1 mL) was 
added and the reaction buffer was exchanged using a Sartorius Vivaspin 2 10000 MWCO CTA 
column (4200 rpm, 4°C, 4 x 20 min, 3 x 2 mL PBS). The protein solution was collected and PBS 
was added to get a final protein concentration of 10 µM. The protein solution was aliquoted 
(20 µL aliquots) and stored in the freezer at -20°C. To check the success of the modification, a 
biotinylation band shift assay was performed. 
The modified protein (7.6 µL) was diluted with PBS (37.4 µL) and mixed with an equimolar 
amount of avidin (1.0 mg/ml in PBS, 5.0 µL). The solution was left standing at RT for 5 min and 
then placed on ice for 1 h. The result of the experiment was controlled by SDS-PAGE (coomassie 
stain). Only the indicated control samples were treated by heat denaturation prior to loading. 
 
Figure 95. Protein biotinylation band shift assays, coomassie stain. Left: HSA band shift, L1: Protein standards,  
L2: HSA unmodified, L3: HSA unmodified + avidin, L4: HSA modified, L5: HSA modified + avidin, L6: Avidin, L7: HSA 
unmodified + avidin (95°C), L8: HSA modified + avidin (95°C). Right: AGP band shift, L1: Protein standards, L2: AGP 
unmodified, L3: AGP modified, L4: AGP modified + avidin, L5: AGP modified + avidin (95°C), L6: AGP unmodified + 
avidin, L7: AGP unmodified + avidin (95°C), L8: Avidin. Note: Avidin tetramer is not visible since it stuck to the stacking 
gel. 
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13.8 DEML Protein Target Selections 
HSA and AGP Selections 
Stock solutions: 
- Biotin solution:  200 mM D-biotin in DMSO (2 mL) 
- PBST:  0.05% Tween-20 in PBS (10 mL)  
- PBST-Biotin:  1:1 mixture of biotin stock solution + 50% DMSO in PBST (2 mL)→ do 
not put on ice! 
- Salmon Sperm DNA: 2 mg/mL in PBS 
- PBST-SS:  PBST containing 200 µg/mL salmon sperm DNA. Mix 1.8 mL PBST 
with 200 µL salmon sperm DNA stock solution (2 mL). 
- DEML-WS:  DEML working solution. DEML stock (9.4 µM, 10.0 µL) was mixed with 
PBST-SS (50 µL) and diluted with PBST (940 µL) to yield the working 
solution (1.0 mL, 94.0 nM for 10 assays). 
- Protein solution:  Biotinylated protein sample (10.0 µL, 10.0 µM) was diluted with PBS 
(90 µL) to the final concentration (1 µM, 100.0 µL)  
All stock solutions were prepared as stated above. The DECL-WS and the protein solution were 
kept on ice. 100 µg hydrophilic streptavidin magnetic beads (25.0 µL, NEB S1421S) were placed 
in a magnetic rack and the buffer was discarded. The beads were washed with PBS (3 x 1 mL). 
The beads were kept in 1 mL PBS on ice until usage. 
The buffer was removed from the beads and the protein solution (100.0 µL, 100.0 pmol) was 
added. The mixture was incubated at 4°C for 30 min while gently mixing by rotation. The tube 
was placed in the magnetic rack and the buffer was discarded. The beads were suspended in 
PBST-Biotin (2 x 200 µL) and the supernatants were removed. The beads were washed with 
PBST (200 µL), 10% PBST in DMSO (200 µL, to remove biotin precipitate) and PBST (2 x 
200 µL). The beads were transferred to a fresh tube and DEML-WS (100.0 µL, 9.4 pmol DECL) 
was added. The mixture was incubated at 4°C for 1 h while gently mixing by rotation. The tube 
was transferred to the magnetic rack and the supernatant was discarded. The beads were 
washed with PBST (5 x 200 µL), exchanging the tube after 2 washing steps (reduce carryover of 
unbound DNA). The washed beads were suspended in TRIS buffer (10.0 mM, pH 8.5, 100.0 µL) 
and the bound DNA was eluted from the protein by heat denaturation (95°C for 10 min). After 
cooling, the magnetic beads were removed and the buffer solution was stored in a 1.5 mL 
Eppendorf tube at -20°C. PCR amplification and high-throughput sequencing were used for 





- PBST:  0.05% Tween-20 in PBS (10 mL)  
- PBST-Im:  PBST with 10 mM imidazole 
- Salmon Sperm DNA: 2 mg/mL in PBS 
- PBST-SS:  PBST containing 200 µg/mL salmon sperm DNA. Mix 1.8 mL PBST 
with 200 µL salmon sperm DNA stock solution (2 mL). 
- DEML-WS:  DEML working solution. DEML stock (9.4 µM, 10.0 µL) was mixed with 
PBST-SS (50 µL) and diluted with PBST (940 µL) to yield the working 
solution (1.0 mL, 94.0 nM for 10 assays). 
- Protein solution:  His-tagged CA9 (2.5 µg, 50.0 pmol) was reconstituted with sterile H2O 
(17.5 µL) and was diluted with PBST (32.5 µL) to yield the final 
concentration (1.0 µM, 50 µL). 
All stock solutions were prepared as stated above. The DECL-WS and the protein solution were 
kept on ice. 250 µg His magnetic beads (6.25 µL, Invitrogen Dynabeads, 10103D) were placed in 
a magnetic rack and the buffer was discarded. The beads were washed with PBS (3 x 1 mL). The 
beads were kept in 1 mL PBS on ice until usage. 
The buffer was removed from the beads and the protein solution (50.0 µL, 50.0 pmol) was added. 
The mixture was incubated at 4°C for 30 min while gently mixing by rotation. The tube was placed 
in the magnetic rack and the buffer was discarded. The beads were suspended in PBST-Im (2 x 
100 µL) and the supernatants were removed. The beads were washed with PBST (3 x 200 µL). 
The beads were transferred to a fresh tube and DEML-WS (100.0 µL, 9.4 pmol DECL) was 
added. The mixture was incubated at 4°C for 1 h while gently mixing by rotation. The tube was 
transferred to the magnetic rack and the supernatant was discarded. The beads were washed 
with PBST (5 x 200 µL), exchanging the tube after 2 washing steps (reduce carryover of unbound 
DNA). The washed beads were suspended in TRIS buffer (10.0 mM, pH 8.5, 100.0 µL) and the 
bound DNA was eluted from the protein by heat denaturation (95°C for 10 min). After cooling, the 
magnetic beads were removed and the buffer solution was stored in a 1.5 mL Eppendorf tube at  
-20°C. PCR amplification and high-throughput sequencing were used for analyzing the target 
binding results. 
Note: For the smDEML the procedure was analog to the described procedure. Due to the higher 
purity and smaller number of individual members the small DEML-WS was prepared from the 
1.0 µM small DEML solution, giving a final work solution concentration of 10.0 nM. Target binding 
assays were performed in duplicates with two freshly prepared working solutions that were used 
on two consecutive days. In the CA9 DEML-WS we spiked in a known CA9 binder in a tenfold 
excess. The positive binder was synthesized according to the established procedures (see 
Chapter 13.4) and was composed of building blocks NP01, AA001 and TA664. Spiking was only 
performed with one selection (protein + dummy) of the DEML. Performed assays with AGP and 
HSA: 2 x smDEML, 2 x DEML, 4 x dummy selections (beads only, no bound target proteins). In 
total: 12 selection assays. Selections performed with CA9: 2 x smDEML, 2 x DEML, 4 x dummy 
selections. In total 8 assays. 
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13.9 PCR Amplification of Eluted DNA 
PCR 1 
Eluted DNA from selection:  5 µL 
Phusion HF buffer (5x):  10 µL 
Phusion MgCl2 (50.0 mM):  2 µL 
dNTPs (10.0 mM):  1.25 µL 
UniPrimAdapt (7.5 µM):  4 µL 
IndexPrimAdapt (10.0 µM):  3 µL 
Phusion (2U/µL):  0.25 µL 
H2O:  24.5 µL 
In a PCR vial all stock solutions were mixed and kept on ice. The polymerase was added shortly 
before the PCR program started. 22 PCR cycles were performed. PCR cycle program: 98°C for 
2 min 15 s then 22 x 98°C (45 s) → 69°C (45 s) → 72°C (45 s), 72°C (5 min). The progress of the 
reactions was controlled by native PAGE analysis (10%, TBE, 150 V, 45 min, SYBR Gold 
staining). The samples were purified with the PCR clean up kit (Macherey&Nagel). Two washing 
steps were included and the purified PCR products were eluted with NE buffer (2 x 20 µl). The 
PCR products were diluted with NE buffer to a final concentration of 100 nM.  
For the fingerprint sample, an aliquot of the DEML (small DEML) working solution was diluted 
1:10 and processed as stated above. 
UniPrimAdapt:  5‘-ACACGACGCTCTTCCGATCTGTAGTTGGATCCGCAC-3‘ (small DEML) 
 5‘-ACACGACGCTCTTCCGATCTAGAGTATCCATCCGTA-3‘ (DEML) 
IndexPrimAdapt:  5'-GACGTGTGCTCTTCCGATCTGGAGCTTGTGAATTCT-3’ (both libraries the same) 
 
Figure 96. 10% Native PAGE gels after PCR1 with the DEML selections (left) and the small DEML selections (right) 
with HSA and AGP, SYBR gold staining. L1: Low MW DNA ladder, L2: (small) DEML, L3 & L4: HSA selections,  
L5 & 6: Dummy selections, L7 & 8: AGP selections, L9 & 10: Library fingerprints. 












Figure 97. 10% Native PAGE gels after PCR1 with the smDEML selections (left) and the DEML selections (right) with 
CA9, SYBR gold staining. L1: Low MW DNA ladder, L2: smDEML, L3 & L5: CA9 selections, L4 & L6: Dummy 
selections, L7: DEML, L8 & L10: CA9 selections, L9 & L11: Dummy selections. 
PCR2 
PCR products from PCR1 were diluted 1:10 with NE buffer prior to PCR2 
PCR 1 DNA (10.0 nM):  10 µL 
Phusion HF buffer (5x):  20 µL 
Phusion MgCl2 (50.0 mM):  4 µL 
dNTPs (10.0 mM):  2.5 µL 
Universal Primer (10.0 µM):  3 µL 
Index Primer (10.0 µM):  3 µL 
Phusion (2U/µL):  0.5 µL 
H2O:  57 µL 
In a PCR vial all stock solutions were mixed and kept on ice. The polymerase was added shortly 
before the PCR program started. 15 PCR cycles were performed. PCR cycle program: 98°C for 
2 min 15 s then 15 x 98°C (45 s) → 69°C (45 s) →72°C (45 s), 72°C (5 min). The progress of the 
reactions was controlled by native PAGE analysis (8%, TBE, 150 V, 45 min, SYBR Gold 
staining). The samples were purified by agarose gel electrophoresis (2%, TBE, 100 V, 45 min) 
and the desired bands were cut out of the gel with subsequent DNA isolation with the PCR clean 
up kit (Macherey&Nagel). Two washing steps were included and the purified PCR products were 
eluted with NE buffer (2 x 20 µl). After ethanol precipitation the amplified and indexed products 
were diluted with NE buffer to a final concentration of 100 nM. 
Primer sequences for Illumina Sequencing (NEBNext Multiplex Oligos for Illumina, Sets 1 and 3): 
UniPrimer:  5‘-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT-3‘ 
IndexPrimers:  5'-
CAAGCAGAAGACGGCATACGAGATNNNNNNGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-3’ 








smDEML Selections DEML Selections 
Primers 
 1  2  3  4  5  6  7  8  9  10  11 
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Figure 98. 8% Native PAGE gels after PCR2 amplification of HSA and AGP selections. L1: Low MW DNA ladder, L2 & 
L11: PCR1 (HSA selection), L3, L6, L12, L15: HSA selections, L4, L7, L13, L16: Dummy selections, L5, L8, L14, L17: 
Fingerprints, L9, L10, L18, L19: AGP selections, L20: Primers. 
 
 
Figure 99. 8% Native PAGE gels after PCR2 amplification of CA9 selections. L1: Low MW DNA ladder, L2 & L7: PCR1, 
L3, L5, L8, L10: CA9 selections, L4, L6, L9, L11: Dummy selections, L12: Primers. 
 
 
Figure 100. 8% Native PAGE gels after PCR2 purification of HSA and AGP selections. L1: Low MW DNA ladder, L2, 




Figure 101. 8% Native PAGE gel after PCR2 purification of CA9 selections. L1: Low MW DNA ladder, L2, L3, L6, L7: 
CA9 selections, L4, L5, L8, L9: Dummy selections. 
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13.10 Next Generation Sequencing (NGS)[227] 
In order to pool the individual selections, the DNA concentration of each sample was measured to 
determine its concentration. The separate selections were then pooled in equal amounts to form 
two pools, one with the small library and one with the full library. These two libraries were pooled 
in equal amounts again and sent to Novogene for next generation sequencing with a targeted 
read count of 240 million reads and paired-end 150 sequencing. 
We extracted the codon hit counts from next generation sequencing data files (.fq) with our 
DECL-Gen software suite on the University of Basel computational cluster (SciCore). The script 
aligns the theoretical DNA strand to the read with the pairwise2 algorithm provided by the 
Biopython package, and then extracts the codons from the aligned read. This is done for the 
mate pair, too, and the two codon sets are controlled for identity, discarding the read if they do 
not match. After extraction, the counts for both replicates have been averaged and the list was 
cleaned from non-existing codon combinations deriving from random mutations during PCR or 
from sequencing errors. The results for each data set are summarized in Table 13. 
Examples 
Expected correct read (black), found (green); the Illumina adapter is marked with underline, the 





Expected correct read (black), found with mistakes (red). Same markings apply as above. As the 




GATACTCTAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTCGCCGTATCATTAAA   
 -169- 
Table 13. Summary of the enrichment assays that were analyzed by NGS. The counts of the different enrichments were 
averaged by replicate and then normalized by their mean. 
[a] Read counts are given in million mate reads. [b] In million reads. Only reads where both read mates have the same 
codons were considered. [c] Coverage is an indication of how many reads per codon can be expected if all compounds 
are distributed equally in the sample. It was calculated by the following equation: 
"𝐶𝑜𝑣𝑒𝑟𝑎𝑔𝑒" = "𝑀𝑎𝑡𝑐ℎ𝑖𝑛𝑔 𝑐𝑜𝑑𝑜𝑛 𝑝𝑎𝑖𝑟𝑠" /"𝐿𝑖𝑏𝑟𝑎𝑟𝑦 𝑆𝑖𝑧𝑒" . [d] This number indicates how many codons were found that did 
not encode for a compound within a library. [e] Depending on sequencing depth, a part of the library population never 
gets sequenced in both replicates even if they are equally distributed. A lower number of found codons indicated a 
strong deviation in the population distribution due to enrichment. 
  













1 2’142 15.77 13.41 6260 
2.6% 2142 (100%) 
2 2 2’142 20.03 17.38 8114 
3 
Beads 
1 2’142 17.23 15.17 7082 
2.1% 2142 (100%) 
4 2 2’142 15.14 13.20 6160 
5 
HSA 
1 2’142 15.81 13.83 6457 
2.1% 2142 (100%) 
6 2 2’142 15.21 13.28 6200 
7 
AGP 
1 2’142 17.43 15.22 7106 
2.1% 2142 (100%) 
8 2 2’142 16.76 14.47 6755 
9 
Ni-Beads 
1 2’142 17.5 15.4 7190 
2.3% 2142 (100%) 
10 2 2’142 19.4 16.6 7750 
11 
CA9 
1 2’142 15.1 13.1 6116 
2.4% 2142 (100%) 
12 2 2’142 17.9 15.6 7283 
13 
Fingerprint 
1 1’420’146 13.07 8.55 6.02 
6.7% 
1’318’952 
(92.9%) 14 2 1’420’146 11.95 7.87 5.54 
15 
Beads 




16 2 1’420’146 12.30 8.97 6.32 
17 
HSA 
1 1’420’146 12.33 9.06 6.38 
4.3% 
838’791 
(59.1%) 18 2 1’420’146 13.28 9.77 6.88 
19 
AGP 




20 2 1’420’146 11.54 8.54 6.01 
21 
Ni-Beads 
1 1’420’146 12.9 8.66 6.10 
6.3% 
756'037 
(53.2%) 22 2 1’420’147 10.9 7.55 5.32 
23 
CA9 
1 1’420’146 10.4 6.85 4.82 
6.1% 
655'821 
(46.2%) 24 2 1’420’147 11.8 8.09 5.70 
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13.11 Macrocycle Resynthesis Procedures 
2-Iodo-N-(2-((2-nitrophenyl)sulfonamido)ethyl)benzamide 2-24 (Nos-Sc-I) 
 
In a 250 mL flask 2-iodobenzoic acid (8.2 g, 33.1 mmol, 1.0 eq.), 2-3 (12.2 g, 49.6 mmol, 1.5 eq.), 
HBTU (15.0 g, 39.7 mmol, 1.2 eq.) and DIPEA (17.3 mL, 99.2 mmol, 3.0 eq.) were dissolved in 
THF (150 mL) and stirred at RT for 2 h, after which UPLC-MS analysis showed 93% conversion 
to the desired product (HBTU dissolved after about 30 min reaction time). The solvent was 
removed in vacuo and the residue was dissolved in EtOAc (250 mL). The organic layer was 
washed with diluted HCl (20 mM, 3 x 100 mL), half-saturated NaHCO3 (3 x 100 mL) and brine 
(100 mL). The organic layer was dried over MgSO4 and concentrated. The crude was purified by 
flash column chromatography on the ISOLERA (Silica, 2 x 340 g, cyclohexane:EtOAc 20%→70% 
EtOAc, UV). The product containing fractions were combined and concentrated. The obtained 
solid was dissolved in MeCN (100 mL), filtered over a G4 glass sintered funnel and concentrated 
to yield the desired product as a yellow solid (14.7 g, 94%).  
1H NMR (400 MHz, CD3CN) δ/ppm: 8.10 – 8.03 (m, 1H), 7.91 – 7.83 (m, 2H), 7.83 – 7.76 (m, 
2H), 7.41 (ddd, J = 7.5, 7.5, 1.1 Hz, 1H), 7.32 (dd, J = 7.6, 1.7 Hz, 1H), 7.14 (ddd, J = 7.9, 7.4, 
1.8 Hz, 1H), 6.90 (brs, 1H), 6.21 (t, J = 5.9 Hz, 1H), 3.44 (dt, J = 5.8, 6.0 Hz, 2H), 3.30 – 3.22 (dt, 
6.0, 6.1 Hz, 2H). 
13C NMR (101 MHz, CD3CN) δ/ppm: 170.75, 143.29, 140.57, 135.19, 135.10, 133.88, 133.80, 
131.97, 131.40, 129.15, 128.88, 126.02, 93.03, 43.98, 40.27. 
HRMS (ESI): C15H14IN3NaO5S+ calcd: 497.9591, found: 497.9597. 
Nos-Sc-NP01-OH 2-18a 
 
In a 250 mL flask 2-24 (3.0 g, 6.3 mmol, 1.0 eq.), 3-(2-carboxyvinyl)benzeneboronic acid (1.8 g, 
9.5 mmol, 1.5 eq.), Pd (π-cinnamyl) chloride dimer (327.0 mg, 631.0 µmol, 10 mol%) and K3PO4 
(4.0 g, 18.9 mmol, 3.0 eq.) were dissolved in EtOH (56 mL) and H2O (24 mL). The solution was 
stirred at 50°C for 1 h, after which UPLC-MS analysis showed full conversion to the desired 
product. The volatiles were removed and the residue was taken up in EtOAc (200 mL) and H2O 
(150 mL). The mixture was acidified with concentrated HCl to pH 1. The biphasic mixture was 
separated and the aqueous layer was extracted with EtOAc (2 x 100 mL, 1 x 50 mL). The 
combined organic layers were washed with brine (100 mL), dried over Na2SO4 and were 
concentrated by rotary evaporation. The crude was purified by reversed phase flash column 
chromatography on the ISOLERA (RP-Silica, 340 g, H2O/MeCN + 0.1% TFA, UV). The product-
containing fractions were freeze dried to yield the desired product as off-white powder (2.2 g, 
70%). 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.22 (t, J = 5.8 Hz, 1H), 8.11 (t, J = 5.9 Hz, 1H), 7.99 (dd, 
J = 5.9, 3.4 Hz, 1H), 7.96 – 7.92 (m, 1H), 7.91 – 7.86 (m, 2H), 7.64 – 7.54 (m, 3H), 7.54 - 7.48 
(m, 1H), 7.47 – 7.40 (m, 3H), 7.38 – 7.30 (m, 2H), 6.50 (d, J = 16.0 Hz, 1H), 3.14 (dt, J = 7.6, 
6.0 Hz, 2H), 2.77 (dt, J = 7.6, 6.2 Hz, 2H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 169.19, 167.48, 147.70, 143.68, 140.77, 138.44, 136.94, 
134.10, 132.71, 132.54, 130.14, 129.81, 129.51, 129.38, 128.63, 127.94, 127.63, 127.34, 126.99, 












HRMS (ESI): C24H21N3NaO7S+ calcd: 518.0992, found: 518.0991. 
Nos-Sc-NP01-TFL(N3)-OMe 2-18b 
 
In a 500 mL flask 2-18a (2.2 g, 4.4 mmol, 1.0 eq.), 2-5 (841.0 mg, 5.3 mmol, 1.2 eq.), HBTU 
(2.0 g, 5.3 mmol, 1.2 eq.) and DIPEA (2.3 mL, 13.3 mmol, 3.0 eq.) were dissolved in THF (40 mL) 
and the mixture was stirred at RT for 1.5 h, after which UPLC-MS analysis showed full conversion 
to the desired product. The volatiles were removed in vacuo and the crude was purified by flash 
column chromatography on the ISOLERA (Silica, 340 g, DCM/MeOH, UV) to yield the desired 
product as a thick, yellow oil (3.7 g, >100%). NMR showed co-eluted byproducts from the 
coupling reagents. The material was used without further purification for the next synthetic step.  
1H NMR (400 MHz, CDCl3) δ/ppm: 8.01 – 7.93 (m, 1H), 7.80 – 7.73 (m, 1H), 7.73 – 7.65 (m, 2H), 
7.58 – 7.25 (m, 9H), 7.00 (d, J = 7.8 Hz, 1H), 6.54 (d, J = 15.7 Hz, 1H), 6.50 (t, J = 5.8 Hz, 1H), 
5.92 (t, J = 5.9 Hz, 1H), 4.70 (td, J = 7.9, 5.0 Hz, 1H), 3.70 (s, 3H), 3.37 (t, J = 6.7 Hz, 2H), 3.33 – 
3.25 (m, 2H), 3.01 – 2.93 (m, 2H), 2.18 – 2.07 (m, 1H), 2.03 – 1.90 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 172.26, 170.70, 166.13, 147.93, 140.97, 140.89, 139.09, 
135.47, 135.00, 133.92, 133.07, 132.98, 130.90, 130.44, 130.25, 130.11, 129.18, 128.23, 127.87, 
127.75, 127.61, 125.30, 121.03, 52.68, 50.34, 47.81, 43.06, 39.85, 31.19. 
HRMS (ESI): C29H29N7NaO8S+ calcd: 658.1691, found: 658.1693. 
Nos-Sc-NP01-TFL(N3)-OH 2-18c 
 
In a 100 mL flask 2-18b (3.6 g, 5.7 mmol, 1.0 eq.) was dissolved in MeCN (34 mL) and a solution 
of LiOH monohydrate (1.2 g, 28.5 mmol, 5.0 eq.) in H2O (17 mL) was added. The mixture was 
stirred at RT for 1.5 h, after which UPLC-MS analysis showed full conversion to the desired 
product. Acidifying the mixture to pH 5-6 with concentrated HCl quenched the reaction and the 
volatiles were removed in vacuo. The residue was taken up in EtOAc (100 mL) and H2O 
(100 mL). The biphasic mixture was acidified to pH 1 with concentrated HCl and the layers were 
separated. The aqueous layer was extracted with EtOAc (2 x 100 mL) and the combined organic 
layers were washed with half-saturated brine (2 x 100 mL) and brine (100 mL), dried over MgSO4 
and concentrated by rotary evaporation to yield the desired product as a yellowish solid (2.8 g, 
79%). NMR showed some residual tetramethylurea from the HBTU coupling step. The material 
was used without further purification for the next synthetic step. 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 12.81 (s, 1H), 8.46 (d, J = 7.9 Hz, 1H), 8.18 (t, J = 5.8 Hz, 
1H), 8.09 (t, J = 6.0 Hz, 1H), 8.02 – 7.97 (m, 1H), 7.96 – 7.92 (m, 1H), 7.92 – 7.87 (m, 2H), 7.55 – 
7.49 (m, 2H), 7.48 – 7.40 (m, 5H), 7.37 – 7.29 (m, 2H), 6.73 (d, J = 15.8 Hz, 1H), 4.44 (ddd, J = 
9.2, 7.9, 4.8 Hz, 1H), 3.51 – 3.38 (m, 2H), 3.14 (dt, J = 7.9, 6.1 Hz, 2H), 2.79 – 2.72 (m, 2H), 2.05 
(dtd, J = 13.9, 7.4, 4.8 Hz, 1H), 1.95 – 1.85 (m, 1H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 173.06, 169.12, 165.00, 147.70, 140.79, 139.12, 138.57, 
136.90, 134.63, 134.10, 132.73, 132.48, 129.72, 129.56, 129.52, 129.39, 128.62, 127.65, 127.60, 
127.33, 126.27, 124.54, 121.81, 49.63, 47.53, 41.56, 38.75, 30.40. 




















In a 50 mL flask 2-18c (1.1 g, 1.8 mmol, 1.0 eq.) was dissolved in THF (16 mL) and H-Ala-OMe 
hydrochloride (298.0 mg, 2.1 mmol, 1.2 eq.) was added, followed by DIPEA (931.0 µL, 5.3 mmol, 
3.0 eq.) and HATU (810.0 mg, 2.1 mmol, 1.2 eq.). The mixture was stirred at RT for 1 h, after 
which UPLC-MS analysis showed full conversion to the desired product. The volatiles were 
removed in vacuo and the residue was taken up in EtOAc (100 mL) and H2O (100 mL). The 
mixture was acidified with concentrated HCl to pH 1. The layers were separated and the aqueous 
phase was extracted with EtOAc (2 x 100 mL) and the combined organic layers were washed 
with diluted HCl solution (1%, 2 x 100 mL), brine (100 mL), dried over Na2SO4 and concentrated 
by rotary evaporation. The crude was purified by flash column chromatography on the ISOLERA 
(Silica, 120 g, DCM/MeOH, UV) to yield the desired product as a slightly yellow solid (1.0 g, 
81%). 
1H NMR (400 MHz, CD3CN) δ/ppm: 8.02 – 7.95 (m, 1H), 7.88 – 7.83 (m, 1H), 7.83 – 7.78 (m, 
2H), 7.58 – 7.51 (m, 2H), 7.51 – 7.45 (m, 3H), 7.44 – 7.38 (m, 2H), 7.37 – 7.33 (m, 2H), 7.19 (d, 
J = 7.0 Hz, 1H), 7.05 (d, J = 8.0 Hz, 1H), 6.70 – 6.55 (m, 2H), 6.12 (t, J = 5.9 Hz, 1H), 4.58 (td, 
J = 8.2, 5.4 Hz, 1H), 4.42 – 4.32 (m, 1H), 3.66 (s, 3H), 3.42 (ddd, J = 9.9, 5.0, 2.4 Hz, 2H), 3.22 
(q, J = 6.2 Hz, 2H), 2.93 (q, J = 6.1 Hz, 2H), 2.05 (ddd, J = 14.3, 7.1, 5.5 Hz, 1H), 1.92 – 1.83 (m, 
1H), 1.32 (d, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CD3CN) δ/ppm: 173.90, 171.89, 170.91, 166.40, 148.89, 142.01, 140.90, 
140.03, 137.31, 135.94, 135.11, 133.87, 133.65, 131.40, 131.01, 130.93, 130.88, 129.79, 128.81, 
128.76, 128.55, 127.87, 126.02, 122.39, 51.64, 49.14, 48.67, 43.67, 40.08, 38.82, 32.29, 17.53. 
HRMS (ESI): C32H34N8NaO9S+ calcd: 729.2062, found: 729.2060. 
NH2-Sc-NP01-TFL(N3)-AA001-OH 2-18e 
 
Under an inert (N2) atmosphere 2-18d (1.0 g, 1.4 mmol, 1.0 eq.) was dissolved in MeCN (12 mL) 
and DIPEA (2.5 mL, 14.2 mmol, 10.0 eq.) was added, followed by thiophenol (725.0 µL, 
7.1 mmol, 5.0 eq.). The yellow solution was stirred at RT for 2 h, after which UPLC-MS analysis 
showed complete Nosyl deprotection. A solution of LiOH monohydrate (468.0 mg, 11.2 mmol, 
8.0 eq.) in H2O (4 mL) was added and the mixture was stirred for 1.5 h, after which UPLC-MS 
analysis showed complete ester deprotection. The mixture was acidified to pH 5-6 by the addition 
of concentrated HCl. The volatiles were removed by rotary evaporation and the crude was 
purified by reversed phase flash column chromatography on the ISOLERA (RP-Silica, 340 g, 
H2O/MeCN + 0.1% TFA, UV (254/280 nm)). Product-containing fractions were combined and 
lyophilized to yield the desired product as white solid (810 mg, >100%). Co-elution of unknown 
side products. NMR and LC-MS analysis showed 18% epimerized product. 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.44 (d, J = 7.1 Hz, 1H), 8.38 – 8.28 (m, 2H), 7.81 (brs, 
3H), 7.59 – 7.51 (m, 4H), 7.49 – 7.41 (m, 4H), 7.37 (dt, J = 7.6, 1.5 Hz, 1H), 6.81 (d, J = 15.8 Hz, 
1H), 4.54 (td, J = 8.2, 5.2 Hz, 1H), 4.27 – 4.16 (m, 1H), 3.40 (tdd, J = 10.1, 8.8, 5.7 Hz, 2H), 3.28 
(q, J = 6.5 Hz, 2H), 2.74 (q, J = 6.3 Hz, 2H), 2.02 – 1.90 (m, 1H), 1.83 (dtd, J = 13.8, 7.9, 6.1 Hz, 
























13C NMR (101 MHz, DMSO-d6) δ/ppm: 173.94, 170.77, 169.58, 164.77, 140.82, 138.69, 136.50, 
134.82, 132.39, 129.84, 129.76, 129.49, 128.77, 127.87, 127.64, 127.36, 126.33, 122.24, 49.97, 
47.57, 47.45, 38.11, 36.74, 31.59, 16.89. 
HRMS (ESI): C25H30N7O5+ calcd: 508.2303, found: 508.2297. 
MC NP01-AA001 2-18 
 
In a 1 L flask 2-18e (764.0 mg, 1.5 mmol, 1.0 eq.) was dissolved in THF (700 mL) and DIPEA 
(787.0 µL, 4.5 mmol, 3.0 eq.) was added, followed by HATU (1.0 g, 2.7 mmol, 1.8 eq.). The 
mixture was stirred at RT for 2 h, after which UPLC-MS analysis showed complete conversion to 
the desired product. The mixture was concentrated by rotary evaporation and purified by 
reversed phase flash column chromatography on the ISOLERA (RP-Silica, 340 g, H2O:MeCN 
+0.1% TFA, UV 254/280 nm). Further purification was necessary due to co-eluted impurities. The 
impure material was purified by reversed phase preparative HPLC (Method A) followed by flash 
column chromatography on the ISOLERA (Silica, DCM:MeOH, UV). Product-containing fractions 
were combined and concentrated by rotary evaporation. The oily product was dissolved in 
MeCN/H2O and lyophilized to yield the desired product as a white solid (37.0 mg, 5%). Mixture of 
diastereomers with the ratio 87:13 (UPLC-MS analysis). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.47 (t, J = 5.4 Hz, 1H), 8.37 (d, J = 7.6 Hz, 1H), 7.74 – 
7.66 (m, 2H), 7.61 (dt, J = 7.4, 1.7 Hz, 1H), 7.54 – 7.52 (m, 2H), 7.51 – 7.48 (m, 2H), 7.48 – 7.45 
(m, 2H), 7.44 – 7.41 (m, 2H), 6.55 (d, J = 15.8 Hz, 1H), 4.22 (ddd, J = 13.8, 8.9, 6.7 Hz, 2H), 
3.51 – 3.39 (m, 2H), 3.31 – 3.25 (m, 1H), 3.12 – 3.07 (m, 2H), 2.90 – 2.82 (m, 1H), 1.93 – 1.86 
(m, 2H), 1.18 (d, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 172.30, 170.85, 169.91, 166.04, 140.50, 140.02, 138.27, 
137.81, 135.00, 129.49, 129.44, 129.30, 129.14, 129.05, 127.40, 127.12, 124.49, 123.14, 53.33, 
48.61, 47.59, 39.60, 38.62, 29.99, 17.61. 
HRMS (ESI): C25H27N7NaO4+ calcd: 512.2017, found: 512.2011. 
Nos-Sc-NP07-OEtOMe 2-19a* 
 
In a 100 mL flask 2-24 (1.5 g, 3.2 mmol, 1.0 eq.), 2-(methylcarboxy)pyridine-5-boronic acid 
pinacol ester (1.0 g, 3.8 mmol, 1.2 eq.), Pd(dppf)Cl2 (348.0 mg, 475.0 µmol, 15 mol%) and 
triethylamine (883.0 µL, 6.3 mmol, 2.0 eq.) were dissolved in methoxyethanol (40 mL) and the 
mixture was stirred at 100°C for 4 h, after which UPLC-MS analysis showed full conversion to the 
desired product as methoxyethylester. The solvent was removed in vacuo and the crude was 
taken up in EtOAc (100 mL). The organic layer was washed with diluted HCl (pH 1, 3 x 100 mL). 
The combined aqueous layers were extracted with EtOAc (3 x 100 mL) and the combined organic 
layers were washed with brine (100 mL), dried over Na2SO4 and concentrated by rotary 
evaporation. The crude was purified by reversed phase flash column chromatography on the 
ISOLERA (RP-Silica, 340 g, H2O/MeCN + 0.1% TFA, UV). The product-containing fractions were 
lyophilized to yield the desired product as dark brown waxy solid (884 mg, 53%). NMR analysis 
























In a 100 mL flask 2-19a* (842 mg, 1.6 mmol, 1.0 eq.) was dissolved in MeCN (10 mL) and a 
solution of LiOH monohydrate (334 mg, 8.0 mmol, 5.0 eq.) in H2O (5 mL) was added. The mixture 
was stirred at RT for 2 h, after which UPLC-MS analysis showed complete conversion to the 
desired product. Acidifying with concentrated HCl to pH 2 quenched the reaction. The volatiles 
were removed in vacuo and the aqueous residue was taken up in EtOAc (50 mL) and H2O 
(50 mL). The mixture was acidified to pH 1 with concentrated HCl. The layers were separated 
(addition of brine for good separation) and the aqueous layer was extracted with EtOAc (2 x 
50 mL). The combined organic layers were washed with half-saturated brine (2 x 50 mL) and 
brine (50 mL), dried over Na2SO4 and were concentrated by rotary evaporation. The crude was 
purified by reversed phase flash column chromatography (RP-Silica, 340 g, 0.1% TFA in 
H2O/MeCN). Product-containing fractions were combined and lyophilized to yield the desired 
product as white solid (366 mg, 49%). 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.65 (dd, J = 2.3, 0.8 Hz, 1H), 8.46 (t, J = 5.7 Hz, 1H), 8.15 
(t, J = 6.0 Hz, 1H), 8.03 (dd, J = 8.1, 0.8 Hz, 1H), 8.02 – 7.94 (m, 2H), 7.92 (dd, J = 8.0, 2.3 Hz, 
1H), 7.90 – 7.83 (m, 2H), 7.65 – 7.45 (m, 4H), 3.23 – 3.13 (m, 2H), 2.96 – 2.85 (m, 2H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 168.59, 165.94, 148.46, 147.68, 146.72, 139.05, 136.93, 
136.76, 135.18, 134.13, 132.76, 132.58, 130.18, 130.06, 129.46, 128.41, 128.12, 124.55, 124.18, 
41.77, 39.02. 
HRMS (ESI): C21H19N4O7S+ calcd: 471.0969, found: 471.0966. 
Nos-Sc-NP07-TFL(N3)-OMe 2-19b 
 
In a 50 mL flask 2-19a (315.0 mg, 670.0 µmol, 1.0 eq.), 2-5 (127.0 mg, 803.0 µmol, 1.2 eq.), 
HBTU (305.0 g, 803.0 µmol, 1.2 eq.) and DIPEA (350.0 µL, 2.0 mmol, 3.0 eq.) were dissolved in 
THF (5 mL) and DMF (1 mL) and the mixture was stirred at RT for 1 h, after which UPLC-MS 
analysis showed full conversion to the desired product. The volatiles were removed in vacuo and 
the residue was dissolved in EtOAc (50 mL) and H2O (50 mL). The mixture was acidified to pH 1 
by addition of concentrated HCl. The layers were separated and the aqueous phase was 
extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with H2O (50 mL), 
brine (50 mL), dried over MgSO4 and concentrated by rotary evaporation The crude material was 
purified by flash column chromatography on the ISOLERA (Silica, 120 g, DCM/MeOH, UV) to 
yield the desired product as a yellowish solid (397 mg, 97%).  
1H NMR (400 MHz, CDCl3) δ/ppm: 8.67 (d, J = 8.3 Hz, 1H), 8.65 (dd, J = 2.3, 0.9 Hz, 1H), 8.19 
(dd, J = 8.0, 0.8 Hz, 1H), 8.09 – 8.04 (m, 1H), 7.93 (dd, J = 8.0, 2.2 Hz, 1H), 7.87 – 7.79 (m, 1H), 
7.80 – 7.68 (m, 2H), 7.64 (dd, J = 7.6, 1.2 Hz, 1H), 7.54 (td, J = 7.6, 1.5 Hz, 1H), 7.47 (td, J = 7.5, 



















4.89 (td, J = 7.9, 5.0 Hz, 1H), 3.79 (s, 3H), 3.50 – 3.40 (m, 4H), 3.18 – 3.11 (m, 2H), 2.28 (dtd, J = 
14.1, 6.9, 5.0 Hz, 1H), 2.12 (ddt, J = 14.3, 7.9, 6.5 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 171.62, 169.34, 161.89, 148.13, 145.35, 140.99, 140.62, 
135.96, 134.43, 133.87, 133.12, 133.02, 131.11, 130.98, 130.59, 129.64, 128.70, 125.32, 124.15, 
52.85, 50.86, 47.89, 42.95, 39.92, 31.24. 
HRMS (ESI): C26H26N8NaO8S+ calcd: 633.1487, found: 633.1495. 
Nos-Sc-NP07-TFL(N3)-OH 2-19c 
 
In a 50 mL flask 2-19b (367 mg, 601.0 µmol, 1.0 eq.) was dissolved in MeCN (5 mL) and a 
solution of LiOH monohydrate (126 mg, 3.0 mmol, 5.0 eq.) in H2O (2.5 mL) was added. The 
mixture was stirred at RT for 1.5 h, after which UPLC-MS analysis showed full conversion to the 
desired product. Acidifying the mixture to pH 5-6 with concentrated HCl quenched the reaction 
and the volatiles were removed in vacuo. The residue was taken up in EtOAc (50 mL) and H2O 
(50 mL). The biphasic mixture was acidified to pH 1 with concentrated HCl and the layers were 
separated. The aqueous layer was extracted with EtOAc (2 x 50 mL) and the combined organic 
layers were washed with half-saturated brine (2 x 50 mL) and brine (50 mL), dried over MgSO4 
and concentrated by rotary evaporation to yield the desired product as a thick, waxy oil (400 mg, 
>100%). NMR showed some residual tetramethylurea from the HBTU coupling step. The material 
was used without further purification for the next synthetic step. 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 12.92 (s, 1H), 8.98 (d, J = 8.3 Hz, 1H), 8.62 (dd, J = 2.2, 
0.9 Hz, 1H), 8.47 (t, J = 5.7 Hz, 1H), 8.15 (t, J = 5.9 Hz, 1H), 8.02 (dd, J = 8.1, 0.8 Hz, 1H), 8.00 – 
7.96 (m, 2H), 7.93 (dd, J = 8.1, 2.2 Hz, 1H), 7.91 – 7.81 (m, 2H), 7.65 – 7.46 (m, 4H), 4.58 (dt, 
J = 8.2, 6.9 Hz, 1H), 3.48 (dt, J = 12.4, 6.2 Hz, 1H), 3.39 (dt, J = 12.5, 7.2 Hz, 1H), 3.19 (q, J = 
6.4 Hz, 2H), 2.94 (q, J = 6.5 Hz, 2H), 2.15 (q, J = 6.8 Hz, 2H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 172.76, 168.56, 163.86, 147.94, 147.66, 147.57, 138.80, 
137.16, 136.72, 135.31, 134.10, 132.71, 132.57, 130.18, 130.01, 129.42, 128.29, 128.10, 124.49, 
121.46, 49.77, 47.76, 41.81, 38.98, 30.03. 
HRMS (ESI): C25H24N8NaO8S+ calcd: 619.1330, found: 619.1332. 
Nos-Sc-NP07-TFL(N3)-AA026-OMe 2-19d 
 
In a 50 mL flask 2-19c (345.0 mg, 578.0 µmol, 1.0 eq.) was dissolved in THF (5 mL) and  
H-D-Ser-OMe hydrochloride (108.0 mg, 694.0 µmol, 1.2 eq.) was added, followed by DIPEA 
(302.0 µL, 1.7 mmol, 3.0 eq.) and HATU (263.0 mg, 692.0 µmol, 1.2 eq.). The mixture was stirred 
at RT for 1 h, after which UPLC-MS analysis showed full conversion to the desired product. The 
volatiles were removed in vacuo and the residue was taken up in EtOAc (50 mL) and H2O 
(50 mL). The mixture was acidified with concentrated HCl to pH 1. The layers were separated 
and the aqueous phase was extracted with EtOAc (2 x 100 mL) and the combined organic layers 
were washed with diluted HCl solution (1%, 2 x 50 mL), brine (50 mL), dried over Na2SO4 and 


























the ISOLERA (Silica, 120 g, DCM/MeOH, UV) to yield the desired product as a waxy solid 
(403.0 mg, 94%). 
1H NMR (500 MHz, CD3CN) δ/ppm: 8.62 (dd, J = 2.3, 0.8 Hz, 1H), 8.57 (d, J = 8.2 Hz, 1H), 8.08 
(dd, J = 8.0, 0.8 Hz, 1H), 8.05 – 8.00 (m, 1H), 7.92 (dd, J = 8.1, 2.2 Hz, 1H), 7.89 – 7.84 (m, 1H), 
7.81 (dd, J = 5.9, 3.4 Hz, 2H), 7.61 – 7.55 (m, 2H), 7.53 – 7.49 (m, 1H), 7.48 (ddd, J = 7.5, 1.4, 
0.6 Hz, 1H), 7.25 (d, J = 7.8 Hz, 1H), 6.89 (t, J = 6.0 Hz, 1H), 6.12 (s, 1H), 4.74 (td, J = 8.3, 
5.1 Hz, 1H), 4.48 (dt, J = 8.1, 4.1 Hz, 1H), 3.89 – 3.82 (m, 1H), 3.76 (ddd, J = 11.2, 5.5, 3.8 Hz, 
1H), 3.66 (s, 3H), 3.46 (ddd, J = 7.5, 6.2, 3.1 Hz, 2H), 3.29 (q, J = 6.0 Hz, 2H), 3.22 (t, J = 6.0 Hz, 
1H), 3.08 (q, J = 5.7 Hz, 2H), 2.19 (ddd, J = 14.5, 7.3, 2.2 Hz, 1H), 2.05 (ddt, J = 14.5, 8.4, 
6.3 Hz, 1H). 
13C NMR (126 MHz, CD3CN) δ/ppm: 171.88, 171.56, 170.37, 164.98, 148.92, 140.13, 138.27, 
137.39, 136.61, 135.13, 133.82, 133.67, 131.38, 131.35, 131.29, 129.55, 129.52, 128.99, 125.99, 
122.42, 62.49, 55.69, 52.79, 51.85, 48.86, 43.76, 40.06, 32.30. 
HRMS (ESI): C29H31N9NaO10S+ calcd: 720.1807, found: 720.1813. 
NH2-Sc-NP07-TFL(N3)-AA026-OH 2-19e 
 
Under an inert (N2) atmosphere 2-19d (374.0 mg, 536.0 µmol, 1.0 eq.) was dissolved in MeCN 
(5 mL) and DIPEA (934.0 µL, 5.4 mmol, 10.0 eq.) was added, followed by thiophenol (273.0 µL, 
2.7 mmol, 5.0 eq.). The yellow solution was stirred at RT for 2 h, after which UPLC-MS analysis 
showed complete Nosyl deprotection. A solution of LiOH monohydrate (170.0 mg, 4.1 mmol, 
8.0 eq.) in H2O (1.5 mL) was added and the mixture was stirred for 1.5 h, after which UPLC-MS 
analysis showed complete ester deprotection. The mixture was acidified to pH 5-6 by the addition 
of concentrated HCl. The volatiles were removed by rotary evaporation and the crude was 
purified by reversed phase flash column chromatography on the ISOLERA (RP-Silica, 120 g, 
H2O/MeCN + 0.1% TFA, UV (254/280 nm)). Product-containing fractions were combined and 
lyophilized to yield the desired product as a white solid (292 mg, >100%). Co-elution of unknown 
side products. NMR and LC-MS analysis showed 19% epimerized product. 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.85 (d, J = 8.6 Hz, 1H), 8.65 (dd, J = 2.3, 0.9 Hz, 1H), 
8.56 (t, J = 5.6 Hz, 1H), 8.47 (d, J = 7.9 Hz, 1H), 8.08 (dd, J = 8.1, 0.8 Hz, 1H), 7.97 (dd, J = 8.1, 
2.2 Hz, 1H), 7.80 (brs, 3H), 7.67 (dd, J = 7.5, 1.5 Hz, 1H), 7.62 (td, J = 7.5, 1.5 Hz, 1H), 7.60 – 
7.49 (m, 2H), 4.77 (td, J = 8.4, 5.1 Hz, 1H), 4.31 (ddd, J = 7.8, 5.3, 4.1 Hz, 1H), 3.72 (dd, J = 
10.8, 5.4 Hz, 1H), 3.66 (dd, J = 10.9, 4.2 Hz, 1H), 3.49 – 3.26 (m, 4H), 2.92 – 2.76 (m, 2H), 2.06 
(dddd, J = 19.8, 13.7, 9.2, 5.5 Hz, 2H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 171.61, 170.66, 168.93, 163.24, 147.86, 147.68, 138.89, 
137.28, 136.28, 135.45, 132.35, 130.31, 130.26, 128.24, 121.48, 61.17, 54.78, 50.37, 47.60, 
38.22, 36.88, 31.99. 



















In a 500 mL flask 2-19e (261.0 mg, 524.0 µmol, 1.0 eq.) was dissolved in THF (260 mL) and 
DIPEA (319.2 µL, 1.8 mmol, 3.5 eq.) was added, followed by HATU (398 mg, 1.1 mmol, 2.0 eq.). 
The mixture was stirred at RT for 1.5 h, after which UPLC-MS analysis showed complete 
conversion to the desired product. The mixture was concentrated by rotary evaporation and 
purified by reversed phase flash column chromatography on the ISOLERA (RP-Silica, 340 g, 
H2O:MeCN +0.1% TFA, UV 254/280 nm) to yield the desired product as a white solid (79.0 mg, 
31%). 18 mg of the product were purified again by preparative RP-HPLC (Method A) for final 
analytics and protein binding assays. Mixture of diastereomers with the ratio 43:57 (UPLC-MS 
analysis). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 9.30 (d, J = 9.6 Hz, 1H), 8.56 (d, J = 2.6 Hz, 1H), 8.17 – 
8.14 (m, 1H), 8.09 (dd, J = 8.0, 2.2 Hz, 1H), 7.67 (t, J = 4.9 Hz, 1H), 7.66 – 7.63 (m, 1H), 7.62 – 
7.59 (m, 1H), 7.53 – 7.51 (m, 2H), 7.24 (d, J = 8.9 Hz, 1H), 6.92 (t, J = 5.3 Hz, 1H), 4.62 (td, J = 
9.6, 5.1 Hz, 1H), 4.19 – 4.15 (m, 1H), 3.58 – 3.54 (m, 1H), 3.53 – 3.46 (m, 3H), 3.21 – 3.13 (m, 
2H), 2.91 – 2.81 (m, 2H), 2.23 – 2.15 (m, 1H), 2.10 – 2.02 (m, 1H). 
13C NMR (500 MHz, 2D NMR, DMSO-d6) δ/ppm: 170.6, 17.40, 169.24, 165.10, 147.99, 147.43, 
137.54, 137.24, 134.38, 134.20, 129.64, 128.90, 128.30, 127.87, 121.79, 60.80, 54.84, 50.42, 
47.73, 40.32, 39.07, 28.51.  
HRMS (ESI): C22H24N8NaO5+ calcd: 503.1762, found: 503.1764. 
MC NP07-AA026-TA256 2-19 
 
In a 2.0 mL Eppendorf tube 2-19f (45.0 mg, 93.7 µmol, 1.0 eq.) and TA256 (28.1 mg, 93.7 µmol, 
1.0 eq.) were dissolved in DMSO (990 µL) and a solution of sodium ascorbate (11.1 mg, 
56.2 µmol, 0.6 eq.) in H2O (187 µL) was added. The solution was degassed by bubbling N2 
through the solution for 1 min. A solution of copper(II) sulfate pentahydrate (7.0 mg, 28.1 µmol, 
0.3 eq.) in H2O (140 µL) was added and the mixture was degassed again for 1 min. The reaction 
was agitated at RT for 2 h, after which UPLC-MS analysis showed full conversion to the desired 
product. The solution was directly purified by preparative RP-HPLC (Method A) and the product-
containing fractions were lyophilized to yield the desired product as a white solid (60 mg, 82%). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 9.40 (d, J = 9.5 Hz, 1H), 8.73 (s, 1H), 8.57 (d, J = 8.5 Hz, 
1H), 8.47 (t, J = 5.5 Hz, 1H), 8.17 (d, J = 8.0 Hz, 1H), 8.09 (dd, J = 8.0, 2.2 Hz, 1H), 7.94 – 7.88 
(m, 1H), 7.70 – 7.65 (m, 1H), 7.64 (s, 1H), 7.63 – 7.54 (m, 1H), 7.53 (d, J = 4.2 Hz, 1H), 7.51 – 
7.45 (m, 1H), 7.39 – 7.31 (m, 2H), 7.31 – 7.28 (m, 1H), 7.28 – 7.21 (m, 1H), 6.92 (t, J = 5.4 Hz, 
1H), 6.13 (t, J = 6.0 Hz, 1H), 4.58 – 4.48 (m, 2H), 4.21 – 4.10 (m, 1H), 3.59 – 3.53 (m, 2H), 3.46 
(dd, J = 10.8, 4.9 Hz, 1H), 3.42 – 3.29 (m, 2H), 3.28 – 3.05 (m, 4H), 2.91 – 2.81 (m, 1H), 2.81 – 
7.23 (m, 1H), 2.66 – 2.54 (m, 1H), 2.49 – 2.37 (m, 1H), 2.34 – 2.15 (m, 1H), 2.01 (dt, J = 12.6, 
4.2 Hz, 1H), 1.73 – 1.67 (m, 1H), 1.67 – 1.61 (m, 1H), 1.58 – 1.49 (m, 1H), 1.40 – 1.29 (m, 1H), 





























13C NMR (500 MHz, 2D NMR, DMSO-d6) δ/ppm: 172.64, 170.34, 169.19, 165.29, 154.92, 
150.59, 148.03, 147.49, 146.19, 140.86, 137.55, 137.27, 136.26, 134.28, 131.03, 129.65, 129.03, 
128.91, 128.32, 121.82, 121.43, 117.91, 116.83, 113.99, 82.89, 67.07, 60.77, 54.87, 50.39, 
46.56, 40.37, 39.40, 39.09, 37.57, 33.05, 30.66, 29.84, 24.86, 24.22, 18.49. 
HRMS (ESI): C40H48N10NaO7+ calcd: 803.3600, found: 803.3585. 
Nos-Sc-NP14-OEt 2-20a* 
 
Under an inert atmosphere 2-24 (3.0 g, 6.3 mmol, 1.0 eq.) and Pd (π-cinnamyl) chloride dimer 
(327.0 mg, 631.0 µmol, 10 mol%) were dissolved in THF (60 mL) and the solution was cooled to 
0°C. 4-Ethoxy-4-oxobutylzinc bromide solution (0.5 M in THF, 18.9 mL, 9.5 mmol, 1.5 eq.) was 
slowly added and the solution was stirred at 0°C for 15 min. The cooling bath was removed and 
the mixture was stirred at RT for 45 min, after which UPLC-MS analysis showed full consumption 
of the starting material. The reaction was stopped by the addition of H2O (5 mL). The mixture was 
filtered and the volatiles were removed in vacuo. The residue was dissolved in EtOAc (150 mL) 
and washed with half-saturated NH4Cl (100 mL) and H2O (2 x 100 mL). The combined aqueous 
layers were extracted with EtOAc (2 x 100 mL) and the combined organic layers were treated 
with brine (100 mL), dried over Na2SO4 and concentrated by rotary evaporation. The crude was 
purified by flash column chromatography on the ISOLERA (Silica, 340g, cycloxexane:EtOAc, UV) 
to yield the desired product as a thick, slightly yellow oil (2.4 g, 82%). 
1H NMR (400 MHz, CD3CN) δ/ppm: 8.09 – 8.03 (m, 1H), 7.88 – 7.83 (m, 1H), 7.82 – 7.76 (m, 
2H), 7.35 (td, J = 7.5, 1.5 Hz, 1H), 7.30 (dd, J = 7.6, 1.4 Hz, 1H), 7.25 (ddd, J = 7.6, 1.3, 0.6 Hz, 
1H), 7.21 (td, J = 7.4, 1.4 Hz, 1H), 6.91 (s, 1H), 6.31 (t, J = 5.7 Hz, 1H), 4.04 (q, J = 7.1 Hz, 2H), 
3.44 (q, J = 5.9 Hz, 2H), 3.27 - 3.21 (m, 2H), 2.76 – 2.68 (m, 2H), 2.24 (t, J = 7.4 Hz, 2H), 1.88 – 
1.78 (m, 2H), 1.19 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CD3CN) δ/ppm: 174.10, 171.32, 140.76, 137.42, 135.06, 133.82, 131.40, 
131.01, 130.71, 129.37, 127.99, 127.94, 126.87, 125.95, 60.89, 44.21, 40.16, 34.38, 32.98, 
27.52, 14.54. 
HRMS (ESI): C21H25N3NaO7S+ calcd: 486.1305, found: 486.1309. 
Nos-Sc-NP14-OH 2-20a 
 
In a 100 mL flask 2-20a* (2.3 g, 4.9 mmol, 1.0 eq.) was dissolved in MeCN (30 mL) and a 
solution of LiOH monohydrate (1.0 g, 24.6 mmol, 5.0 eq.) in H2O (15 mL) was added. The mixture 
was stirred at RT for 2.5 h, after which UPLC-MS analysis showed complete conversion to the 
desired product. Acidifying with concentrated HCl to pH 5-6 quenched the reaction. The volatiles 
were removed and the aqueous residue was taken up in EtOAc (150 mL) and H2O (100 mL). The 
mixture was acidified to pH 1 with concentrated HCl. The layers were separated (addition of brine 
for good separation) and the aqueous layer was extracted with EtOAc (2 x 100 mL). The 
combined organic layers were washed with half-saturated brine (2 x 100 mL) and brine (100 ml), 
dried over Na2SO4 and concentrated by rotary evaporation to yield the desired product as yellow, 
waxy solid (2.1 g, quant. 73% HPLC purity). 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 12.00 (s, 1H), 8.30 (t, J = 5.7 Hz, 1H), 8.17 (t, J = 5.9 Hz, 












7.17 (m, 2H), 3.34 – 3.28 (m, 2H), 3.11 – 3.05 (m, 2H), 2.74 – 2.58 (m, 2H), 2.17 (t, J = 7.5 Hz, 
2H), 1.82 – 1.65 (m, 2H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 174.24, 169.35, 147.71, 139.37, 136.80, 134.07, 132.72, 
132.68, 129.48, 129.35, 128.22, 127.22, 125.66, 124.49, 42.09, 38.97, 33.35, 31.85, 26.32. 
HRMS (ESI): C19H22N3O7S+ calcd: 436.1173, found: 436.1166. 
Nos-Sc-NP14-TFL(N3)-OMe 2-20b 
 
In a 100 mL flask 2-20a (2.1 g, 4.9 mmol, 1.0 eq.), 2-5 (925.0 mg, 5.9 mmol, 1.2 eq.), HBTU 
(2.2 g, 5.9 mmol, 1.2 eq.) and DIPEA (2.5 mL, 14.6 mmol, 3.0 eq.) were dissolved in THF (42 mL) 
and the mixture was stirred at RT for 1.5 h, after which UPLC-MS analysis showed full conversion 
to the desired product. The volatiles were removed in vacuo and the residue was dissolved in 
EtOAc (100 mL) and H2O (100 mL). The mixture was acidified to pH 1 by addition of 
concentrated HCl. The layers were separated and the aqueous phase was extracted with EtOAc 
(2 x 100 mL). The combined organic layers were washed with H2O (100 mL), brine (100 mL), 
dried over MgSO4 and concentrated by rotary evaporation. The crude material was purified by 
flash column chromatography on the ISOLERA (Silica, 340 g, DCM/MeOH, UV) to yield the 
desired product as a yellow oil (2.7 g, 96%). 
1H NMR (400 MHz, CDCl3) δ/ppm: 8.13 – 8.07 (m, 1H), 7.81 – 7.76 (m, 1H), 7.72 – 7.69 (m, 2H), 
7.33 – 7.27 (m, 2H), 7.21 – 7.13 (m, 2H), 6.84 (t, J = 5.9 Hz, 1H), 6.74 (d, J = 7.8 Hz, 1H), 6.60 (t, 
J = 5.8 Hz, 1H), 4.59 (td, J = 7.7, 5.1 Hz, 1H), 3.71 (s, 3H), 3.62 – 3.55 (m, 2H), 3.37 – 3.30 (m, 
4H), 2.83 – 2.75 (m, 2H), 2.29 (t, J = 7.0 Hz, 2H), 2.08 (dtd, J = 14.0, 6.9, 5.1 Hz, 1H), 1.98 – 
1.89 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 173.52, 172.40, 171.16, 148.11, 139.75, 135.81, 133.46, 
132.81, 130.98, 130.38, 130.28, 127.30, 127.17, 126.24, 125.21, 52.67, 50.15, 47.90, 43.44, 
39.80, 35.67, 32.65, 31.25, 27.06. 
HRMS (ESI): C24H29N7NaO8S+ calcd: 598.1691, found: 598.1701. 
Nos-Sc-NP14-TFL(N3)-OH 2-20c 
 
In a 100 mL flask 2-20b (2.6 g, 4.5 mmol, 1.0 eq.) was dissolved in MeCN (25 mL) and a solution 
of LiOH monohydrate (943.0 mg, 22.5 mmol, 5.0 eq.) in H2O (12.5 mL) was added. The mixture 
was stirred at RT for 1.5 h, after which UPLC-MS analysis showed full conversion to the desired 
product. Acidifying the mixture to pH 5-6 with concentrated HCl quenched the reaction and the 
volatiles were removed in vacuo. The residue was taken up in EtOAc (100 mL) and H2O 
(100 mL). The biphasic mixture was acidified to pH 1 with concentrated HCl and the layers were 
separated. The aqueous layer was extracted with EtOAc (2 x 100 mL) and the combined organic 
layers were washed with half-saturated brine (2 x 100 mL) and brine (100 mL), dried over MgSO4 
and concentrated by rotary evaporation to yield the desired product as a yellowish solid (2.5 g, 
98%). NMR showed some residual tetramethylurea from the HBTU coupling step. The material 
















1H NMR (400 MHz, DMSO-d6) δ/ppm: 12.65 (s, 1H), 8.29 (t, J = 5.7 Hz, 1H), 8.19 (t, J = 5.8 Hz, 
1H), 8.11 (d, J = 7.9 Hz, 1H), 8.06 – 8.01 (m, 1H), 8.01 – 7.96 (m, 1H), 7.90 – 7.84 (m, 2H), 7.38 
– 7.28 (m, 2H), 7.28 – 7.17 (m, 2H), 4.27 (ddd, J = 9.6, 7.9, 4.6 Hz, 1H), 3.46 – 3.34 (m, 2H), 3.34 
– 3.27 (m, 2H), 3.12 – 3.05 (m, 2H), 2.65 (dd, J = 8.8, 6.7 Hz, 2H), 2.11 (t, J = 7.5 Hz, 2H), 1.98 – 
1.88 (m, 1H), 1.88 – 1.79 (m, 1H), 1.79 – 1.70 (m, 2H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 173.21, 172.21, 169.35, 147.70, 139.64, 136.70, 134.05, 
132.71, 132.70, 129.72, 129.46, 129.33, 127.23, 125.59, 124.48, 49.27, 47.57, 42.07, 39.00, 
34.89, 32.06, 30.14, 27.12. 
HRMS (ESI): C23H27N7NaO8S+ calcd: 584.1534, found: 584.1546. 
Nos-Sc-NP14-TFL(N3)-AA020-OMe 2-20d 
 
In a 50 mL flask 2-20c (1.3 g, 2.3 mmol, 1.0 eq.) was dissolved in THF (20 mL) and H-Tyr-OMe 
(542.0 mg, 2.8 mmol, 1.2 eq.) was added, followed by DIPEA (1.2 mL, 6.9 mmol, 3.0 eq.) and 
HATU (1.1 g, 2.8 mmol, 1.2 eq.). The mixture was stirred at RT for 1 h, after which UPLC-MS 
analysis showed full conversion to the desired product. The volatiles were removed in vacuo and 
the residue was taken up in EtOAc (100 mL) and H2O (100 mL). The mixture was acidified with 
concentrated HCl to pH 1. The layers were separated and the aqueous phase was extracted with 
EtOAc (2 x 100 mL) and the combined organic layers were washed with diluted HCl solution  
(1%, 2 x 100 mL), brine (100 mL), dried over Na2SO4 and concentrated by rotary evaporation. 
The crude was purified by flash column chromatography on the ISOLERA (Silica, 120 g, 
DCM/MeOH, UV) to yield the desired product as a slightly yellow solid (1.1 g, 66%). 
1H NMR (400 MHz, CD3CN) δ/ppm: 8.11 – 8.02 (m, 1H), 7.88 – 7.81 (m, 1H), 7.81 – 7.73 (m, 
2H), 7.39 – 7.31 (m, 2H), 7.28 – 7.20 (m, 2H), 7.04 (t, J = 6.0 Hz, 1H), 7.00 – 6.89 (m, 3H), 6.76 
(d, J = 8.0 Hz, 1H), 6.72 – 6.64 (m, 2H), 6.51 (t, J = 5.8 Hz, 1H), 4.56 (td, J = 7.7, 5.3 Hz, 1H), 
4.36 (td, J = 8.4, 5.5 Hz, 1H), 3.64 (s, 3H), 3.53 – 3.41 (m, 2H), 3.38 – 3.27 (m, 2H), 3.27 – 3.21 
(m, 2H), 3.00 (dd, J = 14.0, 5.3 Hz, 1H), 2.86 (dd, J = 14.0, 7.7 Hz, 1H), 2.78 – 2.65 (m, 2H), 2.17 
(dt, J = 7.2, 3.5 Hz, 2H), 2.01 – 1.91 (m, 1H), 1.86 – 1.69 (m, 3H). 
13C NMR (101 MHz, CD3CN) δ/ppm: 173.98, 172.67, 171.86, 171.76, 156.84, 148.96, 140.91, 
137.25, 137.16, 135.04, 133.83, 131.34, 131.32, 131.11, 130.87, 128.42, 128.08, 126.89, 125.91, 
116.07, 54.61, 52.74, 51.42, 48.78, 43.97, 40.36, 37.07, 36.15, 33.30, 31.38, 28.05. 
HRMS (ESI): C33H38N8NaO10S+ calcd: 761.2324, found: 761.2320. 
NH2-Sc-NP14-TFL(N3)-AA020-OH 2-20e 
 
Under an inert (N2) atmosphere 2-20d (1.1 g, 1.5 mmol, 1.0 eq.) was dissolved in MeCN (15 mL) 
and DIPEA (2.6 mL, 14.8 mmol, 10.0 eq.) was added, followed by thiophenol (757.0 µL, 
7.4 mmol, 5.0 eq.). The yellow solution was stirred at RT for 2 h, after which UPLC-MS analysis 
showed complete Nosyl deprotection. A solution of LiOH monohydrate (489.0 mg, 11.7 mmol, 


























analysis showed complete ester deprotection. The mixture was acidified to pH 5-6 by the addition 
of concentrated HCl. The volatiles were removed by rotary evaporation and the crude was 
purified by reversed phase flash column chromatography on the ISOLERA (RP-Silica, 340 g, 
H2O/MeCN + 0.1% TFA, UV (200/215 nm)). Product-containing fractions were combined and 
lyophilized to yield the desired product as white solid (1.0 g, >100%). Co-elution of unknown side 
products. NMR and LC-MS analysis showed 16% epimerized product. 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.39 (t, J = 5.6 Hz, 1H), 8.07 (d, J = 7.7 Hz, 1H), 7.99 (d, 
J = 8.2 Hz, 1H), 7.90 (brs, 3H), 7.43 (dd, J = 7.9, 1.5 Hz, 1H), 7.37 (td, J = 7.5, 1.5 Hz, 1H), 7.25 
(dtd, J = 7.5, 3.8, 1.3 Hz, 2H), 7.05 – 6.93 (m, 2H), 6.69 – 6.57 (m, 2H), 4.34 (dtd, J = 16.0, 8.4, 
5.2 Hz, 2H), 3.46 (q, J = 6.2 Hz, 2H), 3.37 – 3.18 (m, 2H), 2.98 (q, J = 6.0 Hz, 2H), 2.92 (dd, J = 
14.0, 5.1 Hz, 1H), 2.79 (dd, J = 13.9, 8.5 Hz, 1H), 2.68 (t, J = 7.8 Hz, 2H), 2.20 – 2.02 (m, 2H), 
1.88 (dtd, J = 13.1, 7.6, 4.7 Hz, 1H), 1.81 – 1.66 (m, 3H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 172.83, 172.03, 171.09, 169.77, 155.97, 139.86, 136.22, 
130.04, 129.87, 129.61, 127.46, 127.33, 125.62, 114.98, 53.80, 49.79, 47.55, 38.56, 36.94, 
35.75, 34.96, 32.20, 31.14, 27.12. 
HRMS (ESI): C26H34N7O6+ calcd: 540.2565, found: 540.2560. 
MC NP14-AA020 2-20f 
 
In a 1 L flask 2-20e (967.0 mg, 1.8 mmol, 1.0 eq.) was dissolved in THF (800 mL) and DIPEA 
(1.1 mL, 6.3 mmol, 3.5 eq.) was added, followed by HATU (1.4 g, 3.6 mmol, 2.0 eq.). The mixture 
was stirred at RT for 1.5 h, after which UPLC-MS analysis showed complete conversion to the 
desired product. The mixture was concentrated by rotary evaporation and purified by reversed 
phase flash column chromatography on the ISOLERA (RP-Silica, 340 g, H2O:MeCN +0.1% TFA, 
UV 200/215 nm) to yield the desired product as a white solid (655.0 mg, 70%). 38 mg of the 
product were purified again by preparative RP-HPLC (Method A) for final analytics and protein 
binding assays. Mixture of diastereomers with the ratio 43:57 (UPLC-MS analysis). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.26 (d, J = 4.4 Hz, 1H), 7.99 (t, J = 5.6 Hz, 1H), 7.49 – 
7.43 (m, 2H), 7.34 (td, J = 7.4, 1.7 Hz, 1H), 7.28 (dd, J = 7.5, 1.6 Hz, 1H), 7.25 (td, J = 7.3, 
1.2 Hz, 2H), 6.96 – 6.92 (m, 2H), 6.64 – 6.61 (m, 2H), 4.32 – 4.29 (m, 1H), 3.78 (ddd, J = 8.1, 6.1, 
4.3 Hz, 1H), 3.44 (ddt, J = 13.4, 5.4, 3.3 Hz, 1H), 3.37 – 3.33 (m, 2H), 3.18 – 3.07 (m, 3H), 3.02 – 
2.95 (m, 1H), 2.85 (ddd, J = 13.9, 8.6, 5.5 Hz, 1H), 2.73 (dd, J = 14.4, 10.4 Hz, 1H), 2.64 (dt, J = 
13.8, 8.1 Hz, 1H), 2.17 (t, J = 7.0 Hz, 2H), 1.90 – 1.82 (m, 1H), 1.74 – 1.63 (m, 2H), 1.64 – 1.56 
(m, 1H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 174.56, 171.21, 171.01, 169.89, 155.79, 138.69, 137.68, 
129.75, 129.68, 129.13, 128.19, 127.27, 125.84, 114.94, 53.93, 53.14, 47.08, 39.24, 38.82, 
35.31, 33.29, 31.82, 29.75, 24.78. 














MC NP14-AA020-TA607 2-20 
 
In a 10 mL flask 2-20f (150.0 mg, 288.0 µmol, 1.0 eq.) and TA607 (32.0 mg, 288.0 µmol, 1.0 eq.) 
were dissolved in DMSO (3 mL) and a solution of sodium ascorbate (34.2 mg, 173.0 µmol, 
0.6 eq.) in H2O (575 µL) was added. The solution was degassed by bubbling N2 through the 
solution for 1 min. A solution of copper(II) sulfate pentahydrate (21.5 mg, 86.3 µmol, 0.3 eq.) in 
H2O (431 µL) was added and the mixture was degassed again for 1 min. The reaction was stirred 
at RT for 2 h, after which UPLC-MS analysis showed full conversion to the desired product. The 
solution was directly purified by preparative RP-HPLC (Method A) and the product-containing 
fractions were lyophilized to yield the desired product as a white solid (90 mg, 50%). Mixture of 
diastereomers in the ratio 27:23:50 (UPLC-MS). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.37 (d, J = 4.6 Hz, 1H), 8.00 (t, J = 5.6 Hz, 1H), 7.93 (t, 
J = 5.7 Hz, 1H), 7.74 (s, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.47 (t, J = 5.6 Hz, 1H), 7.34 (td, J = 7.4, 
1.8 Hz, 1H), 7.26 (dtd, J = 18.1, 7.5, 1.5 Hz, 3H), 6.97 – 6.92 (m, 2H), 6.64 – 6.60 (m, 2H), 4.30 
(ddd, J = 10.2, 8.4, 4.5 Hz, 1H), 4.25 – 4.19 (m, 1H), 4.15 – 4.11 (m, 1H), 3.67 (ddd, J = 8.2, 6.2, 
4.5 Hz, 1H), 3.44 (dtd, J = 13.5, 5.6, 5.2, 2.7 Hz, 1H), 3.38 – 3.33 (m, 2H), 3.30 – 3.25 (m, 2H), 
3.11 (dd, J = 14.4, 4.4 Hz, 1H), 3.04 – 2.96 (m, 1H), 2.84 (ddd, J = 14.1, 8.7, 5.5 Hz, 1H), 2.78 – 
2.72 (m, 3H), 2.65 (dt, J = 13.8, 7.8 Hz, 1H), 2.19 (t, J = 6.9 Hz, 2H), 2.04 – 1.94 (m, 2H), 1.86 
(ddd, J = 13.7, 8.5, 7.1 Hz, 1H), 1.79 (s, 3H), 1.74 – 1.65 (m, 1H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 174.60, 171.15, 170.99, 169.88, 169.25, 155.73, 144.34, 
138.71, 137.67, 129.72, 129.46, 129.14, 128.22, 127.26, 125.83, 122.43, 115.01, 54.07, 52.98, 
45.97, 39.06, 38.78, 38.42, 35.26, 33.35, 31.83, 31.08, 25.58, 24.90, 22.64. 
HRMS (ESI): C32H40N8NaO6+ calcd: 655.2963, found: 655.2964. 
Nos-Sc-NP12-OMe 2-21a* 
 
Under an inert atmosphere 2-24 (3.0 g, 6.3 mmol, 1.0 eq.) and Pd (π-cinnamyl) chloride dimer 
(327.0 mg, 631.0 µmol, 10 mol%) were dissolved in THF (60 mL) and the solution was cooled to 
0°C. A solution of (S)-3-methoxy-2-methyl-3-oxopropylzinc bromide (0.5 M in THF, 18.9 mL, 
9.5 mmol, 1.5 eq.) was slowly added and the solution was stirred at 0°C for 15 min. The cooling 
bath was removed and the mixture was stirred at RT for 45 min, after which UPLC-MS analysis 
showed full consumption of the starting material. The reaction was stopped by the addition of 
H2O (5 mL) and the mixture was filtered over G4. The volatiles were removed in vacuo and the 
residue was dissolved in EtOAc (150 mL). The mixture was washed with half-saturated NH4Cl 
(100 mL) and H2O (2 x 100 mL). The combined aqueous layers were extracted with EtOAc (2 x 
100 mL) and the combined organic layers were treated with brine (100 mL), dried over Na2SO4 
and concentrated by rotary evaporation. The crude was purified by flash column chromatography 
on the ISOLERA (Silica, 340 g, cyclohexane:EtOAc, UV). The product-containing fractions were 
combined and concentrated to yield the desired product as a thick, slightly red oil (2.3 g, 80%). 
1H NMR (400 MHz, CD3CN) δ/ppm: 8.11 – 8.02 (m, 1H), 7.88 – 7.83 (m, 1H), 7.83 – 7.76 (m, 






















3.48 – 3.38 (m, 2H), 3.25 (dt, J = 5.7, 5.9 Hz, 2H), 3.12 – 3.03 (m, 1H), 2.85 – 2.74 (m, 2H), 1.07 
(d, J = 6.6 Hz, 3H). 
13C NMR (101 MHz, CD3CN) δ/ppm: 177.33, 171.17, 148.94, 138.72, 137.49, 135.06, 133.82, 
133.81, 131.55, 131.40, 130.65, 128.20, 127.28, 125.96, 52.04, 44.12, 41.99, 40.24, 37.43, 
17.53. 
HRMS (ESI): C20H23N3NaO7S+ calcd: 472.1149, found: 472.1152. 
Nos-Sc-NP12-OH 2-21a 
 
In a 100 mL flask 2-21a* (2.2 g, 4.9 mmol, 1.0 eq.) was dissolved in MeCN (30 mL) and a 
solution of LiOH monohydrate (1.0 g, 24.7 mmol, 5.0 eq.) in H2O (15 mL) was added. The mixture 
was stirred at RT for 2.5 h, after which UPLC-MS analysis showed complete conversion to the 
desired product. Acidifying with concentrated HCl to pH 5-6 quenched the reaction. The volatiles 
were removed in vacuo and the aqueous residue was taken up in EtOAc (150 mL) and H2O 
(100 mL). The mixture was acidified to pH 1 with concentrated HCl. The layers were separated 
(addition of brine for good separation) and the aqueous layer was extracted with EtOAc (2 x 
100 mL). The combined organic layers were washed with half-saturated brine (2 x 100 mL) and 
brine (100 mL), dried over Na2SO4 and concentrated by rotary evaporation. The desired product 
was obtained as an off-white solid (2.2 g, quant. 93% HPLC purity). 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 12.06 (s, 1H), 8.34 (t, J = 5.7 Hz, 1H), 8.18 (t, J = 5.9 Hz, 
1H), 8.06 – 8.00 (m, 1H), 8.00 – 7.95 (m, 1H), 7.91 – 7.83 (m, 2H), 7.37 – 7.31 (m, 2H), 7.28 – 
7.19 (m, 2H), 3.35 – 3.26 (m, 2H), 3.12 – 3.05 (m, 2H), 3.02 (dd, J = 13.3, 6.9 Hz, 1H), 2.72 (dd, 
J = 13.3, 7.6 Hz, 1H), 2.67 – 2.57 (m, 1H), 0.97 (d, J = 6.9 Hz, 3H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm 177.00, 169.29, 147.70, 137.53, 136.89, 134.08, 132.72, 
132.67, 130.29, 129.48, 129.25, 127.38, 125.99, 124.51, 42.04, 40.28, 39.00, 36.05, 16.90. 
HRMS (ESI): C19H22N3O7S+ calcd: 436.1173, found: 436.1167. 
Nos-Sc-NP12-TFL(N3)-OMe 2-21b 
 
In a 100 mL flask 2-21a (2.2 g, 4.9 mmol, 1.0 eq.), 2-5 (937.0 mg, 5.9 mmol, 1.2 eq.), HBTU 
(2.2 g, 5.9 mmol, 1.2 eq.) and DIPEA (2.6 mL, 14.8 mmol, 3.0 eq.) were dissolved in THF (42 mL) 
and the mixture was stirred at RT for for 1 h, after which UPLC-MS analysis showed full 
conversion to the desired product. The solvent was removed by rotary evaporation and the crude 
mixture was purified by flash column chromatography on the ISOLERA (Silica, 340 g, 
DCM/MeOH, UV). Product-containing fractions were combined and concentrated to yield the 
desired product as a thick, yellow oil (4.0 g, >100%). NMR showed co-eluted byproducts from the 
coupling reagent. The material was used without further purification for the next synthetic step. 
1H NMR (400 MHz, CDCl3) δ/ppm: 8.13 – 8.05 (m, 1H), 7.81 – 7.74 (m, 1H), 7.75 – 7.66 (m, 2H), 
7.58 (t, J = 5.8 Hz, 1H), 7.41 – 7.28 (m, 2H), 7.25 – 7.16 (m, 2H), 6.79 (d, J = 8.1 Hz, 1H), 6.75 (t, 
J = 6.0 Hz, 1H), 4.53 (td, J = 8.3, 4.6 Hz, 1H), 3.67 (s, 3H), 3.66 – 3.61 (m, 1H), 3.54 – 3.44 (m, 
















(dddd, J = 14.2, 7.7, 6.6, 4.7 Hz, 1H), 1.66 (ddt, J = 14.5, 8.4, 6.2 Hz, 1H), 1.21 (d, J = 6.7 Hz, 
3H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 176.43, 172.10, 171.06, 148.07, 137.35, 136.20, 133.75, 
133.67, 132.81, 130.84, 130.32, 130.19, 127.94, 126.69, 125.15, 52.66, 49.60, 47.10, 43.39, 
43.22, 43.04, 40.39, 31.04, 18.21. 
HRMS (ESI): C24H29N7NaO8S+ calcd: 598.1691, found: 598.1693. 
Nos-Sc-NP12-TFL(N3)-OH 2-21c 
 
In a 100 mL flask 2-21b (3.9 g, 6.8 mmol, 1.0 eq.) was dissolved in MeCN (40 mL) and a solution 
of LiOH monohydrate (1.4 g, 34.0 mmol, 5.0 eq.) in H2O (20 mL) was added. The mixture was 
stirred at RT for 1.5 h, after which UPLC-MS analysis showed full conversion. Acidifying the 
mixture to pH 5-6 with concentrated HCl quenched the reaction and the volatiles were removed in 
vacuo. The residue was taken up in EtOAc (100 mL) and H2O (100 mL). The biphasic mixture 
was acidified to pH 1 with concentrated HCl and the layers were separated. The aqueous layer 
was extracted with EtOAc (2 x 100 mL) and the combined organic layers were washed with half-
saturated brine (2 x 100 mL) and brine (100 mL), dried over MgSO4 and concentrated to yield the 
desired product as a slightly yellow solid (2.8 g, 73%). NMR showed some residual 
tetramethylurea from the HBTU coupling step. The material was used without further purification 
for the next synthetic step.  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 12.65 (s, 1H), 8.31 (t, J = 5.7 Hz, 1H), 8.21 (t, J = 5.9 Hz, 
1H), 8.06 – 8.01 (m, 1H), 8.01 – 7.94 (m, 2H), 7.91 – 7.83 (m, 2H), 7.37 – 7.28 (m, 2H), 7.27 – 
7.17 (m, 2H), 4.23 (ddd, J = 9.7, 8.1, 4.4 Hz, 1H), 3.48 – 3.20 (m, 3H), 3.18 – 2.98 (m, 4H), 2.95 – 
2.83 (m, 1H), 2.76 – 2.62 (m, 1H), 1.86 (dtd, J = 13.9, 7.7, 4.5 Hz, 1H), 1.76 – 1.57 (m, 1H), 0.98 
(d, J = 6.4 Hz, 3H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 175.30, 173.04, 169.30, 147.72, 137.80, 136.86, 134.07, 
132.70, 132.67, 129.93, 129.47, 129.13, 127.32, 125.82, 124.49, 48.94, 47.25, 42.08, 41.26, 
36.33, 30.13, 17.83. 
HRMS (ESI): C23H27N7NaO8S+ calcd: 584.1534, found: 584.1540. 
Nos-Sc-NP12-TFL(N3)-AA070-OMe 2-21d 
 
In a 50 mL flask 2-21c (1.3 g, 2.3 mmol, 1.0 eq.) was dissolved in THF (20 mL) and H-Dab(Boc)-
OMe hydrochloride (747.0 mg, 2.8 mmol, 1.2 eq.) was added, followed by DIPEA (1.2 mL, 
6.9 mmol, 3.0 eq.) and HATU (1.1 g, 2.8 mmol, 1.2 eq.). The mixture was stirred at RT for 1 h, 
after which UPLC-MS analysis showed full conversion to the desired product. The volatiles were 
removed in vacuo and the residue was taken up in EtOAc (100 mL) and half-saturated NH4Cl 
solution (100 mL). The biphasic mixture was separated and the aqueous layer was extracted with 
EtOAc (2 x 100 mL) and the combined organic layers were washed with saturated NH4Cl solution 
(2 x 100 mL), brine (100 mL), dried over Na2SO4 and concentrated by rotary evaporation. The 
























UV) to yield the desired product as a slightly yellow solid (1.8 g, >100%). NMR showed some 
residual tetramethylurea from the coupling step. The material was used without further 
purification for the next synthetic transformation. 
1H NMR (400 MHz, CD3CN) δ/ppm: 8.11 – 8.04 (m, 1H), 7.88 – 7.82 (m, 1H), 7.82 – 7.77 (m, 
2H), 7.41 – 7.31 (m, 3H), 7.31 – 7.20 (m, 2H), 7.06 (d, J = 8.5 Hz, 1H), 6.93 (d, J = 8.1 Hz, 1H), 
6.89 – 6.81 (m, 1H), 5.40 (s, 1H), 4.38 (ddd, J = 9.1, 8.0, 4.8 Hz, 1H), 4.30 (ddd, J = 9.0, 8.0, 
4.8 Hz, 1H), 3.64 (s, 3H), 3.63 – 3.51 (m, 1H), 3.42 – 3.34 (m, 1H), 3.33 – 3.12 (m, 3H), 3.11 – 
3.02 (m, 2H), 3.01 – 2.84 (m, 3H), 2.82 – 2.76 (m, 2H), 1.82 (dtd, J = 14.0, 7.6, 4.9 Hz, 1H), 1.70 
(ddt, J = 14.7, 9.1, 6.0 Hz, 1H), 1.57 (dddd, J = 14.4, 9.0, 7.1, 5.6 Hz, 1H), 1.38 (s, 9H), 1.14 (d, 
J = 6.5 Hz, 3H). 
13C NMR (101 MHz, CD3CN) δ/ppm: 177.24, 173.07, 172.00, 171.26, 156.86, 148.97, 138.68, 
137.59, 135.00, 133.97, 133.79, 131.40, 131.30, 130.70, 128.48, 127.28, 125.84, 80.09, 53.61, 
52.89, 51.25, 50.77, 48.16, 44.01, 43.47, 40.60, 37.68, 32.43, 31.66, 28.60, 18.36. 
HRMS (ESI): C33H45N9NaO11S+ calcd: 798.2851, found: 798.2862. 
NH2-Sc-NP12-TFL(N3)-AA070-OH 2-21e 
 
Under an inert (N2) atmosphere 2-21d (1.8 g, 2.3 mmol, 1.0 eq.) was dissolved in MeCN (24 mL) 
and DIPEA (4.0 mL, 22.8 mmol, 10.0 eq.) was added, followed by thiophenol (1.2 mL, 11.4 mmol, 
5.0 eq.). The yellow solution was stirred at RT for 2 h, after which UPLC-MS analysis showed 
complete Nosyl deprotection. A solution of LiOH monohydrate (764.0 mg, 18.2 mmol, 8.0 eq.) in 
H2O (8 mL) was added and the mixture was stirred for 1.5 h, after which UPLC-MS analysis 
showed complete ester deprotection. The volatiles were removed by rotary evaporation and the 
crude was purified by reversed phase flash column chromatography on the ISOLERA (RP-Silica, 
340 g, H2O/MeCN, UV (200/215 nm)). Product-containing fractions were combined and 
lyophilized to yield the desired product as a white solid (999 mg, 76%). NMR and LC-MS analysis 
showed 19% epimerized product. 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.55 (t, J = 5.9 Hz, 1H), 8.25 (d, J = 8.1 Hz, 1H), 7.66 (d, 
J = 6.9 Hz, 1H), 7.48 – 7.26 (m, 2H), 7.27 – 7.02 (m, 2H), 6.66 (t, J = 5.7 Hz, 1H), 4.16 (td, J = 
8.8, 8.2, 4.2 Hz, 1H), 3.73 (q, J = 6.5 Hz, 1H), 3.50 – 3.34 (m, 1H), 3.37 – 3.20 (m, 1H), 3.15 – 
2.52 (m, 9H), 2.03 – 1.61 (m, 2H), 1.63 – 1.39 (m, 2H), 1.35 (s, 9H), 1.04 (d, J = 6.2 Hz, 3H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 175.43, 173.73, 169.99, 169.43, 155.34, 137.73, 137.19, 
130.05, 129.03, 127.24, 125.79, 77.34, 52.51, 50.27, 47.31, 41.60, 39.80, 39.51, 37.31, 36.28, 
33.22, 30.68, 28.26, 17.95. 
















MC NP12-AA070 2-21f 
 
In a 1 L flask 2-21e (955.0 mg, 1.7 mmol, 1.0 eq.) was dissolved in THF (600 mL) and DIPEA 
(865.0 µL, 5.0 mmol, 3.0 eq.) was added, followed by HATU (1.1 g, 3.0 mmol, 1.8 eq.). The 
mixture was stirred at RT for 2 h, after which UPLC-MS analysis showed complete conversion to 
the desired product. The mixture was concentrated by rotary evaporation and purified by 
reversed phase flash column chromatography on the ISOLERA (RP-Silica, 340 g, H2O:MeCN, 
UV 200/215 nm) to yield the desired product as a white solid (370.0 mg, 40%). 89 mg of the 
product were purified again by preparative RP-HPLC (Method A, no TFA) for final analytics and 
protein binding assays. Mixture of diastereomers with the ratio 10:85:5 (UPLC-MS analysis). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.20 (d, J = 5.4 Hz, 1H), 8.09 (t, J = 5.4 Hz, 1H), 7.74 – 
7.68 (m, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.36 (td, J = 7.4, 1.6 Hz, 1H), 7.29 (d, J = 7.2 Hz, 1H), 7.27 
(dd, J = 7.6, 1.6 Hz, 1H), 7.22 (td, J = 7.4, 1.3 Hz, 1H), 6.76 (t, J = 5.5 Hz, 1H), 4.05 (ddd, J = 
10.2, 7.9, 4.3 Hz, 1H), 3.72 (dt, J = 8.5, 5.8 Hz, 1H), 3.53 – 3.46 (m, 1H), 3.46 – 3.37 (m, 2H), 
3.29 – 3.19 (m, 3H), 3.16 – 3.09 (m, 1H), 2.98 – 2.87 (m, 2H), 2.72 – 2.62 (m, 1H), 2.56 (dd, J = 
13.9, 7.1 Hz, 1H), 2.06 – 1.99 (m, 1H), 1.99 – 1.89 (m, 2H), 1.78 – 1.69 (m, 1H), 1.36 (s, 9H), 
1.18 (d, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 176.63, 171.27, 171.08, 169.56, 155.53, 137.72, 137.34, 
129.51, 129.09, 127.47, 125.84, 77.52, 53.44, 51.25, 47.65, 42.21, 38.84, 38.72, 37.17, 35.67, 
30.40, 29.33, 28.27, 17.94. 
HRMS (ESI): C26H38N8NaO6+ calcd: 581.2807, found: 581.2808. 
MC NP12-AA070-TA333 2-21 
 
In a 10 mL flask 2-21f (150.0 mg, 269.0 µmol, 1.0 eq.) and TA333 (66.1 mg, 269.0 µmol, 1.0 eq.) 
were dissolved in DMSO (2.9 mL) and a solution of sodium ascorbate (31.9 mg, 161.0 µmol, 
0.6 eq.) in H2O (537 µL) was added. The solution was degassed by bubbling N2 through the 
solution for 1 min. A solution of copper(II) sulfate pentahydrate (20.1 mg, 80.6 µmol, 0.3 eq.) in 
H2O (403 µL) was added and the mixture was degassed again for 1 min. The reaction was stirred 
at RT for 2 h, after which UPLC-MS analysis showed full conversion to the desired product. The 
solution was directly purified by preparative RP-HPLC (Method A, no TFA) and the product-
containing fractions were lyophilized to yield the desired product as a white solid (142 mg, 66%). 
Mixture of diastereomers in the ratio 87:6:7 (NMR). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.24 (d, J = 5.3 Hz, 1H), 8.11 (t, J = 5.6 Hz, 1H), 7.91 (s, 
1H), 7.72 – 7.67 (m, 2H), 7.65 (d, J = 8.1 Hz, 2H), 7.55 (dd, J = 7.6, 1.4 Hz, 1H), 7.48 (td, J = 7.5, 
1.5 Hz, 1H), 7.41 (d, J = 7.6 Hz, 1H), 7.39 – 7.34 (m, 2H), 7.33 – 7.29 (m, 2H), 7.28 – 7.25 (m, 
2H), 7.22 (td, J = 7.4, 1.2 Hz, 1H), 6.76 (t, J = 5.7 Hz, 1H), 5.33 (s, 2H), 4.36 (t, J = 7.2 Hz, 2H), 
4.06 (ddd, J = 10.5, 8.0, 4.3 Hz, 1H), 3.61 (dt, J = 8.8, 5.8 Hz, 1H), 3.49 – 3.46 (m, 1H), 3.30 – 






























– 2.57 (m, 1H), 2.27 – 2.16 (m, 2H), 2.15 (s, 3H), 2.04 – 1.96 (m, 1H), 1.75 – 1.66 (m, 1H), 1.31 
(s, 9H), 1.14 (d, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 176.72, 171.08, 171.02, 169.54, 155.54, 152.28, 141.80, 
140.64, 138.00, 137.69, 137.29, 134.10, 130.50, 130.22, 129.51, 129.09, 128.77, 128.48, 127.48, 
125.86, 125.80, 123.63, 122.90, 122.60, 118.48, 111.47, 77.52, 53.40, 51.12, 46.60, 42.25, 
39.40, 38.78, 38.77, 37.10, 35.68, 30.72, 30.47, 28.24, 19.43, 17.83. 
HRMS (ESI): C43H53N10O6+ calcd: 805.4144, found: 805.4142. 
Nos-Sc-NP12-TFL(N3)-AA118-OMe 2-22d 
 
In a 25 mL flask 2-21c (350.0 mg, 623.0 µmol, 1.0 eq.) was dissolved in THF (5 mL) and methyl 
3-amino-3-(2-chlorophenyl)propanoate (160.0 mg, 748.0 µmol, 1.2 eq.) was added, followed by 
DIPEA (326.0 µL, 1.9 mmol, 3.0 eq.) and HATU (284.0 mg, 746.0 µmol, 1.2 eq.). The mixture 
was stirred at RT for 1 h, after which UPLC-MS analysis showed full conversion to the desired 
product. The volatiles were removed in vacuo and the residue was taken up in EtOAc (50 mL) 
and H2O (50 mL). The mixture was acidified with concentrated HCl to pH 1. The layers were 
separated and the aqueous phase was extracted with EtOAc (2 x 50 mL) and the combined 
organic layers were washed with diluted HCl solution (1%, 2 x 50 mL), brine (50 mL), dried over 
Na2SO4 and concentrated by rotary evaporation. The crude was purified by flash column 
chromatography on the ISOLERA (Silica, 120 g, DCM/MeOH, UV) to yield the desired product as 
a slightly yellow solid (403 mg, 85%). NMR and UPLC-MS analysis showed a mixture of four 
diastereomers in the ratio 7:36:42:15. 
1H NMR (500 MHz, CD3CN) δ/ppm: 8.12 – 7.99 (m, 1H), 7.91 – 7.80 (m, 1H), 7.80 – 7.70 (m, 
2H), 7.40 – 7.34 (m, 3H), 7.34 – 7.13 (m, 7H), 6.96 (t, J = 6.0 Hz, 1H), 6.86 (d, J = 8.1 Hz, 1H), 
5.58 – 5.44 (m, 1H), 4.42 – 4.14 (m, 1H), 3.59 – 3.55 (m, 3H), 3.49 – 3.11 (m, 4H), 3.12 – 3.03 
(m, 1H), 2.90 (dddd, J = 14.5, 12.7, 7.3, 5.4 Hz, 1H), 2.83 – 2.73 (m, 3H), 2.72 – 2.56 (m, 2H), 
1.83 – 1.67 (m, 1H), 1.61 – 1.44 (m, 1H), 1.18 (d, J = 6.6 Hz, 3H). 
13C NMR (101 MHz, CD3CN) δ/ppm: 177.21, 171.70, 171.23, 166.26, 149.09, 139.60, 139.45, 
138.74, 137.70, 137.56, 134.93, 132.74, 131.45, 131.24, 131.13, 130.54, 129.82, 128.52, 128.42, 
128.31, 127.28, 125.75, 52.29, 51.25, 48.45, 48.08, 43.80, 43.43, 40.56, 39.37, 37.52, 31.36, 
18.33. 
HRMS (ESI): C33H37ClN8NaO9S+ calcd: 779.1985, found: 779.1992. 
NH2-Sc-NP12-TFL(N3)-AA118-OH 2-22e 
 
Under an inert (N2) atmosphere 2-22d (406.0 mg, 536.0 µmol, 1.0 eq.) was dissolved in MeCN 
(5 mL) and DIPEA (934.0 µL, 5.4 mmol, 10.0 eq.) was added, followed by thiophenol (273.0 µL, 
2.7 mmol, 5.0 eq.). The yellow solution was stirred at RT for 2 h, after which UPLC-MS analysis 
showed complete Nosyl deprotection. A solution of LiOH monohydrate (171.0 mg, 4.1 mmol, 




























analysis showed complete ester deprotection. The mixture was acidified to pH 5-6 by the addition 
of concentrated HCl. The volatiles were removed by rotary evaporation and the crude was 
purified by reversed phase flash column chromatography on the ISOLERA (RP-Silica, 120 g, 
H2O/MeCN + 0.1% TFA, UV (200/215 nm)). Product-containing fractions were combined and 
lyophilized to yield the desired product as a white solid (331 mg, >100%). Co-elution of unknown 
side products. NMR and LC-MS analysis showed a diastereomeric ratio of 9:36:43:12. 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.56 (d, J = 7.7 Hz, 1H), 8.39 (t, J = 5.4 Hz, 1H), 8.17 – 
7.58 (m, 4H), 7.57 – 6.82 (m, 8H), 5.48 (dd, J = 8.0, 6.3 Hz, 1H), 4.38 – 4.21 (m, 1H), 3.58 – 3.17 
(m, 2H), 3.09 – 2.81 (m, 4H), 2.80 – 2.54 (m, 4H), 2.48 – 2.33 (m, 1H), 1.80 – 1.44 (m, 2H), 0.96 
(d, J = 6.3 Hz, 3H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 171.41, 171.35, 170.06, 169.71, 139.51, 139.48, 137.97, 
136.41, 131.70, 131.50, 130.07, 129.41, 128.80, 127.47, 127.34, 125.84, 49.78, 47.17, 46.98, 
41.23, 39.22, 38.63, 36.91, 36.48, 31.14, 17.76. 
HRMS (ESI): C26H33ClN7O5+ calcd: 558.2226, found: 558.2218. 
MC NP12-AA118 2-22f 
 
In a 500 mL flask 2-22e (298.0 mg, 534 µmol, 1.0 eq.) was dissolved in THF (250 mL) and DIPEA 
(326.0 µL, 1.9 mmol, 3.5 eq.) was added, followed by HATU (406.0 mg, 1.1 mmol, 2.0 eq.). The 
mixture was stirred at RT for 1.5 h, after which UPLC-MS analysis showed complete conversion 
to the desired product. The mixture was concentrated by rotary evaporation and purified by 
reversed phase flash column chromatography on the ISOLERA (RP-Silica, 120 g, H2O:MeCN 
+0.1% TFA, UV 200/215 nm) to yield the desired product as a white solid (148.0 mg, 51%). 
32 mg of the product were purified again by preparative RP-HPLC (Method A) for final analytics 
and protein binding assays. Mixture of diastereomers with the ratio 50:38:12 (UPLC-MS 
analysis). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.75 (dd, J = 7.0, 3.7 Hz, 1H), 8.39 (d, J = 7.1 Hz, 1H), 
8.01 (d, J = 4.7 Hz, 1H), 7.85 (t, J = 5.6 Hz, 1H), 7.42 – 7.39 (m, 2H), 7.37 – 7.35 (m, 1H), 7.34 – 
7.33 (m, 1H), 7.31 – 7.29 (m, 1H), 7.26 (dd, J = 5.3, 2.2 Hz, 2H), 7.21 (td, J = 7.4, 1.3 Hz, 1H), 
5.35 (ddd, J = 10.2, 7.1, 2.9 Hz, 1H), 3.75 – 3.57 (m, 3H), 3.38 – 3.30 (m, 2H), 3.17 – 3.14 (m, 
1H), 3.13 – 3.10 (m, 2H), 2.90 – 2.80 (m, 1H), 2.63 – 2.58 (m, 1H), 2.49 – 2.46 (m, 1H), 2.37 (dd, 
J = 15.5, 3.0 Hz, 1H), 1.72 – 1.62 (m, 1H), 1.64 – 1.53 (m, 1H), 1.13 (d, J = 6.7 Hz, 3H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 175.93, 170.03, 169.33, 168.88, 140.21, 137.89, 137.63, 
131.18, 129.42, 129.33, 129.16, 128.66, 127.72, 127.40, 125.93, 125.67, 51.25, 47.22, 40.98, 
40.83, 39.17, 39.16, 38.99, 35.51, 29.13, 18.36. 














MC NP12-AA118-TA622 2-22 
 
In a 10 mL flask 2-22f (100.0 mg, 185.0 µmol, 1.0 eq.) and TA622 (38.6 mg, 185.0 µmol, 1.0 eq.) 
were dissolved in DMSO (2 mL) and a solution of sodium ascorbate (22.0 mg, 111.0 µmol, 
0.6 eq.) in H2O (370 µL) was added. The solution was degassed by bubbling N2 through the 
solution for 1 min. A solution of copper(II) sulfate pentahydrate (13.9 mg, 55.6 µmol, 0.3 eq.) in 
H2O (278 µL) was added and the mixture was degassed again for 1 min. The reaction was stirred 
at RT for 14 h, after which UPLC-MS analysis showed full conversion to the desired product. The 
solution was directly purified by preparative RP-HPLC (Method A) and the product-containing 
fractions were lyophilized to yield the desired product as a white solid (129 mg, 93%). Mixture of 
diastereomers in the ratio 57:31:11 (UPLC). NMR showed the protonated species of the tertiary 
amine sidechain. 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 9.77 (s, 1H), 9.09 – 9.00 (m, 1H), 8.81 (dd, J = 6.8, 3.8 Hz, 
1H), 8.31 (d, J = 7.3 Hz, 1H), 8.14 (d, J = 5.7 Hz, 1H), 7.93 (t, J = 5.7 Hz, 1H), 7.87 (s, 1H), 7.47 
– 7.42 (m, 1H), 7.42 – 7.40 (m, 1H), 7.40 – 7.38 (m, 1H), 7.38 – 7.35 (m, 1H), 7.32 – 7.23 (m, 
4H), 5.40 (ddd, J = 10.3, 7.3, 3.2 Hz, 1H), 4.37 (t, J = 5.7 Hz, 2H), 4.18 (ddd, J = 14.2, 9.0, 
5.6 Hz, 1H), 4.10 (ddd, J = 13.8, 8.9, 6.6 Hz, 1H), 3.87 (s, 2H), 3.80 – 3.78 (m, 1H), 3.69 – 3.65 
(m, 1H), 3.52 – 3.43 (m, 1H), 3.34 – 3.30 (m, 2H), 3.29 – 3.24 (m, 1H), 3.24 – 3.20 (m, 1H), 3.19 
– 3.11 (m, 1H), 2.92 – 2.82 (m, 1H), 2.64 (dd, J = 13.6, 6.5 Hz, 1H), 2.59 – 2.53 (m, 2H), 2.49 – 
2.35 (m, 2H), 2.12 – 2.03 (m, Hz, 1H), 2.00 – 1.93 (m, 2H), 1.93 – 1.88 (m, 1H), 1.73 (d, J = 
13.0 Hz, 1H), 1.15 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 6.6 Hz, 6H), 0.76 (q, J = 12.2 Hz, 1H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 175.89, 169.77, 169.38, 168.95, 163.93, 143.62, 140.17, 
137.85, 136.99, 131.19, 129.44, 129.40, 129.37, 128.65, 127.92, 127.64, 127.39, 125.80, 122.98, 
57.75, 56.79, 51.03, 47.46, 46.23, 40.87, 40.81, 39.39, 39.18, 38.55, 35.78, 34.23, 30.73, 28.15, 
18.26, 17.97. 
HRMS (ESI): C38H51ClN9O5+ calcd: 748.3696, found: 748.3685. 
Nos-Sc-NP01-TFL(N3)-AA058-OMe 2-23d 
 
In a 50 mL flask 2-18c (1.1 g, 1.8 mmol, 1.0 eq.) was dissolved in THF (16 mL) and H-p-Nitro-D-
Phe-OMe hydrochloride (560.0 mg, 2.2 mmol, 1.2 eq.) was added, followed by DIPEA (936.0 µL, 
5.4 mmol, 3.0 eq.) and HATU (815.0 mg, 2.1 mmol, 1.2 eq.). The mixture was stirred at RT for 
1 h, after which UPLC-MS analysis showed full conversion to the desired product. The volatiles 
were removed in vacuo and the residue was taken up in EtOAc (100 mL) and H2O (100 mL). The 
mixture was acidified with concentrated HCl to pH 1. The layers were separated and the aqueous 
phase was extracted with EtOAc (2 x 100 mL) and the combined organic layers were washed 
with diluted HCl solution (1%, 2 x 100 mL), brine (100 mL), dried over Na2SO4 and concentrated 
by rotary evaporation. The crude was purified by flash column chromatography on the ISOLERA 






























1H NMR (400 MHz, CD3CN) δ/ppm: 8.14 – 8.03 (m, 2H), 8.01 – 7.94 (m, 1H), 7.92 – 7.73 (m, 
3H), 7.64 – 7.54 (m, 1H), 7.54 – 7.44 (m, 4H), 7.44 – 7.37 (m, 4H), 7.38 – 7.31 (m, 2H), 7.19 (d, 
J = 8.2 Hz, 1H), 6.97 (d, J = 7.8 Hz, 1H), 6.63 (t, J = 6.1 Hz, 1H), 6.58 (d, J = 15.7 Hz, 1H), 6.11 
(t, J = 5.8 Hz, 1H), 4.78 – 4.68 (m, 1H), 4.47 (dtd, J = 13.4, 8.3, 5.3 Hz, 1H), 3.66 (s, 3H), 3.38 – 
3.18 (m, 5H), 3.09 (dt, J = 13.9, 8.6 Hz, 1H), 3.01 – 2.88 (m, 2H), 2.03 – 1.85 (m, 1H), 1.85 – 1.68 
(m, 1H). 
13C NMR (101 MHz, CD3CN) δ/ppm: 172.12, 171.96, 170.93, 166.48, 147.93, 145.95, 142.00, 
141.08, 140.02, 137.29, 135.88, 135.11, 133.86, 133.65, 131.47, 131.46, 131.40, 131.02, 130.96, 
130.94, 129.80, 128.85, 128.78, 128.57, 127.91, 126.02, 124.33, 122.16, 53.85, 53.02, 51.95, 
48.62, 43.70, 40.09, 37.59, 31.78. 
HRMS (ESI): C38H37N9NaO11S+ calcd: 850.2225, found: 850.2225. 
NH2-Sc-NP01-TFL(N3)-AA058-OH 2-23e 
 
Under an inert (N2) atmosphere 2-23d (1.3 g, 1.6 mmol, 1.0 eq.) was dissolved in MeCN (15 mL) 
and DIPEA (2.7 mL, 15.5 mmol, 10.0 eq.) was added, followed by thiophenol (788.0 µL, 
7.7 mmol, 5.0 eq.). The yellow solution was stirred at RT for 2 h, after which UPLC-MS analysis 
showed complete Nosyl deprotection. A solution of LiOH monohydrtae (511.0 mg, 12.2 mmol, 
8.0 eq.) in H2O (5 mL) was added and the mixture was stirred for 1.5 h, after which UPLC-MS 
analysis showed complete ester deprotection. The mixture was acidified to pH 5-6 by the addition 
of concentrated HCl. The volatiles were removed by rotary evaporation and the crude was 
purified by reversed phase flash column chromatography on the ISOLERA (RP-Silica, 340 g, 
H2O/MeCN + 0.1% TFA, UV (254/280 nm)). Product-containing fractions were combined and 
lyophilized to yield the desired product as white solid (940 mg, 97%). NMR and LC-MS analysis 
showed 25% epimerized product. 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.55 (d, J = 8.5 Hz, 1H), 8.33 (t, J = 5.6 Hz, 1H), 8.28 (dd, 
J = 8.3, 2.9 Hz, 1H), 8.13 (dd, J = 8.8, 7.1 Hz, 2H), 7.80 (brs, 3H), 7.64 – 7.50 (m, 6H), 7.50 – 
7.41 (m, 4H), 7.37 (dt, J = 7.6, 1.5 Hz, 1H), 6.79 (d, J = 15.9 Hz, 1H), 4.56 (dddd, J = 10.3, 8.0, 
6.4, 3.7 Hz, 1H), 4.48 (td, J = 8.7, 5.5 Hz, 1H), 3.37 – 3.10 (m, 4H), 3.10 – 2.99 (m, 2H), 2.80 – 
2.62 (m, 2H), 1.95 – 1.68 (m, 1H), 1.66 – 1.50 (m, 1H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 172.29, 170.72, 169.57, 164.70, 146.29, 146.00, 140.82, 
138.97, 138.68, 136.49, 134.79, 130.64, 130.57, 129.83, 129.75, 128.75, 127.86, 127.63, 127.36, 
123.18, 123.13, 122.15, 52.65, 50.04, 47.22, 38.10, 36.73, 36.47, 31.45. 
HRMS (ESI): C31H33N8O7+ calcd: 629.2467, found: 629.2463. 
MC-NP01-AA058 2-23f 
 
In a 50 mL flask 2-23e (15.0 mg, 23.9 µmol, 1.0 eq.) was dissolved in DMF (20 mL) and DIPEA 
(12.5 µL, 71.6 µmol, 3.0 eq.) was added, followed by HATU (18.0 mg, 47.7 µmol, 2.0 eq.). The 

























starting material. The mixture was concentrated by rotary evaporation and purified by preparative 
reversed phase HPLC (Method A). Product-containing fractions were combined and lyophilized to 
yield the desired product as white solid (13.0 mg, 89%).  
1H NMR (600 MHz, DMSO-d6) δ/ppm: 8.61 – 8.59 (m, 1H), 8.57 (d, J = 8.5 Hz, 1H), 8.38 (d, J = 
9.2 Hz, 1H), 8.13 – 8.12 (m, 2H), 7.61 – 7.58 (m, 1H), 7.57 – 7.54 (m, 2H), 7.53 – 7.52 (m, 2H), 
7.48 – 7.47 (m, 4H), 7.43 – 7.41 (m, 2H), 7.41 – 7.39 (m, 1H), 6.47 (d, J = 15.9 Hz, 1H), 4.51 – 
4.48 (m, 1H), 4.32 (q, J = 7.6 Hz, 1H), 3.28 – 3.26 (m, 1H), 3.19 – 3.17 (m, 2H), 3.17 – 3.14 (m, 
2H), 3.13 – 3.11 (m, 1H), 2.95 (dd, J = 13.8, 10.2 Hz, 2H), 1.89 – 1.82 (m, 1H), 1.78 – 1.72 (m, 
1H). 
13C NMR (600 MHz, 2D NMR, DMSO-d6) δ/ppm: 170.52, 170.49, 169.97, 166.13, 146.76, 
146.14, 140.0, 137.92, 137.82, 134.76, 130.30, 130.28, 129.25, 129.15, 128.90, 128.85, 128.54, 
127.19, 126.84, 124.78, 122.89, 122.58, 53.53, 50.33, 47.32, 39.10, 38.11, 35.58, 28.75  
HRMS (ESI): C31H30N8NaO6+ calcd: 633.2181, found: 633.2176. 
MC NP01-AA058-TA229 2-23 
 
In a 1.5 mL Eppendorf tube 2-23f (10.0 mg, 16.4 µmol, 1.0 eq.) and TA229 (4.2 mg, 16.4 µmol, 
1.0 eq.) were dissolved in DMSO (200 µL) and a solution of sodium ascorbate (2.0 mg, 9.8 µmol, 
0.6 eq.) in H2O (32.8 µL) was added. The solution was degassed by bubbling N2 through the 
solution for 1 min. A solution of copper(II) sulfate pentahydrate (1.2 mg, 4.9 µmol, 0.3 eq.) in H2O 
(24.6 µL) was added and the mixture was degassed again for 1 min. The reaction was agitated at 
RT for 12 h, after which UPLC-MS analysis showed full conversion to the desired product. The 
solution was directly purified by preparative RP-HPLC (Method A) and the product-containing 
fractions were lyophilized to yield the desired product as a white solid (5 mg, 35%). Mixture of 
diastereomers in the ratio 61:39 (UPLC)/47:42:6:5 (NMR).  
1H NMR (500 MHz, DMSO-d6) δ 9.24 – 9.19 (m, 1H), 8.89 (d, J = 3.3 Hz, 1H), 8.64 (d, J = 8.4 Hz, 
1H), 8.61 – 8.55 (m, 1H), 8.34 (dt, J = 7.0, 4.3 Hz, 1H), 8.27 (d, J = 9.2 Hz, 1H), 8.11 (t, J = 
8.3 Hz, 2H), 8.00 (s, 1H), 7.91 – 7.89 (m, 1H), 7.65 (t, J = 5.6 Hz, 1H), 7.63 – 7.59 (m, 1H), 7.55 – 
7.54 (m, 1H), 7.53 – 7.50 (m, 2H), 7.49 – 7.47 (m, 2H), 7.47 – 7.45 (m, 2H), 7.43 – 7.41 (m, 2H), 
7.41 – 7.37 (m, 2H), 6.55 (d, J = 15.8 Hz, 1H), 6.16 (s, 1H), 4.56 – 4.53 (m, 2H), 4.52 – 4.47 (m, 
1H), 4.28 – 4.23 (m, 1H), 4.23 – 4.18 (m, 2H), 3.20 – 3.17 (m, 2H), 3.13 – 3.08 (m, 2H), 2.96 – 
2.87 (m, 2H), 2.61 (s, 3H), 2.21 (s, 3H), 2.10 – 2.02 (m, 1H), 2.00 – 1.92 (m, 1H). 
13C NMR (500 MHz, 2D NMR, DMSO-d6) δ/ppm: 175.58, 169.91, 165.81, 165.69, 163.64, 
154.18, 149.45, 146.76, 146.08, 145.84, 145.80, 144.42, 141.08, 139.93, 137.76, 137.62, 134.50, 
130.17, 130.14, 129.53, 128.95, 128.47, 127.13, 126.85, 126.16, 124.76, 123.84, 122.84, 122.74, 
122.59, 122.45, 113.83, 109.57, 53.29, 50.13, 45.89, 39.11, 36.52, 35.71, 34.54, 30.68, 14.30, 
13.06.  




















13.12 Differential Scanning Fluorimetry (DSF) 
Stock Solutions: 
MC 2-18, 250 µM (25% DMSO/PBS) 
MC 2-19f, 500 µM (PBS) 
MC 2-19, 500 µM (25% DMSO/PBS) 
MC 2-20f, 500 µM (PBS) 
MC 2-20, 500 µM (PBS) 
MC 2-21f, 500 µM (5% DMSO/PBS) 
MC 2-22f, 500 µM (PBS) 
MC 2-22, 500 µM (PBS) 
MC 2-23f, 250 µM (25% DMSO/PBS) 
MC 2-23, 250 µM (25% DMSO/PBS) 
AGP 10 mg/ml (PBS) 
HSA 10 mg/ml (PBS) 
Sample Preparation:  
The MC stock solution (97.5 µL) was mixed with the protein solution (2.5 µL), giving a final 
protein concentration of 0.25 mg/ml and 487.5 µM MC concentration in the according buffer. For 
every buffer system, a reference sample (buffer + protein) was prepared. All MCs were tested 
against HSA and AGP (2-23f and 2-23 were not completely soluble). The measurements were 
performed in triplicates on a Prometheus NT.48 with a rate of 1.5°C per minute in a temperature 
range from 20°C - 95°C.  
Remark: AGP (10 mg/ml, 1 mL) was dialyzed against PBS (3 x 1000 mL, 4°C, 3 x 18 h) prior to 
the binding assay. 2-21 could not be tested due to high fluorescence activity of the compound. 
13.13 Isothermal Titration Calorimetry (ITC) 
General: 
For ITC measurements the protein solution (50.0 µM in PBS, approx. 300 µL) was placed in the 
sample cell and the ligand (macrocycle) solution (500.0 µM in PBS, approx. 40 µL) was placed in 
the syringe. The titrations were performed at 25°C or 10°C with a stirring rate of 750 rpm. 
Reference power was set to 6 µcal/s. In total 17 injections were performed with an initial delay of 
300 s. The added volume per injection was 2.3 µL over a duration of 4.6 s (first injection 0.5 µL in 
1.0 s) with a spacing of 150 s between the additions and a filter time of 2 s. The data was 
analyzed by NitPick and Sedphat for fitting and KD determinations.  
  
 -193- 
2-22f versus AGP: 
 
Figure 102. The three ITC titrations of 2-22f versus AGP. All graphs were analyzed and integrated using NITPIC. For 
the physicochemical calculations all three measurements were fitted and processed using SEDPHAT. 
For optimal binding constant analysis ligand 2-22f was used as a 260 µM solution in PBS buffer 
with 50 µM AGP in PBS buffer at 25°C. Triplicate measurements were conducted as well as the 
reference titration (2-22f into PBS buffer). After subtraction of the reference titration from the 
binding measurements, the data was globally fitted to give the following calculated values: 
KD = 4.1 µM with a confidence interval (95%) from 2.9 - 6.1 µM. 
ΔKD= 2.0 µM 
ΔH = -4.78 kcal/mol = -20.01 kJ/mol with a confidence interval (95%) from -5.51 - -4.28 
kcal/mol.  


























































































2-22 versus AGP:  
 
Figure 103. The three ITC titrations of 2-22 versus AGP. All graphs were analyzed and integrated using NITPIC. For the 
physicochemical calculations all three measurements were fitted and processed using SEDPHAT. 
The optimal conditions were found to be 100 µM AGP and 520 µM 2-22 in PBS buffer. Triplicate 
measurements were performed with a reference titration. Due to the small binding enthalpies the 
temperature of the assay was lowered to 10°C. After subtraction of the reference titration from the 
binding measurements, the data was globally fitted to give the following calculated values: 
KD = 7.0 µM with a confidence interval (95%) from 4.7 - 10.7 µM. 
ΔKD= 3.7 µM 
ΔH = 2.72 kcal/mol = 11.39 kJ/mol with a confidence interval (95%) from 2.43 - 3.14 kcal/mol. 






































































































































2-20 and 2-21 versus AGP:  
 
Figure 104. a) ITC titration of 2-21 versus AGP with the reference titration 2-21 vs PBS buffer. The data was not 
analyzed and integrated. b) ITC titration of 2-20 versus AGP. The data was not analyzed and integrated. 
The titrations were performed at 50 µM AGP and 260 µM macrocycle ligand (5% DMSO in PBS 
for 2-21, pure PBS for 2-20) in single measurements at 25°C. A reference titration of 2-21 was 
conducted to evaluate the solvation enthalpy. The measurements were not further improved nor 
the data analyzed due to the very weak binding. We assumed no binding for 2-20 due to the very 
weak differential power (DP) changes that probably uniquely arose from the solvation enthalpy. 
2-18, 2-20 and 2-22 versus HSA:  
 
Figure 105. ITC titrations of 2-18, 2-20 and 2-22 versus HSA. The data was not analyzed and integrated. Reference 
titrations not shown. 
The 2-18 versus HSA assay was performed at 25 µM HSA in 25% DMSO/PBS and 250 µM 
macrocycle ligand in 25% DMSO/PBS at 25°C. Care was taken to exactly match the DMSO/PBS 
ratios in all samples and buffers.  
2-20 and 2-22 versus HSA measurements were performed at 50µM/500µM in PBS buffer at 
25°C. 
In all three assays no strong binding events were observed. Therefore, no further measurement 


















































13.14 Building Block Synthesis 
Synthesis of NP01 
 
2-4 (43.0 mg, 71.5 µmol, 1.0 eq.), 3-(2-carboxyvinyl)phenylboronic acid (27.5 mg, 143.0 µmol, 
2.0 eq.), Pd (π-cinnamyl) chloride dimer (7.4 mg, 14.3 µmol, 20 mol%) and K3PO4 (45.5 mg, 
215.0 µmol, 3.0 eq.) were suspended in EtOH (800 µL) and H2O (400 µL). The mixture was 
stirred at 50°C for 1 h, after which UPLC-MS analysis showed complete conversion to the desired 
product. The black mixture was filtered and purified by reversed-phase preparative HPLC 
(Method A). Product-containing fractions were combined and lyophilized to yield the desired 
product as white solid (28 mg, 63%).  
1H NMR (500 MHz, DMSO-d6) δ/ppm: 12.43 (s, 1H), 8.65 (t, J = 5.7 Hz, 1H), 8.33 (t, J = 5.9 Hz, 
1H), 8.14 (t, J = 6.0 Hz, 1H), 8.00 (dd, J = 5.8, 3.3 Hz, 1H), 7.96 – 7.92 (m, 1H), 7.92 – 7.85 (m, 
4H),  
7.69 – 7.66 (m, 1H), 7.64 – 7.55 (m, 2H), 7.53 (d, J = 8.4 Hz, 1H), 7.42 – 7.33 (m, 2H), 6.52 (d, 
J = 16.0 Hz, 1H), 3.41 (t, J = 6.7 Hz, 2H), 3.37 – 3.34 (m, 2H), 3.15 (dt, J = 7.9, 6.1 Hz, 2H), 2.77 
(dt, J = 8.2, 6.1 Hz, 2H), 1.79 (p, J = 6.8 Hz, 2H). 
13C NMR (500 MHz, HMBC/HMQC, DMSO-d6) δ/ppm: 166.97, 168.24, 165.11, 147.52, 143.29, 
139.92, 139.83, 139.56, 138.75, 138.04, 134.89, 133.88, 132.47, 129.89, 129.09, 128.43, 128.17, 
127.70, 127.49, 127.04, 126.05, 124.31, 119.37, 48.22, 41.17, 38.46, 36.42, 28.00. 
HRMS (ESI): C28H27N7NaO8S+ calcd: 644.1534, found: 644.1534. 
Synthesis of NP02 
 
2-4 (20.0 mg, 33.3 µmol, 1.0 eq.), 4-(2-carboxyvinyl)phenylboronic acid (12.8 mg, 66.5 µmol, 
2.0 eq.), Pd (π-cinnamyl) chloride dimer (3.5 mg, 6.7 µmol, 20 mol%) and K3PO4 (21.2 mg, 
99.8 µmol, 3.0 eq.) were suspended in EtOH (400 µL) and H2O (200 µL). The mixture was stirred 
at 50°C for 2 h, after which UPLC-MS analysis showed complete conversion to the desired 
product. The black mixture was filtered and purified by reversed-phase preparative HPLC 
(Method A). Product-containing fractions were combined and lyophilized to yield the desired 
product as white solid (16 mg, 77%).  
1H NMR (400 MHz, Acetone-d6) δ/ppm: 8.13 – 8.08 (m, 1H), 8.05 (t, J = 5.7 Hz, 1H), 7.99 – 7.94 
(m, 1H), 7.93 – 7.86 (m, 4H), 7.71 – 7.64 (m, 3H), 7.59 (d, J = 8.5 Hz, 1H), 7.55 – 7.45 (m, 3H), 
6.75 (t, J = 6.0 Hz, 1H), 6.54 (d, J = 16.1 Hz, 1H), 3.54 – 3.44 (m, 4H), 3.39 (q, J = 6.3 Hz, 2H), 
3.13 (q, J = 6.1 Hz, 2H), 1.90 (p, J = 6.7 Hz, 2H). 
13C NMR (500 MHz, HMBC/HMQC, Acetone-d6) δ/ppm: 169.71, 167.35, 166.37, 148.91, 144.75, 
142.56, 142.47, 139.76, 136.73, 134.80, 134.53, 133.85, 133.43, 131.21, 129.91, 129.19, 128.89, 
128.79, 127.04, 125.66, 119.28, 49.60, 43.32, 39.89, 37.60, 29.35. 



















Synthesis of NP03 
 
2-4 (20.0 mg, 33.3 µmol, 1.0 eq.), 3-(2-carboxyethyl)phenylboronic acid (12.9 mg, 66.5 µmol, 
2.0 eq.), Pd (π-cinnamyl) chloride dimer (3.5 mg, 6.7 µmol, 20 mol%) and K3PO4 (21.2 mg, 
99.8 µmol, 3.0 eq.) were suspended in EtOH (400 µL) and H2O (200 µL). The mixture was stirred 
at 50°C for 2 h, after which UPLC-MS analysis showed complete conversion to the desired 
product. The black mixture was filtered and purified by reversed-phase preparative HPLC 
(Method A). Product-containing fractions were combined and lyophilized to yield the desired 
product as white solid (15 mg, 72%).  
1H NMR (500 MHz, Acetone-d6) δ/ppm: 8.13 – 8.07 (m, 1H), 7.99 – 7.94 (m, 1H), 7.95 – 7.90 (m, 
2H), 7.88 (dd, J = 7.9, 1.8 Hz, 1H), 7.86 (dd, J = 1.8, 0.6 Hz, 1H), 7.56 (dd, J = 7.8, 0.5 Hz, 1H), 
7.32 – 7.29 (m, 1H), 7.28 (dd, J = 7.1, 0.7 Hz, 1H), 7.26 – 7.21 (m, 2H), 3.48 (dt, J = 15.6, 6.8 Hz, 
4H), 3.33 (t, J = 6.5 Hz, 2H), 3.05 (t, J = 6.5 Hz, 2H), 2.91 (t, J = 7.7 Hz, 2H), 2.61 (t, J = 7.7 Hz, 
2H), 1.90 (p, J = 6.7 Hz, 2H). 
13C NMR (500 MHz, HMBC/HMQC, Acetone-d6) δ/ppm: 173.62, 169.79, 166.57, 148.92, 141.85, 
141.25, 140.59, 140.40, 139.74, 136.55, 134.74, 133.42, 131.20, 129.31, 129.23, 129.02, 128.74, 
128.29, 127.09, 126.57, 125.64, 49.57, 43.17, 39.78, 37.53, 35.51, 31.16, 29.32. 
HRMS (ESI): C28H29N7NaO8S+ calcd: 646.1691, found: 646.1695. 
Synthesis of NP04 
 
2-4 (20.0 mg, 33.3 µmol, 1.0 eq.), 4-(2-carboxyethyl)phenylboronic acid (12.9 mg, 66.5 µmol, 
2.0 eq.), Pd (π-cinnamyl) chloride dimer (3.5 mg, 6.7 µmol, 20 mol%) and K3PO4 (21.2 mg, 
99.8 µmol, 3.0 eq.) were suspended in EtOH (400 µL) and H2O (200 µL). The mixture was stirred 
at 50°C for 2 h, after which UPLC-MS analysis showed complete conversion to the desired 
product. The black mixture was filtered and purified by reversed-phase preparative HPLC 
(Method A). Product-containing fractions were combined and lyophilized to yield the desired 
product as white solid (14 mg, 68%).  
1H NMR (500 MHz, Acetone-d6) δ/ppm: 8.14 – 8.09 (m, 1H), 8.00 – 7.95 (m, 1H), 7.96 – 7.90 (m, 
2H), 7.87 (dd, J = 7.9, 1.8 Hz, 1H), 7.84 (d, J = 1.6 Hz, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.37 – 7.30 
(m, 2H), 7.29 – 7.23 (m, 2H), 3.48 (dt, J = 15.9, 6.8 Hz, 4H), 3.34 (t, J = 6.3 Hz, 2H), 3.09 (t, J = 
6.3 Hz, 2H), 2.91 (t, J = 7.7 Hz, 2H), 2.62 (t, J = 7.7 Hz, 2H), 1.90 (p, J = 6.7 Hz, 2H). 
13C NMR (500 MHz, HMBC/HMQC, Acetone-d6) δ/ppm: 173.60, 169.93, 166.46, 148.91, 141.23, 
140.33, 140.22, 139.62, 138.36, 136.49, 134.78, 133.43, 131.22, 129.31, 129.19, 128.97, 128.81, 
126.56, 125.66, 49.58, 43.30, 39.84, 37.56, 35.45, 30.89, 29.33. 



















Synthesis of NP05 
 
2-4 (20.0 mg, 33.3 µmol, 1.0 eq.), 3-carboxyphenylboronic acid (12.9 mg, 77.8 µmol, 2.3 eq.), 
Pd (π-cinnamyl) chloride dimer (3.5 mg, 6.7 µmol, 20 mol%) and K3PO4 (21.2 mg, 99.8 µmol, 
3.0 eq.) were suspended in EtOH (400 µL) and H2O (200 µL). The mixture was stirred at 50°C for 
2 h, after which UPLC-MS analysis showed complete conversion to the desired product. The 
black mixture was filtered and purified by reversed-phase preparative HPLC (Method A). Product-
containing fractions were combined and lyophilized to yield the desired product as white solid 
(16 mg, 81%).  
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.70 (t, J = 5.7 Hz, 1H), 8.39 (t, J = 5.8 Hz, 1H), 8.13 (t, J = 
6.0 Hz, 1H), 8.02 – 7.97 (m, 2H), 7.97 – 7.93 (m, 1H), 7.92 – 7.85 (m, 5H), 7.61 (ddd, J = 7.6, 1.9, 
1.2 Hz, 1H), 7.54 (d, J = 7.8 Hz, 1H), 7.46 (t, J = 7.7 Hz, 1H), 3.41 (t, J = 6.7 Hz, 2H), 3.34 (td, J = 
6.8, 5.5 Hz, 2H), 3.14 (dt, J = 7.9, 6.0 Hz, 2H), 2.82 (dt, J = 8.3, 6.1 Hz, 2H), 1.79 (p, J = 6.8 Hz, 
2H). 
13C NMR (500 MHz, HMBC/HMQC, DMSO-d6) δ/ppm: 168.29, 166.84, 165.12, 147.44, 139.64, 
139.44, 138.90, 137.93, 135.09, 133.92, 132.57, 132.52, 130.52, 129.16, 129.04, 128.25, 128.14, 
128.11, 127.69, 126.23, 124.35, 48.28, 41.25, 38.56, 36.48, 28.05. 
HRMS (ESI): C26H25N7NaO8S+ calcd: 618.1378, found: 618.1381. 
Synthesis of NP06 
 
2-4 (20.0 mg, 33.3 µmol, 1.0 eq.), 5-carboxythiophene-2-boronic acid pinacol ester (16.9 mg, 
66.5 µmol, 2.0 eq.), Pd (π-cinnamyl) chloride dimer (3.5 mg, 6.7 µmol, 20 mol%) and K3PO4 
(21.2 mg, 99.8 µmol, 3.0 eq.) were suspended in EtOH (400 µL) and H2O (200 µL). The mixture 
was stirred at 50°C for 2 h, after which UPLC-MS analysis showed complete conversion to the 
desired product. The black mixture was filtered and purified by reversed-phase preparative HPLC 
(Method A). Product-containing fractions were combined and lyophilized to yield the desired 
product as white solid (2 mg, 10%).  
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.72 (t, J = 5.6 Hz, 1H), 8.59 (t, J = 5.8 Hz, 1H), 8.18 (t, J = 
6.0 Hz, 1H), 8.03 – 7.94 (m, 3H), 7.92 – 7.85 (m, 3H), 7.64 (d, J = 3.9 Hz, 1H), 7.52 (d, J = 
7.9 Hz, 1H), 7.26 (d, J = 3.9 Hz, 1H), 3.44 – 3.40 (m, 2H), 3.37 – 3.32 (m, 2H), 3.24 (dt, J = 7.4, 
6.1 Hz, 2H), 2.98 (dt, J = 7.8, 6.1 Hz, 2H), 1.80 (p, J = 6.8 Hz, 2H). 
13C NMR (500 MHz, HMBC/HMQC, DMSO-d6) δ/ppm: 168.00, 164.76, 162.44, 147.44, 146.74, 
138.67, 135.06, 134.38, 134.00, 133.23, 132.61, 132.20, 130.16, 129.27, 128.09, 127.96, 127.55, 
127.15, 124.38, 48.33, 41.45, 38.75, 36.56, 28.06. 




















Synthesis of NP07 
 
2-4 (20.0 mg, 33.3 µmol, 1.0 eq.), 2-methoxycarbonylpyridine-5-boronic acid (16.9 mg, 
93.4 µmol, 2.8 eq.), Pd (π-cinnamyl) chloride dimer (3.5 mg, 6.7 µmol, 20 mol%) and K3PO4 
(21.2 mg, 99.8 µmol, 3.0 eq.) were suspended in EtOH (400 µL) and H2O (200 µL). The mixture 
was stirred at 50°C for 2 h, after which UPLC-MS analysis showed complete conversion to the 
desired product. The black mixture was filtered and purified by reversed-phase preparative HPLC 
(Method A). Product-containing fractions were combined and lyophilized to yield the impure 
methyl ester of the product as beige solid (7.0 mg, 35%). The material was dissolved in MeCN 
(0.5 mL) and a solution of LiOH monohydrate (4.8 mg, 115.0 µmol, 10.0 eq.) in H2O (382 µL) was 
added. The solution was stirred at RT for 2 h, after which UPLC-MS analysis showed full 
conversion to the desired product. The reaction mixture was purified by reversed-phase 
preparative HPLC (Method A). Product-containing fractions were combined and lyophilized to 
yield the desired product as white solid (6.0 mg, 88%). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.75 – 8.66 (m, 2H), 8.57 (t, J = 5.8 Hz, 1H), 8.18 (t, J = 
6.0 Hz, 1H), 8.06 (dd, J = 8.0, 0.8 Hz, 1H), 8.02 – 7.92 (m, 5H), 7.91 – 7.84 (m, 2H), 7.64 (d, J = 
7.9 Hz, 1H), 3.42 (t, J = 6.8 Hz, 2H), 3.35 (td, J = 6.8, 5.5 Hz, 2H), 3.19 (q, J = 6.4 Hz, 2H), 2.92 
(dt, J = 7.5, 6.1 Hz, 2H), 1.80 (p, J = 6.8 Hz, 2H). 
13C NMR (500 MHz, HMBC/HMQC, DMSO-d6) δ/ppm: 167.81, 165.73, 165.03, 148.41, 147.44, 
146.84, 138.34, 138.27, 136.70, 135.24, 134.97, 133.92, 132.56, 132.30, 129.23, 128.58, 128.06, 
127.04, 124.32, 123.98, 48.26, 41.43, 38.76, 36.50, 28.03. 
HRMS (ESI): C25H23N8O8S- calcd: 595.1365, found: 595.1371. 
Synthesis of NP08 
 
2-4 (20.0 mg, 33.3 µmol, 1.0 eq.), 3-methoxycarbonyl-5-trifluoromethylphenylboronic acid pinacol 
ester (22.0 mg, 66.5 µmol, 2.0 eq.), Pd (π-cinnamyl) chloride dimer (3.5 mg, 6.7 µmol, 20 mol%) 
and K3PO4 (21.2 mg, 99.8 µmol, 3.0 eq.) were suspended in EtOH (400 µL) and H2O (200 µL). 
The mixture was stirred at 50°C for 1 h, after which UPLC-MS analysis showed complete 
conversion to the desired product. The black mixture was filtered and purified by reversed-phase 
preparative HPLC (Method A). Product-containing fractions were combined and lyophilized to 
yield the impure methyl ester of the product (12.0 mg, 53%). The material was dissolved in MeCN 
(500 µL) and a solution of LiOH monohydrate (7.4 mg, 177.0 µmol, 10.0 eq.) in H2O (590 µL) was 
added. The solution was stirred at RT for 2 h, after which UPLC-MS analysis showed full 
conversion to the desired product. The reaction mixture was purified by reversed-phase 
preparative HPLC (Method A). Product-containing fractions were combined and lyophilized to 
yield the desired product as white solid (8.0 mg, 68%). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 13.62 (s, 1H), 8.72 (t, J = 5.7 Hz, 1H), 8.51 (t, J = 5.9 Hz, 
1H), 8.24 – 8.20 (m, 1H), 8.17 (t, J = 6.0 Hz, 1H), 8.14 – 8.10 (m, 1H), 8.00 – 7.96 (m, 1H), 7.96 – 
7.90 (m, 4H), 7.90 – 7.84 (m, 2H), 7.60 (d, J = 7.9 Hz, 1H), 3.42 (t, J = 6.7 Hz, 2H), 3.35 (td, J = 






















13C NMR (500 MHz, HMBC/HMQC, DMSO-d6) δ/ppm: 167.87, 165.38, 164.91, 147.22, 140.92, 
138.64, 136.23, 135.33, 133.85, 132.77, 132.44, 129.00, 128.97, 128.47, 128.05, 127.79, 126.97, 
124.30, 124.27, 122.17, 120.00, 48.23, 41.00, 38.61, 36.44, 28.02. 
HRMS (ESI): C27H24F3N7NaO8S+ calcd: 686.1251, found: 686.1262. 
Synthesis of NP09 
 
2-4 (20.0 mg, 33.3 µmol, 1.0 eq.), 3-carboxy-4-fluorophenylboronic acid (12.2 mg, 66.5 µmol, 
2.0 eq.), Pd (π-cinnamyl) chloride dimer (3.5 mg, 6.7 µmol, 20 mol%) and K3PO4 (21.2 mg, 
99.8 µmol, 3.0 eq.) were suspended in EtOH (400 µL) and H2O (200 µL). The mixture was stirred 
at 50°C for 1 h, after which UPLC-MS analysis showed complete conversion to the desired 
product. The black mixture was filtered and purified by reversed-phase preparative HPLC 
(Method A). Product-containing fractions were combined and lyophilized to yield the desired 
product as brownish solid (18.0 mg, 88%).  
1H NMR (500 MHz, DMSO-d6) δ/ppm: 13.32 (s, 1H), 8.70 (t, J = 5.6 Hz, 1H), 8.44 (t, J = 5.8 Hz, 
1H), 8.15 (t, J = 6.0 Hz, 1H), 8.01 – 7.95 (m, 2H), 7.92 – 7.83 (m, 5H), 7.61 (ddd, J = 8.5, 4.5, 
2.5 Hz, 1H), 7.54 (d, J = 7.9 Hz, 1H), 7.30 (dd, J = 10.7, 8.5 Hz, 1H), 3.41 (t, J = 6.7 Hz, 2H), 3.34 
(q, J = 6.6 Hz, 2H), 3.16 (dt, J = 7.5, 6.0 Hz, 2H), 2.88 (dt, J = 8.1, 6.1 Hz, 2H), 1.79 (p, J = 
6.8 Hz, 2H). 
13C NMR (126 MHz, DMSO-d6) δ/ppm: 168.44, 165.38, 164.84, 159.62, 147.66, 138.93, 137.17, 
135.84, 135.41, 134.50, 134.11, 132.73, 132.60, 131.72, 129.37, 128.33, 127.94, 126.50, 124.54, 
119.07, 116.94, 116.76, 48.54, 41.61, 38.89, 36.75, 28.34. 
HRMS (ESI): C26H24FN7NaO8S+ calcd: 636.1283, found: 636.1291. 
Synthesis of Ethyl 2-bromoethoxyacetate NP10a 
 
Under an inert atmosphere 2-bromoethanol (709.0 µL, 10.0 mmol, 1.0 eq.) was dissolved in DCM 
(17 mL) and cooled in an ice bath. Rh2(OAc)4 (44.2 mg, 100.0 µmol, 1.0 mol%) was added and 
the mixture was stirred for 5 min. The ice bath was removed and a solution of ethyl  
2-diazoacetate (1.2 mL, 9.6 mmol, 0.96 eq.) in DCM (8 mL) was added dropwise while gas 
evolution occurred. The green mixture was stirred at RT for 2 h. The mixture was filtered over 
Celite and concentrated in vacuo. The crude product was purified by bulb-to-bulb distillation 
(80°C, 3.6 x 10-1 mbar) to yield the desired product as a colorless liquid (1.3 g, 61%). Analytical 
data was in agreement with reported data.[245] 
1H NMR (400 MHz, CDCl3) δ/ppm: 4.23 (q, J = 7.2 Hz, 2H), 4.15 (s, 2H), 3.89 (t, J = 6.2 Hz, 2H), 
3.51 (t, J = 6.2 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H). 
Synthesis of 3-Ethyloxycarbonylmethoxyethoxyphenylboronic acid pinacol ester NP10b 
 
Under an inert atmosphere 3-hydroxyphenylboronic acid pinacol ester (47.0 mg, 214.0 µmol, 
1.0 eq.), NP10a (54.1 mg, 256.0 µmol, 1.2 eq.) and potassium carbonate (88.5 mg, 641.0 µmol, 
3.0 eq.) were mixed in MeCN (1 mL). The suspension was stirred at 65°C for 39 h, after which 



















(29.5 mg, 213.4 µmol, 1.0 eq.) and NP10a (10.8 mg, 51.2 µmol, 0.2 eq.) were added and the 
mixture was stirred at 65°C for another 24 h. UPLC-MS analysis showed >95% conversion to the 
desired product. The solvent was removed by rotary evaporation and the residue was taken up in 
DCM (5 mL) and H2O (5 mL). The organic layer was separated and the aqueous layer was 
extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine (10 mL), 
dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (Silica, 9 g, 10:1→5:1 cyclohexane: EtOAc, Rf= 0.29, KMnO4) to yield the 
desired product as colorless oil (53 mg, 71%).  
1H NMR (400 MHz, CDCl3) δ/ppm: 7.40 (dt, J = 7.2, 1.0 Hz, 1H), 7.33 (dd, J = 2.8, 0.9 Hz, 1H), 
7.28 (dd, J = 8.3, 7.3 Hz, 1H), 7.03 (ddd, J = 8.2, 2.8, 1.1 Hz, 1H), 4.24 – 4.18 (m, 6H), 3.97 – 
3.91 (m, 2H), 1.34 (s, 12H), 1.28 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 170.57, 158.18, 129.11, 127.62, 119.72, 118.53, 83.98, 
70.27, 69.09, 67.66, 61.04, 25.01, 14.35. 
HRMS (ESI): C18H27BNaO6+ calcd: 373.1793, found: 373.1793. 
Synthesis of NP10 
 
2-4 (20.0 mg, 33.3 µmol, 1.0 eq.), NP10b (23.3 mg, 66.5 µmol, 2.0 eq.), Pd (π-cinnamyl) chloride 
dimer (3.5 mg, 6.7 µmol, 20 mol%) and K3PO4 (21.2 mg, 99.8 µmol, 3.0 eq.) were suspended in 
EtOH (400 µL) and H2O (200 µL). The mixture was stirred at 50°C for 1 h, after which UPLC-MS 
analysis showed complete conversion to the desired product. The black mixture was filtered and 
purified by reversed-phase preparative HPLC (Method A). Product-containing fractions were 
combined and lyophilized to yield the product as an ester/acid mixture (12.0 mg, 52%). The 
material was dissolved in MeCN (0.5 mL) and a solution of LiOH monohydrate (7.2 mg, 
177.0 µmol, 10.0 eq.) in H2O (573 µL) was added. The solution was stirred at RT for 2 h, after 
which UPLC-MS analysis showed full conversion to the desired product. The reaction mixture 
was purified by reversed-phase preparative HPLC (Method A). Product-containing fractions were 
combined and lyophilized to yield the desired product as a white solid (8.0 mg, 70%). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.66 (t, J = 5.7 Hz, 1H), 8.24 (t, J = 5.9 Hz, 1H), 8.13 (t, J = 
6.0 Hz, 1H), 8.03 – 7.98 (m, 1H), 7.98 – 7.94 (m, 1H), 7.93 – 7.87 (m, 2H), 7.86 – 7.82 (m, 2H), 
7.49 (d, J = 8.4 Hz, 1H), 7.20 (t, J = 7.9 Hz, 1H), 6.98 (dd, J = 2.6, 1.6 Hz, 1H), 6.95 – 6.91 (m, 
1H), 6.86 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 4.12 – 4.06 (m, 4H), 3.82 – 3.79 (m, 2H), 3.41 (t, J = 
6.7 Hz, 2H), 3.34 (q, J = 6.5 Hz, 2H), 3.15 (dt, J = 8.0, 6.1 Hz, 2H), 2.79 (dt, J = 8.3, 6.1 Hz, 2H), 
1.79 (p, J = 6.8 Hz, 2H). 
13C NMR (500 MHz, HMBC/HMQC, DMSO-d6) δ/ppm: 171.35, 168.53, 165.26, 157.94, 147.49, 
140.71, 138.87, 138.56, 134.89, 133.95, 132.60, 132.28, 129.20, 128.99, 128.06, 127.52, 125.95, 
124.37, 120.64, 114.61, 113.04, 68.76, 67.38, 66.83, 48.29, 41.25, 38.50, 36.48, 28.06. 
HRMS (ESI): C29H31N7NaO10S+ calcd: 692.1745, found: 692.1751. 
Synthesis of the Aldehyde Precursor Building Block 2-25 
 
2-4 (53.0 mg, 88.1 µmol, 1.0 eq.), 3-formylphenylboronic acid (26.4 mg, 176.0 µmol, 2.0 eq.), 




















3.0 eq.) were suspended in EtOH (1 mL) and H2O (500 µL). The mixture was stirred at 50°C for 
1 h, after which UPLC-MS analysis showed complete conversion to the desired product. The 
black mixture was filtered and purified by reversed-phase preparative HPLC (Method A). Product-
containing fractions were combined and lyophilized to yield the desired product as a white solid 
(34.0 mg, 67%).  
1H NMR (400 MHz, CDCl3) δ/ppm: 9.89 (s, 1H), 8.13 – 7.98 (m, 1H), 7.88 – 7.81 (m, 1H), 7.80 – 
7.66 (m, 4H), 7.58 (d, J = 1.6 Hz, 1H), 7.55 – 7.39 (m, 3H), 7.38 – 7.27 (m, 3H), 6.08 (t, J = 
5.9 Hz, 1H), 3.50 (q, J = 6.4 Hz, 2H), 3.43 (t, J = 6.5 Hz, 2H), 3.33 (q, J = 5.5 Hz, 2H), 3.06 (t, J = 
5.6 Hz, 2H), 1.89 (p, J = 6.7 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 192.55, 169.98, 167.53, 148.08, 140.04, 138.72, 137.89, 
136.48, 136.01, 134.64, 133.92, 133.36, 132.97, 131.06, 130.20, 129.50, 128.86, 128.79, 128.41, 
126.34, 125.44, 49.52, 42.97, 39.97, 38.15, 28.64. 
HRMS (ESI): C26H25N7NaO7S+ calcd: 602.1428, found: 602.1438. 
Synthesis of NP11 
 
Under an inert atmosphere 18-crown-6 ether (3.0 mg, 11.2 µmol, 1.3 eq.) was dissolved in THF 
(500 µL) and KHMDS (2.1 mg, 10.4 µmol, 1.2 eq.) was added. The mixture was cooled to -78°C 
in a dry ice/acetone bath. Methyl 2-[bis(2,2,2-trifluoroethoxy)phosphoryl]acetate (2.0 µL, 
9.5 µmol, 1.1 eq.) was added and the mixture was stirred at -78°C for 5 min. 2-25 (5.0 mg, 
8.6 µmol, 1.0 eq.) was added and the mixture was stirred at -78°C for 3 h. The cooling bath was 
removed and the solution was slowly warmed to RT. After a total reaction time of 6 h, UPLC-MS 
analysis showed full conversion to the methyl ester product. A solution of LiOH monohydrate 
(3.6 mg, 86.3 µmol, 10.0 eq.) in H2O (288 µL) was added and the mixture was continued stirring 
overnight. UPLC-MS analysis showed full conversion to the acid in a 3:1 isomeric ratio. The 
mixture was filtered and purified by reversed-phase preparative HPLC (Method A). Product-
containing fractions were combined and lyophilized to yield the desired product as a white solid 
(2.5 mg, 47%, 24:1 cis:trans mixture).  
1H NMR (500 MHz, DMSO-d6) δ/ppm: 12.51 (s, 1H), 8.66 (t, J = 5.6 Hz, 1H), 8.32 (t, J = 5.9 Hz, 
1H), 8.15 (t, J = 6.0 Hz, 1H), 8.03 – 7.99 (m, 1H), 7.98 – 7.94 (m, 1H), 7.92 – 7.88 (m, 2H), 7.87 – 
7.83 (m, 2H), 7.59 – 7.55 (m, 2H), 7.51 (d, J = 7.8 Hz, 1H), 7.37 – 7.27 (m, 2H), 6.85 (d, J = 
12.7 Hz, 1H), 5.94 (d, J = 12.7 Hz, 1H), 3.45 – 3.41 (m, 2H), 3.34 (q, J = 6.2 Hz, 2H), 3.16 (dt, J = 
7.9, 6.0 Hz, 2H), 2.81 (dt, J = 8.2, 6.1 Hz, 2H), 1.79 (p, J = 6.8 Hz, 2H). 
13C NMR (500 MHz, HMBC/HMQC, DMSO-d6) δ/ppm: 168.31, 167.00, 165.26, 147.32, 139.93, 
139.23, 138.75, 138.51, 135.11, 134.55, 133.96, 132.59, 130.73, 129.51, 129.19, 128.61, 128.28, 
128.18, 127.64, 127.62, 125.90, 124.37, 121.19, 48.30, 41.28, 38.58, 36.50, 28.06. 
HRMS (ESI): C28H27N7NaO8S+ calcd: 644.1534, found: 644.1540. 
Synthesis of NP12 
 
2-4 (20.0 mg, 33.3 µmol, 1.0 eq.) and Pd (π-cinnamyl) chloride dimer (1.7 mg, 3.3 µmol, 
10 mol%) were placed in a dry 5 mL Schlenk tube, which was evacuated and backfilled with N2 




















(S)-(3-methoxy-2-methyl-3-oxopropyl)zinc(II) bromide (99.8 µL, 49.9 µmol, 500 mM in THF, 
1.5 eq.) was slowly added and the yellow solution was stirred at 0°C for 15 min. The solution was 
warmed to RT and stirred for another 45 min. UPLC-MS analysis showed full conversion to the 
methyl ester product. A solution of LiOH monohydrate (7.0 mg, 166.0 µmol, 5.0 eq.) in H2O 
(333 µL) was added and the mixture was stirred overnight. UPLC-MS analysis showed complete 
conversion to the desired product. The mixture was filtered and purified by reversed-phase 
preparative HPLC (Method A). Product-containing fractions were combined and lyophilized to 
yield the desired product as a white solid (15 mg, 80%).  
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.55 (t, J = 5.7 Hz, 1H), 8.44 (t, J = 5.7 Hz, 1H), 8.20 (t, J = 
5.9 Hz, 1H), 8.04 – 8.00 (m, 1H), 8.00 – 7.96 (m, 1H), 7.90 – 7.85 (m, 2H), 7.73 – 7.68 (m, 2H), 
7.44 – 7.40 (m, 1H), 3.41 (t, J = 6.7 Hz, 2H), 3.32 (qd, J = 6.2, 3.0 Hz, 4H), 3.11 – 3.01 (m, 3H), 
2.76 (dd, J = 13.5, 7.8 Hz, 1H), 2.65 (h, J = 7.1 Hz, 1H), 1.79 (p, J = 6.8 Hz, 2H), 0.97 (d, J = 
7.0 Hz, 3H). 
13C NMR (500 MHz, HMBC/HMQC, DMSO-d6) δ/ppm: 176.50, 168.42, 165.38, 147.43, 138.92, 
137.58, 137.34, 134.63, 133.88, 132.52, 129.23, 128.87, 127.14, 124.57, 124.28, 48.26, 41.67, 
39.92, 38.74, 36.41, 35.68, 28.05, 16.50. 
HRMS (ESI): C23H27N7NaO8S+ calcd: 584.1534, found: 584.1542. 
Synthesis of NP13 
 
2-4 (20.0 mg, 33.3 µmol, 1.0 eq.) and Pd (π-cinnamyl) chloride dimer (1.7 mg, 3.3 µmol, 
10 mol%) were placed in a dry 5 mL Schlenk tube, which was evacuated and backfilled with N2 
three times. THF (400 µL) was added and the yellow solution was cooled to 0°C. A solution of  
(3-ethoxy-3-oxopropyl)zinc(II) bromide (99.8 µL, 49.9 µmol, 500 mM in THF, 1.5 eq.) was slowly 
added and the yellow solution was stirred at 0°C for 15 min. The solution was warmed to RT and 
stirred for another 45 min. UPLC-MS analysis showed full conversion to the ethyl ester product. A 
solution of LiOH monohydrate (14.0 mg, 333.0 µmol, 10.0 eq.) in H2O (665 µL) was added and 
the mixture was stirred at RT for 2 h. UPLC-MS analysis showed complete conversion to the 
desired product. The mixture was filtered and purified by reversed-phase preparative HPLC 
(Method A). Product-containing fractions were combined and lyophilized to yield the desired 
product as a white solid (16 mg, 88%).  
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.55 (t, J = 5.7 Hz, 1H), 8.44 (t, J = 5.7 Hz, 1H), 8.22 (t, J = 
6.0 Hz, 1H), 8.05 – 8.00 (m, 1H), 8.00 – 7.96 (m, 1H), 7.90 – 7.84 (m, 2H), 7.75 (d, J = 1.7 Hz, 
1H), 7.69 (dd, J = 7.9, 1.8 Hz, 1H), 7.41 (d, J = 7.9 Hz, 1H), 3.41 (t, J = 6.8 Hz, 2H), 3.35 – 3.29 
(m, 4H), 3.09 (q, J = 6.5 Hz, 2H), 2.91 (dd, J = 8.7, 7.1 Hz, 2H), 2.53 (dd, J = 8.7, 7.2 Hz, 2H), 
1.79 (p, J = 6.8 Hz, 2H). 
13C NMR (500 MHz, HMBC/HMQC, DMSO-d6) δ/ppm: 173.51, 168.47, 165.50, 147.47, 138.64, 
138.57, 135.03, 133.96, 132.63, 129.31, 128.31, 127.17, 126.62, 124.53, 124.38, 48.35, 41.79, 
38.86, 36.48, 34.97, 28.15, 27.89. 












Synthesis of NP14 
 
2-4 (20.0 mg, 33.3 µmol, 1.0 eq.) and Pd (π-cinnamyl) chloride dimer (1.7 mg, 3.3 µmol, 
10 mol%) were placed in a dry 5 mL Schlenk tube, which was evacuated and backfilled with N2 
three times. THF (400 µL) was added and the yellow solution was cooled to 0°C. A solution of  
(4-ethoxy-4-oxobutyl)zinc(II) bromide (99.8 µL, 49.9 µmol, 500.0 mM in THF, 1.5 eq.) was slowly 
added and the yellow solution was stirred at 0°C for 15 min. The solution was warmed to RT and 
stirred for another 45 min. UPLC-MS analysis showed full conversion to the ethyl ester product. A 
solution of LiOH monohydrate (14.0 mg, 333.0 µmol, 10.0 eq.) in H2O (665 µL) was added and 
the mixture was stirred at RT for 2 h. UPLC-MS analysis showed complete conversion to the 
desired product. The mixture was filtered and purified by reversed-phase preparative HPLC 
(Method A). Product-containing fractions were combined and lyophilized to yield the desired 
product as a white solid (7 mg, 38%).  
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.57 (t, J = 5.7 Hz, 1H), 8.40 (t, J = 5.7 Hz, 1H), 8.20 (t, J = 
5.9 Hz, 1H), 8.06 – 8.00 (m, 1H), 8.01 – 7.96 (m, 1H), 7.90 – 7.84 (m, 2H), 7.71 (d, J = 1.7 Hz, 
1H), 7.69 (dd, J = 7.9, 1.7 Hz, 1H), 7.38 (d, J = 7.9 Hz, 1H), 3.41 (t, J = 6.7 Hz, 2H), 3.32 (p, J = 
6.3 Hz, 4H), 3.08 (q, J = 6.4 Hz, 2H), 2.73 – 2.67 (m, 2H), 2.19 (t, J = 7.5 Hz, 2H), 1.78 (dt, J = 
10.2, 7.1 Hz, 4H). 
13C NMR (500 MHz, HMBC/HMQC, DMSO-d6) δ/ppm: 173.93, 168.52, 165.48, 147.44, 139.23, 
139.02, 138.80, 134.82, 133.91, 132.56, 129.27, 128.17, 127.01, 124.34, 124.30, 48.31, 41.77, 
38.75, 36.44, 33.13, 31.63, 28.11, 25.95. 
HRMS (ESI): C23H27N7NaO8S+ calcd: 584.1534, found: 584.1533. 
Synthesis of NP15 
 
2-4 (20.0 mg, 33.3 µmol, 1.0 eq.) and Pd (π-cinnamyl) chloride dimer (6.7 mg, 13.3 µmol, 
40 mol%) were placed in a dry 5 mL Schlenk tube, which was evacuated and backfilled with N2 
three times. THF (400 µL) was added and the yellow solution was cooled to 0°C. A solution of  
(5-ethoxycarbonyl-2-furyl)zinc(II) bromide (99.8 µL, 49.9 µmol, 500.0 mM in THF, 1.5 eq.) was 
slowly added and the yellow solution was stirred at 0°C for 15 min. The solution was warmed to 
RT and stirred for another 45 min. UPLC-MS analysis showed 50% conversion to the ethyl ester 
product. The mixture was filtered and purified by reversed-phase preparative HPLC (Method A). 
Product-containing fractions were combined and lyophilized to yield the desired product as a 
yellow-brown solid (6 mg, 29%). The material was dissolved in MeCN (300 µL) and a solution of 
LiOH monohydrate (4.1 mg, 97.8 µmol, 10.0 eq.) in H2O (196 µL) was added and the mixture was 
stirred at RT for 2 h. UPLC-MS analysis showed complete conversion to the desired product. The 
mixture was filtered and purified by reversed-phase preparative HPLC (Method A). Product-
containing fractions were combined and lyophilized to yield the desired product as a white solid 
(3 mg, 52%).  
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.74 (t, J = 5.6 Hz, 1H), 8.60 (t, J = 5.7 Hz, 1H), 8.23 – 
8.18 (m, 2H), 8.04 – 8.01 (m, 1H), 8.01 – 7.97 (m, 1H), 7.91 – 7.85 (m, 3H), 7.50 (d, J = 7.9 Hz, 
1H), 7.25 (d, J = 3.6 Hz, 1H), 6.85 (d, J = 3.6 Hz, 1H), 3.43 (t, J = 6.7 Hz, 2H), 3.34 (dq, J = 19.1, 




















13C NMR (500 MHz, HMBC/HMQC, DMSO-d6) δ/ppm: 168.20, 164.92, 153.68, 147.43, 144.15, 
137.36, 135.03, 133.89, 132.57, 129.22, 127.92, 126.99, 126.00, 125.59, 124.30, 119.27, 110.50, 
99.05, 48.27, 41.54, 38.86, 36.52, 28.03. 
HRMS (ESI): C24H23N7NaO9S+ calcd: 608.1170, found: 608.1167. 
Synthesis of NP16 
 
2-4 (20.0 mg, 33.3 µmol, 1.0 eq.) and Pd (π-cinnamyl) chloride dimer (1.7 mg, 3.3 µmol, 
10 mol%) were placed in a dry 5 mL Schlenk tube, which was evacuated and backfilled with N2 
three times. THF (400 µL) was added and the yellow solution was cooled to 0°C. A solution of  
(6-ethoxy-6-oxohexyl)zinc(II) bromide (99.8 µL, 49.9 µmol, 500.0 mM in THF, 1.5 eq.) was slowly 
added and the yellow solution was stirred at 0°C for 15 min. The solution was warmed to RT and 
stirred for another 45 min. UPLC-MS analysis showed 16% conversion to the ethyl ester product 
plus a lot of byproduct. A solution of LiOH monohydrate (14.0 mg, 333.0 µmol, 10.0 eq.) in H2O 
(665 µL) was added and the mixture was stirred at RT for 2 h. UPLC-MS analysis showed 
complete conversion to the desired product. The mixture was filtered and purified by reversed-
phase preparative HPLC (Method A). Product-containing fractions were combined and lyophilized 
to yield the desired product as a brownish solid (3 mg, 15%).  
1H NMR (500 MHz, DMSO-d6) δ/ppm: 11.96 (s, 1H), 8.54 (t, J = 5.7 Hz, 1H), 8.38 (t, J = 5.7 Hz, 
1H), 8.20 (t, J = 6.0 Hz, 1H), 8.04 – 8.00 (m, 1H), 8.00 – 7.96 (m, 1H), 7.91 – 7.85 (m, 2H), 7.70 
(d, J = 1.7 Hz, 1H), 7.67 (dd, J = 7.9, 1.8 Hz, 1H), 7.37 (d, J = 7.9 Hz, 1H), 3.41 (t, J = 6.7 Hz, 
2H),  
3.33 – 3.28 (m, 4H), 3.10 – 3.03 (m, 2H), 2.72 – 2.64 (m, 2H), 2.16 (t, J = 7.4 Hz, 2H), 1.78 (p, 
J = 6.8 Hz, 2H), 1.56 – 1.42 (m, 4H), 1.32 – 1.20 (m, 2H). 
13C NMR (500 MHz, HMBC/HMQC, DMSO-d6) δ/ppm: 174.21, 168.64, 165.59, 147.46, 139.96, 
138.83, 138.74, 134.79, 133.92, 132.55, 129.16, 128.17, 126.95, 124.31, 124.16, 48.32, 41.76, 
38.70, 36.44, 33.29, 32.21, 30.45, 28.25, 28.11, 23.99. 
HRMS (ESI): C25H31N7NaO8S+ calcd: 612.1847, found: 612.1846. 
Synthesis of NP17 
 
In a dry Schlenk tube triethyl-4-phosphonocrotonate (5.0 µL, 22.4 µmol, 1.3 eq.) was dissolved in 
THF (400 µL) and cooled to 0°C. n-BuLi (16.2 µL, 25.9 µmol, 1.5 eq. 1.6 M in hexanes) was 
added and the yellow solution was stirred for 15 min at 0°C. 2-25 (10.0 mg, 17.3 µmol, 1.0 eq.) 
was added and the yellow solution was stirred at 0°C for 15 min. The ice bath was removed and 
the solution was stirred at RT overnight, after which UPLC- MS analysis showed complete 
conversion of the starting material. The mixture was filtered and purified by reversed-phase 
preparative HPLC (Method A). Product-containing fractions were combined and lyophilized to 
yield the ethyl ester product as a white solid (5 mg, 43%). The material was dissolved in MeCN 
(500 µL) and a solution of LiOH monohydrate (6.2 mg, 148.0 µmol, 20.0 eq.) in H2O (493 µL) was 
added and the mixture was stirred at RT for 2 h. UPLC-MS analysis showed complete conversion 
to the desired product. The mixture was filtered and purified by reversed-phase preparative HPLC 
(Method A). Product-containing fractions were combined and lyophilized to yield the desired 


















1H NMR (500 MHz, DMSO-d6) δ/ppm: 12.29 (brs, 1 H), 8.66 (t, J = 5.7 Hz, 1H), 8.31 (t, J = 
5.9 Hz, 1H), 8.14 (t, J = 6.0 Hz, 1H), 8.02 – 7.97 (m, 1H), 7.96 – 7.92 (m, Hz, 1H), 7.91 – 7.88 (m, 
2H), 7.88 – 7.85 (m, 2H), 7.57 – 7.51 (m, 2H), 7.48 (dt, J = 7.2, 1.8 Hz, 1H), 7.38 – 7.28 (m, 3H), 
7.14 – 7.00 (m, 2H), 6.01 (d, J = 15.2 Hz, 1H), 3.41 (t, J = 6.8 Hz, 2H), 3.34 – 3.31 (m, 2 H), 3.15 
(dt, J = 8.0, 6.1 Hz, 2H), 2.76 (dt, J = 8.4, 6.2 Hz, 2H), 1.79 (p, J = 6.8 Hz, 2H). 
13C NMR (500 MHz, HMBC/HMQC, DMSO-d6) δ/ppm: 168.31, 167.23, 165.19, 147.47, 144.03, 
143.89, 139.95, 139.31, 138.81, 138.39, 135.71, 135.00, 133.95, 132.56, 129.17, 128.63, 128.36, 
128.19, 127.54, 126.95, 126.79, 126.04, 125.97, 124.38, 122.26, 48.30, 41.24, 38.53, 36.50, 
28.07. 
HRMS (ESI): C30H29N7NaO8S+ calcd: 670.1691, found: 670.1694. 
Synthesis of 6-Bromo methyl sorbate NP18a[198] 
 
Methyl sorbate (517.0 µL, 4.0 mmol, 1.0 eq.) and NBS (733.0 mg, 4.1 mmol, 1.0 eq.) were 
suspended in chlorobenzene (3.4 mL) and stirred at 100°C for 1 h. Benzoylperoxide (86.6 mg, 
359.0 µmol, 9 mol%) was added and the mixture was refluxed for 5 h. The reaction was 
concentrated in vacuo and the residue was dissolved in Et2O (8 mL). The organic layer was 
washed with aqueous NaOH (5%, 2 mL per wash) until the aqueous layer remained colorless. 
The organic layer was dried over Na2SO4, concentrated by rotary evaporation and the crude was 
purified by flash column chromatography (Silica, 60 g, cyclohexane:EtOAc, 30:1→25:1 →20:1, 
Rf = 0.31, UV) to yield the desired product as yellow oil (254 mg, 31%). Analytical data was in 
agreement with reported data.[246] 
1H NMR (400 MHz, CDCl3) δ/ppm: 7.29 – 7.23 (m, 1H), 6.42 – 6.35 (m, 1H), 6.28 – 6.20 (m, 1H), 
5.94 (d, J = 15.2 Hz, 1H), 4.03 (d, J = 7.7 Hz, 2H), 3.75 (s, 3H). 
Synthesis of Methyl (2E,4E)-6-(diethoxyphosphoryl)hexa-2,4-dienoate NP18b[198] 
 
NP18a (100.0 mg, 488.0 µmol, 1.0 eq.) was dissolved in toluene (935 µL) and P(OEt)3 (1.0 mL, 
5.9 mmol, 12.0 eq.) was dropwise added. The mixture was refluxed for 2 h, after which the 
solvent was removed by rotary evaporation. The crude residue was purified by flash column 
chromatography (Silica, 15 g, petrol ether:EtOAc, 1:1→1:4→100% EtOAc, Rf = 0.25, UV) to yield 
the desired product as a colorless oil (104 mg, 81%). Analytical data was in agreement with 
reported data.[247] 
1H NMR (400 MHz, CDCl3) δ/ppm: 7.29 – 7.22 (m, 1H), 6.34 – 6.26 (m, 1H), 6.10 – 6.00 (m, 1H), 
5.85 (dd, J = 15.4, 2.4 Hz, 1H), 4.14 – 4.06 (m, 4H), 3.74 (s, 3H), 2.71 (dd, J = 23, 7.6 Hz, 2H), 
1.31 (t, J = 7.1 Hz, 3H). 
Synthesis of NP18[198] 
 
NP18b (10.9 mg, 41.4 µmol, 1.2 eq.) was dissolved in THF (600 µL) and cooled to -78°C. n-BuLi 
(32.4 µL, 51.8 µmol, 1.5 eq. 1.6 M in hexanes) was added and the mixture was stirred at -78°C 
for 15 min. A solution of 2-25 (20.0 mg, 34.5 µmol, 1.0 eq.) in THF (400 µL) was added and the 
mixture was stirred at -78°C for 2 h. The mixture was slowly warmed to RT and stirred for another 














overnight, filtered and purified by reversed-phase preparative HPLC (Method A). Product-
containing fractions were combined and lyophilized to yield the desired product as a yellowish 
solid (14 mg, 59%). The material was dissolved in MeCN (400 µL) and a solution of LiOH 
monohydrate (8.5 mg, 203.7 µmol, 10.0 eq.) in H2O (310 µL) was added. The mixture was 
agitated at RT for 1 h, after which UPLC-MS analysis showed complete conversion to the desired 
product. The solution was acidified to pH 3 with aqueous HCl. The crude was purified by 
reversed-phase preparative HPLC (Method A). Product-containing fractions were combined and 
lyophilized to yield the desired product as a yellowish solid (2.6 mg, 24%). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 12.26 (s, 1H), 8.70 – 8.61 (m, 1H), 8.30 (td, J = 5.8, 
3.3 Hz, 1H), 8.17 – 8.09 (m, 1H), 8.03 – 7.97 (m, 1H), 7.96 – 7.92 (m, 1H), 7.92 – 7.81 (m, 4H), 
7.67 – 7.43 (m, 3H), 7.42 – 7.24 (m, 3H), 7.23 – 6.99 (m, 1H), 6.90 – 6.72 (m, 1H), 6.62 – 6.45 
(m, 1H), 6.40 – 6.13 (m, 1H), 5.95 (dd, J = 17.3, 15.1 Hz, 1H), 3.41 (t, J = 6.7 Hz, 2H), 3.34 – 
3.31 (m, 2H), 3.15 (q, J = 6.7 Hz, 2H), 2.83 – 2.71 (m, 2H), 1.79 (p, J = 6.8 Hz, 2H). 
13C NMR (500 MHz, HMBC/HMQC, DMSO-d6) δ/ppm: 168.42, 167.36, 165.25, 147.44, 139.95, 
138.88, 138.53, 136.81, 136.26, 135.83, 135.01, 133.94, 132.58, 130.62, 129.19, 128.61, 128.22, 
128.20, 127.53, 127.08, 127.00, 126.51, 125.99, 125.95, 125.73, 124.38, 121.67, 48.31, 41.27, 
38.55, 36.51, 28.07. 
HRMS (ESI): C32H31N7NaO8S+ calcd: 696.1847, found: 696.1855. 
Synthesis of NP19 
  
In a dry Schlenk tube triethyl 3-methyl-4-phosphono-2-butenoate (24.2 µL, 89.8 µmol, 1.3 eq.) 
was dissolved in THF (1.6 mL) and cooled to 0°C. n-BuLi (64.8 µL, 103.6 µmol, 1.5 eq. 1.6 M in 
hexanes) was added and the yellow solution was stirred at 0°C for 15 min. 2-25 (40.0 mg, 
69.0 µmol, 1.0 eq.) was added and the yellow solution was stirred at 0°C for 15 min. The ice bath 
was removed and the solution was stirred at RT for 38 h, after which UPLC-MS analysis showed 
about 60% conversion to the product. The mixture was filtered and purified by reversed-phase 
preparative HPLC (Method A). Product-containing fractions were combined and lyophilized to 
yield the two isomeric ethyl ester products as white solids (major isomer, 26 mg, 54%)/(minor 
isomer, 6 mg, 13%). The major isomer was dissolved in MeCN (1 mL) and a solution of LiOH 
monohydrate (22.8 mg, 544.0 µmol, 15.0 eq.) in H2O (1.1 mL) was added and the mixture was 
stirred at RT for 22 h. UPLC-MS analysis showed complete conversion to the desired product. 
The mixture was acidified with conc. HCl, filtered and purified by reversed-phase preparative 
HPLC (Method A). Product-containing fractions were combined and lyophilized to yield the 
desired product as a white solid (15 mg, 63%). NOE analysis confirmed the correct structure of 
the product. 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 12.15 (s, 1H), 8.67 (t, J = 5.6 Hz, 1H), 8.30 (t, J = 5.8 Hz, 
1H), 8.14 (t, J = 6.0 Hz, 1H), 8.02 – 7.97 (m, 1H), 7.96 – 7.92 (m, 1H), 7.91 – 7.86 (m, 4H), 7.60 
(d, J = 1.6 Hz, 1H), 7.54 – 7.50 (m, 2H), 7.34 – 7.27 (m, 2H), 7.08 – 6.98 (m, 2H), 5.96 (d, J = 
1.4 Hz, 1H), 3.45 – 3.40 (m, 2H), 3.34 (q, J = 6.6 Hz, 2H), 3.15 (dt, J = 7.9, 6.0 Hz, 2H), 2.78 (dt, 
J = 8.4, 6.1 Hz, 2H), 2.31 (d, J = 1.2 Hz, 3H), 1.79 (p, J = 6.8 Hz, 2H). 
13C NMR (500 MHz, HMBC/HMQC, DMSO-d6) δ/ppm: 168.36, 167.51, 165.23, 150.72, 147.47, 
139.95, 138.82, 138.51, 135.96, 134.99, 133.95, 133.22, 132.55, 132.08, 129.18, 128.35, 128.34, 










HRMS (ESI): C31H31N7NaO8S+ calcd: 684.1847, found: 684.1859. 
Synthesis of NP20 
 
The isolated minor isomer from NP19 synthesis (5.0 mg, 7.3 µmol, 1.0 eq.) was dissolved in 
MeCN (200 µL) and a solution of LiOH monohydrate (4.6 mg, 109.0 µmol, 15.0 eq.) in H2O 
(217 µL) was added. The solution was stirred at RT for 22 h, after which UPLC-MS analysis 
showed full conversion. The solution was acidified with HCl (2 M) and purified by reversed-phase 
preparative HPLC (Method A). Product-containing fractions were combined and lyophilized to 
yield the desired product as a white solid (3 mg, 63%). NOE analysis confirmed the correct 
structure of the product. 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 12.15 (s, 1H), 8.67 (t, J = 5.4 Hz, 1H), 8.33 – 8.25 (m, 2H), 
8.13 (dt, J = 9.9, 5.8 Hz, 1H), 8.03 – 7.97 (m, 1H), 7.93 (dd, J = 6.2, 3.2 Hz, 1H), 7.90 – 7.86 (m, 
4H), 7.56 – 7.48 (m, 2H), 7.44 (dt, J = 7.6, 1.5 Hz, 1H), 7.35 – 7.28 (m, 2H), 7.02 (d, J = 16.1 Hz, 
1H), 5.76 (s, 1H), 3.44 – 3.39 (m, 3H), 3.36 – 3.33 (m, 2H), 3.17 – 3.12 (m, 2H), 2.74 (dt, J = 8.3, 
6.1 Hz, 2H), 2.08 (d, J = 1.3 Hz, 3H), 1.79 (td, J = 6.7, 1.3 Hz, 2H). 
13C NMR (500 MHz, HMBC/HMQC, DMSO-d6) δ/ppm: 168.28, 166.77, 165.23, 149.53, 147.30, 
140.01, 138.82, 138.56, 136.23, 135.02, 134.40, 133.92, 132.52, 129.16, 128.46, 128.43, 128.11, 
127.50, 127.34, 127.10, 126.00, 125.69, 125.54, 124.34, 118.65, 48.28, 41.22, 38.50, 36.48, 
28.04, 20.18. 
HRMS (ESI): C31H31N7NaO8S+ calcd: 684.1847, found: 684.1857. 
Synthesis of NP21 
 
In a dry Schlenk tube 2-methyl-triethyl-4-phosphonocrotonate (44.5 mg, 135.0 µmol, 1.3 eq.) was 
dissolved in THF (1 mL) and cooled to 0°C. n-BuLi (97.1 µL, 155.3 µmol, 1.5 eq. 1.6 M in 
hexanes) was added and the yellow solution was stirred at 0°C for 15 min. 2-25 (60.0 mg, 
104.0 µmol, 1.0 eq.) was added and the yellow solution was stirred at 0°C for 15 min. The ice 
bath was removed and the solution was stirred at RT for 25 h, after which UPLC-MS analysis 
showed about 66% conversion to the product. The solvent was removed by rotary evaporation 
and purified by reversed-phase preparative HPLC (Method A). Product-containing fractions were 
combined and lyophilized to yield the ethyl ester product as a white solid (41 mg, 57%). The 
material was dissolved in MeCN (1.5 mL) and a solution of LiOH monohydrate (24.9 mg, 
594.0 µmol, 10.0 eq.) in H2O (743 µL) was added and the mixture was stirred at RT for 23 h. 
UPLC-MS analysis showed complete conversion to the desired product. The mixture was 
acidified with conc. HCl, filtered and purified by reversed-phase preparative HPLC (Method A). 
Product-containing fractions were combined and lyophilized to yield the desired product as a 
white solid (30 mg, 76%). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.67 (t, J = 5.7 Hz, 1H), 8.34 (t, J = 5.9 Hz, 1H), 8.14 (t, J = 
6.0 Hz, 1H), 8.01 – 7.97 (m, 1H), 7.96 – 7.92 (m, 1H), 7.91 – 7.85 (m, 4H), 7.62 (s, 1H), 7.57 – 
7.49 (m, 2H), 7.33 (t, J = 7.5 Hz, 1H), 7.30 (dt, J = 7.6, 1.6 Hz, 1H), 7.27 – 7.18 (m, 2H), 6.97 (d, 
J = 13.4 Hz, 1H), 3.41 (t, J = 6.7 Hz, 2H), 3.37 – 3.32 (m, 2H), 3.16 (dt, J = 7.9, 6.0 Hz, 2H), 2.79 


















13C NMR (126 MHz, DMSO-d6) δ/ppm: 169.11, 168.68, 165.50, 147.70, 140.20, 139.17, 138.78, 
138.28, 137.63, 136.38, 135.22, 134.10, 132.72, 132.57, 129.37, 128.64, 128.57, 128.43, 128.06, 
127.71, 126.98, 126.36, 126.19, 124.64, 124.57, 48.57, 41.52, 38.85, 36.78, 28.33, 12.86. 
HRMS (ESI): C31H31N7NaO8S+ calcd: 684.1847, found: 684.1854. 
Synthesis of AA008[198] 
 
Under an inert atmosphere rac-H-β,β-Dicyclohexyl-Ala-OH (100.0 mg, 395.0 µmol, 1.0 eq.) was 
suspended in MeOH (3 mL) and cooled to 0°C. SOCl2 (288 µL, 4.0 mmol, 10.0 eq.) was slowly 
added, whereby a clear solution formed. The solution was stirred in the ice bath for 10 min and 
was then warmed to RT. After 20 h another portion of SOCl2 (288.0 µL, 4.0 mmol, 10.0 eq.) was 
added and the solution continued stirring. After 72 h more SOCl2 (144.0 µL, 2.0 mmol, 5.0 eq.) 
was added. After in total 7 d UPLC-MS analysis showed >98% conversion to the product. The 
volatiles were removed by rotary evaporation and the residue was dissolved in DCM (20 mL) and 
washed with half-saturated NaHCO3 solution (3 x 20 mL). The combined aqueous layers were 
extracted with DCM (2 x 20 mL) and the combined organic layers were washed with brine 
(20 mL), dried over Na2SO4 and concentrated in vacuo to yield the desired product as yellowish 
oil (94 mg, 89%).  
1H NMR (400 MHz, CD2Cl2) δ/ppm: 3.66 (s, 3H), 3.61 (d, J = 2.6 Hz, 1H), 1.74 – 1.54 (m, 11H), 
1.41 – 1.37 (m, 1H), 1.28 – 1.03 (m, 11H). 
13C NMR (101 MHz, CD2Cl2) δ/ppm: 178.61, 54.59, 52.37, 52.14, 38.83, 36.88, 32.89, 32.43, 
32.42, 30.61, 27.66, 27.65, 27.60, 27.51, 27.32, 27.20. 
HRMS (ESI): C16H30NO2+ calcd: 268.2271, found: 268.2272. 
Synthesis of AA076[198] 
 
H-tBu-Gly-OH (100.0 mg, 762.0 µmol, 1.0 eq.) was suspended in MeOH (5 mL) under an inert 
atmosphere and cooled to 0°C. SOCl2 (1.7 mL, 22.9 mmol, 30.0 eq.) was slowly added, whereby 
a clear solution was formed. The solution was stirred at 0°C for 10 min and was then heated to 
45°C. After 63 h reaction time, more SOCl2 (278.0 µL, 3.8 mmol, 5.0 eq.) was added. After 110 h 
reaction time, the volatiles were removed in vacuo and the desired product was obtained as a 
yellow solid (142 mg, quant.). 
1H NMR (400 MHz, CD3OD) δ/ppm: 3.85 (s, 3H), 3.81 (s, 1H), 1.10 (s, 9H). 
13C NMR (126 MHz, CD3OD) δ/ppm: 168.77, 61.53, 51.96, 32.89, 25.33. 
HRMS (ESI): C7H16NO2+ calcd: 146.1176, found: 146.1177. 
Synthesis of AA077 
 
Aminooxyacetic acid (1.0 g, 11.0 mmol, 1.0 eq.) was suspended in MeOH (25 mL) and cooled to 
0°C. SOCl2 (4.0 mL, 54.9 mmol, 5.0 eq.) was slowly added and the solution was stirred at 0°C for 
10 min. The cooling bath was removed and the solution was stirred at RT for 20 h. The solvent 
was removed by rotary evaporation and the residue was dissolved in half-saturated NaHCO3 







layers were washed with brine (25 mL), dried over Na2SO4 and concentrated. The crude material 
was purified by bulb-to-bulb distillation (100°C, 90 mbar). The desired product was isolated as 
colorless liquid (300 mg, 26%). Analytical data was in agreement with reported data.[248] 
1H NMR (400 MHz, CDCl3) δ/ppm: 4.48 (s, 2H), 3.80 (s, 3H). 
Synthesis of AA078 
 
3-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]propanoic acid (118.0 mg, 533.0 µmol, 1.0 eq.) was 
dissolved in MeOH (3 mL) and cooled in an ice bath. SOCl2 (389.0 µL, 5.3 mmol, 10.0 eq.) was 
dropwise added and the mixture was stirred at 0°C for 10 min. The ice bath was removed and the 
mixture was stirred at RT for 14 h, after which UPLC-MS analysis showed full conversion to the 
desired product. The volatiles were removed by rotary evaporation and the residue was dissolved 
in MeOH (5 mL), filtered and concentrated to yield the desired product as yellow oil (121 mg, 
84%).  
1H NMR (500 MHz, CD3OD) δ/ppm: 3.75 (t, J = 6.1 Hz, 2H), 3.73 – 3.70 (m, 2H), 3.69 – 3.67 (m, 
3H), 3.67 – 3.65 (m, 3H), 3.66 – 3.59 (m, 5H), 3.15 – 3.11 (m, 2H), 2.60 (t, J = 6.1 Hz, 2H). 
13C NMR (126 MHz, CD3OD) δ/ppm: 173.91, 71.52, 71.34, 71.20, 71.18, 67.83, 67.60, 52.18, 
40.68, 35.62. 
HRMS (ESI): C10H22NO5+ calcd: 236.1492, found: 236.1494. 
Synthesis of AA087 
 
NaH in mineral oil (38.5 mg, 1.0 mmol, 1.6 eq. 60%) was suspended in THF (3 mL) and the 
mixture was cooled to 0°C. Methyl 2-diethoxyphosphorylacetate (173.0 µL, 942.0 µmol, 1.5 eq.) 
was added and the solution was stirred at 0°C for 15 min. 2-(N-Boc)acetaldehyde (100.0 mg, 
628.0 µmol, 1.0 eq.) was added and the mixture was stirred for 15 min. The cooling bath was 
removed and the solution was stirred at RT for 3.5 h, after which TLC showed full conversion of 
the starting material. The reaction was quenched by the addition of EtOH (3 mL). The solvent 
was removed by rotary evaporation and the crude was purified by flash column chromatography 
(Silica, 37 g, 4:1 cyclohexane:EtOAc, Rf= 0.28, KMnO4). Product-containing fractions were 
combined and concentrated to yield the Boc protected intermediate as colorless oil (77 mg, 57%). 
The material was dissolved in DCM (2 mL) and cooled in an ice bath. HCl in dioxane (895.0 µL, 
3.6 mmol, 10.0 eq. 4.0 M) was slowly added and the solution was stirred at 0°C for 10 min. The 
cooling bath was removed and the mixture was stirred at RT for 16 h. The volatiles were removed 
by rotary evaporation and the residue was co-evaporated with DCM (5 mL) to yield the desired 
product as beige solid (47 mg, 86%). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.28 (brs, 3H), 6.87 (dt, J = 16.0, 5.6 Hz, 1H), 6.18 (dt, J = 
16.0, 1.8 Hz, 1H), 3.71 (s, 3H), 3.70 – 3.66 (m, 2H). 
13C NMR (126 MHz, DMSO-d6) δ/ppm: 165.36, 140.61, 123.35, 51.71, 40.11. 











Synthesis of AA088 
 
18-crown-6 ether (216.0 mg, 817.0 µmol, 1.3 eq.) was dissolved in THF (3 mL) and KHMDS 
(150.0 mg, 754.0 µmol, 1.2 eq.) was added. The yellow solution was cooled to -78°C, methyl  
2-[bis(2,2,2-trifluoroethoxy)phosphoryl]acetate (147.0 µL, 691.0 µmol, 1.1 eq.) was added and the 
solution was stirred at 0°C for 5 min. 2-(N-Boc)acetaldehyde (100.0 mg, 628.0 µmol, 1.0 eq.) was 
added and the solution was stirred at -78°C for 1 h. The cooling bath was removed and the 
solution was stirred at RT for 1 h, after which TLC showed full conversion of the starting material. 
The reaction was quenched by the addition of EtOH (3 mL). The solvent was removed by rotary 
evaporation and the crude was purified by flash column chromatography (Silica, 37 g, 5:1 
cyclohexane:EtOAc, Rf= 0.23, KMnO4). Product-containing fractions were combined and 
concentrated to yield the Boc protected intermediate as a beige solid (60 mg, 44%). The material 
was dissolved in DCM (2 mL) and cooled in an ice bath. HCl in dioxane (696.0 µL, 2.8 mmol, 
10.0 eq. 4.0 M) was slowly added and the solution was stirred at 0°C for 10 min. The cooling bath 
was removed and the mixture was stirred at RT for 15 h. The volatiles were removed by rotary 
evaporation and the residue was co-evaporated with DCM (5 mL) to yield the desired product as 
beige solid (41 mg, 96%). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 8.21 (brs, 3H), 6.37 (dt, J = 11.7, 5.9 Hz, 1H), 6.08 (dt, J = 
11.5, 2.2 Hz, 1H), 4.00 (s, 2H), 3.69 (s, 3H). 
13C NMR (126 MHz, DMSO-d6) δ/ppm: 165.51, 141.74, 121.89, 51.50, 37.58. 
HRMS (ESI): C5H10NO2+ calcd: 116.0706, found: 116.0708. 
Synthesis of AA089 
 
Under an inert atmosphere in a Schlenk tube methyl (E)-3-bromo-2-methylprop-2-enoate 
(250.0 mg, 1.4 mmol, 1.0 eq.), bis-(Boc)-allylamine (719.0 mg, 2.8 mmol, 2.0 eq.), Pd(OAc)2 
(9.4 mg, 41.9 µmol, 3 mol%), tris(o-tolyl)phosphine (25.5 mg, 83.8 µmol, 6 mol%) and 
triethylamine (389.0 µL, 2.8 mmol, 2.0 eq.) were mixed and heated to 100°C and stirred at this 
temperature for 19 h, after which UPLC-MS analysis showed complete conversion. The black 
mixture was quenched with NaOH (10%, 10 mL) and extracted with MtBE (3 x 10 ml). The 
combined organic layers were washed with brine (10 mL), dried over Na2SO4 and concentrated 
by rotary evaporation. The crude material was purified by flash column chromatography (Silica, 
95g, cyclohexane:EtOAc 20:1→10:1, Rf= 0.20, UV/KMnO4) to yield the desired product as yellow 
oil (341 mg, 69%). The material (287.0 mg, 807 µmol, 1.0 eq.) was dissolved in DCM (4 mL) and 
cooled in an ice bath. HCl in dioxane (4.0 mL, 16.1 mmol, 20.0 eq. 4.0 M in dioxane) was added 
and the solution was stirred at 0°C for 15 min. The mixture was warmed to RT and stirred for 
19 h, after which UPLC-MS analysis showed full conversion to the desired product. The volatiles 
were removed by rotary evaporation and the residue was dissolved in MeOH (3 mL). The mixture 
was filtered by syringe filter, cooled in an ice bath to 0°C and Et2O (5 x 3 mL) was added 
portionwise. The formed suspension was continued stirring at 0°C for 30 min and the precipitate 
was filtered off, washed with cold Et2O (10 mL), dried in vacuo to yield the desired product as a 
white solid (100 mg, 65%). 
1H NMR (400 MHz, CD3OD) δ/ppm: 7.19 (d, J = 11.3 Hz, 1H), 6.82 (ddd, J = 15.2, 11.3, 1.7 Hz, 







13C NMR (101 MHz, CD3OD) δ/ppm: 169.88, 137.43, 132.10, 131.96, 130.75, 52.52, 42.03, 
12.93. 
HRMS (ESI): C8H14NO2+ calcd: 156.1019, found: 156.1018. 
Synthesis of AA106 
 
(Trans-racemic) 1-tert-butyl-3-methyl-4-(5,6-dimethoxypyridin-3-yl)pyrrolidine-1,3-dicarboxylate 
(250.0 mg, 682.0 µmol, 1.0 eq.) and triethylsilane (1.1 mL, 6.8 mmol, 10.0 eq.) were dissolved in 
DCM (3 mL) and cooled in an ice bath. HCl in dioxane (1.7 mL, 6.8 mmol, 10.0 eq. 4.0 M in 
dioxane) was added dropwise over 5 min and the solution was stirred in the ice bath for 10 min. 
The cooling bath was removed and the solution was stirred at RT for 50 min, after which  
UPLC-MS analysis showed full conversion to the desired product. The volatiles were removed by 
rotary evaporation and the crude was purified by reversed phase column chromatography on the 
ISOLERA (RP-Silica, 100 g, H2O:MeCN, UV). Product-containing fractions were combined and 
lyophilized to yield the desired product as a white, hygroscopic solid (38 mg, 16%).  
1H NMR (500 MHz, D2O) δ/ppm: 7.65 (d, J = 1.9 Hz, 1H), 7.37 (d, J = 2.1 Hz, 1H), 3.97 (s, 3H), 
3.91 (s, 3H), 3.87 (ddd, J = 11.7, 8.5, 5.0 Hz, 2H), 3.80 – 3.73 (m, 2H), 3.69 (s, 3H), 3.61 – 3.55 
(m, 1H), 3.46 (t, J = 11.4 Hz, 1H). 
13C NMR (126 MHz, D2O) δ/ppm: 172.81, 153.96, 144.19, 135.21, 126.19, 117.38, 55.71, 53.91, 
52.95, 50.82, 48.60, 47.05, 44.36. 
HRMS (ESI): C13H19N2O4+ calcd: 267.1339, found: 267.1338. 
Synthesis of AA107 
 
H-β-(2-thiazolyl)-Ala-OH (88.0 mg, 511.0 µmol, 1.0 eq.) was suspended in MeOH (4.5 mL) and 
cooled in an ice bath. SOCl2 (373.0 µL, 5.1 mmol, 10.0 eq.) was dropwise added and the mixture 
was stirred at 0°C for 10 min. The ice bath was removed and the mixture was stirred at RT for 
23 h, after which UPLC-MS analysis showed full conversion to the desired product. The volatiles 
were removed by rotary evaporation and the residue was dissolved in MeOH (10 mL), filtered 
over a G4 glass sintered funnel and cooled in an ice bath. Et2O (15 mL) was slowly added and 
the mixture was stirred in the ice bath for 30 min. The formed precipitate was filtered off, washed 
with cold Et2O (3 x 5 mL) and dried in vacuo to yield the desired product as a white solid (104 mg, 
79%).  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.75 (s, 4H), 7.77 (d, J = 3.3 Hz, 1H), 7.70 (d, J = 3.3 Hz, 
1H), 4.56 – 4.48 (m, 1H), 3.69 (s, 3H), 3.63 (d, J = 5.8 Hz, 2H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 168.68, 163.23, 142.32, 120.87, 52.85, 51.27, 32.23. 














Synthesis of AA108 
 
H-β-(2-quinolyl)-Ala-OH (100.0 mg, 462.0 µmol, 1.0 eq.) was suspended in MeOH (3 mL) and 
cooled in an ice bath. SOCl2 (337.0 µL, 4.6 mmol, 10.0 eq.) was dropwise added and the mixture 
was stirred at 0°C for 10 min. The ice bath was removed and the mixture was stirred at RT for 
20 h, after which UPLC-MS analysis showed full conversion to the desired product. The volatiles 
were removed by rotary evaporation, the residue was dissolved in MeOH (2.5 mL), filtered by a 
syringe filter and cooled in an ice bath. Et2O (3 mL) was slowly added and the mixture was stirred 
in the ice bath for 30 min. The formed precipitate was filtered off, washed with cold Et2O (3 x 
5 mL) and dried in vacuo to yield the desired product as a white solid (103 mg, 74%).  
1H NMR (400 MHz, CD3OD) δ/ppm: 9.08 (d, J = 8.6 Hz, 1H), 8.33 (ddd, J = 13.9, 8.5, 1.1 Hz, 
2H), 8.16 (ddd, J = 8.6, 7.0, 1.4 Hz, 1H), 8.07 (d, J = 8.6 Hz, 1H), 7.96 (ddd, J = 8.1, 6.9, 1.1 Hz, 
1H), 4.90 (t, J = 7.3 Hz, 1H), 3.93 (d, J = 7.3 Hz, 2H), 3.79 (s, 3H). 
13C NMR (126 MHz, CD3OD) δ/ppm: 169.07, 155.65, 147.49, 140.56, 136.04, 131.03, 130.29, 
129.50, 124.15, 122.28, 54.25, 52.84, 35.65. 
HRMS (ESI): C13H15N2O2+ calcd: 231.1128, found: 231.1131. 
Synthesis of AA109 
 
H-β-(7-methoxycoumarin-4-yl)-Ala-OH (87.0 mg, 330.0 µmol, 1.0 eq.) was suspended in MeOH 
(3.5 mL) and cooled in an ice bath. SOCl2 (241.0 µL, 3.3 mmol, 10.0 eq.) was dropwise added 
and the mixture was stirred at 0°C for 10 min. The ice bath was removed and the mixture was 
stirred at RT for 21 h, after which UPLC-MS analysis showed full conversion to the desired 
product. The volatiles were removed by rotary evaporation and the residue was dissolved in 
MeOH (2.5 mL) and cooled in an ice bath. Et2O (5 mL) was slowly added and the mixture was 
stirred in the ice bath for 30 min. The formed precipitate was filtered off, washed with cold Et2O 
(3 x 5 mL) and dried in vacuo to yield the desired product as a white solid (82 mg, 79%).  
1H NMR (250 MHz, DMSO-d6) δ/ppm: 8.55 (s, 3H), 7.69 (d, J = 8.8 Hz, 1H), 7.06 (d, J = 2.5 Hz, 
1H), 7.02 (dd, J = 8.7, 2.6 Hz, 1H), 6.32 (s, 1H), 4.37 (t, J = 7.2 Hz, 1H), 3.87 (s, 3H), 3.72 (s, 
3H),  
3.43 – 3.34 (m, 1H), 3.24 (dd, J = 14.4, 8.2 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6) δ/ppm: 168.80, 162.52, 159.75, 155.21, 149.32, 125.87, 113.83, 
112.29, 111.76, 101.19, 56.02, 52.94, 50.95, 31.68. 











Synthesis of AA110 
 
H-1-Nal-OH (100.0 mg, 465.0 µmol, 1.0 eq.) was dissolved in MeOH (2 mL) and cooled in an ice 
bath. SOCl2 (74.6 µL, 1.0 mmol, 2.2 eq.) was added dropwise and the mixture was stirred at 0°C 
for 10 min. The ice bath was removed and the mixture was stirred at RT for 26 h, after which 
UPLC-MS analysis showed full conversion to the desired product. The volatiles were removed by 
rotary evaporation and the residue was dissolved in MeOH (500 µL) and cooled in an ice bath. 
Et2O (4 mL) was slowly added and the mixture was stirred in the ice bath for 30 min. The formed 
precipitate was filtered off, washed with cold Et2O (3 x 5 mL) and dried in vacuo to yield the 
desired product as a white solid (92 mg, 75%).  
1H NMR (400 MHz, D2O) δ/ppm: 8.11 (d, J = 8.4 Hz, 1H), 8.06 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 
8.2 Hz, 1H), 7.71 (t, J = 7.6 Hz, 1H), 7.66 (t, J = 7.4 Hz, 1H), 7.56 (t, J = 7.6 Hz, 1H), 7.50 (d, J = 
7.0 Hz, 1H), 4.55 (dd, J = 8.6, 6.3 Hz, 1H), 3.94 (dd, J = 14.7, 6.4 Hz, 1H), 3.76 (s, 3H), 3.63 (dd, 
J = 14.6, 8.5 Hz, 1H). 
13C NMR (126 MHz, D2O) δ/ppm: 170.55, 134.17, 131.51, 130.29, 129.57, 129.28, 128.86, 
127.49, 126.85, 126.20, 123.19, 53.95, 53.77, 33.49. 
HRMS (ESI): C14H16NO2+ calcd: 230.1176, found: 230.1176. 
Synthesis of N,N-bis(Boc)-2-methyl-prop-2-enamine AA124a 
 
NaH (212.0 mg, 5.5 mmol, 1.5 eq. 60% in mineral oil) was suspended in DMF (6 mL) and cooled 
to 0°C. A solution of Boc2NH (800.0 mg, 3.7 mmol, 1.0 eq.) in DMF (6 mL) was added dropwise. 
The cooling bath was removed and the suspension was stirred at RT for 45 min. 3-Bromo-2-
methylpropene (483.0 µL, 4.8 mmol, 1.3 eq.) was added and the solution was stirred at RT for 
4 h. The reaction was quenched by the addition of H2O (1 mL). The solvent was removed by 
rotary evaporation and the residue was dissolved in Et2O (25 mL) and H2O (20 mL). The layers 
were separated and the aqueous layer was extracted with Et2O (25 mL). The combined organic 
layers were washed with brine (2 x 15 mL), dried over Na2SO4 and concentrated. The crude 
material was purified by flash column chromatography (Silica, 56 g, cyclohexane:EtOAc 20:1, 
Rf= 0.23, KMnO4). Product-containing fractions were combined and concentrated in vacuo to 
yield the desired product as a white solid (864 mg, 87%). Analytical data was in agreement with 
reported data.[249] 
1H NMR (400 MHz, CDCl3) δ/ppm: 4.82 (p, J = 1.5 Hz, 1H), 4.75 (qd, J = 1.6, 0.8 Hz, 1H), 4.12 
(q, J = 0.8 Hz, 2H), 1.72 (t, J = 1.2 Hz, 3H), 1.49 (s, 18H). 
Synthesis of AA124 
 
Under an inert atmosphere in a Schlenk tube methyl (E)-3-bromo-2-methyl-prop-2-enoate 
(422.0 mg, 2.4 mmol, 1.6 eq.), AA124a (400.0 mg, 1.5 mmol, 1.0 eq.), Pd(OAc)2 (9.9 mg, 
44.2 µmol, 3 mol%), tri(o-tolyl)phosphine (26.9 mg, 88.4 µmol, 6 mol%) and NEt3 (411.0 µL, 
3.0 mmol, 2.0 eq.) were mixed and heated to 100°C. After 19 h UPLC-MS showed full conversion 
to the desired product. The reaction was quenched with 10% NaOH (10 mL). The mixture was 
extracted with MtBE (3 x 10 mL) and the combined organic layers were washed with brine 







flash column chromatography (Silica, 67 g, 20:1→10:1 cyclohexane:EtOAc, Rf= 0.22, 
UV/KMnO4). Product-containing fractions were combined and concentrated in vacuo to yield the 
desired product as a yellow waxy solid (351 mg, 64%). The material was dissolved in DCM 
(4 mL) and cooled in an ice bath. HCl in dioxane (4.7 mL, 18.8 mmol, 20.0 eq. 4.0 M in dioxane) 
was added and the solution was stirred at 0°C for 15 min. The mixture was warmed to RT and 
stirred for 6 h, after which UPLC-MS analysis showed full conversion to the desired product. The 
volatiles were removed by rotary evaporation and the residue was dissolved in MeOH (2 mL). 
The mixture was filtered by syringe filter, cooled in an ice bath to 0°C and Et2O (5 x 2 mL) was 
added portionwise. The formed suspension was continued stirring at 0°C for 30 min and the 
precipitate was filtered off, washed with cold Et2O (10 mL) and dried in vacuo to yield the desired 
product as a white solid (104 mg, 54%). 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.34 (s, 3H), 7.34 (dd, J = 11.6, 1.7 Hz, 1H), 6.50 (dq, J = 
11.8, 1.6 Hz, 1H), 3.70 (s, 3H), 3.55 (s, 2H), 1.93 (s, 3H), 1.90 (s, 3H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 167.91, 139.00, 132.36, 127.46, 122.86, 51.84, 45.17, 
15.64, 12.65. 
HRMS (ESI): C9H16NO2+ calcd: 170.1176, found: 170.1175. 
Synthesis of Benzyl (E)-penta-2,4-dienoate AA125a[198] 
 
Pentadienoic acid (200.0 mg, 2.0 mmol, 1.0 eq.) was suspended in DCM (3 mL) and benzylic 
alcohol (422.0 µL, 4.1 mmol, 2.0 eq.) was added. The mixture was cooled in an ice bath and EDC 
hydrochloride (782.0 mg, 4.1 mmol, 2.0 eq.) and DMAP (167.0 mg, 1.4 mmol, 0.7 eq.) were 
added. The mixture was warmed to RT and stirred for 5.5 h. HCl solution (1.0 M) was added to 
acidify the mixture and the phases were separated. The aqueous phase was extracted with DCM 
(2 x 8 mL) and the combined organic layers were washed with saturated NaHCO3 solution, dried 
over Na2SO4 and concentrated by rotary evaporation. The crude was purified by column 
chromatography (Silica, 50 g, cyclohexane:EtOAc 1:1) to yield the desired product as a colorless 
liquid (271 mg, 71%). Analytical data was in agreement with reported data.[250] 
1H NMR (400 MHz, CDCl3) δ/ppm: 7.41 – 7.27 (m, 6H), 6.46 (dt, J = 17.1, 10.1 Hz, 1H), 5.96 (d, 
J = 15.6 Hz 1H), 5.62 (d, J = 17.1 Hz, 1H), 5.50 (d, J = 10.1 Hz, 1H), 5.20 (s, 2H). 
Synthesis of Benzyl (2E, 4E)-6-(bis-(Boc)aminohexa-2,4-dienoate AA125b[198] 
 
AA125a (100.0 mg, 531.0 µmol, 1.0 eq.) and bis-Boc allylamine (342.0 mg, 1.3 mmol, 2.5 eq.) 
were dissolved in DCM (1.5 mL). A solution of the Hoveyda-Grubbs catalyst (23.3 mg, 37.2 µmol, 
7.0 mol%) in DCM (1.2 mL) was added and the reaction mixture was stirred at 40°C for 16 h. The 
reaction mixture was concentrated by rotary evaporation and purified by preparative reversed 
phase HPLC (Method A, no TFA) to yield the desired product as a greenish solid (70 mg, 32%). 
1H NMR (400 MHz, CD3CN) δ/ppm: 7.45 – 7.62 (m, 6H), 6.33 – 6.625 (m, 1H), 6.23 – 6.14 (m, 
1H), 5.97 (d, J = 15.4 Hz, 1H), 5.16 (s, 2H), 4.25 (d, J = 5.5 Hz, 2H), 1.46 (s, 18H). 
13C NMR (101MHz, CD3CN) δ/ppm: 167.2, 153.1, 145.0, 139.8, 137.6, 129.7, 129.5, 129.0, 
129.0, 121.8, 83.2, 66.7, 48.3, 28.2. 








Synthesis of (2E, 4E)-6-(bis-(Boc)aminohexa-2,4-dienoic acid AA125c[198] 
 
AA125b (60.0 mg, 144.0 µmol, 1.0 eq.) was dissolved in H2O (1.2 mL) and MeCN (1.2 mL) and 
LiOH monohydrate (90.5 mg, 2.2 mmol, 15.0 eq.) was added. The mixture was stirred at RT for 
18 h. The mixture was purified by preparative reversed phase HPLC (Method A, no TFA) to yield 
the desired product as a brownish solid (32 mg, 68%). 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 6.71 – 6.63 (m, 1H), 6.18 – 6.10 (m, 1H), 5.78 – 5.70 (m, 
2H), 4.11 (d, J = 6.4 Hz, 2H), 1.43 (s, 18H). 
13C NMR (126 MHz, DMSO-d6) δ/ppm: 169.4, 151.8, 134.7, 134.4, 131.8, 130.1, 81.8, 47.4, 27.6. 
HRMS (ESI): C16H25NNaO6+ calcd: 350.1574, found: 350.1576. 
Synthesis of AA0125[198] 
 
AA125c (32.0 mg, 97.7 µmol, 1.0 eq.) was suspended in MeOH (5.3 mL) and cooled in an ice 
bath. SOCl2 (71.3 µL, 97.7 µmol, 10.0 eq.) was added and the mixture was stirred for 15 min at 
0°C. The cooling bath was removed and the mixture was stirred at RT for 3 h. The volatiles were 
removed by rotary evaporation and the crude was recrystallized from MeOH/Et2O to yield the 
desired product as a brown solid (10 mg, 58%). 
1H NMR (400 MHz, CD3OD) δ/ppm: 7.31 (dd, J = 15.4, 10.9 Hz, 1H), 6.59 (dd, J = 15.4, 11.0 Hz, 
1H), 6.19 (dt, J = 15.4, 6.4 Hz, 1H), 6.06 (d, J = 15.4 Hz, 1H), 3.75 (s, 3H), 3.69 (d, J = 6.4 Hz, 
2H). 
13C NMR (126 MHz, CD3OD) δ/ppm:169.5, 144.0, 134.5, 133.5, 124.2, 52.2, 41.8. 
HRMS (ESI): C7H12NO2+ calcd: 142.0863, found: 142.0863. 
Synthesis of AA0126 
 
Ethyl 2-(Boc-aminomethyl)thiazole-4-carboxylate (100.0 mg, 349.0 µmol, 1.0 eq.) was dissolved 
in DCM (1.2 mL) and cooled in an ice bath. HCl in dioxane (1.7 mL, 7.0 mmol, 20.0 eq. 4.0 M) 
was added and the mixture was stirred at 0°C for 15 min. The ice bath was removed and the 
mixture was stirred at RT for 2 h, after which UPLC-MS analysis showed full conversion to the 
desired product. The volatiles were removed by rotary evaporation and the residue was dissolved 
in MeOH (1 mL) and cooled in an ice bath. Et2O (6 mL) was slowly added and the mixture was 
stirred in the ice bath for 30 min. The formed precipitate was filtered off, washed with cold Et2O 
(3 x 5 mL) and dried in vacuo to yield the desired product as a brownish solid (51 mg, 66%). 
Analytical data was in agreement with reported data.[251] 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.66 (s, 3H), 8.61 (s, 1H), 4.48 (s, 2H), 4.32 (q, J = 7.1 Hz, 
2H), 1.31 (t, J = 7.1 Hz, 3H). 
Synthesis of 6-hydrazinopyridine-3-carboxylic acid TA229a 
 
In a 10 mL screw-capped vial 6-chloropyridine-3-carboxylic acid (1.0 g, 6.4 mmol, 1.0 eq.) was 















stirred at 100°C for 17 h, after which UPLC-MS analysis showed full conversion to the desired 
product. The mixture was evaporated to dryness and the white residue was dissolved in H2O 
(20 mL). The mixture was acidified to pH 5.5 by addition of conc. HCl whereby precipitation 
occurred. The yellow suspension was stirred at RT for 15 min and the precipitate was filtered off. 
The yellow solid was washed with EtOH (20 mL), Et2O (20 mL) and dried in vacuo to yield the 
desired product as yellow solid (774 mg, 80%). Analytical data was in agreement with reported 
data.[252] 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.53 (d, J = 2.1 Hz, 1H), 8.08 (dd, J = 9.0, 2.1 Hz, 1H), 
6.93 (d, J = 9.0 Hz, 1H). 
Synthesis of 6-(3,5-dimethyl-1H-pyrazol-1-yl)nicotinic acid TA229b 
 
In a 50 mL flask TA229a (749.0 mg, 4.9 mmol, 1.0 eq.) was suspended in H2O (35 mL) and 
acetylacetone (600 µL, 5.9 mmol, 1.2 eq.) and acetic acid (839.0 µL, 14.7 mmol, 3.0 eq.) were 
added subsequently. The mixture was stirred at RT for 1 h, after which UPLC-MS showed full 
conversion to the desired product. The mixture was diluted with EtOAc (150 mL) and H2O 
(100 mL). The biphasic mixture was acidified with conc. HCl to pH 1. The layers were separated 
and the aqueous layer was extracted with EtOAc (2 x 100 mL). The combined organic layers 
were washed with 1% aqueous HCl (2 x 100 mL), brine (100 mL), dried over Na2SO4 and was 
concentrated in vacuo. The desired product was obtained as small white needles (966 mg, 91%).  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 13.32 (s, 1H), 8.90 (dd, J = 2.3, 0.8 Hz, 1H), 8.34 (dd, J = 
8.7, 2.3 Hz, 1H), 7.93 (dd, J = 8.7, 0.8 Hz, 1H), 6.16 (s, 1H), 2.62 (s, 3H), 2.21 (s, 3H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 165.77, 155.42, 150.14, 149.07, 141.75, 139.65, 123.31, 
114.23, 110.17, 14.78, 13.39. 
HRMS (ESI): C11H12N3O2+ calcd: 218.0924, found: 218.0924. 
Synthesis of TA229 
 
In a 50 mL flask TA229b (500.0 mg, 2.3 mmol, 1.0 eq.) was dissolved in THF (18 mL) and H2O 
(2 mL) and propargylamine (177.0 µL, 2.8 mmol, 1.2 eq.) was added, followed by DIPEA (2.0 mL, 
11.5 mmol, 5.0 eq.), HOAt (407.0 mg, 3.0 mmol, 1.3 eq.) and EDC hydrochloride (574.0 mg, 
3.0 mmol, 1.3 eq.). The yellow mixture was stirred at RT 17 h. The volatiles were removed by 
rotary evaporation and the residue was dissolved in EtOAc (50 mL) and H2O (50 mL). The 
mixture was acidified with conc. HCl to pH 1. The layers were separated and the aqueous layer 
was extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with 
1% aqueous HCl (2 x 50 mL), half-saturated bicarbonate solution (3 x 50 mL), brine (50 mL), 
dried over Na2SO4 and concentrated in vacuo to yield the desired product as white solid (477 mg, 
82%).  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 9.12 (t, J = 5.5 Hz, 1H), 8.87 (dd, J = 2.4, 0.8 Hz, 1H), 8.33 
(dd, J = 8.7, 2.4 Hz, 1H), 7.91 (dd, J = 8.7, 0.8 Hz, 1H), 6.16 (s, 1H), 4.09 (dd, J = 5.5, 2.5 Hz, 
2H), 3.16 (t, J = 2.5 Hz, 1H), 2.62 (d, J = 0.9 Hz, 3H), 2.21 (s, 3H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 163.90, 154.58, 149.84, 147.02, 141.47, 137.90, 126.12, 









HRMS (ESI): C14H14N4NaO+ calcd: 277.1060, found: 277.1063. 
Synthesis of (2-methylcyclohexyl)oxyacetic acid TA256a 
 
In a dry 100 mL flask under an inert atmosphere 2-methylcyclohexanol (5.7 mL, 46.6 mmol, 
2.2 eq.) was dissolved in THF (30 mL) and lithium (375.0 mg, 54.0 mmol, 2.6 eq. in pellets) was 
added. The mixture was refluxed for 16 h, after which the suspension was filtered and a solution 
of 2-chloroacetic acid (2.0 g, 21.2 mmol, 1.0 eq.) in THF (10 mL) was slowly added. The solution 
was refluxed for 6 h, whereafter H2O (35 mL) was added and the volatiles were removed by 
rotary evaporation. The residue was dissolved in H2O (30 mL) and extracted with IPE (3 x 30 mL) 
to remove residual alcohol. The combined IPE layers were washed with H2O (30 mL) and the 
combined aqueous layers were acidified to pH 1-2 with conc. HCl and extracted with Et2O (3 x 
30 mL). The combined Et2O layers were washed with H2O (30 mL), brine (30 mL), dried over 
Na2SO4 and were concentrated in vacuo to yield the desired product as yellow oil (3.3 g, 89%).  
1H NMR (400 MHz, CDCl3) δ/ppm: 9.01 (sbr, 1H), 4.24 – 4.03 (m, 2H), 2.94 (td, J = 9.7, 4.1 Hz, 
1H), 2.10 – 1.95 (m, 1H), 1.88 – 1.66 (m, 2H), 1.65 – 1.55 (m, 1H), 1.55 – 1.42 (m, 1H), 1.31 – 
1.09 (m, 3H), 1.08 – 0.82 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 174.27, 85.71, 65.89, 38.13, 33.78, 30.95, 25.40, 24.88, 
18.90. 
HRMS (ESI): C9H16NaO3+ calcd: 195.0992, found: 195.0989. 
Synthesis of 2-((2-methylcyclohexyl)oxy)acetamide TA256b 
 
In a 50 mL flask TA256a (3.0 g, 17.4 mmol, 1.0 eq.) was dissolved in SOCl2 (6.4 mL, 87.1 mmol, 
5.0 eq.) and the solution was stirred at 50°C for 2 h, after which TLC showed full consumption of 
the SM. The generated gas during the reaction was washed and neutralized with conc. NaOH 
solution. Residual SOCl2 was removed by distillation (60°C, water-jet vacuum). In a 50 mL flask 
the residue was slowly added to aqueous ammonia (7.2 mL, 122.0 mmol, 7.0 eq. 32%) while 
cooling in an ice bath. A white precipitate immediately formed. The mixture was stirred for 15 h 
while slowly warming to RT. The mixture was suspended in H2O (100 mL) and extracted with 
Et2O (3 x 100 mL). The combined etheral layers were washed with H2O (100 mL), brine (100 mL), 
dried over Na2SO4 and were concentrated in vacuo to yield the desired product as a white solid 
(2.3 g, 76%).  
1H NMR (400 MHz, CDCl3) δ/ppm: 6.60 (s, 1H), 6.20 (s, 1H), 4.05 (d, J = 15.5 Hz, 1H), 3.86 (d, 
J = 15.6 Hz, 1H), 2.87 (td, J = 9.6, 3.8 Hz, 1H), 2.13 – 1.91 (m, 1H), 1.87 – 1.67 (m, 2H), 1.64 – 
1.54 (m, 1H), 1.52 – 1.40 (m, 1H), 1.31 – 1.07 (m, 3H), 1.06 – 0.89 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 173.93, 85.30, 67.89, 38.16, 33.71, 31.02, 25.43, 24.82, 
19.00. 
HRMS (ESI): C9H17NNaO2+ calcd: 194.1151, found: 194.1154. 











In a 100 mL flask under an inert atmosphere TA256b (2.0 g, 11.7 mmol, 1.0 eq.) was dissolved in 
THF (20 mL) and a suspension of LiAlH4 (975.0 mg, 25.7 mmol, 2.2 eq.) in THF (15 mL) was 
slowly added while cooling in an ice bath. After addition, the cooling bath was removed and the 
grey mixture was warmed to RT, followed by refluxing for 22 h, after which TLC (5% MeOH in 
DCM, KMnO4 and Ninhydrin) showed full consumption of the SM. The mixture was cooled in an 
ice bath and the reaction was quenched by the addition of H2O (3 mL), NaOH (15%, 3 mL) and 
H2O (3 mL). The solids were filtered off and washed with Et2O (3 x 20 mL). The combined filtrates 
were washed with brine (50 mL), dried over Na2SO4 and concentrated by rotary evaporation to 
yield the desired product as a colorless liquid (1.7 g, 94%).  
1H NMR (400 MHz, CDCl3) δ/ppm: 3.65 – 3.58 (m, 1H), 3.37 – 3.30 (m, 1H), 2.83 (dd, J = 5.7, 
4.7 Hz, 2H), 2.74 (td, J = 9.9, 4.0 Hz, 1H), 2.06 – 1.99 (m, 1H), 1.88 (s, 2H), 1.76 – 1.64 (m, 2H), 
1.59 – 1.53 (m, 1H), 1.43 – 1.34 (m, 1H), 1.21 – 1.08 (m, 3H), 1.01 – 0.92 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 84.36, 70.64, 42.39, 38.52, 34.03, 31.41, 25.69, 25.10, 18.98. 
HRMS (ESI): C9H20NO+ calcd: 158.1539, found: 158.1540. 
Synthesis of TA256 
 
Under an inert atmosphere in a 50 mL flask triphosgene (101.0 mg, 341.0 µmol, 0.4 eq.) was 
dissolved in THF (8 mL) and cooled in an ice bath. A solution of 3-ethynylaniline (100.0 mg, 
854.0 µmol, 1.0 eq.) and triethylamine (180.0 µL, 1.3 mmol, 1.5 eq.) in THF (2 mL) was added 
over a period of 1 h by syringe pump. The white suspension was stirred at 0°C for another 
15 min, then the cooling bath was removed and the mixture was slowly warmed to RT. A solution 
of TA256c (201.0 mg, 1.3 mmol, 1.5 eq.) and triethylamine (180.0 µL, 1.3 mmol, 1.5 eq.) in THF 
(1 mL) was added dropwise over 5 min. The mixture was stirred at RT for 45 min, after which 
UPLC-MS analysis showed full consumption of the starting materials. The reaction was quenched 
by the addition of H2O (5 mL) and the volatiles were removed by rotary evaporation. The residue 
was taken up in Et2O (20 mL) and H2O (20 mL). The mixture was acidified to pH 1 with conc. HCl 
and the layers were separated. The aqueous layer was extracted with Et2O (2 x 20 mL) and the 
combined organic layers were washed with H2O (20 mL), brine (20 mL), dried over Na2SO4 and 
concentrated in vacuo. The crude material was purified by flash column chromatography on the 
ISOLERA (Silica, 50 g, UV). Product-containing fractions were combined and concentrated to 
yield the desired product as colorless oil (192 mg, 75%).  
1H NMR (400 MHz, CDCl3) δ/ppm: 7.44 (t, J = 1.8 Hz, 1H), 7.35 (ddd, J = 8.0, 2.3, 1.3 Hz, 1H), 
7.23 (t, J = 7.8 Hz, 1H), 7.17 (dt, J = 7.6, 1.4 Hz, 1H), 3.70 (ddd, J = 9.5, 6.2, 3.6 Hz, 1H), 3.48 
(td, J = 6.4, 3.5 Hz, 1H), 3.42 (td, J = 6.3, 3.2 Hz, 2H), 3.04 (s, 1H), 2.80 (td, J = 9.9, 4.1 Hz, 1H), 
2.07 – 1.98 (m, 1H), 1.77 – 1.71 (m, 1H), 1.70 – 1.65 (m, 1H), 1.62 – 1.54 (m, 1H), 1.41 – 1.32 
(m, 1H), 1.24 – 1.04 (m, 4H), 1.02 – 0.86 (m, 5H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 156.98, 138.54, 129.32, 127.58, 124.12, 123.09, 121.34, 
84.94, 83.32, 77.54, 68.46, 41.54, 38.41, 33.92, 31.33, 25.55, 25.01, 18.91. 









Synthesis of 2-(2-methylphenyl)-1H-benzimidazole TA333a 
 
In a 50 mL flask phenylenediamine (300.0 mg, 2.8 mmol, 1.0 eq.) was dissolved in DMF (25 mL) 
and H2O (2.5 mL) was added, followed by 2-methylbenzaldehyde (353.0 µL, 3.1 mmol, 1.1 eq.). 
The solution was heated to 80°C and stirred under air (open flask) for 4.5 h, after which TLC and 
UPLC-MS analysis showed full conversion to the desired product. The volatiles were removed by 
rotary evaportaion and the crude was directly purified by flash column chromatography on the 
ISOLERA (Silica, 50g, cyclohexane:EtOAc, UV). Product-containing fractions were combined and 
concentrated to yield the desired product as slightly yellow solid (437 mg, 76%). Analytical data 
was in agreement with reported data.[253] 
1H NMR (500 MHz, DMSO-d6) δ/ppm: 12.60 (s, 1H), 7.74 (dt, J = 7.5, 1.1 Hz, 1H), 7.70 – 7.47 
(m, 2H), 7.43 – 7.33 (m, 3H), 7.21 (dd, J = 6.4, 3.0 Hz, 2H), 2.61 (s, 3H). 
Synthesis of TA333 
 
In a 50 mL flask TA333a (385 mg, 1.9 mmol, 1.0 eq.) was dissolved in DMF (15 mL) and 
propargyl bromide (339.0 µL, 3.1 mmol, 1.7 eq.) and potassium carbonate (766.0 mg, 5.6 mmol, 
3.0 eq.) were added subsequently. The mixture was stirred at RT for 4 h, after which UPLC-MS 
analysis showed full conversion to the desired product. The solids were filtered off and the 
volatiles were removed by rotary evaporation. The residue was purified by flash column 
chromatography on the ISOLERA (Silica, 50 g, cyclohexane:EtOAc, UV). Product-containing 
fractions were combined and concentrated to yield the desired product as a yellowish solid 
(439 mg, 96%).  
1H NMR (400 MHz, CDCl3) δ/ppm: 7.92 – 7.84 (m, 1H), 7.64 – 7.57 (m, 1H), 7.47 – 7.41 (m, 2H), 
7.40 – 7.31 (m, 4H), 4.73 (d, J = 2.5 Hz, 2H), 2.38 (t, J = 2.5 Hz, 1H), 2.32 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 152.61, 138.67, 134.09, 130.87, 130.52, 130.32, 128.53, 
126.02, 123.46, 123.20, 119.91, 110.49, 76.73, 74.10, 34.25, 20.01. 
HRMS (ESI): C17H15N2+ calcd: 247.1230, found: 247.1230. 
Synthesis of TA607 
 
Under an inert atmosphere in a 10 mL flask but-3-ynamine (59.2 µl, 724 µmol, 1.0 eq.), DMAP 
(2.2 mg, 18.1 µmol, 2.5 mol%) and triethylamine (101.0 µL, 724.0 µmol, 1.0 eq.) were dissolved 
in THF (3 mL) and cooled to 0°C. Acetic anhydride (137.0 µL, 1.5 mmol, 2.0 eq.) was added 
dropwise and the cooling bath was removed. The solution was stirred at RT for 1 h, after which 
TLC (10% MeOH in DCM, KMnO4/Ninhydrin, Rf= 0.58) showed complete consumption of the 
starting material. The volatiles were removed and the residue was dissolved in EtOAc (10 mL). 
The solution was washed with H2O (3 x 10 mL) and the combined aqueous layers were extracted 
with DCM (7 x 10 mL). The combined organic layers were dried over Na2SO4 and concentrated in 
vacuo to yield the desired product as clear oil (66 mg, 82%). Analytical data was in agreement 
with reported data.[254] 
1H NMR (400 MHz, CDCl3) δ/ppm: 5.79 (sbr, 1H), 3.41 (q, J = 6.2 Hz, 2H), 2.41 (td, J = 6.4, 










Synthesis of TA622 
 
Under an inert atmosphere in a 100 mL flask propargylamine (407.0 µL, 6.4 mmol, 1.0 eq.) and 
triethylamine (1.2 mL, 8.3 mmol, 1.3 eq.) were dissolved in DCM (30 mL) and cooled to 0°C.  
2-Chloroacetyl chloride (557.0 µL, 7.0 mmol, 1.1 eq.) was added dropwise over 5 min. The 
reaction was stirred at 0°C for 1 h, after which TLC (1:1 cyclohexane:EtOAc, Rf= 0.51, KMnO4) 
showed full consumption of the starting material. The solution was mixed with H2O (30 mL) and 
acidified with conc. HCl to pH 1. The layers were separated and the organic layer was washed 
with diluted HCl (30 mL, pH 1) and H2O (30 mL). The combined aqueous layers were extracted 
with DCM (2 x 30 mL), the combined organic layers were washed with brine (30 mL), dried over 
Na2SO4 and concentrated by rotary evaporation. The residue was purified by flash column 
chromatography on the ISOLERA (Silica, 50 g, cyclohexane:EtOAc, KMnO4) to yield 2-chloro-N-
(propargyl)acetamide as a yellow oil (571 mg, 68%). In a 50 mL flask 2-chloro-N-
(propargyl)acetamide (200.0 mg, 1.5 mmol, 1.0 eq.), 3,5-dimethylpiperidine (303.0 µl, 2.3 mmol, 
1.5 eq.) and potassium carbonate (420.0 mg, 3.0 mmol, 2.0 eq.) were suspended in THF 
(15 mL). The mixture was stirred at RT for 21 h, after which TLC (5% MeOH in DCM, Rf= 0.44, 
KMnO4) showed full consumption of the starting material. The volatiles were removed by rotary 
evaporation and the crude material was purified by flash column chromatography on the 
ISOLERA (Silica, 50g, DCM:MeOH, KMnO4) to yield the desired product as a yellow oil (141 mg, 
45%).  
1H NMR (400 MHz, CDCl3) δ/ppm: 7.60 (sbr, 1H), 4.06 (dd, J = 5.6, 2.5 Hz, 2H), 3.08 (sbr, 2H), 
2.81 (sbr, 2H), 2.22 (t, J = 2.6 Hz, 1H), 1.86 – 1.68 (m, 4H), 0.91 (t, J = 6.8 Hz, 1H), 0.87 (s, 3H), 
0.85 (s, 3H), 0.64 – 0.49 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ/ppm: 160.72, 79.70, 71.34, 61.49, 42.64, 41.33, 31.22, 28.79, 
19.40. 
HRMS (ESI): C12H21N2O+ calcd: 209.1648, found: 209.1649. 
Synthesis of TA660 
 
In a 5 mL flask 3-chloro-1H-indol-7-amine (50.0 mg, 300.0 µmol,1.0 eq.) was dissolved in EtOAc 
(1 mL) and propiolic acid (27.7 µL, 450.0 µmol, 1.5 eq.), DIPEA (157.0 µL, 900.0 µmol, 3.0 eq.) 
and T3P (447.0 µL, 750.0 µmol, 2.5 eq. 50% in EtOAc) were added subsequently. The black 
solution was stirred at RT for 3 h. Saturated NaHCO3 solution (1 mL) was added and the mixture 
was stirred overnight. The biphasic mixture was diluted with H2O (10 mL) and EtOAc (10 mL). 
The layers were separated and the aqueous layer was extracted with EtOAc (2 x 10 mL). The 
combined organic layers were washed with brine (10 mL), dried over Na2SO4 and were 
concentrated by rotary evaporation. The crude was purified by flash column chromatography 
(Silica, 10 g, cyclohexane:EtOAc 2:1, Rf= 0.26) to yield the desired product as a greenish solid 
(37 mg, 56%).  
1H NMR (500 MHz, CDCl3) δ/ppm: 9.73 (s, 1H), 7.84 (s, 1H), 7.53 (dt, J = 8.0, 0.9 Hz, 1H), 7.22 
(d, J = 2.6 Hz, 1H), 7.11 (t, J = 7.8 Hz, 1H), 6.82 (dd, J = 7.6, 1.0 Hz, 1H), 3.03 (s, 1H). 
13C NMR (126 MHz, CDCl3) δ/ppm: 149.72, 128.46, 127.00, 122.13, 121.79, 120.10, 116.97, 











HRMS (ESI): C11H7ClN2NaO+ calcd: 241.0139, found: 241.0138. 
Synthesis of TA661 
 
Propargyl bromide (1.9 mL, 18.0 mmol, 1.0 eq.) and sodium sulfite (2.9 g, 22.7 mmol, 1.3 eq.) 
were dissolved in MeOH (7 mL) and H2O (7 mL) and the mixture was heated to 65°C for 7 h. 
After cooling, MeOH (120 mL) was added and the mixture was filtered over a G4 sintered glass 
funnel. The filtrate was concentrated to an approximate volume of 5 mL. Acetone (100 mL) was 
added and the precipitate was filtered off, washed with acetone (2 x 10 mL) and dried in vacuo to 
yield the desired product as white solid (2.4 g, 93%). Analytical data was in agreement with 
reported data.[255] 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 3.29 (d, J = 2.7 Hz, 2H), 2.92 (t, J = 2.7 Hz, 1H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 78.87, 73.24, 42.09. 
Synthesis of TA662 
 
In a dry flask 5-hexynenitrile (1.1 mL, 10.7 mmol, 1.0 eq.) was dissolved in toluene (20 mL) and 
sodium azide (2.1 g, 32.2 mmol, 3.0 eq.) and triethylamine hydrochloride (4.4 g, 32.2 mmol, 
3.0 eq.) were added subsequently. The mixture was heated to reflux for 9 h. After cooling the 
mixture was extracted with H2O (4 x 10 mL) and the combined aqueous layers were acidified to 
pH 1 by addition of concentrated HCl. The aqueous phase was extracted with EtOAc (4 x 20 mL) 
and the combined EtOAc layers were dried over Na2SO4 and concentrated by rotary evaporation. 
The crude red oil was purified by flash column chromatography (Silica, 80 g, cyclohexane:EtOAc 
2:1 + 1% formic acid→1:1 + 1% formic acid, Rf= 0.36, KMnO4) to yield the desired product as 
yellowish oil that crystallized in the fridge (1.0 g, 69%).  
1H NMR (400 MHz, DMSO-d6) δ/ppm: 15.89 (s, 1H), 2.96 (dd, J = 8.1, 7.2 Hz, 2H), 2.85 (t, J = 
2.7 Hz, 1H), 2.26 (td, J = 7.0, 2.7 Hz, 2H), 1.88 (dq, J = 8.3, 7.0 Hz, 2H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 155.44, 83.44, 72.00, 25.90, 21.81, 17.21. 
HRMS (ESI): not measurable on the ESI. 
Synthesis of TA663 
 
In a screw-capped vial pomalidomide (100.0 mg, 366.0 µmol, 1.0 eq.) was suspended in DMF 
(2 mL) and THF (5 mL). Propargyl bromide (59.2 µL, 549.0 µmol, 1.5 eq.) and potassium 
carbonate (152.0 mg, 1.1 mmol, 3.0 eq.) were added and the mixture was heated to 65°C for 
15 h, after which UPLC-MS analysis showed full conversion to the desired product. The solvent 
was removed by rotary evaporation and the residue was dissolved in EtOAc (25 mL) and H2O 
(25 mL). The layers were separated and the aqueous layer was extracted with EtOAc (2 x 
25 mL). The combined organic layers were washed with brine (25 mL), dried over Na2SO4 and 
were concentrated. The crude material was purified by flash column chromatography (Silica, 
20 g, DCM + 1% MeOH, Rf= 0.34 (2% MeOH in DCM), UV). Product-containing fractions were 















1H NMR (400 MHz, DMSO-d6) δ/ppm: 7.48 (dd, J = 8.5, 7.0 Hz, 1H), 7.02 (dd, J = 7.7, 5.6 Hz, 
2H), 6.55 (s, 2H), 5.20 (dd, J = 13.0, 5.4 Hz, 1H), 4.38 (t, J = 2.4 Hz, 2H), 3.11 (t, J = 2.4 Hz, 1H), 
3.03 (ddd, J = 17.3, 13.9, 5.4 Hz, 1H), 2.80 (ddd, J = 17.3, 4.4, 2.5 Hz, 1H), 2.57 (td, J = 13.3, 
4.4 Hz, 1H), 2.05 (dtd, J = 12.9, 5.4, 2.4 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6) δ/ppm: 170.84, 169.02, 168.45, 167.27, 146.77, 135.51, 131.95, 
121.76, 111.01, 108.44, 79.06, 72.99, 49.01, 31.03, 29.05, 21.18. 
HRMS (ESI): C16H13N3NaO4+ calcd: 334.0798, found: 334.0796. 
Synthesis of TA664a 
 
Azetazolamide (1.0 g, 4.5 mmol, 1.0 eq.) was suspended in aqueous HCl (8.0 mL, 24.0 mmol, 
5.3 eq. 3.0 M) and the mixture was heated to reflux for 3 h, after which UPLC-MS analysis 
showed full conversion to the desired product. The solution was neutralized with NaOH (4.0 M, 
7.0 mL), whereby precipitation occurred. The mixture was extracted with EtOAc (3 x 80 mL) and 
the combined organic layers were washed with brine (80 mL), dried over Na2SO4 and 
concentrated in vacuo to yield the desired product as a white solid (436 mg, 54%). Analytical data 
was in agreement with reported data.[256] 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 8.05 (s, 2H), 7.80 (s, 2H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 171.62, 157.84. 
Synthesis of TA664 
 
Under an inert atmosphere 5-hexynoic acid (91.9 µL, 832.0 µmol, 1.0 eq.) was dissolved in DCM 
(3.5 mL) and DMF (5.0 µL, 64.6 µmol, 8 mol%) was added. The solution was cooled in an ice 
bath while oxalyl chloride (65.0 µL, 757.0 µmol, 0.91 eq.) was added dropwise over 15 min. The 
cooling bath was removed and the solution was stirred at RT for 1 h. The mixture was 
concentrated by rotary evaporation, the residue was slowly added to a solution of TA664a 
(150.0 mg, 832.0 µmol, 1.0 eq.) and pyridine (134.0 µL, 1.7 mmol, 2.0 eq.) in DMF (1 mL). The 
yellow solution was stirred at RT for 3 h. The volatiles were removed by rotary evaporation and 
the crude material was purified by reversed phase column chromatography on the ISOLERA 
(100 g, H2O/MeCN + 0.1% TFA, UV). Product-containing fractions were combined and lyophilized 
to yield the desired product as a white solid (131 mg, 57%). Analytical data was in agreement 
with reported data.[228] 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 13.02 (s, 1H), 8.31 (s, 2H), 2.82 (t, J = 2.6 Hz, 1H), 2.64 (t, 













13.15 Building Block Encoding and Virtual Library Assembly 
Virtual Library Assembly with SMILES 
To generate our macrocycle library in silico we divided the macrocycle structure into the three 
diversity elements, the basic scaffold and the linker scaffold. These parts were depicted as 
SMILES strings and could therefore be easily connected with each other using our self-developed 
DECL-Gen software (see Chapter 8.2 for details about the software, the connection is based on 
the idea used in Smilib[257]). Meanwhile, every building block of the three diversity elements was 
encoded by a unique DNA sequence (codon). Connecting the SMILES strings of the building 
blocks with the corresponding DNA codons generated the macrocycle structures along with their 
full DNA sequences. This methodology could also be used in the other direction to generate the 
macrocycle structure from the DNA coding information after next generation sequencing (see 
Chapters 9.2 and 9.3). 
 
Figure 106. a) Basic scaffold with the linkage sites R1 and R4. b) Trifunctional scaffold with the linkage sites R2 and R3. 
c) Schematic representation of the DE-1 building blocks with linkage sites R1 and R2. d) Schematic representation of the 
DE-2 building blocks with linkage sites R3 and R4. e) Schematic representation of the DE-3 building blocks with linkage 
site R5. The triazole moiety from the click reaction is already included in this smiles element. 
The SMILES string for the basic scaffold with the trifunctional linker scaffold included (Figure 
106 a/b) has the following structure: 
c1ccc(C(=O)NCCN[R4])c([R1])c1.N([R2])[C@@H](C[R5])C(=O)[R3] 




The {de1}, {de2} and {de3} parts represent the defined codons for the building blocks with 3, 4 
and 6 DNA bases respectively. For the generation of the small macrocycle library (smDEML) we 
used the same SMILES structures as stated above and for the DE-3 elements we just defined 
one element for the sidechain azide with the SMILES code: [R5]C-N=[N+]=[N-] 
We used the following DNA sequence for the analysis of the smDEML selections: 
GGAGCTTGTGAATTCTGG{de1}GGACGTGTGTGAATTGTC{de2}GTGTGCGGATCCAACTAC 
SMILES codons and DNA codons for the building blocks of DE1, DE-2 and DE-3 are found in 
Table 16, Table 17 and Table 18. 
  























13.16 Synthesis of the Small Molecule Library Scaffold 
(S)-2-azido-5-(tert-butoxy)-5-oxopentanoic Acid 2-26a 
 
Under an inert atmosphere H-Glu(OtBu)-OH (100.0 mg, 492.0 µmol, 1.0 eq.) and 2-5a (124.0 mg, 
590.0 µmol, 1.2 eq.) were dissolved in MeOH (3 mL) and potassium carbonate (184.0 mg, 
1.3 mmol, 2.7 eq.) was added followed by coppersulfate pentahydrate (1.2 mg, 4.9 µmol, 
1 mol%). The blue suspension was stirred at RT for 2 h, after which TLC showed full 
consumption of the starting material. The solvent was removed by rotary evaporation and the 
residue was dissolved in H2O (10 mL) and EtOAc (10 mL). The mixture was acidified with 
concentrated aqueous HCl to pH 1-2. The layers were separated and the aqueous phase was 
extracted with EtOAc (2 x 15 mL). The combined organic layers were washed with H2O (2 x 
20 mL), brine (20 mL), dried over Na2SO4 and concentrated in vacuo. The crude material was 
purified by flash column chromatography (Silica, 12 g, DCM/2% MeOH/0.25% formic acid, Rf= 
0.21, Bromocresol Green stain) to yield the desired product as yellow oil (110 mg, 98%). 
1H NMR (400 MHz, DMSO-d6) δ/ppm: 13.42 (s, 1H), 4.14 (dd, J = 8.8, 4.8 Hz, 1H), 2.36 – 2.23 
(m, 2H), 2.03 – 1.93 (m, 1H), 1.86 – 1.73 (m, 1H), 1.40 (s, 9H). 
13C NMR (101 MHz, DMSO-d6) δ/ppm: 171.45, 171.22, 60.64, 55.49, 31.15, 27.71, 26.29. 
HRMS (ESI): C9H15N3NaO4+ calcd: 252.0955, found: 252.0950. 
5-(tert-butyl) 1-methyl (S)-2-azidopentanedicarboxylate 2-26b 
 
Under an inert atmosphere 2-26a (100.0 mg, 436.0 µmol, 1.0 eq.) was dissolved in MeOH (4 mL) 
and cooled in an ice bath. TMS-diazomethane (2.2 mL, 4.4 mmol, 10.0 eq. 2.0 M in hexane) was 
added dropwise over 10 min while cooling. Strong gas evolution was observed at the beginning. 
The yellow solution was stirred at 0°C for 10 min and was then slowly warmed to RT. After 17 h 
TLC showed complete conversion of the starting material. The volatiles were removed by rotary 
evaporation and the residue was dissolved in DCM (30 mL). The solution was washed with half-
saturated bicarbonate solution (20 mL) and H2O (2 x 20 mL). The combined aqueous layers were 
extracted with DCM (2 x 20 mL. The combined organic layers were washed with brine (20 mL), 
dried over Na2SO4 and concentrated in vacuo to yield the desired product as a yellow oil 
(101 mg, 95%).  
1H NMR (400 MHz, CDCl3) δ/ppm: 3.99 (dd, J = 8.8, 5.1 Hz, 1H), 3.80 (s, 3H), 2.44 – 2.31 (m, 
2H), 2.15 (dtd, J = 14.2, 7.5, 5.1 Hz, 1H), 2.05 – 1.91 (m, 1H), 1.45 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ/ppm: 171.64, 170.73, 81.07, 61.33, 52.85, 31.42, 28.23, 26.83. 
HRMS (ESI): C10H17N3NaO4+ calcd: 266.1111, found: 266.1112. 
(S)-4-azido-5-methoxy-5-oxopentanoic Acid; Linker Scaffold 2-26 
 
2-26b (289.0 mg, 1.2 mmol, 1.0 eq.) was dissolved in formic acid (7.6 mL, 202.0 mmol, 170 eq.) 
and stirred at RT for 17 h. The volatiles were removed by rotary evaporation and the crude 
material was purified by flash column chromatography (Silica, 10 g, DCM/2%MeOH/0.25% formic 









1H NMR (400 MHz, CDCl3) δ/ppm: 4.05 (dd, J = 8.7, 5.1 Hz, 1H), 3.82 (s, 3H), 2.59 – 2.48 (m, 
2H), 2.20 (dtd, J = 14.3, 7.5, 5.1 Hz, 1H), 2.08 – 1.97 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ/ppm: 177.54, 170.48, 61.04, 52.94, 29.76, 26.33. 
HRMS (ESI): C6H9N3NaO4+ calcd: 210.0485, found: 210.0487. 
13.17 Validation of the Small Molecule Library Chemistry 
DNA Coupling with the Scaffold 2-26 
 
In a 5 mL Eppendorf tube, 5'-amine modified DNA with the sequence 5'-GGAGCTTGTATAT 
GCTGGAAATGCAATGTCACAGTCTTA-3' (825.0 µL, 100.0 µM in MOPS buffer, 1.0 eq.) was 
mixed with 2-26 (454.0 µL, 200.0 mM in DMSO, 1100.0 eq.), EDC hydrochloride (206.0 µL, 
400.0 mM in DMSO, 1000.0  q.), HOAt (206.0 µL, 400.0 mM in DMSO, 1000.0 eq.) and DIPEA 
(413.0 µL, 300.0 mM in DMSO, 1500.0 eq.). The yellow solution was agitated at RT for 23 h, after 
which HPLC analysis showed 76% conversion. The reaction was purified by EtOH precipitation. 
The DNA pellet was further purified by reversed-phase preparative HPLC (Method C). The 
product-containing fractions were combined and lyophilized. The white solid was dissolved in 
H2O (500 µL) to yield a 90 µM solution.  
 
Figure 107. LC-MS analysis of the purified DNA-encoded scaffold 2-27a. 
Ester Hydrolysis of 2-27a 
 
In a 5 mL Eppendorf tube 2-27a (1.0 mL, 85.0 µM in H2O, 1.0 eq.) was mixed with LiOH 
monohydrate (142.0 µL, 300.0 mM in H2O, 500.0 eq.) and MeCN (571 µL). The solution was 
agitated at RT for 5 h. The reaction was purified by EtOH precipitation and the DNA pellet was 
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Figure 108. LC-MS analysis of the ester hydrolysis product 2-27b after purification. 
Amide Coupling with AA006 
 
In a 1.5 mL Eppendorf tube 2-27b (15.0 µL, 50.0 µM in MOPS buffer, 1.0 eq.) was mixed with 
AA006 (1.5 µL, 500.0 mM in DMSO, 1000.0 eq.), DMTMM-BF4 (7.5 µL, 100.0 mM in DMSO, 
1000.0 eq.) and NMM (12.5 µL, 180.0 mM in DMSO, 3000.0 eq.). The solution was agitated at 
RT for 25 h. The reaction was purified by EtOH precipitation and the DNA pellet was redissolved 
in TEAA buffer (15 µL, 500 mM, pH 7.2) to yield a 55 µM solution.  
 
Figure 109. LC-MS analysis of the purified compound 2-27c. 
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Click Reaction between 2-27c and TA662 
 
In a 0.5 mL Eppendorf tube 2-27c (12.0 µL, 24.0 µM in TEAA, 1.0 eq.) was mixed with TA662 
(2.9 µL, 10.0 mM, 100.0 eq.), NaOAsc (2.9 µL, 20.0 mM in H2O, 200.0 eq.) and DMSO (11 µL). 
The solution was degassed with N2 for 30 s. Cu-TBTA complex (5.8 µL, 10.0 mM in 55% DMSO, 
200.0 eq.) was added and the solution was degassed again with N2 for 30 s. The solution was 
agitated at RT for 21 h. The reaction was purified by EtOH precipitation and the DNA pellet was 
dissolved in H2O (10 µL) to yield a 29 µM solution.  
 
Figure 110. LC-MS of the clicked product 2-27. The UV peak at 4.5 min arises from incomplete scaffold ester hydrolysis 
in a previous reaction. Optimizations showed that this peak could be avoided and only the desired product was found. 
Staudinger Reduction with TCEP of 2-27c 
 
In a 1.5 mL Eppendorf tube 2-27c (30.0 µL, 63.0 µM in 500 mM TEAA, 1.0 eq.) was mixed with 
TCEP (30.0 µL, 100.0 mM in H2O, 1587.0 eq.) and the solution was agitated at RT for 16 h. The 
reaction was purified by EtOH precipitation and the DNA pellet was redissolved in MOPS buffer 
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Figure 111. LC-MS analysis of the azide reduction of 2-27c. 
Carboxylic Acid Coupling with 2-27d 
 
In a 0.5 mL Eppendorf tube 2-27d (4.5 µL, 18.5 µM in MOPS buffer, 1.0 eq.), CA001 (0.8 µL, 
100.0 mM in DMSO, 1000.0 eq.), EDC hydrochloride (1.7 µL, 50.0 mM in DMSO, 1000.0 eq.), 
HOAt (1.7 µL, 50.0 mM in DMSO, 1000.0 eq.) and DIPEA (2.5 µL, 50.0 mM in DMSO, 
1500.0 eq.) were mixed and the solution was left standing at RT for 21 h. The mixture was 
purified by EtOH precipitation, followed by LC-MS analysis. 
 
Figure 112. LC-MS analysis of the carboxylic acid coupling with 2-27d. 
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13.18 Small Molecule Library Assembly and Building Block Validations 
DE-1 Building Block Validation 
 
In PCR 96-well plates, 126 amino acids 26 secondary amines and 26 primary amines were tested 
for their coupling efficiencies. Each reaction was conducted with the following amounts. 2-27b 
(2.5 µL, 50.0 µM in MOPS buffer, 1.0 eq.) was mixed with the DE-1 building block (2.5 µL, 50.0 
mM in DMSO, 1000.0 eq.), NMM (2.1 µL, 180.0 mM in DMSO, 3000.0 eq.) and DMTMM-BF4 
(2.1 µL, 60.0 mM in DMSO, 1000.0 eq.). The reactions were left standing at RT for 9 h. The 
reactions were purified by EtOH precipitation and the DNA pellets were redissolved in H2O (20 µL 
each). All reactions were analyzed by LC-MS.  
Reactions with EDC/HOAt/DIPEA conditions were performed accordingly. EDC hydrochloride 
and HOAt were used at 120.0 mM concentration and 1.1 µL each.  
Table 14. DE-1 building blocks screening results. 126 amino acids, 26 primary amines and 26 secondary amines were 
tested for their reactivity in amide coupling. Red coloring indicates the building blocks that were excluded from the final 
DEML assembly due to insufficient purity. Blue coloring indicates building blocks that fulfilled the criteria but were not 

































































































































































MOPS, DMSO, RT, 19 h
Cond. 2
EDC*HCl, HOAt, DIPEA
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[a] Sodium adducts were often observed as main mass. [b] Unknown product(s). [c] Diastereomers were found. [d] 
upper value: DMTMM conditions, lower value: EDC/HOAt/DIPEA reaction conditions. [e] tBu ester hydrolysis in ESI-MS 


























































































DE-1 Introduction into the Small Molecule Library, Split Synthesis 
 
In low bind 96 U-shaped well-plates (Eppendorf) 150 evaluated building blocks (114 amino acids, 
21 primary amines and 15 secondary amines) for library synthesis were treated according to the 
following reaction conditions. 2-27b (7.7 µL, 65.5 µM in MOPS buffer, 1.0 eq.), the DE-1 building 
block (10.1 µL, 50.0 mM in DMSO, 1000.0 eq.), DMTMM-BF4 (5.0 µL, 100.0 mM in DMSO, 
1000.0 eq.) and NMM (8.4 µL, 180.0 mM in DMSO, 3000.0 eq.) were mixed and the plates were 
left standing at RT for 20 h. The reactions were purified by EtOH precipitation. The DNA pellets 
were redissolved in nuclease-free H2O (50 µL per well) yielding a theoretical concentration of 
10.1 µM. For building blocks containing phenolic groups (4 in total) DIPEA was used instead of 
NMM and EDC hydrochloride (200.0 mM, 2.6 µL) and HOAt (200.0 mM, 2.6 µL) replaced the 
DMTMM-BF4. 
Encoding of the DE-1 Building Blocks by Splint Ligation 
 
DNA Phosphorylation:  
In PCR 96-well plates (Eppendorf, Low-Bind) encoding DNA with the sequence 5'-GTAGTTGGA 
TCCGCACACYYYYGACAATTCACACACGTCC-3' with YYYY representing the building block 
codon (10.1 µL, 100.0 µM in H2O, 2.0 eq.) was dissolved in DNAse free H2O (41 µL) and 10X 
ligase buffer (10.0 µL) was added, followed by ATP (20.0 µL, 10.0 mM in H2O, 396.5 eq.) and the 
T4 PNK (19.0 µL, 1 U/µL in 1X ligase buffer, 19 U). The mixture was incubated at 37°C for 30 min 
and the reaction was stopped by heating to 65°C for 20 min.  
Ligation:  
The phosphorylated DNA was mixed with the DNA-SM-library (50.0 µL, 10.1 µM in H2O). H2O 
(8 µL), splint DNA with the sequence 5'-ATCCAACTACTAAGACTGTG-3' (9.5 µL, 80.0 µM in 
H2O, 1.5 eq.) and 10X ligase buffer (10.0 µL) were added and the solution was incubated at 65°C 
for 5 min. After cooling to RT ATP (20.0 µL, 10.0 mM in H2O, 396.5 eq.) was added and after 
further cooling on ice the reaction was started by the addition of T4 DNA ligase (2.5 µL, 400 U/µL, 
1000 U). The well-plates were kept in the fridge at 4°C for 16 h. The ligations were stopped by 
heating to 65°C for 10 min. The encoding performance was analyzed by 12% denaturing PAGE 
(150V, TBE, 65 min, SYBR Gold). All wells were combined and each well was subsequently 
washed with H2O (40 µL). The combined reactions and washing phases were lyophilized and 
redissolved in H2O (8 mL). The encoded sub-library was purified by EtOH precipitation. The 
obtained DNA pellet was dissolved in H2O (3.6 mL), filtered by syringe filter and purified by 
preparative reversed-phase HPLC (Method C). The obtained fractions were analyzed by 
denaturing PAGE (12%, 150V, 65 min, SYBR gold) and library containing fractions were 
combined, lyophilized and redissolved in 500 mM TEAA buffer (2.1 mL) to yield a 16 µM encoded 
library solution. 
Note: The used 10X ligase buffer was freshly prepared (no commercial ligase buffer due to DTT!) 
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Figure 113. a) Chromatogram of the preparative small molecule library purification. Blue coloring indicates the library 
containing fractions. b) HPLC analysis of the purified small molecule library after DE-1 encoding. 
DE-2 Carboxylic Acids Validation 
 
In a U-shaped 96 well-plate 39 carboxylic acids screening reactions were conducted with the 
following conditions. 2-27d (1.5 µL, 34.0 µM in MOPS buffer, 1.0 eq.) was mixed with the 
carboxylic acid (0.5 µL, 100.0 mM in DMSO, 1000.0 eq.), EDC hydrochloride (1.0 µL, 50.0 mM in 






































































DMSO, 1000.0 eq.), HOAt (1.0 µL, 50.0 mM in DMSO, 1000.0 eq.) and DIPEA (1.5 µL, 50.0 mM 
in DMSO, 1500.0 eq.). The reactions were left standing at RT for 17 h. The reactions were 
purified by EtOH precipitation and were analyzed by LC-MS. 19 carboxylic acids were considered 
unsuitable for library construction due to low yields and purities. 89 carboxylic acids were chosen 
for further library synthesis. Cut-off: >50% purity. 
Table 15. List of all carboxylic acid DE-2 building blocks with the screening assay results. 39 representative members 
were screened for their coupling efficiency. Red coloring indicates insufficient reaction purity. Blue coloring indicates 
compounds that were excluded from library synthesis due to their similarity to low yielding building blocks. These 
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Part III: Appendix 
16. Building Blocks 
16.1 Diversity Element 1 
Table 16. SMILES codes and DNA codons for the building blocks of diversity element 1. Complete DNA sequence: 5'-
hexyne-GGAGCTTGTGAATTCTGGXXX GGACGTGTGTGAATTGTC-3’ with XXX representing the given codon 
sequence in the table. 































































16.2 Diversity Element 2 
Table 17. SMILES codes and DNA codons for the building blocks of diversity element 2. Complete DNA sequence:  
5'-GTAGTTGGATCCGCACACYYYYGACAA TTCACACACGTCC-3’ with YYYY representing the given codon sequence 
in the table. 


















































AA006 [R3]N[C@@H](CC1C AATT AA048 [R3]N1[C@H](C([R4]) AGCC AA090 CC(CC(C([R4])=O)N[ TTGT 
 -250- 














































































































































































































































































































































































































16.3 Diversity Element 3 
Table 18. SMILES codes and DNA codons for the building blocks of diversity element 3. Complete DNA sequence:  
5'-GTTCAAGCCACTTACCTZZZZZZTGATGCCTACCTATGAGA-3' with ZZZZZZ representing the given codon 
sequence in the table. Note that the given SMILES code already includes the triazole, formed after the click reaction. 
The corresponding terminal alkyne structure was the actually used compound for the DEML synthesis. 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TA664: O=C(CCCC1=CN(C[R5])N=N1)NC2=NN=C(S(=O)(N)=O)S2, AGGTTC 
 
 
